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Abstract	  
Uveal	   melanoma	   (UM)	   is	   the	   most	   common	   intraocular	   malignancy	   in	   adults.	  
Despite	  successful	  ocular	  treatment,	  about	  50%	  of	  patients	  succumb	  to	  metastatic	  
dissemination,	  which	  occurs	  haematogenously	  and	  mainly	  affects	  the	  liver.	  On	  the	  
basis	  of	  clinical,	  histopathological	  and	  genetic	  features	  of	  the	  primary	  tumour	   it	   is	  
possible	   to	   predict	   if	   the	   individual	   patient	   is	   at	   high	   risk	   (HR)	   or	   low	   risk	   (LR)	   of	  
developing	  metastases.	  However,	  the	  mechanisms	  responsible	  for	  the	  development	  
of	   metastatic	   disease	   in	   UM	   are	   still	   largely	   unknown;	   therefore	   no	   adjuvant	  
treatment	   is	   currently	   offered	   to	   HR	   patients	   to	   prevent	   development	   of	   fatal	  
disease.	  As	  the	  time	  to	  discovery	  of	  clinically	  detectable	  metastases	  can	  range	  from	  
months	  to	  decades,	  a	  secreted	  biomarker(s)	  that	  could	  be	  routinely	  tested	  in	  blood	  
is	   much	   needed.	   The	   scope	   of	   the	   work	   presented	   in	   this	   thesis	   was	   to	   use	  
proteomics	  as	  a	  tool	  to	  identify	  potential	  novel,	  UM-­‐specific	  biomarkers.	  Moreover,	  
the	   proteomic	   data	   acquired	   would	   complement	   genomic	   and	   transcriptomic	  
information	  already	  generated	  by	   the	  Liverpool	  Ocular	  Oncology	  Research	  Group,	  
with	   the	   ultimate	   aim	   of	   increasing	   our	   understanding	   of	   UM	   development	   and	  
dissemination.	  The	  aim	  of	  Chapter	  2’s	  project	  was	  to	  compare	  the	  proteome	  of	  UM	  
tissue	  samples	  at	  HR	  versus	  LR	  of	  developing	  metastatic	  disease	  using	  isobaric	  tags	  
for	   relative	   and	   absolute	   quantitation	   (iTRAQ)	   labelling	   and	   mass	   spectrometry	  
(MS).	  The	  quantification	  of	  proteins	  in	  our	  samples,	  proteomic	  analysis	  and	  further	  
validation	   by	   immunohistochemistry	   has	   led	   to	   the	   identification	   of	   two	   novel	  
prognostic	  and	  potentially	   therapeutic	   target,	  S100A6	  and	   the	   tumour	  suppressor	  
PDCD4.	   In	  Chapter	  3	  we	  focused	  on	  proteins	  released	   in	   the	  conditioned	  medium	  
(secretome)	   of	   short-­‐term	   cultures	   of	   HR	   and	   LR	   UM	   cells,	   as	   well	   as	   normal	  
melanocytes.	   Using	   a	   label-­‐free	   quantitative	   proteomic	   approach,	   almost	   2000	  
proteins	  were	  identified	  and	  quantified,	  with	  more	  than	  30%	  of	  these	  identified	  as	  
secreted	  and/or	  previously	  described	  in	  exosomes.	  Using	  these	  data,	  an	  18-­‐protein	  
signature	   able	   to	   discriminate	   between	   HR	   and	   LR	   UM	   was	   identified.	   Further	  
validation	  will	   be	   necessary	   in	   secretome	   samples	   and	   in	   the	   peripheral	   blood	  of	  
UM	  patients,	   but	   this	  has	   the	  potential	   of	  being	   translated	   into	  a	   clinically	  useful	  
assay	  to	  detect	  early	  development	  of	  metastatic	  disease.	  As	  reported	  in	  Chapter	  4,	  
we	   also	   conducted	   a	   pilot	   clinical	   study	   on	   circulating	   tumour	   cells	   (CTC)	   in	   UM,	  
using	   the	  CellSearch®	  platform	  with	   the	  novel	  melanoma	  kit	   to	  enumerate	  CTC	   in	  
the	  peripheral	  blood	  of	  UM	  patients	  at	  LR,	  HR	  or	  with	  overt	  metastatic	  disease.	  CTC	  
were	   detected	   in	   metastatic	   and	   HR	   tumours	   and	   were	   not	   present	   in	   LR	   UM,	  
however,	   the	   number	   of	   CTC	   detected	   varied	   widely,	   calling	   into	   question	   the	  
clinical	  value	  of	  using	  this	  platform	  in	  UM	  patients.	  The	  research	  detailed	  in	  Chapter	  
5	  had	  a	  direct	  clinical	  value,	  as	  it	  addressed	  the	  procedures	  undertaken	  during	  the	  
acquisition	   and	   processing	   of	   prognostic	   biopsies	   from	   UM	   tumours	   treated	  
conservatively.	   The	  modifications	   introduced	   led	   to	   a	   significant	   improvement	   of	  
the	  success	  rate	  of	  such	  prognostic	  biopsies	  for	  risk	  stratification,	  which	  is	  essential	  
for	  clinical	  management,	  follow-­‐up	  and	  research	  purposes.	  	  
In	  conclusion,	  the	  work	  conducted	  throughout	  this	  PhD	  has	  provided	  further	  insight	  
into	   the	  molecular	   characteristics	   that	   can	   differentiate	   between	  HR	   and	   LR	  UM,	  
identifying	   novel	   potential	   biomarkers	   that	   will	   need	   validation	   in	   the	   clinical	  
setting.	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Chapter	  1 	  
General	  introduction	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1.1 Uveal	  melanoma	  
1.1.1 Incidence	  and	  risk	  factors	  
Uveal	   melanoma	   (UM)	   is	   the	   most	   common	   primary	   intraocular	   malignancy	   in	  
adults.1	   The	   average	   incidence	   is	   5-­‐7	   cases	   per	   million	   individuals	   per	   year	   in	  
Europe,	   ranging	   from	  4.3	  to	  10.9	  wordwide.2,	  3	  UM	  most	  commonly	  affects	   faired-­‐
skinned,	   grey/blue	   eyed	   Caucasians,	   where	   it	   is	   eight	   times	   more	   common	   than	  
among	  African	  blacks,	  and	  three	  times	  more	  common	  than	  amongst	  Asians.4	  	  
UM	  has	  been	  reported	  in	  patients	  of	  all	  ages,	  but	  only	  1%	  of	  cases	  occur	  in	  younger	  
patients	  under	  the	  age	  of	  eighteen.5	  The	  incidence	  increases	  with	  age,	  climbing	  to	  
more	   than	  20	  cases	  per	  million	   individuals	  per	  year	  by	   the	  age	  of	  70.2	  Males	  and	  
females	  are	  affected	  in	  equal	  numbers.	  
UM	  typically	  occurs	   sporadically,	  but	   it	   is	   known	   in	  association	  with	  oculo-­‐dermal	  
melanocytosis,6	   familial	   atypical	   mole	   and	   melanoma	   (FAM-­‐M)	   syndrome,7	  
neurofibromatosis	   type	   1	   (NF1),8	   and	   Li-­‐Fraumeni	   syndrome.9	   The	   occurrence	   of	  
familial	  UM	  has	  been	  reported	  but	  it	  is	  exceptionally	  rare,	  comprising	  only	  0.6	  %	  of	  
all	  UM	  patients.10	  	  
Recently,	  germline	  mutations	  in	  the	  BRCA1	  associated	  protein-­‐1	  (BAP1)	  gene	  have	  
been	  identified	  to	  be	  responsible	  for	  a	  cancer	  predisposition	  syndrome	  associated	  
with	   UM,	   malignant	   mesothelioma,	   meningioma	   and	   lung	   adenocarcinoma	  
development.11	   In	   particular,	   a	   BAP1	   germline	   inactivating	   mutation	   has	   been	  
identified	  in	  a	  family	  affected	  by	  familial	  melanoma.12	  On	  the	  basis	  of	  this	  finding,	  
the	  authors	  advocate	   screening	  and	  counselling	  of	   families	  with	   such	  a	  mutation,	  
even	   in	   absence	   of	   other	   cancers.	   Germline	   BAP1	   mutations	   have	   also	   been	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investigated	  in	  a	  particular	  subset	  of	  young	  patients	  (14	  cases,	  age	  ranging	  from	  3	  
months	  to	  29	  years)	  affected	  by	  UM,	  but	  only	  one	  of	  them	  tested	  positive.13	  
The	  aetiology	  of	  UM	  remains	  unclear.	  Ultraviolet	  radiation	  has	  been	  proposed	  as	  a	  
possible	   environmental	   cause	   and	   a	   number	   of	   epidemiological	   studies	  
(summarised	   here14)	   have	   been	   performed,	   however	   there	   is	   still	   no	   definite	  
evidence	  for	  it.	  
1.1.2 Anatomical	  considerations	  and	  clinical	  features	  
UM	   is	   a	   neoplasm	   thought	   to	   arise	   from	   the	   uncontrolled	   proliferation	   of	  
melanocytes	  of	   the	  uveal	   tract,	  which	   is	   the	  vascularised	  middle	   layer	  of	   the	  eye,	  
between	   the	   sclera	   and	   the	   retina.	   The	  name	  uvea	   (uva	  =	   grape	   in	   Latin)	   derives	  
from	   the	   resemblance	   of	   this	   vascularised	   and	   pigmented	   layer	   to	   a	   black	   grape,	  
noted	  by	  early	  anatomists	  when	  removing	  the	  outer	  scleral	  layer.15	  The	  uveal	  tract	  
is	  composed	  of	  three	  parts:	  the	  choroid,	  the	  ciliary	  body	  and	  the	  iris.	  (Figure	  1.1)	  
1.1.2.1 Choroidal	  melanoma	  
Ninety	   percent	   of	  UM	  cases	   arise	   in	   the	   choroid,16	  which	   is	   the	   largest	   and	  most	  
posterior	   component	   of	   the	   uveal	   tract.	   It	   is	   composed	   of	   three	   interconnected	  
layers	   of	   blood	   vessels	   of	   decreasing	   size,	   interspersed	   with	   scarce	   connective	  
tissue	  and	  dendritic	  melanocytes	  containing	  melanin	  granules.	  The	  inner	  surface	  of	  
the	  choroid,	  formed	  by	  a	  network	  of	  fenestrated	  tiny	  vessels	  called	  choriocapillaris,	  
rests	   directly	   beneath	   a	   specialised	   layer	   of	   connective	   tissue	   called	   Bruch’s	  
membrane,	  which	  separates	  the	  choroid	  from	  the	  inner	  layer	  of	  the	  eye,	  the	  retina.	  
Initially,	   choroidal	  melanomas	   are	   restricted	   by	   Bruch’s	  membrane	   and	   therefore	  
assume	   a	   “dome	   shaped”	   appearance,	   often	   associated	   with	   exudative	   retinal	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detachment	   and	  deposits	   of	   lipofuscin.	   If	   they	   break	   through	  Bruch’s	  membrane,	  
the	  choroidal	  melanomas	  may	  take	  on	  a	  “collar-­‐stud‟	  or	  “mushroom”	  appearance,	  
which	  is	  a	  pathognomonic	  clinical	  feature	  of	  this	  disease.	  Depending	  on	  the	  size	  and	  
location	   of	   the	   tumour,	   choroidal	   melanomas	   can	   present	   symptomatically	   with	  
visual	   loss,	  photopsia	  or	  floaters.	   In	  30%	  of	  cases	  UM	  is	  completely	  asymptomatic	  
and	  detected	  by	  chance	  on	  routine	  examination.17	  
	  
	  
Figure	  1.1	  Anatomical	  location	  and	  clinical	  appearance	  of	  UM.	  A)	  Choroidal	  melanoma;	  B)	  
Ciliary	  body	  melanoma;	  C)	  Iris	  melanoma.	  (Courtesy	  of	  Prof.	  B.	  Damato)	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1.1.2.2 Ciliary	  body	  melanoma	  
The	  choroid	  continues	  anteriorly	  with	  the	  ciliary	  body,	  which	  is	  a	  circular	  structure	  
composed	  of	  the	  pars	  plana,	  posteriorly,	  and	  the	  pars	  plicata,	  anteriorly.	  The	  pars	  
plicata	  contains	  the	  ciliary	  muscles	  and	  the	  ciliary	  processes.	  The	  ciliary	  muscles	  are	  
responsible	  for	  changing	  the	  shape	  of	  the	  lens	  providing	  accommodation	  of	  vision.	  
The	   ciliary	   processes	   are	   finger-­‐like	   projections	   lined	   by	   the	   ciliary	   epithelium,	  
which	  produces	  of	  the	  aqueous	  humour,	  the	  fluid	  that	  fills	  the	  eye.	  	  
UM	   develops	   in	   the	   ciliary	   body	   in	   five	   percent	   of	   cases.16	   These	   are	   the	   most	  
challenging	  to	  diagnose	  because	  of	  difficulties	  in	  visualising	  the	  area	  during	  routine	  
ophthalmological	  examination.	  Patients	  can	  present	  with	  unilateral	  cataract,	  raised	  
intraocular	   pressure,	   dilated	   episcleral	   vessels	   in	   the	   corresponding	   sector	   of	   the	  
eye,	  but	  visual	  symptoms	  do	  not	  usually	  occur	  until	  the	  lesion	  is	  so	  large	  as	  to	  cause	  
a	  visual	  field	  defect.	  	  
1.1.2.3 Iris	  melanoma	  
The	  iris	  is	  the	  most	  anterior	  part	  of	  the	  uveal	  tract.	  It	  is	  a	  thin,	  varyingly	  pigmented	  
diaphragm,	  which	  can	  contract	  or	  dilate	  to	  change	  the	  intensity	  of	  light	  entering	  the	  
eye.	  	  
Iris	  melanomas	  are	  usually	  small,	  pigmented,	  vascularised	  nodular	  lesions,	  with	  an	  
indolent	   clinical	   course.	   Because	   of	   the	   anterior	   location,	   iris	  melanomas	  may	   be	  
detected	  by	   the	  patient	  externally,	   and	   therefore	  be	  promptly	  diagnosed	   in	  most	  
cases.	   A	   rare,	   more	   aggressive	   variant	   is	   diffuse	   iris	   melanoma,	   which	   is	   often	  
associated	  with	  glaucoma	  and	  has	  an	  increased	  prevalence	  of	  metastatic	  disease.	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1.1.3 Diagnosis	  and	  treatment	  
The	   diagnosis	   of	   UM	   relies	   on	   clinical	   examination	   (slit	   lamp	   examination	   and	  
ophthalmoscopy)	   and	   ocular	   ultrasonography.	   Traditionally,	   UM	   have	   been	  
subdivided	  according	  to	  their	  largest	  basal	  diameter	  (LBD)	  and	  thickness	  into	  small,	  
medium	  or	   large.	   Small	  melanomas	  have	  a	   LBD	  >	  5	  mm	  with	  a	   thickness	  of	  1-­‐2.5	  
mm;	  medium	  tumours	  have	  a	  LBD	  ≤	  16	  mm	  with	  a	   thickness	  of	  2.5-­‐10	  mm;	   large	  
melanomas	  have	  a	  LBD	  >	  16	  mm	  and/or	  a	  thickness	  >	  10	  mm.18	  More	  recently,	  this	  
anatomical	  classification	  has	  been	  updated	  to	  new	  evidence-­‐based	  categories	  that	  
provide	  basis	  for	  staging	  UM	  as	  part	  of	  the	  tumour,	  node,	  metastasis	  (TNM)	  system	  
used	  in	  all	  cancer	  types.	  The	  “T”	  categories	  define	  the	  anatomic	  extent	  of	  primary	  
UM	   and	   take	   into	   consideration	   not	   only	   the	   LBD	   and	   thickness,	   but	   also	   the	  
presence	  of	  extraocular	  extension	  (EOE)	  and/or	  ciliary	  body	  involvement.19,20	  
Large	   to	   medium-­‐sized	   UM	   are	   reliably	   diagnosed	   clinically,	   with	   an	   accuracy	   of	  
99.5%.18	  Small	  melanomas	  are	  more	  difficult	  to	  differentiate	  from	  choroidal	  naevi.	  
Shields	  et	  al.	  have	  devised	  the	  mnemonic	  “TFSOM”,	  which	  stands	  for	  “to	  find	  small	  
ocular	   melanomas”,	   to	   identify	   indicators	   of	   potential	   malignancy:	   tumour	  
‘Thickness’	   of	   more	   than	   2	   mm,	   subretinal	   ‘Fluid’,	   visual	   ‘Symptoms’,	   ‘Orange’	  
pigment,	  and	  location	  of	  the	  tumour	  ‘Margin’	  within	  3	  mm	  of	  the	  optic	  disc.21	  Each	  
of	  the	  risk	  characteristics	  roughly	  doubles	  the	  likelihood	  of	  growth	  so	  that	  the	  risk	  
for	  malignant	  transformation	  is	  about	  30	  times	  higher	  when	  all	  five	  characteristics	  
are	   present.22	   Additional	   risk	   factors	   are	   a	   low	   internal	   acoustic	   reflectivity	   on	  
ultrasound,	   the	  absence	  of	   a	  halo	  around	   the	   tumour	  and	   the	  absence	  of	  drusen	  
over	  its	  surface.23	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Optical	  coherence	  tomography	  and	  fundus	  autofluorescence	  imaging	  are	  becoming	  
part	  of	   routine	  examination	  as	   they	  are	  non-­‐invasive	  diagnostic	   tools	   that	  help	   in	  
identifying	  subretinal	  fluid,	  drusen	  and	  orange	  pigment,	  as	  well	  as	  in	  measuring	  the	  
thickness	   of	   thin	   choroidal	   tumours.24	   On	   the	   contrary,	   invasive	   diagnostic	   tools	  
that	   require	   intravenous	   injection	   of	   dye,	   such	   as	   fluorescein	   angiography	   and	  
indocyanine	  green	  angiography,	  are	  performed	  only	   rarely	   to	  help	   the	  differential	  
diagnosis	   with	   infective	   and	   inflammatory	   chorioretinal	   diseases	   or	   vascular	  
tumours.25	  	  
The	   differential	   diagnosis	   of	   UM	   includes	   several	   conditions,	   the	   most	   common	  
being	   choroidal	  naevus,	  eccentric	  disciform,	   congenital	  hypertrophy	  of	   the	   retinal	  
pigment	   epithelium,	   systemic	   metastases	   to	   the	   choroid,	   and	   circumscribed	  
choroidal	   haemangioma.26	   In	   case	  of	   diagnostic	   uncertainty,	   a	   choroidal	   biopsy	   is	  
performed.	  	  
1.1.3.1 Treatment	  of	  primary	  UM	  
The	  management	   of	  UM	  depends	  on	   tumour	   size	   and	   location,	   associated	  ocular	  
co-­‐morbidities,	  visual	  acuity	  status	  of	  each	  eye,	  and	  patient	  wishes.	  The	  treatment	  
options	  include	  various	  types	  of	  radiotherapy,	  surgical	  excision,	  or	  phototherapy,	  as	  
detailed	  below.	  
The	   most	   widely	   employed	   treatment	   for	   posterior	   UM	   is	   radiotherapy,	   in	  
particular	   brachytherapy	   using	   a	   radioactive	   plaque,	   with	   Ruthenium-­‐106	   and	  
Iodine-­‐125	   being	   the	   most	   commonly	   used	   isotopes,	   in	   Europe	   and	   the	   USA,	  
respectively.27	  The	  overall	  tumour	  control	  rate	  is	  approximately	  90%	  at	  5	  years	  and	  
treatment	   failure	   is	   associated	   with	   greater	   size	   and	   posterior	   extension	   of	   the	  
	  
	   22	  
tumour.28	  Local	  recurrence	  rate	  is	  significantly	  reduced	  for	  smaller	  tumours,	  being	  
only	   3%	   at	   7	   years.29	   Radiation-­‐induced	   complications,	   such	   as	   radiation	  
retinopathy,	   exudative	   retinal	   detachment,	   radiation	   maculopathy,	   neovascular	  
glaucoma,	   can	   occur	   and	   eventually	   lead	   to	   secondary	   enucleation	   in	   12-­‐17%	   of	  
cases,	  depending	  on	  the	  isotope	  and	  dose	  of	  radiation	  used.30,	  31	  
In	  selected	  centres,	  it	  is	  possible	  to	  treat	  UM	  with	  proton	  beam	  radiotherapy	  (PBR),	  
which	  delivers	  a	  very	  precise	  focused	  beam	  of	  radiation	  to	  the	  region	  of	  the	  tumour	  
from	  an	  external	  source,	  sparing	  the	  surrounding	  tissues.32	  It	  can	  be	  modulated	  to	  
treat	  UM	  of	  any	  size	  and	  location,	  including	  iris	  melanoma.33	  To	  ensure	  the	  precise	  
delivery	  of	   the	  radiation	  beam,	  the	  patient	   is	  postured	   in	  a	   fixed	  position	  and	  the	  
eye	  is	  monitored	  with	  x-­‐ray	  to	  visualise	  the	  tantalum	  markers.	  These	  are	  small	  inert	  
metal	   buttons	   that	   are	   sutured	   to	   the	   sclera	   overlying	   the	   tumour	   prior	   to	   the	  
PBR.34	  Tumour	  control	  is	  excellent,	  but	  visual	  loss	  almost	  inevitably	  occurs	  if	  either	  
the	  optic	  nerve	  or	  the	  macula	  are	  in	  the	  field	  of	  radiation.35	  	  
A	  more	  widely	   available	   alternative	   source	  of	   radiation	   that	   can	  be	  used	   to	   treat	  
UM	   is	   fractionated	   stereotactic	   radiotherapy,	   which	   can	   be	   performed	   using	   a	  
gammaknife,	   a	   cyberknife	   or	   a	   linear	   accelerator.36	   The	   rate	   of	   local	   control	   is	  
similar	  to	  that	  of	  brachytherapy;	  however	  there	  is	  a	  higher	   incidence	  of	  radiation-­‐
related	   complications,	   in	   particular	   neovascular	   glaucoma,	   leading	   to	   secondary	  
enucleation.37	  
Following	   any	   source	   of	   irradiation,	   large	   UM	   are	   at	   risk	   of	   developing	   “toxic	  
tumour	  syndrome”,	  which	  manifests	  as	  exudative	  retinal	  detachment,	  rubeosis	  and	  
neovascular	  glaucoma	  and	  can	  ultimately	  lead	  to	  loss	  of	  the	  eye.38	  Surgical	  removal	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of	   the	   ischemic	   irradiated	   tumour	   is	   an	   effective	   way	   to	   deal	   with	   such	  
complications.39	  	  
The	   surgical	   removal	   of	   a	   primary	   or	   irradiated	   tumour	   can	   be	   performed	   ab	  
externo	   using	   a	   partial	   lamellar	   sclerouvectomy	   technique	   commonly	   known	   as	  
local	  resection,40	  or	  ab	  interno	  using	  a	  25G	  cutter	  to	  “hoover”	  the	  choroidal	  tumour	  
through	   the	   retina,	   known	   as	   endoresection.41	   Adjunctive	   brachytherapy	   is	   being	  
routinely	   applied	   after	   resections	   of	   primary	   tumours	   to	   improve	   local	   control.42	  
With	  these	  techniques,	  it	  is	  possible	  to	  preserve	  the	  eye,	  and	  in	  some	  cases	  useful	  
vision,	  also	  for	  UM	  that	  would	  not	  have	  been	  suitably	  treated	  with	  radiotherapy.43	  	  
Enucleation,	   which	   is	   the	   removal	   of	   the	   eye	   globe,	   has	   been	   the	   standard	  
treatment	  for	  UM	  in	  the	  past,	  as	   it	  was	  considered	  the	  safest	  way	  to	  treat	   it.	  The	  
Collaborative	   Ocular	   Melanoma	   Study	   (COMS)	   group	   conducted	   a	   large,	  
multicentre,	  randomised	  trial	  in	  the	  USA	  comparing	  enucleation,	  with	  conservative	  
treatment	  using	  radioactive	  plaque	  brachytherapy.44	  No	  difference	   in	  survival	  was	  
seen,	   therefore	  enucleation	   is	  currently	  being	  reserved	   for	  advanced	  UM	  that	  are	  
larger	   than	   18mm	   in	   LBD	  or	   thicker	   than	   10	  mm,	   that	   involve	   the	  optic	   nerve	   or	  
cause	  severe	  ocular	  complications	  such	  as	  total	  retinal	  detachment	  or	  neovascular	  
glaucoma.	   The	   volume	   of	   the	   globe	   is	   replaced	   by	   an	   orbital	   implant;	   the	  
extraocular	  muscles	  are	  sutured	  to	  it	  to	  ensure	  postoperative	  ocular	  motility,	  and	  a	  
customised	  prosthesis	  designed	  to	  match	  the	  fellow	  eye	  is	  clipped	  under	  the	  eyelid	  
to	  provide	  pleasing	  cosmetic	  appearance.	  
Phototherapy	   for	   UM	   includes	   photodynamic	   therapy	   and	   transpupillary	  
thermotherapy.	   Photodynamic	   therapy	   requires	   the	   intravenous	   injection	   of	   the	  
photosensitiser	  verteporfin,	  which	  circulates	  in	  the	  choroid	  and	  is	  activated	  with	  by	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laser	  shone	  over	  the	  tumour.45	  The	  success	  in	  local	  tumour	  control	  is	  inconsistent,	  
although	   some	   small	   amelanotic	   choroidal	   melanomas	   regress	   completely;	  
therefore	   it	   is	   not	   a	   preferred	   choice	   of	   treatment	   for	   UM,	   but	   rather	   for	  
circumscribed	   choroidal	   haemangioma	   and	   vascular	   tumours.46	   Transpupillary	  
thermotherapy	   uses	   an	   infrared	   laser	   to	   disrupt	   the	   metabolic	   activity	   of	   the	  
tumour	   cells	   by	   increasing	   their	   temperature	   for	   about	   1	   minute,	   without	   any	  
contrast	  agent	  being	  necessary.47	  After	  initial	  enthusiasm	  for	  this	  minimally	  invasive	  
treatment	   option,	   concerns	   have	   been	   raised	   on	   its	   efficacy.48	   A	   recent	   paper	  
reporting	   the	   results	   for	  391	  patients	  has	   shown	  a	   recurrence	   rate	  of	  up	   to	  42%,	  
and	   hence	   concluded	   that	   this	   technique	   should	   only	   be	   reserved	   for	   small	  
choroidal	   melanoma	   with	   no	   more	   than	   two	   risk	   factors	   such	   as	   lipofuscin,	  
subretinal	  fluid,	  acoustic	  hollowness,	  etc.49	  
1.1.4 Metastatic	  dissemination	  of	  UM	  
In	  medicine,	   the	  aim	  of	   treating	  cancer	   is	   to	  cure	  patients	  and,	   if	  not	  possible,	   to	  
prolong	  the	  survival	  of	   the	  patient.	  For	  UM	  patients,	   it	   is	   still	  not	  known	  whether	  
ocular	   treatment	   influences	   survival,	   and	   if	   so,	   in	  whom.50	   Indeed,	   approximately	  
50%	  of	  UM	  patients	  develop	  metastatic	  disease	  despite	  successful	  treatment	  of	  the	  
primary	  tumour.1	  	  
Due	   to	   the	   lack	   of	   lymphatic	   vessels	   in	   the	   eye,	  metastatic	   dissemination	   of	   UM	  
occurs	  via	  the	  bloodstream,	  while	  local	  spread	  to	  surrounding	  tissues	  is	  rare	  as	  long	  
as	   the	   conjunctiva	   is	   not	   infiltrated	   transclerally.51	   Circulating	   tumour	   cells	   (CTC)	  
have	  indeed	  been	  detected	  in	  the	  peripheral	  blood	  of	  UM	  patients	  at	  all	  stages	  of	  
the	  disease.52	  As	  detailed	  in	  Chapter	  4,	  we	  also	  investigated	  the	  clinical	  value	  of	  CTC	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detection	  in	  UM	  patients	  using	  a	  novel	  platform	  (CellSearch®	  by	  Veridex)	  that	  had	  
been	  approved	  for	  clinical	  use	  in	  other	  cancer	  types.	  	  
The	  liver	  is	  the	  main	  target	  organ	  of	  metastatic	  UM	  dissemination,	  being	  involved	  in	  
up	  to	  90%	  of	  UM	  patients	  with	  metastatic	  disease,	  while	  other	  potential	  sites	  are	  
lung,	   bone	   and	   skin,	   but	   almost	   exclusively	   after	   liver	   invasion.53	   This	   marked	  
hepatic	   tropism	   suggests	   that	   there	   must	   be	   something	   peculiar	   about	   the	   liver	  
(“soil”)	  in	  terms	  of	  metastatic	  niche	  development	  for	  UM	  cells	  (“seeds”).	  It	  is	  indeed	  
by	   examining	   UM	   patients	   that	   the	   Austrian	   Ophthalmologist	   Ernst	   Fuchs	   first	  
described	   in	   1882	   the	   ‘predisposition’	   of	   an	   organ	   to	   be	   the	   recipient	   of	   specific	  
growths,54	  inspiring	  Paget’s	  well	  known	  seed	  and	  soil	  theory	  of	  metastasis.55	  	  
More	   recently,	   Logan	   et	   al.56	   provided	   experimental	   evidence	   for	   this	   in	   UM	   by	  
injecting	   green	   fluorescent	   protein	   (GFP)-­‐labelled	   92.1	   cells	   into	   the	   tail	   vein	   of	  
nude	   mice	   and	   showing	   their	   dissemination	   via	   skin-­‐flap	   and	   epifluorescence	  
microscopy.	   Post-­‐injection,	   cells	   were	   present	   in	   multiple	   organs;	   however	   after	  
two	   weeks	   they	   survived	   exclusively	   in	   the	   liver,	   where	   they	   persisted	   as	   single	  
metastatic	   seeds	   for	   the	   whole	   duration	   of	   the	   experiment	   (42	   days).	   There	   is	  
further	   experimental	   evidence	   from	   a	  murine	   xenograft	   model	   that,	   once	   in	   the	  
liver,	   individual	  melanoma	  cells	   can	  give	   rise	   to	  micrometastases,	  which	  have	   the	  
capacity	  to	  remain	  dormant,	  as	  avascular	  small	  aggregates	  of	  cells	  in	  the	  G0	  phase	  
of	  the	  cell	  cycle.57	  By	  evaluating	  histological	  and	   immunohistochemical	   findings	  of	  
post-­‐mortem	   livers	   from	   10	   metastatic	   UM	   patients,	   Grossniklaus	   has	  
demonstrated	  the	  presence	  of	  such	  dormant	  micrometastases	  in	  humans.58	  Based	  
on	   size,	   Grossniklaus	   categorised	  UM	  metastases	   into	   three	   stages,	   showing	   that	  
avascular	   stage	   1	   (≤50	   μm	   in	   diameter)	   metastases	   progress	   through	   stage	   2	   to	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larger	   stage	   3	   (>500	   μm	   in	   diameter)	   tumours,	   becoming	   vascularized	   and	  
mitotically	  active	  during	  this	  process.	  How	  and	  why	  such	  progression	  occurs	  has	  not	  
yet	  been	  clarified.	  The	  innate	   immune	  system	  is	  known	  to	  play	  an	   important	  role,	  
with	  natural	  killer	  cells	  residing	  in	  the	  liver	  eliminating	  UM	  cells	  on	  one	  side,59	  and	  
polarised	   tumour	   associated	   macrophages	   (TAM)	   creating	   a	   favourable	  
microenvironment	  on	  the	  other.60	  	  
On	   the	  basis	  of	   tumour	  doubling	   times	  and	  mathematical	  modelling	  published	  by	  
Eskelin	   et	   al.61,	   it	   has	   been	   suggested	   that	   metastatic	   spread	   commences	   years	  
before	  the	  primary	  ocular	   tumour	   is	   large	  enough	  to	  be	  detected	  clinically,	  hence	  
occult	  micrometastatic	  disease	  may	  already	  be	  present	  in	  UM	  patients	  at	  the	  time	  
of	  ocular	  treatment.	  Interestingly,	  however,	  only	  1-­‐2%	  of	  UM	  patients	  are	  found	  to	  
have	  detectable	  metastatic	  disease	  at	   the	   time	  of	  diagnosis	  of	   the	  primary	  ocular	  
tumour.62	   Indeed,	   liver	  metastases	   are	   typically	   detected	   1-­‐3	   years	   following	   the	  
ocular	   treatment.	   Moreover,	   there	   have	   been	   reports	   of	   metastatic	   disease	  
developing	  10,	  20	  and	  even	  40	  years	  later.	  The	  reason	  for	  such	  latency	  is	  not	  fully	  
understood	  yet,	  but	  tumour	  dormancy	  is	  indeed	  a	  very	  challenging	  and	  fascinating	  
topic	  that	  is	  being	  investigated	  by	  scientists	  in	  the	  field	  of	  UM.63	  	  
For	  the	  clinicians,	  the	  rationale	  behind	  early	  detection	  and	  treatment	  of	  UM	  is	  the	  
hope	   that	   ocular	   treatment	   may	   prolong	   life,	   even	   once	   metastatic	   spread	   has	  
commenced,	   by	   stopping	   the	   shedding	   of	   tumour	   cells	   into	   the	   bloodstream	  and	  
therefore	  limiting	  the	  metastatic	  burden.64,	  65	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1.1.5 Personalised	  prognostication	  in	  UM	  
Although	   50%	   of	   UM	   patients	   develop	  metastatic	   disease,	   the	   risk	   of	   developing	  
metastatic	   disease	   for	   a	   given	   patient	   is	   not	   50%.	   Over	   the	   years,	   a	   number	   of	  
clinical,	  histopathological	  and	  more	  recently	  genetic	  features	  of	  the	  ocular	  tumour	  
have	   been	   identified	   as	   being	   significantly	   correlated	   with	   the	   development	   of	  
systemic	  disease.	   It	   is	   now	   therefore	  possible	   to	   estimate	   the	   survival	   probability	  
for	   the	   individual	   patient	   by	   examining	   a	   tissue	   sample	   at	   the	   time	   of	   ocular	  
treatment.	  	  
1.1.5.1 Clinical	  and	  histopathological	  features	  
The	   size	   of	   UM	   at	   the	   time	   of	   diagnosis	   has	   been	   long	   known	   as	   an	   important	  
clinical	   prognostic	   factor	   for	   development	   of	   metastatic	   disease,	   with	   larger	  
tumours	  having	  a	  more	  aggressive	  behaviour.	  Other	  negative	   clinical	   features	  are	  
the	   presence	   of	   extraocular	   extension	   and	   an	   anterior	   location	   with	   ciliary	   body	  
involvement.	  A	  recent	  collaborative	  study	  on	  7731	  patients	  has	  demonstrated	  that	  
the	   “T”	   category	   defined	   according	   to	   the	   7th	   edition	   of	   the	   American	   Joint	  
Committee	  on	  Cancer	  (AJCC)	  classification,	  which	  takes	  into	  consideration	  of	  all	  the	  
above	  elements,	  predicts	  prognosis.	  In	  particular,	  the	  risk	  for	  metastasis	  and	  death	  
increased	  2-­‐fold	  with	  each	  increasing	  melanoma	  category	  from	  T1	  to	  T4.66	  
	  Histopathological	  assessment	  of	  haematoxylin	  and	  eosin	  (H&E)	  staining	  allows	  the	  
identification	   of	   the	   prevalent	  melanoma	   cell	   type	   in	   the	   sample,	   categorised	   as	  
spindle,	  epithelioid	  and	  mixed	  based	  on	  the	  modified	  Callender	  classification.67	  The	  
mortality	   is	   greater	   if	   the	   tumour	   contains	  epithelioid	   cells,	  which	  have	  abundant	  
cytoplasm,	   are	   polygonal	   in	   size	   and	   are	   poorly	   cohesive,	   as	   opposed	   to	   spindle	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cells,	   which	   have	   a	   fusiform	   configuration	   and	   form	   interweaving	   fascicles	   of	  
parallel	  oriented	  cells.	  However,	  melanoma	  cells	  constitute	  a	  continuous	  biological	  
spectrum,	  thus	  there	  can	  be	  a	  degree	  of	  subjectivity	  in	  determining	  cell	  category.	  	  
Other	   histopathological	   features	   commonly	   used	   for	   assessing	   the	   malignant	  
potential	  of	  UM	  are	  the	  number	  of	  mitotic	  figures	  and	  the	  presence	  of	  closed	  loops.	  
The	   number	   of	  mitotic	   figures	   in	   40	   high	   power	   fields	   indicates	   the	   proliferation	  
rate	   of	   the	   tumour,	   hence	   the	   higher	   the	   figure	   the	   worse	   the	   prognosis.	   As	  
detecting	  mitotic	  figures	  in	  H&E	  stained	  slides	  can	  be	  tedious	  and	  time	  consuming,	  
we	   have	   previously	   demonstrated	   that	   this	   can	   be	   facilitated	   by	  
immunohistochemical	   staining	   using	   the	  mitosis-­‐specific	  marker	   Phospho-­‐Histone	  
H3	  Ser10	   (PHH3).68	  The	  presence	  of	  extracellular	  matrix	  Periodic	  Acid	  Schiff	   (PAS)	  
positive	  closed	   loops,	  which	  are	  vasculogenic	  mimicry	  patterns,	   is	  another	  feature	  
associated	  with	  death	  from	  metastatic	  melanoma.69	  	  
Other	  histopathological	  features	  have	  been	  identified	  as	  having	  a	  prognostic	  value	  
but	  are	   less	  commonly	  assessed	   in	  routine	  clinical	  practice:	  mean	  diameter	  of	  ten	  
largest	   nucleoli,70	   presence	   of	   tumour	   infiltrating	   lymphocytes,71	   degree	   of	  
pigmentation	  and	  necrosis.	  
1.1.5.2 Genetic	  features	  
The	  majority	  of	  UM	  contain	  non-­‐random	  gross	  chromosomal	  aberrations	  on	  either	  
the	  short	  arm	  (p)	  or	  the	  long	  arm	  (q)	  of	  chromosomes	  1,	  3,	  6	  and	  8,	  which	  can	  be	  
used	  as	  prognostic	  markers.	  	  
A	   variety	   of	   genetic	   techniques	   are	   being	   used	   for	   prognostication	   in	   UM.	   These	  
vary	   from	   lower	   resolution	   techniques	   such	   as	   fluorescence	   in	   situ	   hybridization	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(FISH)	   and	   microsatellite	   analysis	   (MSA),	   to	   high	   resolution	   microarray	   based	  
techniques,	  such	  as	  comparative	  genome	  hybridisation	  (CGH)	  and	  single	  nucleotide	  
polymorphism	   (SNP)	   analysis.	   In	   Liverpool,	   the	   preferred	   technique	   at	   present	   is	  
multiplex	  ligation-­‐dependent	  probe	  amplification	  (MLPA),	  which	  allows	  the	  relative	  
quantification	  of	  multiple	  loci	  on	  chromosomes	  1p,	  3,	  6	  and	  8	  in	  a	  single	  reaction,	  
making	   it	   an	   affordable	   and	   accurate	   screening	   assay.	  When	   the	   amount	   of	  DNA	  
extracted	   from	   the	   sample	   is	   insufficient	   for	   MLPA,	   chromosome	   3	   status	   is	  
assessed	  by	  MSA.	  Please	  refer	  to	  Chapter	  5	  for	  more	  details.	  
The	  most	   important	   chromosomal	   abnormality	   in	   UM	   is	   the	   loss	   of	   one	   copy	   of	  
chromosome	  3,	  monosomy	  3	   (M3),	  which	   is	  associated	  with	  a	   reduction	   in	   the	  5-­‐
year	   survival	   probability	   from	   approximately	   100%	   to	   less	   than	   50%,	   as	   first	  
reported	  by	  Prescher	  et	  al.	  in	  1996.72	  	  
Polysomy	   8q	   (8q	   gain	   –	   8qG)	   is	   also	   strongly	   linked	  with	   a	   poor	   prognosis.73	  Our	  
group	   has	   recently	   analysed	   chromosomal	   data	   from	   602	  UM	   tested	  with	  MLPA,	  
and	   demonstrated	   that	   M3	   or	   8qG	   have	   a	   similar	   impact	   on	   survival,	   when	  
occurring	   in	   isolation.	   In	   combination,	  M3	  and	  8qG	   reduce	   the	  5-­‐year	   cumulative	  
survival	  rate	  to	  30%.74	  	  
Deletion	   of	   chromosome	   1p	   occurs	   in	   approximately	   in	   30%	   of	   UM.	   	   When	  
occurring	  together	  with	  M3	  the	  disease-­‐free	  survival	  time	  in	  shorter.75	  
In	   contrast	   to	   chromosomal	   aberrations	   associated	   with	   a	   poor	   prognosis,	   the	  
presence	   of	   polysomy	   6p	   (6p	   gain,	   6pG)	   is	   frequently	   found	   in	   disomy	   3	   (D3)	  
tumours	  and	   is	  associated	  with	  prolonged	  survival.73	  Based	  on	  this	  observation,	   it	  
has	  been	  suggested	  a	  “protective”	  effect	  of	  6pG,	  however	  no	  single	  gene	  that	  may	  
justify	   this	   benign	   tumour	   biology	   has	   been	   identified	   to	   date.	   Furthermore,	   6pG	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has	   been	   observed	   in	   a	   small	   proportion	   of	   M3	   cases	   and	   is	   additionally	   found	  
together	  with	   8qG	   in	   D3	   tumours,76	   therefore,	   no	   conclusive	   clinical	   implications	  
can	  be	  drawn	  as	  yet.	  	  
1.1.5.3 The	  Liverpool	  Uveal	  Melanoma	  Prognostic	  Online	  (LUMPO)	  tool	  
Liverpool	  was	  the	  first	  specialist	  centre	  to	  combine	  the	  clinical,	  histomorphological	  
and	  genetic	  features	  discussed	  above	  to	  provide	  a	  personalised	  prognostic	  curve	  for	  
each	   UM	   patient	   based	   on	   a	   clinically	   validated	   mathematical	   algorithm.	   This	  
software	  is	  freely	  available	  as	  the	  LUMPO	  tool	  (www.ocularmelanomaonline.org).77	  
A	  recent	  Google	  Analysis	  of	  the	  tool	  demonstrated	  that	  over	  the	  last	  2	  years,	  there	  
have	  been	  1133	  hits	  from	  552	  users	  in	  291	  cities	  around	  the	  globe.	  	  
The	   parameters	   included	   are:	   gender	   and	   age	   of	   the	   patient;	   tumour	   LBD	   and	  
thickness;	   ciliary	   body	   involvement;	   extraocular	   extension;	   cell	   type;	   presence	   of	  
PAS-­‐positive	   connective	   tissue	   loops;	   mitotic	   rate;	   chromosome	   3	   status.	   A	  
personalized	  survival	  curve	  is	  generated	  indicating	  the	  patient’s	  survival	  probability	  
at	   10	   years	   as	   compared	   to	   healthy	   population	  matched	   for	   age	   and	   sex	   (Figure	  
1.2).	  
The	  data	  is	  interpreted	  by	  a	  Consultant	  Ophthalmologist,	  who	  classifies	  the	  patient	  
as	  at	  high	  risk	  (HR)	  or	  at	  low	  risk	  (LR)	  of	  developing	  metastatic	  disease.	  HR	  patients	  
are	   referred	   to	   a	   Medical	   Oncologist	   specialized	   in	   UM	   for	   intense	   follow-­‐up	  
screening	  with	  6-­‐monthly	  liver	  MRI	  and	  serological	  liver	  function	  tests,	  whereas	  LR	  
patients	  are	  reassured	  and	  discharged	  to	  their	  referring	  ophthalmologist.78	  A	  small	  
proportion	   of	   patients	   have	   ambiguous	   or	   incomplete	   results	   and	   is	   therefore	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clustered	   as	   “indeterminate”.	   Systemic	   screening	   is	   performed	   at	   patient’s	  
discretion	  in	  such	  rare	  cases.	  	  
	  
Figure	  1.2	  Example	  of	  a	  personalised	  survival	  curve	  indicating	  HR	  of	  developing	  metastatic	  
disease.	   This	   60-­‐year-­‐old	   woman	   with	   a	   cilio-­‐choroidal	   melanoma	   containing	   epithelioid	  
cells	  with	  M3	  has	  a	  60%	  greater	  chance	  to	  be	  dead	  in	  ten-­‐year	  time	  as	  compared	  to	  sex	  and	  
age-­‐matched	  population.	   The	   continuous	  black	   line	   at	   the	   top	  of	   the	   graph	   refers	   to	   the	  
normal	  population;	  the	  patient’s	  line	  is	  the	  blue	  continuous	  one.	  The	  dash	  line	  indicates	  the	  
confidence	   interval.	   The	   pictograph	   on	   the	   right	   hand	   side	   is	   provided	   to	   facilitate	   the	  
explanation	  of	  the	  results	  to	  the	  patients.	  
	  
	  
	   32	  
1.1.5.4 Gene	  expression	  profiling	  (GEP)	  
GEP	   is	  a	  high-­‐throughput	  tool	  capable	  of	  simultaneous	  quantitative	  detection	  of	  a	  
large	   number	   of	   genes	   in	   a	   single	   experiment.	   It	   is	   most	   commonly	   done	   using	  
cDNA	   microarrays	   and	   fluorescent-­‐based	   detection.79	   GEP	   has	   been	   used	   as	   an	  
alternative	  approach	  for	  metastatic	  risk	  stratification	  in	  UM	  patients.	  Onken	  et	  al.80	  
examined	   the	   expression	   profile	   of	   35	   untreated	   UM	   using	   high-­‐density	  
oligonucleotide	   arrays	   and	   performed	   unsupervised	   analyses	   that	   clustered	   them	  
into	   two	   groups,	   named	   class	   1	   and	   class	   2.	   They	   then	   performed	   supervised	  
techniques	  to	  identify	  genes	  that	  discriminated	  the	  tumour	  classes.	  (Figure	  1.3	  A)	  
	  
Figure	  1.3	  A)	  Hierarchical	  clustering	  heatmap	  of	  62	  discriminating	  genes	  from	  the	  original	  
GEP	  analysis	  of	  25	  UM.80	  Class	  1	  (low-­‐grade)	  and	  class	  2	  (high-­‐grade)	  tumours	  are	  indicated.	  
Blue	   asterisks	   indicate	   chromosome	   3	   genes	   that	   are	   down-­‐regulated	   in	   class	   2,	   red	  
asterisks	   indicate	   chromosome	   8q	   genes	   that	   are	   up-­‐regulated	   in	   class	   2,	   and	   black	  
asterisks	   indicate	   chromosome	  8q	  genes	   that	   are	  down-­‐regulated	   in	   class	   2.	  B)	  Heatmap	  
showing	   normalised	   expression	   of	   the	   12	   discriminating	   genes	   chosen	   for	   the	   clinical	  
assay.81	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By	   correlating	   the	   molecular	   findings	   with	   the	   clinical	   data	   of	   the	   tumour	   and	  
patient	  outcomes,	  class	  1	  was	  defined	  as	  low	  risk	  for	  metastatic	  disease,	  while	  class	  
2	  as	  high	  risk.	  These	  data	  have	  since	  been	  used	  to	  develop	  a	  commercially	  available	  
assay	  comprising	  12	  discriminating	  genes	  (listed	  in	  Figure	  1.3	  B)	  and	  3	  control	  genes	  
(DecisionDx-­‐UM;	  Castle	  Biosciences,	  Friendswood,	  Texas,	  USA).81	  
Based	  on	   recent	  observations	   that	   some	  Class	  1	  patients,	   considered	   to	  have	   low	  
metastatic	   risk,	   developed	   metastases,	   the	   DecisionDx-­‐UM	   assay	   now	   has	   an	  
additional	   discriminatory	   category,	   Class	   1B,	   for	   UMs	   with	   an	   ‘intermediate‘	  
metastatic	  risk.	  
Whether	   GEP	   or	   DNA-­‐based	   chromosomal	   analyses	   are	   more	   accurate	   in	  
determining	  a	  UM	  patient’s	  risk	  of	  developing	  metastasis	  is	  still	  being	  debated	  and	  
clearly	  depends	  on	  the	  sensitivity	  of	  the	  technique	  used	  to	  determine	  chromosome	  
3	   status.	   Estimates	   of	   the	   percentage	   of	   UM	   that	   are	   currently	   not	   accurately	  
stratified	  by	  molecular	  testing	  vary	  from	  5-­‐25%	  of	  tumours.82	  	  
The	  advantages	  and	  limitations	  of	  both	  approaches	  and	  the	  clinical	  implications	  are	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1.1.6 Detection	  and	  treatment	  of	  metastatic	  UM	  
Despite	   the	   advances	   in	   chemotherapy,	   radiotherapy,	   and	   surgical	   treatment	   for	  
metastatic	   UM,	   the	   5-­‐year	   relative	   survival	   rate	   has	   not	   improved	   over	   the	   last	  
three	   decades.83-­‐86	   The	   median	   survival	   from	   the	   time	   of	   the	   development	   of	  
metastatic	  disease	  is	  2	  to	  12	  months	  and	  1-­‐year	  survival	  is	  only	  10-­‐15%.87	  	  
Patients	   typically	   die	   from	   liver	   failure	   because	   of	   parenchymal	   invasion	   of	  
disseminated	  disease	  or	  toxicity	  from	  chemotherapeutic	  agents.87	  In	  recent	  years,	  a	  
number	   of	   targeted	   systemic	   therapies,	   immunotherapies	   and	   loco-­‐regional	  
treatments	   have	   shown	  promising	   results	   in	   preclinical	   settings	   and	   are	   currently	  
being	  investigated	  in	  clinical	  trials	  across	  the	  world.88	  
So	   far,	   however,	   the	   best	   results	   in	   terms	   of	   survival	   have	   been	   seen	   in	   those	  
patients	  with	  localised	  liver	  disease,	  who	  have	  been	  diagnosed	  early	  enough	  to	  be	  
eligible	  for	  surgical	  removal	  by	  liver	  resection.78,	  89,	  90	  Likewise,	  the	  earlier	  detection	  
of	  metastatic	  disease	  may	  potentially	  increase	  the	  effectiveness	  of	  already	  existing	  
therapies.	  	  
1.1.6.1 Conventional	  screening	  tools	  for	  metastatic	  UM	  
The	  mainstream	  of	  systemic	  surveillance	  is	  based	  on	  liver	  imaging.	  Ultrasound	  is	  a	  
cheap,	  non-­‐invasive	  methodology	  that	   is	  widely	  available.	  However,	   it	   is	  operator-­‐
dependent,	   non-­‐specific	   (hence	   leading	   to	   a	   number	   of	   incidental	   false-­‐positive	  
findings),	   and	   difficult	   to	   perform	   in	   patients	   with	   elevated	   body	   mass	   index.	   In	  
Liverpool,	  we	  have	  been	  offering	  liver	  MRI	  to	  HR	  UM	  patients,	  and	  this	  allowed	  for	  
pre-­‐symptomatic	  detection	  of	  liver	  disease	  in	  92%	  of	  patients.78	  However,	  MRI	  has	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a	   significant	   cost	   and	   therefore	   it	   cannot	   be	   proposed	   as	   life-­‐long	   monitoring	  
system	  for	  all	  UM	  patients.	  	  
Liver-­‐function	  tests	  are	  also	  routinely	  used	  to	  detect	  asymptomatic	  liver	  metastasis.	  
In	  UM	  patients	  they	  have	  high	  specificity	  (90-­‐96%)	  but	  a	  very	  low	  sensitivity	  (27%)	  
as	   they	   are	   markers	   of	   liver	   damage,	   released	   when	   a	   significant	   portion	   of	   the	  
organ	  has	  been	  invaded	  by	  cancer	  cells.91	  On	  the	  other	  hand,	  they	  may	  be	  also	  be	  
influenced	   by	   other	   factors	   that	   elevate	   liver	   functions,	   such	   as	   the	   use	   of	  
cholesterol-­‐lowering	  agents.92	  
1.1.6.2 Other	  blood	  biomarkers	  
Based	   on	   the	   experience	   in	   cutaneous	  melanoma	   patients,	   a	   number	   of	   proteins	  
with	   high	   specificity	   for	   cells	   of	   the	  melanoma	   lineage	   have	   also	   been	   tested	   as	  
potential	  blood	  biomarkers	  for	  metastatic	  disease	  in	  UM	  patients.	  (Table	  1.1)	  
Melanoma	   inhibitory	   activity	   (MIA)	   is	   an	   integrin	   ligand	   normally	   expressed	   in	  
cartilage	  and	  aberrantly	  produced	  by	  melanoma	  and,	   to	  a	   lesser	  degree,	  by	  other	  
cancer	  cells.	  It	  is	  implicated	  in	  metastasis	  through	  interaction	  with	  the	  components	  
of	  the	  extracellular	  matrix.93	  MIA	  has	  been	  the	  first	  and	  the	  most	  widely	  melanoma-­‐
specific	  blood	  biomarker	  to	  be	  investigated	  in	  UM.94	  It	  is	  expressed	  in	  primary	  and	  
metastatic	  UM	  tumours.92,	  95	  	  
S100B,	  a	  member	  of	  a	  family	  of	  calcium-­‐binding	  proteins,	  is	  expressed	  by	  a	  variety	  
of	   cells	   and	   is	   implicated	   in	   the	   aberrant	   proliferation	   and	   differentiation	   that	  
characterise	   tumours.96	   In	  contrast	   to	  cutaneous	  melanoma,	  where	  S100B	   is	  used	  
for	   early	   detection	   of	   relapse/metastasis,97	   in	   UM	   patients	   S100B	   serum	   con-­‐
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centration	  is	  not	  of	  prognostic	  value	  and	  does	  not	  correlate	  with	  other	  prognostic	  
factors.98	  
Osteopontin	  (OPN)	  is	  a	  component	  of	  the	  noncollagenous	  bone	  matrix,	  associated	  
with	   aggressive	   tumour	   behaviour	   and	   metastases	   in	   other	   cancers.99	   Increased	  
levels	   of	   OPN	   described	   have	   been	   described	   in	  metastatic	   UM,	   up	   to	   6-­‐months	  
prior	  to	  clinically	  detectable	  liver	  disease.100	  	  
However,	  none	  of	  these	  markers	  alone	  has	  clinical	  value	  as	  a	  prognostic	  marker	  in	  
UM.	  Moreover,	  clinical	  value	  was	  assessed	  for	  the	  most	  part	  by	  comparing	  serum	  
levels	  of	  the	  protein	  of	  interest	  with	  clinical	  and	  pathological	  surrogate	  predictors,	  
and	   not	   actual	   survival.	   They	   may	   have	   utility	   in	   monitoring	   patient	   status,	   as	  
elevation	   on	   serial	   samples	   usually	   indicated	   the	   presence	   of	  metastatic	   disease.	  
However,	  these	  same	  markers	  can	  also	  rise	  in	  presence	  of	  other	  conditions,	  such	  as	  
autoimmune	   conditions	   and	   liver	   alcohol	   disease.	   They	   are	   therefore	   being	  
implemented	   in	   addition	   but	   not	   as	   substitute	   for	   routine	   liver	   function	   tests	   in	  
some	  ocular	  oncology	  centres,	  and	  do	  not	  represent	  the	  standard	  of	  care.101,102	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1.1.7 The	  need	  for	  novel	  biomarkers	  
As	  detailed	  above,	  enormous	  progress	  has	  been	  made	  in	  the	  treatment	  of	  primary	  
UM	   and	   in	   our	   ability	   to	   identify	   those	   patients	   at	   HR	   of	   developing	   metastatic	  
disease.	   However,	   the	   time	   to	   discovery	   of	   clinically	   detectable	   metastases	   can	  
range	  from	  months	  to	  decades	  and	  assessment	  of	  primary	  tissue	  cannot	  be	  used	  to	  
monitor	  tumour	  dissemination	  or	  response	  to	  (a	  potential)	  adjuvant	  therapy.	  Novel	  
biomarkers	   of	   UM	   metastasis	   are	   much	   needed.	   As	   UM	   disseminates	  
haematogenously,	   blood	   biomarkers	   would	   be	   ideal	   because	   they	   could	   be	  
assessed	  serially	  in	  a	  minimally	  invasive	  way.	  
Proteins	  are	  the	  ideal	  biomarkers,	  as	  they	  can	  be	  easily	  assessed	  with	  a	  number	  of	  
non-­‐expensive,	   antibody-­‐based	   techniques	   that	   are	   already	   available	   in	   most	  
pathology	  laboratories.	  The	  most	  widely	  used	  clinical	  biomarkers	  for	  monitoring	  of	  
metastatic	   relapse	   in	   other	   cancer	   types	   are	   indeed	   proteins:	   prostate-­‐specific	  
antigen,	  carcino-­‐embryonic	  antigen,	  alpha-­‐feto-­‐protein,	  etc.103	  
As	  melanoma-­‐specific	  proteins	  derived	  from	  studies	   in	  cutaneous	  melanoma	  have	  
not	   proven	   successful	   for	   UM	   patients,	   the	   aims	   of	   the	   studies	   described	   in	   this	  
thesis	  were	  to	  investigate	  and	  compare	  the	  entire	  complement	  of	  proteins	  present	  
in	  UM	  samples	  at	  HR	  versus	  LR	  of	  developing	  metastatic	  disease	  in	  search	  for	  novel	  
biomarkers	  for	  clinical	  use.	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1.2 Proteomics	  
Proteomics	   is	   the	   large-­‐scale	   study	  of	   the	  entire	   complement	  of	  proteins,	   the	   so-­‐
called	  proteome,	  present	  in	  a	  cell,	  tissue,	  biofluid	  or	  organism	  in	  any	  given	  state.104	  
It	  can	  be	  used	  to	   investigate	  the	  abundance,	  activity,	  modification	  and	  interaction	  
of	  proteins	  in	  a	  given	  tissue.	  	  
1.2.1 Proteomics	  workflow	  
The	   proteomic	   workflow	   involves	   a	   multi-­‐step	   process,	   which	   includes:	   sample	  
acquisition,	   digestion	   into	   peptides,	   fractionation	   of	   the	   peptide	  mixture	   (or	   pre-­‐
fractionation	   of	   the	   proteins,	   depending	   on	   the	   technique	   chosen),	   and	   protein	  
identification	  by	  mass	   spectrometry	   (MS)	  and	  data	  analysis.	   The	  various	  methods	  
differ	   in	   their	   requirements	   for	   sample	   preparation,	   the	   extent	   and	   the	   level	   of	  
sample	  fractionation	  (proteins	  or	  peptides),	  the	  type	  of	  MS	  and	  the	  data	  processing	  
tool	   used.105	   Because	   proteomes	   are	   very	   complex	   mixtures,	   a	   number	   of	  
techniques	  have	  been	  employed	  to	  extract	  them	  prior	  to	  analysis.	  (Figure	  1.4)	  
Protein	   fractionation	   is	   often	   referred	   to	   as	   “top-­‐down	   proteomics”.	   The	   most	  
common	   techniques	   for	   this	   purpose	   are	   affinity	   chromatography	   for	   protein	  
depletion	  and	  gel	  electrophoresis	  for	  protein	  separation.	  
Peptide	   fractionation	   is	   used	   in	   “bottom-­‐up	   proteomics”	   where	   the	   entire	  
proteome	   is	  digested	   into	  peptides,	  which	  are	  then	  fractionated	  and	   identified	  by	  
MS.	  This	  approach	  is	  gel-­‐free	  and	  is	  thought	  to	  introduce	  less	  bias	  into	  a	  biological	  
sample,	   hence	   it	   is	   most	   frequently	   used	   in	   quantitative	   protein	   expression	  
profiling.	  Column	  chromatography	  plays	  a	  major	  role	  in	  this	  phase.	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Figure	  1.4	  Workflow	  and	  techniques	  of	  discovery	  proteomics.	  	  
All	  techniques	  and	  abbreviations	  are	  explained	  in	  the	  text	  of	  this	  chapter.	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1.2.1.1 Protein	  separation	  by	  gel	  electrophoresis	  
Sodium	   dodecyl	   sulphate	   –	   polyacrylamide	   gel	   electrophoresis	   (SDS-­‐PAGE)	  
separates	   proteins	   according	   to	   their	   electrophoretic	  mobility.	   The	   sample	   is	   first	  
denatured	  with	  a	  buffer	  containing	  SDS,	  which	  charges	  each	  protein	  with	  a	  negative	  
charge,	   identical	   per	   unit	   mass,	   so	   that	   the	   electrophoretic	   run	   leads	   to	  
fractionation	  based	  solely	  on	  size.	  Depending	  on	  gel	  size	  and	  resolution,	  SDS-­‐PAGE	  
enables	  separation	  of	  proteins	   into	  about	  10-­‐50	  fractions,	  which	  are	  recovered	  by	  
excision	  and	  digested	  into	  peptides	  for	  sequencing	  by	  MS.	  	  
For	  separation	  of	  complex	  protein	  mixtures	  with	  a	  higher	  resolution,	  SDS-­‐PAGE	  has	  
been	  combined	  with	   isoelectric	   focusing	   (IEF),	  which	   separates	  proteins	  based	  on	  
isoelectric	   points.	   This	   is	   called	   two-­‐dimensional	   (2D)	   gel	   electrophoresis,	   (2-­‐DE)	  
and	  has	  been	  used	   for	   several	  decades	   in	  proteomics.	  The	  use	  of	   immobilised	  pH	  
gradient	  strips	  for	  IEF	  is	  an	  improved	  technique	  that	  allows	  resolution	  of	  hundreds	  
of	  denatured	  proteins	  in	  a	  single	  2-­‐DE	  gel.106	  After	  electrophoresis,	  the	  proteins	  in	  
the	   gel	   are	   stained	   for	   visualisation,	   quantification	   and	   comparison.	   The	   various	  
detection	  methods	  (radioactivity,	  dyes,	  fluorescence,	  and	  silver)	  as	  well	  as	  the	  data	  
analysis	   issues	   that	   must	   be	   taken	   into	   account	   when	   quantitative	   comparative	  
analysis	  of	  2D	  gels	  is	  performed	  have	  been	  critically	  reviewed	  in	  a	  recent	  work.107	  
2-­‐DE	   has	   been	   the	   pre-­‐fractionation	   technique	   of	   choice	   in	   the	   majority	   of	  
proteomic	  studies	  on	  UM	  conducted	  to	  date.108-­‐112	  The	  stain	  and	  detection	  software	  
used	   evolved	   over	   time,	   moving	   from	   Coomassie	   brilliant	   blue	   (CBB)	   for	   global	  
protein	   detection	   to	   fluorescent	   dyes	   with	   higher	   sensitivity	   and	   dynamic	   range,	  
such	   as	   SYPRO	   Ruby	   protein	   stain.	   Relative	   quantification	   of	   protein	   expression	  
levels	   between	   samples	  was	   estimated	  based	  on	   the	   assumption	   that	   the	  optical	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density	   of	   the	   spots	   (OD%)	   had	   to	   be	   proportional	   to	   the	   protein	   concentration.	  
Differences	   in	   apparent	   protein	   expression	   levels	   between	   the	  UM	   samples	  were	  
considered	  potentially	  significant	  when	  matched	  spots	  exhibited	  at	  least	  a	  two-­‐	  fold	  
difference	  in	  their	  averaged	  OD%.	  	  
A	   more	   reproducible	   method	   of	   relative	   protein	   quantitation	   from	   two	   or	   more	  
samples	   is	  2D	   fluorescence	  difference	  gel	  electrophoresis	   (DIGE),	  a	  version	  of	  2D-­‐
PAGE	  where	  the	  proteins	  of	  each	  sample	  are	  labelled	  with	  a	  different	  fluorophore	  
prior	   to	   electrophoresis.113	   Gels	   are	   scanned	   at	   wavelengths	   unique	   to	   each	  
fluorescent	   label	  and	   the	   images	  are	  analysed	   for	  differences	   in	  protein	  patterns,	  
such	   as	   spot	   density	   or	  mass	   shift.	   As	   DIGE	   is	   extremely	   sensitive,	   however,	   the	  
amount	  of	  proteins	  present	  in	  the	  spots	  to	  be	  excised	  is	  sometime	  not	  sufficient	  for	  
downstream	  MS	  analysis,	  hence	  limiting	  the	  capability	  for	  protein	  identification.	  
1.2.1.2 Protein	  identification	  
MS	   is	   the	   key	   analytical	   technique	   in	   proteomics	   for	   the	   identification	   and,	  
increasingly,	   for	   the	  quantification	  of	  proteins.	   The	  principle	  of	  MS	   is	   to	  measure	  
the	  mass	  (m)	  to	  charge	  (z)	  ratio	  of	  ions	  in	  the	  gas	  phase,	  hence	  the	  peptides	  need	  to	  
be	  first	  transferred	  into	  the	  gas	  phase	  and	  ionised.	  	  
The	   two	   relevant	   techniques	   for	   ionization	   are	   matrix	   assisted	   laser	  
desorption/ionization	   (MALDI)114	   and	   electrospray	   ionization	   (ESI).115	   For	   MALDI,	  
the	  analyte	  is	  dissolved	  and	  co-­‐crystallised	  with	  a	  matrix	  on	  a	  probe	  surface,	  which	  
is	  then	  irradiated	  by	  UV	  laser	  pulses.	  The	  laser	  evaporates	  and	  converts	  the	  analyte	  
into	  gas	  phase	  at	  the	  ion	  source.	  The	  ionised	  analyte	  is	  then	  separated	  by	  the	  time-­‐
of-­‐flight	  (TOF)	  analyzer,	  most	  commonly	  employed	  in	  MALDI-­‐MS.	  The	  m/z	  value	  of	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peptides	  is	  measured	  by	  recording	  the	  time	  required	  for	  ions	  to	  travel	  over	  a	  fixed	  
distance	  inside	  the	  mass	  analyser.	  In	  ESI,	  the	  peptide	  mixture	  is	  dissolved	  in	  a	  liquid	  
solvent	   system	   instead	  of	   the	  matrix.	  Highly	   charged	  analyte	  droplets	   from	  a	   fine	  
spray	  outlet	  are	  ionised	  at	  atmospheric	  pressure	  in	  the	  presence	  of	  a	  strong	  electric	  
field,	   to	   generate	   a	   series	   of	   charged	   gas-­‐phase	   ions.	   The	   charged	   ions	   are	   then	  
emitted	   and	   focused	   into	   the	   high-­‐vacuum	   region	   of	   the	   mass	   analyser,	   which	  
records	  the	  various	  charge	  states	  of	  the	  molecule	  separated	  according	  to	  their	  m/z	  
ratios.	   There	   are	   a	   number	   of	  mass	   analysers	   in	   addition	   to	   the	   above-­‐described	  
TOF:	   e.g.	   quadrupole,	   ion	   trap,	   orbitrap,	   and	   fourier	   transform	   cyclotron	   ion	  
resonance	   (FT-­‐ICR).	   Each	   one	   works	   differently,	   having	   their	   own	   strengths	   and	  
weaknesses	  and	  can	  be	  used	  alone	  or	  in	  combination.116	  
The	  mass	  spectra	  can	  be	  directly	  compared	  with	  protein	  databases	  for	  matching	  the	  
molecular	   weights	   using	   appropriated	   scoring	   algorithm	   (peptide	   mass	  
fingerprinting).117	  This	  technique,	  however,	  is	  limited	  by	  the	  database	  (as	  it	  should	  
contain	  prior	  information	  on	  the	  protein	  for	  matching)	  and	  by	  the	  complexity	  of	  the	  
protein	  mixture	  (as	  it	  becomes	  difficult	  to	  select	  the	  right	  peptide	  mass	  from	  a	  lot	  
of	  peaks).118	  Tandem	  mass	  spectrometry	  (MS/MS)	   involves	  two	  consecutive	  steps:	  
peptide	   mass	   determination	   and	   generation	   of	   partial	   amino	   acid	   sequence	  
information	   for	   a	   particular	   peptide	   based	   on	   further	   fragmentation.	   The	   m/z	  
values	  of	  the	  fragments	  are	  then	  recorded	  in	  the	  tandem	  mass	  spectrum.	  Tandem	  
MS	  can	  be	  done	  by	  two	  separate	  analysers	  (e.g.	  TOF-­‐TOF)	  or	  inside	  the	  same	  mass	  
analyser	  (e.g.	  ion	  trap).	  
To	   enhance	   detection	   of	   proteins	   from	   very	   complex	   mixtures,	   frequently	   used	  
platforms	  are	  the	  LC-­‐MS/MS	  instruments,	  where	  ion-­‐pair	  reversed	  chromatography	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or	   nano	  high	  performance	   liquid	   chromatography	   (HPLC)	   is	   used	  prior	   to	   tandem	  
MS.119	   Advances	   in	   LC-­‐MS/MS	   have	   greatly	   improved	   the	   dynamic	   range	   and	  
sensitivity	   for	   analysis	   of	   complex	   protein	   mixtures.120	   Large-­‐scale	   proteome	  
profiling	   has	   been	   verified	   for	   different	   organisms,	   as	  well	   as	  mammalian	   tissues	  
and	  cell	  lines	  by	  using	  multi-­‐dimensional	  LC-­‐MS/MS.121	  	  
1.2.1.3 Gel-­‐free	  quantitative	  proteomics	  
Quantitative	   proteomics	   allows	   for	   accurate	   measurements	   of	   quantitative	  
differences	   between	   two	   analytes,	   for	   example	   healthy	   and	   disease,	   and	   has	  
therefore	   been	   largely	   applied	   for	   biomarker	   discovery.122	   There	   are	   two	   main	  
methods:	   incorporation	  of	  metabolic	  or	  chemical	   labels,	  and	   label-­‐free	  analysis	  of	  
MS/MS	  spectra.	  
Metabolic	  labelling	  requires	  incorporation	  into	  the	  cell	  of	  specific	  amino	  acids	  with	  
“heavy”	  isotypes	  (such	  as	  13C	  and	  15N),	  which	  can	  then	  be	  distinguished	  from	  their	  
“light”	   (normal)	  counterpart	  by	  MS,	  and	  quantified.	  This	   technique,	  named	  Stable	  
Isotope	   Labelling	   by	   Amino	   acids	   in	   Cell	   cultures	   (SILAC),	   reflects	   the	   immediate	  
metabolic	   state	   of	   the	   cells	   and	   is	   regarded	   as	   an	   extremely	   accurate	   proteomic	  
technique.123	  However,	   it	  requires	  that	  cells	  be	  grown	  in	  special	  culture	  media	  for	  
five	  to	  ten	  passages	  to	  ensure	  complete	  incorporation	  of	  labels,	  and	  it	  is	  therefore	  
only	  suitable	  for	  use	  in	  stable	  cell	  lines.	  
Chemical	  labelling	  is,	  on	  the	  other	  hand,	  suitable	  for	  use	  in	  all	  types	  of	  analytes,	  as	  
it	   relies	   on	   biochemical	   reactions	   to	   bind	   specific	   “tags”	   to	   peptides	   post	   sample	  
processing.	   Isobaric	   Tag	   for	   Relative	   and	   Absolute	   Quantification	   (iTRAQ)	   is	   the	  
most	   widely	   used	   technique	   for	   biological	   samples,	   as	   it	   allows	   for	   parallel	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identification	  and	  quantification	  of	  peptides	  from	  up	  to	  8	  different	  samples	   in	  the	  
same	  MS	   run.	   As	   detailed	   in	   Chapter	   2,	   iTRAQ	  was	   used	   to	   compare	   the	   protein	  
profile	  of	  20	  primary	  UM	  specimens	  at	  HR	  or	  LR	  of	  developing	  metastatic	  disease.	  	  
Complex	   sample	   preparation,	   need	   for	   greater	   sample	   concentration,	   and	  
incomplete	   labelling	   are	   potential	   limitations	   of	   label-­‐based	   quantification,	  
therefore	   label-­‐free	  proteomic	  techniques	  have	  been	  developed	  based	  on	  the	  use	  
of	   technologically	   advanced	   MS	   and	   bioinformatic	   platforms.124	   Approaches	   of	  
label-­‐free	  quantitative	  proteomics	  can	  be	  divided	  into	  two	  different	  quantification	  
strategies.	  In	  the	  spectral-­‐counting	  approach,	  peptide	  and	  protein	  abundances	  can	  
be	   estimated	   based	   on	   the	   number	   of	   acquired	   peptide	   spectrum	  matches.	   This	  
quantification	  method	  has	  been	  widely	  used	  but	  remains	  controversial,	  as	   it	  relies	  
on	  a	  simple	  counting	  of	  acquired	  MS/MS	  spectra,	  rather	  than	  on	  measuring	  physical	  
data.	   In	  the	   ion-­‐intensity-­‐based	  approach,	   the	  changes	  of	  peptide	  abundances	  are	  
determined	  by	  measuring	   and	   comparing	   the	   chromatographic	   peak	   areas	   of	   the	  
corresponding	  peptides.	  The	  areas	  of	  chromatographic	  peaks	  have	  been	  shown	  to	  
correlate	   linearly	   in	  a	  wide	   range	  with	   the	  protein	  abundance,	  which	  makes	   their	  
measurement	  feasible	  for	  quantitative	  studies.125	  
iTRAQ	   and	   label-­‐free	   approaches	   have	   been	   compared	   by	   Patel	   et	   al.126	   to	  
characterise	  the	  proteome	  of	  a	  bacterium,	  showing	  good	  agreement,	  with	  respect	  
to	  protein	  identification	  and	  relative	  quantification.	  The	  label-­‐free	  experiment	  did,	  
however,	   have	   advantages	   in	   terms	   of	   sample	   requirement,	   sample	   preparation	  
and	  instrumental	  time	  requirements.	  Sample	  requirement	  and	  preparation	  are	  very	  
important	  when	  looking	  at	  low	  protein	  abundance,	  such	  as	  for	  secretome	  analysis.	  
As	   discussed	   in	   Chapter	   3,	   an	   ion-­‐intensity-­‐based	   label-­‐free	   proteomic	   workflow	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was	   successfully	   developed	   to	   analyse	   the	   secretome	   of	   short	   term	   primary	   UM	  
cells	  in	  culture.	  	  
1.2.1.4 Data	  analysis	  
Protein	   identification	   traditionally	   relies	   on	   complex	   algorithms	   that	   match	   the	  
information	   contained	   in	   mass	   spectra	   against	   a	   database	   of	   theoretical	   or	  
previously	   identified	   spectra.	   Label-­‐free	   technologies	   have	   been	   made	   possible	  
thanks	   to	   the	   development	   of	   sophisticated	   software	   for	   peptide	   identification.	  
Algorithms,	   however,	   can	   generate	   both	   false-­‐positive	   and	   false-­‐negative	  
assignments,	  which	  are	  influenced	  by	  the	  stringency	  of	  spectra	  to	  sequence	  criteria.	  
Discerning	   a	   true	  match	   from	  a	   false	  match	   is	   critical	   in	   proteomic	   data	   analysis.	  
Discussing	  this,	  however,	  is	  behind	  the	  scope	  of	  this	  thesis.	  The	  most	  common	  tools	  
for	   MS/MS	   based	   peptide	   identification	   and	   data	   analysis	   have	   been	  
comprehensively	  reviewed	  elsewhere.127	  
1.2.1.5 Validation	  
Because	   of	   the	   complexity	   of	   the	   proteomic	   workflow	   and	   data	   analysis,	   many	  
argue	   that	   it	   is	   essential	   to	   validate	   the	   identified	   candidate	   proteins	   using	  
independent	   techniques,	   such	   as	   Western	   Blot	   or	   ELISA.	   Using	   an	   antibody-­‐
dependent	  method	  of	  validation,	  however,	  relies	  on	  extensive	  optimisation	  of	  the	  
methodology,	   and	   can	   produce	   false	   negatives	   (e.g.	   related	   to	   poor	   antibody-­‐
antigen	   binding).	   For	   this	   reason,	   targeted	   proteomics	   techniques	   have	   been	  
developed,	  that	  are	  highly	  sensitive,	  specific	  and	  high	  throughput.	  Selected	  reaction	  
monitoring	   (SRM)	   and	   multiple	   reaction	   monitoring	   (MRM)	   are	   MS-­‐based	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technologies	  that	  can	  detect	  low-­‐abundance	  molecules	  in	  complex	  mixtures	  by	  only	  
recording	  the	  ions	  of	  interest	  corresponding	  to	  preselected	  proteins.128	  	  
In	   summary,	   proteomics	   offers	   a	   number	   of	   powerful	   tools	   to	   investigate	  
similarities	   and	   peculiarities	   of	   biological	   samples,	   potentially	   leading	   to	   the	  
identification	   of	   specific	   proteins	   that	   could	   be	   used	   as	   clinical	   biomarker.	  
Experiments	   need	   to	   be	   carefully	   designed	   and	   the	   most	   suitable	   proteomic	  
approach	   chosen	   by	   taking	   into	   consideration	   the	   complexity	   of	   the	   tissue	   of	  
interest,	   the	   amount	   and	   concentration	   of	   proteins	   it	   contains,	   the	   degree	   of	  
biological	   variability,	   etc.105	   Moreover,	   potential	   biomarkers	   then	   need	   to	   be	  
validated	   in	   a	   large	   cohort	   of	   independent	   clinical	   samples,	   making	   discovery	  
proteomic	  just	  the	  first	  step	  of	  a	  long	  path	  towards	  clinical	  benefit	  for	  patients.	  	  	  
	  
1.2.2 Previous	  proteomics	  studies	  in	  UM	  
Proteomic	  technologies	  have	  been	  largely	  used	  to	  study	  different	  ocular	  structures	  
and	  diseases	  (as	  comprehensively	  reviewed	  here	  by	  Jay	  and	  Gillies129).	  UM	  has	  been	  
extensively	  investigated	  at	  the	  DNA	  and	  RNA	  level;	  however,	  only	  a	  limited	  number	  
of	  proteomics	  studies	  have	  been	  published	  to	  date	  (Table	  1.2).	  
The	  first	  paper	  was	  published	  in	  2003	  by	  Missotten	  et	  al.130	  who	  compared	  the	  MS	  
of	   aqueous	   humour	   from	   24	   UM	   patients	   with	   24	   controls	   using	   a	   strong	   anion	  
exchange	   surface	   protein	   chip	   array	   and	   surface-­‐enhanced	   laser	   desorption	  
ionization	   (SELDI)	   TOF	   MS.	   A	   large	   number	   of	   samples,	   especially	   among	   the	  
controls,	  could	  not	  be	  assessed	  because	  of	  low	  protein	  content.	  Nevertheless,	  two	  
proteins	   were	   identified	   that	   could	   distinguish	   between	   UM	   and	   control	   eyes	   in	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89%	   of	   cases.	   Although	   this	   study	   has	   not	   been	   translated	   clinically	   (the	   two	  
proteins	  have	   yet	   to	  be	  named),	   it	   suggested	   that	  proteomic	  evaluation	   could	  be	  
relevant	  to	  find	  diagnostic	  markers	  for	  UM	  patients.	  	  
In	  2005,	  Pardo	  et	  al.	  performed	  the	  first	  global	  proteome	  analysis	  of	  UM.108	  Using	  2-­‐
DE	  and	  LC-­‐MS/MS	  with	  a	  quadrupole	  TOF	  they	  were	  able	  to	   identify	  683	  proteins	  
from	  a	  primary	  UM	  cell	   culture	   (UM-­‐A).	   Sixty-­‐nine	   (18%)	  of	   the	  683	  proteins	  had	  
been	   previously	   described	   in	   cancer-­‐related	   processes,	   such	   as	   invasion	   and	  
metastasis,	   oncogenesis,	   drug	   resistance,	   invasion,	   etc.	   Interestingly,	   the	  
melanoma-­‐associated	   antigen	   MUC18,	   which	   has	   been	   recently	   used	   to	  
characterise	   CTC	   in	   UM	   patients	   (as	   discussed	   in	   Chapter	   4),	   was	   amongst	   the	  
proteins	  detected	  in	  this	  original	  work.	  	  
The	  following	  year,	  the	  same	  group	  published	  a	  follow-­‐up	  study	  where	  they	  focused	  
on	   the	   characterisation	   of	   the	   invasion	   phenotype	   of	   UM	   tumour	   cells.109	   By	  
performing	  differential	  2-­‐DE,	   they	  compared	   the	  proteome	  of	  primary	  UM-­‐A	  cells	  
versus	  that	  of	   its	  derived,	  highly	   invasive,	  cell	   line	  UM-­‐A	  >7.	  New	  nuclear	  proteins	  
were	   identified	   in	   the	   invasive	   cell	   line,	   such	   as	   BRCA-­‐1	   and	   high	  mobility	   group	  
protein	  HMG-­‐1.	  The	  authors	  validated	  by	  Western	  Blot	  a	  selection	  of	  novel	  proteins	  
in	  5	  different	  UM	  cell	   lines,	   showing	  a	  possible	  correlation	  of	  MUC18	  and	  HMG-­‐1	  
expression	   with	   UM	   invasiveness.	   They	   also	   showed	   the	   overexpression	   of	   the	  
oncoprotein	  DJ-­‐1,	  which	  had	  also	  been	   identified	   in	   their	  previous	  study,	  but	  was	  
shown	   here	   to	   be	   secreted.	  Moreover,	   they	   indicated	   DJ-­‐1	   as	   a	   potential	   serum	  
biomarker	   of	   UM.	   A	   later	   study	   from	   the	   same	   group	   has	   indeed	   shown	   that	  
elevated	   serum	   levels	   of	   DJ-­‐1	   are	   associated	   with	   risks	   factor	   for	   malignant	  
transformation	  of	  choroidal	  naevi.133	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Pardo	  et	  al.	  were	  also	  the	  first	  to	  perform	  proteomic	  analysis	  on	  the	  secretome	  of	  
UM	  cell	   lines,	   identifying	  cathepsin	  D,	  syntenin	  and	  gp100	  as	  potential	  biomarkers	  
in	   UM.110	   As	   discussed	   in	   Chapter	   3,	   these	   studies	   formed	   the	   basis	   for	   the	  
development	  of	  our	  work	  on	  UM	  secretome.	  
In	  2006,	  Zuidervaart	  et	  al.111	  performed	  differential	  proteomic	  analyses	  of	  UM	  cell	  
lines	  by	  2-­‐DE	  and	  MALDI-­‐TOF/TOF.	  They	  compared	  Mel270,	  which	  is	  a	  primary	  UM	  
cell	   line,	   with	   two	   cell	   lines	   derived	   from	   liver	   metastases	   in	   the	   same	   patient	  
(OMM	   1.3	   and	   OMM	   1.5).	   They	   could	   identify	   only	   24	   differentially	   expressed	  
proteins,	  but	  amongst	  these	  were	  a	  number	  of	  novel	  proteins	  expressed	  only	  by	  the	  
metastatic	   cell	   lines,	   such	   as	   heat-­‐shock	   αβ-­‐crystallin,	   cofilin,	   and	   heat	   shock	  
protein	   27	   (HSP27).	   Interestingly,	   differential	   proteomic	   analysis	   of	   primary	   UM	  
tissues	  performed	  by	  our	  group	  has	  also	  identified	  HSP27	  as	  differentially	  expressed	  
between	   tumours	   at	   a	   HR	   versus	   LR	   of	   developing	   metastatic	   disease.112	   Please	  
refer	   to	   Chapter	   2	   for	   further	   details	   on	   this	   study,	   as	   it	   posed	   the	   basis	   for	   the	  
current	  proteomic	  analysis	  of	  UM	  tissue	  samples	  described	  in	  that	  chapter.	  
More	   recently,	   proteomic	   analyses	   of	   nine	   primary	   UM	   tumour	   samples	   from	  
patients	  who	  developed	  metastatic	  disease	  versus	  16	  primary	  UM	  tumour	  samples	  
from	  patients	  who	  did	  not	  develop	  metastatic	  disease,	  with	  a	  minimum	  of	  7	  years	  
follow-­‐up	  was	  performed	  using	  2D	  DIGE.137	  Fourteen	  protein	  spots	  were	  identified	  
as	   being	   differentially	   expressed,	   and	   those	   proteins	   were	   then	   identified	   by	   LC-­‐
MS/MS.	  Nine	   proteins	  were	   upregulated	   and	   four	   downregulated	   in	   primary	  UM	  
tissue	  from	  patients	  who	  developed	  metastasis.	  IHC	  validation	  on	  a	  small	  cohort	  of	  
FFPE	   UM	   samples	   showed	   correlation	  with	   the	   2D	   DIGE	   results	   for	   two	   of	   these	  
proteins:	  fatty	  acid-­‐binding	  protein	  3	  (FABP3)	  and	  trioseposphate	  isomerase	  (TPI1).	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Their	  functional	  role	  was	  tested	  by	  siRNA	  knockdown	  in	  the	  92.1	  UM	  cell	  line,	  which	  
caused	  reduction	  in	  invasion	  and	  migration.	  In	  a	  recent	  review	  article	  published	  by	  
the	  same	  group,138	   the	  authors	  mention	  unpublished	  results	   from	  a	   label-­‐free	  LC-­‐
MS/MS	  analysis	  of	  eight	  primary	  UM	  tumour	  samples	  from	  patients	  who	  developed	  
metastatic	  disease	  versus	  eight	  primary	  UM	  tumour	  samples	  from	  patients	  who	  did	  
not.	  Interestingly,	  FABP3,	  TPI1	  and	  HSP27	  were	  also	  identified	  as	  being	  differentially	  
expressed	  here,	  in	  keeping	  with	  previous	  studies.	  	  
Finally,	   two	   independent	   studies	   published	   in	   2013	   used	   SILAC	   and	   LC-­‐MS/MS	   to	  
study	   the	   change	   in	   protein	   expression	   following	   irradiation	   in	   the	   92.1	   UM	   cell	  
line.139,	   140	   Their	   aim,	   however,	   was	   to	   develop	   novel	   insight	   to	   enhance	   the	  
sensitivity	   of	   primary	   UM	   cells	   to	   radiotherapy,	   which	   is	   outside	   the	   scope	   this	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Table	  1.2	  Summary	  of	  previous	  proteomic	  studies	  in	  UM	  
Authors	  
(year)	  
Samples	   Proteomics	  
technique	  
Main	  findings	  
Missotten	   et	   al.	  
(2003)	  
Aqueous	  humour	  from	  
24	  UM	  patients	  and	  24	  
healthy	  controls	  	  
SELDI-­‐TOF-­‐MS	   Two	   proteins	   discriminating	  
between	  UM	  and	  control	  eyes	  
Pardo	   et	   al.	  
(2005)	  
Primary	   UM	   cell	  
culture	  (UM-­‐A)	  
2-­‐DE	  LC-­‐MS/MS	   683	   proteins	   identified,	   96%	   of	  
which	  novel	  in	  UM	  
Pardo	   et	   al.	  
(2006)	  
UM-­‐A	   versus	   its	  
derived	  aggressive	  cell	  
line	  (UM-­‐A>7)	  
Differential	  2-­‐DE	  	  
LC-­‐MS/MS	  
HMG-­‐1	   and	  MUC18	   in	   aggressive	  
UM.	   DJ-­‐1	   as	   potential	   serum	  
marker	  
Zuidervaart	   et	  
al.	  (2006)	  
Primary	   (Mel270)	  
versus	   metastatic	  
(OMM	   1.3,	   OMM	   1.5)	  
UM	  cell	  lines	  
Differential	  2-­‐DE	  	  
LC-­‐MS/MS	  
24	   differentially	   expressed	  
proteins.	  Upregulation	   of	  HSP-­‐27,	  
aB-­‐crystallin	   and	   cofilin	   in	  
metastatic	  cell	  lines	  
Pardo	   et	   al.	  
(2007)	  
Secretome	   of	   5	   UM	  
cell	   lines	   (UM-­‐A,	  
SP6.5,	   UW-­‐1,	   92.1,	  
OCM-­‐1);	   serum	   from	  
11	  UM	  patients	   and	   8	  
controls	  
PAGE	  LC-­‐MS/MS	  
of	  secretomes;	  	  
Differential	  2-­‐DE	  	  
	  LC-­‐MS/MS	   of	  
depleted	  sera	  
Secretome	   analysis	   as	   promising	  
tool	   for	   biomarker	   discovery	   in	  
UM.	   Syntenin,	   Cathepsin	   D,	   and	  
gp100	  as	  potential	  candidates	  
Coupland	  et	  al.	  
(2010)	  
UM	  tissue:	  	  
3	  D3	  versus	  4	  M3	  
Differential	  2-­‐DE	  	  
LC-­‐MS/MS	  
Downregulation	   of	   HSP-­‐27	   in	   M3	  
UM	  	  
Linge	  et	  al.	  
(2012)	  
UM	  tissue:	  	  
16	   non-­‐metastasising	  
versus	  9	  metastasising	  	  
2D-­‐DIGE	  	  
LC-­‐MS/MS	  
Upregulation	  of	  FABP3	  and	  TPI1	  in	  
metastasising	  primary	  UM	  
Wang	  et	  al.	  
(2013)	  
UM	   Cell	   line	   (92.1)	  
after	  15	  h	  and	  48	  h	  of	  





regulation	   of	   cell	   cycle-­‐	   and	  
immunity-­‐related	  proteins	  
Yang	  et	  al.	  
(2013)	  
UM	   Cell	   line	   (92.1)	  
after	   15	   h	   of	   10	   Gy	  




Changes	  in	  metabolism	  and	  signal	  
transduction	   protein	   pathways	   in	  
irradiated	  UM	  
Ramasamy	  et	  al.	  
(2014)	  
UM	  tissue:	  
8	   non-­‐metastasising	  
versus	  8	  metastasising	  
Label-­‐free	  	  
LC-­‐MS/MS	  
Upregulation	   of	   DJ-­‐1,	   syntenin-­‐1,	  
TPI1,	  FABP3,	  PHB2,	  PFKM,	  and	  
downregulation	   of	   HSP-­‐27	   in	  
metastasising	  primary	  UM	  	  
Adapted	  in	  part	  from	  Ramasamy	  et	  al.138	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1.3 Scope	  and	  outline	  of	  this	  thesis	  
The	  aims	  of	  this	  thesis	  were	  to	  identify	  novel	  biomarkers	  for	  the	  early	  detection	  of	  
metastatic	  disease	  in	  UM	  patients	  and	  to	  generate	  proteomics	  data	  to	  increase	  the	  
understanding	  of	  the	  biology	  of	  this	  disease.	  
The	  objectives	  of	  this	  work	  were:	  
• To	  perform	  comparative	  quantitative	  proteomic	  analyses	  of	  primary	  UM	  tissues	  
with	  different	  metastatic	  risk	  
• To	   perform	   comparative	   quantitative	   proteomic	   analyses	   of	   the	   conditioned	  
medium	  (secretome)	  from	  primary	  UM	  cells	  and	  normal	  choroidal	  melanocytes	  
in	  short-­‐term	  culture	  
• To	  investigate	  the	  role	  of	  CTC	  as	  an	  alternative	  biomarker	  for	  early	  detection	  of	  
metastatic	  disease	  in	  UM	  patients	  
The	   aims	   and	   objectives	   are	   described	   in	   further	   details	   below,	   alongside	   a	   brief	  
explanation	  of	  the	  content	  of	  each	  chapter	  of	  this	  thesis.	  	  
In	  Chapter	  2	  we	  compared	  the	  protein	  profile	  of	  primary	  UM	  tissue	  samples	  from	  
patients	  at	  HR	  versus	  LR	  of	  developing	  metastatic	  disease	  using	  iTRAQ	  labelling	  and	  
MS.	  A	  selection	  of	  differentially	  expressed	  proteins	  was	  then	  validated	  by	  IHC	  in	  an	  
independent	  cohort	  of	  FFPE	  samples.	  To	  enhance	  our	  chance	   to	   identify	   secreted	  
proteins,	  we	  performed	  quantitative	  label-­‐free	  MS	  to	  compare	  the	  secretome	  from	  
short-­‐term	   primary	   UM	   cells	   in	   culture,	   as	   well	   as	   normal	   melanocytes.	  
Bioinformatic	   analysis	  was	   then	   applied	   to	   identify	   a	   panel	   a	   proteins	   that	   could	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differentiate	  between	  patients	  at	  HR	  versus	  LR	  of	  developing	  metastatic	  disease,	  as	  
detailed	  in	  Chapter	  3.	  
Simultaneously,	   we	   investigated	   CTC	   as	   an	   alternative	   biomarker	   of	   metastatic	  
disease	  in	  UM	  patients.	  In	  collaboration	  with	  the	  Paterson	  Institute	  in	  Manchester	  
(now	   the	  Manchester	   CRUK	   Institute),	   we	   conducted	   a	   pilot	   study	   to	   assess	   the	  
value	  of	   the	  CellSearch®	  platform	   for	   CTC	  detection	   in	   patients	  with	   primary	   and	  
metastatic	  UM.	  As	  discussed	   in	  Chapter	  4,	  we	  also	   investigated	   the	  expression	  of	  
the	  antigens	  used	  for	  CTC	  capture	  and	  detection	  in	  UM	  cell	  lines	  grown	  in	  different	  
conditions.	  
While	   conducting	   the	   above-­‐mentioned	   study,	   we	   realised	   that	   some	   prognostic	  
UM	  biopsies	  were	  unsuccessful,	  despite	  great	  efforts	  of	  the	  surgical	  and	  pathology	  
teams,	   but	   obviously	   to	   the	   disappointment	   of	   the	   patient.	   We	   therefore	  
performed	   a	   large	   audit,	   reviewing	   the	   whole	   biopsy	   process	   (from	   surgical	  
technique,	   to	   sample	   handling	   and	   processing).	   As	   a	   consequence,	   a	   change	   in	  
practice	   was	   adopted,	   with	   a	   successful	   increase	   in	   the	   success	   rate.	   This	   is	  
described	  in	  Chapter	  5.	  
Finally,	   in	  Chapter	  6	  we	  summarise	  the	  main	  findings	  and	  limitations	  of	  this	  work,	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Chapter	  2 	  
Quantitative	  proteomic	  analysis	  of	  uveal	  melanoma	  tumour	  
tissue	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2.1 Introduction	  
During	  the	  last	  decade,	  enormous	  progress	  has	  been	  made	  in	  our	  understanding	  of	  
the	   molecular	   features	   of	   UM	   thanks	   to	   numerous	   genomic	   and	   transcriptomic	  
studies.141	  Such	  studies	  have	  identified	  characteristic	  DNA	  copy	  number	  alterations	  
and	  mutations,	  and	  RNA	  expression	  profiles	  that	  strongly	  correlated	  with	  prognosis,	  
but	   the	   search	   for	   tumour	   biomarkers	   and	   therapeutic	   targets	   is	   still	   at	   a	  
preliminary	   stage.	   Proteomics	   is	   a	   complementary	   technique	   to	   genetic	   analyses	  
that	  has	  been	  heralded	  as	  a	  novel	  tool	  for	  identifying	  new	  and	  specific	  biomarkers	  
in	   many	   cancer	   types.142	   In	   UM,	   only	   a	   limited	   number	   of	   studies	   (reviewed	   in	  
Chapter	   1)	   have	   been	   published	   to	   date	   using	   proteomics	   technologies	   and	   the	  
large	  majority	  of	  these	  have	  been	  performed	  on	  cells	  in	  culture.108-­‐112,	  130,	  137,	  139,	  140,	  
143	  
The	   first	   proteomic	   analysis	   of	  UM	   tissue	  was	  published	  by	  our	   group	   comparing	  
the	  protein	  expression	  profile	  of	  frozen	  UM	  samples,	  three	  with	  D3	  and	  four	  with	  
M3,	   as	   determined	   by	   FISH	   analysis.112	   The	   samples	   were	   subjected	   to	   high-­‐
resolution,	   two-­‐dimensional	   (2D)	   gel	   electrophoresis	   for	   protein	   fractionation,	  
followed	  by	   silver	   staining	   and	   densitometric	   image	   analysis.	   Four	  well-­‐separated	  
and	   clearly	   focused	   protein	   spots	   showing	   at	   least	   1.5	   fold	   change	   in	   expression	  
between	   the	   two	   metastatic	   risk	   groups	   were	   excised	   and	   subjected	   to	   in-­‐gel	  
digestion.	  Nine	  proteins	  were	   identified	  by	  nano-­‐LC-­‐MS/MS,	   three	  of	  which	  could	  
be	   detected	   by	   Western	   Blot:	   vimentin,	   HSP-­‐27	   and	   pyruvate	   dehydrogenase	   β.	  
Immunohistochemical	   studies	   on	   an	   independent	   cohort	   of	   41	   formalin-­‐fixed	  
paraffin	   embedded	   (FFPE)	   UM	   specimens	   demonstrated	   a	   statistically	   significant	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association	  between	  chromosome	  3	  loss	  and	  downregulation	  of	  HSP-­‐27,	  raising	  the	  
possibility	   of	   using	   such	   immunohistochemical	   staining	   as	   a	   surrogate	   prognostic	  
indicator	  where	  genetic	  analyses	  were	  not	  possible.	   	  The	  clinical	  usefulness	  of	  the	  
immunohistochemical	  assessment	  of	  HSP-­‐27	  protein	  expression	  has	  been	  validated	  
in	   a	   further	   study	   on	   a	   larger	   series,	   showing	   that	   a	   low	   HSP-­‐27	   expression	  
correlated	   with	   monosomy	   3	   and	   with	   increased	   predicted	   mortality.	   When	  
assessed	   together	  with	  other	  clinical	  and	  pathological	   variables,	   the	  HSP-­‐27	  score	  
was	   found	   to	   enhance	   estimation	   of	   survival	   probability.144	   HSP-­‐27	  
immunohistochemistry	  is	  routinely	  used	  in	  our	  ocular	  pathology	  service.	  
These	  encouraging	  results	  constituted	  the	  basis	  of	  this	  study,	  to	  pursue	  the	  chase	  
for	  biomarkers	  of	  metastatic	  disease	  in	  UM	  patients	  using	  more	  advanced	  discovery	  
proteomics	   techniques	   on	   a	   larger	   number	   of	   samples.	   It	   is	   indeed	   known	   that	  
proteomics	   results	   depend	   largely	   on	   the	   quality	   of	   the	   samples	   and	   on	   the	  
proteomic	   methodologies	   used.104,	   145	   For	   example,	   2D-­‐gel-­‐based	   fractionation	  
techniques	   can	   introduce	   quantitative	   bias	   into	   a	   biological	   sample,	   as	   large	  
proteins	  and	  integral	  membrane	  proteins	  are	  difficult	  to	  display	  on	  2D	  gels	  because	  
they	  become	  insoluble	  at	  pH	  values	  close	  to	  their	  isoelectric	  points	  and	  precipitate	  
out,	  while	  co-­‐migration	  of	  multiple	  proteins	  poses	  problems	  for	  spot	  boundary.146	  
Other	   problems	   include	   consistency	   when	   quantifying	   lower	   intensity	   proteins,	  
which	  is	  limited	  by	  the	  sensitivity	  of	  the	  stain	  and	  of	  the	  sample	  acquisition	  device,	  
as	   well	   as	   by	   the	   amount	   of	   sample	   that	   can	   be	   loaded	   onto	   gels	   without	  
compromising	   spot	   resolution.147	   We	   therefore	   decided	   to	   adopt	   a	   “shotgun	  
proteomics”	   approach,	  where	   the	   entire	   proteome	   is	   digested	   into	   peptides	   that	  
are	  subsequently	  fractionated	  and	  identified	  by	  MS.	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2.1.1 iTRAQ	  
To	   be	   able	   to	   quantify	   the	   relative	   abundance	   of	   the	   same	   peptide	   in	   different	  
samples,	   we	   applied	   the	   isobaric	   tags	   for	   relative	   and	   absolute	   quantification	  
(iTRAQ)	   labelling	   method,	   which	   had	   been	   successfully	   used	   in	   the	   discovery	   of	  
biomarkers	  from	  a	  variety	  of	  clinical	  specimens,	  including	  plasma.148-­‐151	  	  
The	  iTRAQ	  method	  allows	  for	  the	  differential	  labelling	  of	  peptides	  from	  up	  to	  eight	  
different	  biological	  samples.	  The	  labels	  consist	  of	  three	  elements:	  a	  peptide	  reactive	  
group,	   which	   binds	   to	   the	   N-­‐terminal	   of	   peptides;	   a	   balance	   group,	   which	  
compensates	   for	   the	   difference	   in	   mass	   of	   the	   labels;	   and	   a	   reporter	   group	   of	  
variable	  mass.152	   (Figure	   2.1)	   Prior	   to	   iTRAQ	   labelling,	   the	   samples	   are	  denatured	  
and	  digested	  into	  peptides.	  The	  labelled	  peptides	  from	  each	  sample	  are	  then	  mixed,	  
separated	  using	  2D-­‐liquid	  chromatography	  and	  analysed	  by	  tandem	  MS.	  Because	  of	  
the	  isobaric	  nature	  of	  these	  reagents,	  the	  same	  peptide	  from	  each	  sample	  appears	  
as	   a	   single	   peak	   in	   the	   MS	   spectrum.	   Upon	   collision-­‐induced	   dissociation,	   the	  
iTRAQ-­‐tagged	   peptides	   fragment	   to	   release	   reporter	   ions.	   The	   peak	   areas	   of	   the	  
reporter	   ions	  are	  used	  to	  assess	  relative	  abundance	  of	  peptides	  and	  consequently	  
the	  proteins	  from	  which	  they	  are	  derived.153	  (Figure	  2.2)	  	  
Relative	  quantification	  is	  possible	  across	  large	  patient	  cohorts	  by	  creating	  a	  pooled	  
standard	  control,	  which	  is	  analysed	  in	  every	  run	  and	  against	  which	  all	  samples	  are	  
then	  compared.	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Figure	  2.2	  iTRAQ	  workflow	  (Courtesy	  of	  Dr	  C.	  Lane,	  AB	  Sciex)	  
	   	  
	  
	  
iTRAQ® Reagent - 8Plex Structure
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2.2 Methods	  
2.2.1 Sample	  preparation	  
2.2.1.1 Selection	  of	  samples	  
Snap-­‐frozen	  UM	  tumour	  tissues	  of	  different	  weights	  (17	  μg,	  30	  μg	  and	  50	  μg)	  were	  
obtained	   from	   the	   Liverpool	   Ocular	   Oncology	   Biobank	   (OOB)	   following	   approvals	  
from	   the	   local	   and	   national	   ethics	   committees	   (NRES	   Ref	   No.	   11/NW/0568).	  
Preliminary	  experiments	  were	   conducted	   to	  determine	   the	  optimal	  weight	  of	   the	  
frozen	   sample	  necessary	   to	  obtain	   a	   good	   spread	  of	   proteins	   following	  digestion,	  
iTRAQ	   labelling	   and	  MS	   analysis.	   Following	   determination	   of	   the	   optimal	   sample	  
weight	   (50	  μg),	   a	   prospective	   collection	   of	   fresh-­‐frozen	   samples	  was	   commenced	  
from	  March	  2011	   from	   those	  patients	  undergoing	  enucleation	  or	   transcleral	   local	  
resection	   as	   their	   primary	   treatment	   for	   UM.	   Twenty	   samples	  were	   used	   for	   the	  
final	  iTRAQ	  analysis:	  10	  were	  from	  patients	  at	  HR	  of	  developing	  metastatic	  disease,	  
and	  10	  from	  patients	  at	  LR.	  The	  risk	  category	  was	  determined	  on	  the	  basis	  of	   the	  
clinical,	   histopathological	   and	   genetic	   characteristics,	   as	   explained	   in	   detail	   in	  
Chapter	  1.	  
Snap-­‐frozen	  non-­‐involved	  choroid	  was	  also	  obtained	  from	  fresh	  enucleated	  globes,	  
to	  be	  used	  as	  a	  normal	  reference	  in	  the	  proteomic	  experiments.	  This	  was	  harvested	  
from	  a	  macro-­‐	   and	  microscopically	  unaffected	  area	  distant	   from	   the	   tumour.	   The	  
genetic	  profile	  of	   the	  non-­‐involved	  choroid	  harvested	   from	  eyes	  harbouring	  a	  M3	  
UM	  was	  analysed	  by	  MLPA	  to	  verify	  the	  absence	  of	  such	  alteration	  and	  substantiate	  
its	  use	  as	  a	  normal	  reference	  sample.	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1.5.1.2	  	  Protein	  extraction	  and	  quantification	  
Unless	   otherwise	   state,	   all	   the	   reagents	   were	   supplied	   by	   Sigma	   (Sigma-­‐Aldrich,	  
Dorset,	  UK).	  
A	   maximum	   of	   four	   samples	   were	   thawed	   at	   the	   one	   time	   and	   kept	   on	   ice	   to	  
minimise	   protein	   degradation.	   200	   μl	   of	   iTRAQ-­‐compatible	   lysis	   buffer	   (0.5M	  
triethylammonium	  bicarbonate	   (TEAB)/0.1%	  sodium	  dodecyl	   sulphate	   (SDS))	  were	  
added	   to	   the	   tissue,	  which	  was	  mechanically	  masticated	  using	  a	  blunt	  probe.	  The	  
sample	  was	  then	  re-­‐frozen	  in	  dry	   ice	  and	  allowed	  to	  defrost	  at	  room	  temperature	  
(RT).	   Samples	   were	   further	   broken	   down	   by	   ultrasonication	   for	   ~	   10	   seconds	   (s)	  
using	  a	  Tekmar	  TM50	  Sonic	  Disruptor	  with	  the	  output	  set	  at	  45%.	  If	  the	  sample	  was	  
not	   yet	   completely	   dissolved,	   100	   μl	   of	   buffer	   was	   added	   and	   ultrasonication	  
repeated.	   Samples	   were	   then	   centrifuged	   at	   14,000	   rpm	   (~10,000	   x	   G;	   5415	   C	  
centrifuge,	  Eppendorf,	  Hamburg,	  Germany)	   for	  20	  minutes	   (mins)	   at	  4°C,	   and	   the	  
supernatant	   collected,	   transferred	   to	   a	   fresh	   Eppendorf	   tube	   and	   stored	   at	   -­‐80°C	  
until	  required.	  
The	   protein	   concentration	   of	   the	   samples	   was	   calculated	   using	   the	   method	   of	  
Bradford.154	  To	  generate	  a	  standard	  curve,	  a	  range	  of	  known	  concentrations	  were	  
made	   by	   diluting	   bovine	   serum	   albumin	   (BSA)	   in	   iTRAQ	   buffer	   to	   final	  
concentrations	  of	  2,	  1.4,	  1.0,	  0.8,	  0.4,	  0.2	  and	  0.1	  mg/ml,	  and	  placed	  in	  triplicate	  in	  
a	  96	  well	  plate.	  Serial	  dilutions	  of	  each	  sample	  were	  made	  at	  concentrations	  of	  1:5,	  
1:10,	   1:20,	   1:40,	   and	   placed	   in	   triplicate	   in	   the	   same	   96	   well	   plate.	   250	   μl	   of	  
Bradford	  reagent	  (Bio-­‐Rad	  Laboratories	  Ltd.,	  Hertfordshire,	  UK)	  was	  added	  to	  each	  
well,	  and	  the	  samples	  mixed	  thoroughly	  by	  repeat	  pipetting.	  	  Colour	  densitometry	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was	   measured	   using	   a	   plate	   reader	   (Multiskan	   FC,	   Thermo	   Scientific)	   at	   an	  
absorbance	  of	  570	  nm.	  Protein	  concentration	  within	  the	  samples	  was	  calculated	  by	  
comparison	  with	  the	  standard	  curve.	  
2.2.2 iTRAQ	  labelling	  
The	   iTRAQ	   labelling	   procedure	   was	   undertaken	   according	   to	   the	   manufacturer’s	  
instructions	   (AB	   Sciex,	   Framingham,	   MA).	   100	   μg	   of	   protein	   was	   prepared	   in	   a	  
volume	   of	   20	   μl	   of	   the	   iTRAQ-­‐compatible	   lysis	   buffer.	   2	   μl	   of	   tris(2-­‐
carboxyethyl)phosphine	   (TCEP)	   reducing	   agent	   was	   added,	   the	   sample	   was	  
vortexed	   and	   then	   incubated	   at	   60	   °C	   for	   one	   hour.	   Cysteine	   sulfhydryls	   were	  
blocked	  by	   addition	  of	   1	   μl	   of	  methyl	  methanethiosulfonate	   (MMTS),	   the	   sample	  
was	   vortexed,	   and	   then	   incubated	   at	   RT	   for	   10	  mins.	   Proteins	   were	   digested	   by	  
addition	   of	   10	   μl	   of	   reconstituted	   porcine	   trypsin	   (Promega	   UK,	   Southampton,	  
Hants,	   UK)	   and	   incubated	   at	   37	   °C	   overnight	   (12−16	   hours).	   Individual	   iTRAQ	  
reagents	  were	  reconstituted	  by	  the	  addition	  of	  50	  μl	  of	  isopropanol,	  vortexed,	  then	  
added	   to	   individual	   sample	   tubes	   and	   incubated	   at	   RT	   for	   2	   hours.	   The	   labelled	  
proteins	   were	   then	   combined,	   and	   the	   final	   volume	  was	  made	   up	   to	   5	  ml	   using	  
cation	  exchange	  buffer	  A	  (10	  mM	  potassium	  dihydrogen	  phosphate	  (KH2PO4)/25%	  
acetonitrile	   (ACN)	   pH	   <	   3).	   The	   pH	   was	   adjusted	   to	   between	   pH	   2	   and	   pH	   3	   by	  
addition	  of	  concentrated	  phosphoric	  acid	  where	  necessary.	  
2.2.2.1 Creation	  of	  reference	  pool	  
Eight-­‐plex	   iTRAQ	   is	   restricted	   by	   the	   number	   of	   available	   labelling	   reagents	   to	   8	  
different	  samples	  per	  run.	  To	  overcome	  this	  limitation,	  we	  created	  a	  reference	  pool	  
of	  normal	  choroid	  that	  was	  analysed	  in	  each	  run	  and	  used	  as	  common	  denominator	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to	  calculate	  relative	  quantitation.	  The	  pool	  was	  formed	  from	  22	  snap-­‐frozen	  normal	  
choroid	   samples	   from	   19	   eyes,	   homogenised	   together	   as	   detailed	   above.	   Protein	  
concentration	  was	  calculated	  using	  a	  Bradford	  assay.	  This	  mix	  was	  then	  aliquoted,	  
and	   stored	   at	   -­‐80°C	   until	   required.	   For	   each	   iTRAQ	   run,	   an	   aliquot	  was	   removed	  
from	   the	   freezer,	   brought	   to	   room	   temperature	   and	   vortexed	   for	   5	   mins.	   An	  
adequate	  amount	  of	  reference	  pool	  protein	  was	  removed	  and	  combined	  with	  10	  μl	  
of	  lysis	  buffer,	  to	  give	  a	  final	  concentration	  of	  100	  μg	  of	  reference	  pool	  protein	  in	  20	  
μl,	  and	  labelled	  with	  one	  of	  the	  isobaric	  tags.	  	  
2.2.2.2 Allocation	  of	  samples	  to	  iTRAQ	  experiment	  labelling	  
Samples	  were	  randomly	  allocated	  to	  each	  8-­‐plex	  run.	  Eight	  cards	  labelled	  113,	  114,	  
115,	  116,	  117,	  118,	  119	  and	  121	  were	  placed	  in	  a	  sealed	  bag.	  Patient	  samples	  and	  
reference	   pool	  were	   allocated	   to	   a	   specific	   label	   on	   the	  morning	   of	   the	   labelling	  
part	  of	  the	  experiment	  by	  picking	  a	  numbered	  card	  from	  the	  bag.	  	  
2.2.3 MS	  analysis	  
2.2.3.1 Cation	  Exchange	  
Sample	   clean-­‐up	   and	   pre-­‐fractionation	   was	   performed	   using	   strong	   cation-­‐
exchange	  chromatography.	  A	  Polysulfoethyl	  A	  Column	  (PolyLC,	  Columbia,	  MD)	  5	  μm	  
of	   200	  mm	   length	   ×	   2.1	  mm	   inner	   diameter,	   200	   Å	   pore	   size,	   on	   a	   Agilent	   1100	  
quaternary	  HPLC	  unit	  (Agilent	  Technologies,	  Santa	  Clara,	  CA),	  at	  a	  flow-­‐rate	  of	  300	  
μl	   /	   min	   was	   used.	   Peptides	   were	   eluted	   using	   a	   gradient	   of	   0−15%	   B	   (10	   mM	  
KH2PO4/25%	  ACN/	  1M	  KCl	  pH	  <	  3)	   in	  45	  mins	  and	  15-­‐50%	  B	   in	  15	  mins	  at	  a	   flow	  
rate	  of	  1ml/min.	  A	  total	  of	  40	  2-­‐mins	  fractions	  were	  collected	  and	  dried	  in	  a	  vacuum	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concentrator	  (Eppendorf	  Speedvac).	  They	  were	  desalted	  using	  a	  macroporous	  C18	  
high-­‐recovery	  reversed	  phase	  column	  (4.6	  x	  50	  mm,	  Agilent	  Technologies)	  installed	  
on	   a	   Vision	  workstation	   (AB	   Sciex	  UK	   Ltd,	   Cheshire,	   UK)	   before	   being	   dried	   once	  
more.	  
2.2.3.2 Mass	  spectrometry	  
The	  peptides	  were	   resuspended	   in	  40	  µl	  0.1%	   formic	  acid	   just	  prior	   to	  LC-­‐MS/MS	  
analysis.	   Samples	   were	   delivered	   into	   a	   Triple	   TOF	   5600	  mass	   spectrometer	   (AB	  
Sciex)	   by	   automated	   in-­‐line	   reversed	   phase	   liquid	   chromatography,	   using	   an	  
Eksigent	   NanoUltra	   cHiPLC	   System	  mounted	  with	  microfluidic	   trap	   and	   analytical	  
column	  (15 cm × 75 μm)	  packed	  with	  ChromXP	  C18-­‐CL	  3μm.	  A	  NanoSpray	  III	  source	  
was	   fitted	  with	  a	  10	  μm	   inner	  diameter	  PicoTip	  emitter	   (New	  Objective).	  Samples	  
loaded	  onto	  the	  trap	  were	  washed	  with	  2%	  ACN	  /	  0.1%	  formic	  acid	  for	  10	  mins	  at	  
2μl	  /	  min	  before	  switching	  in-­‐line	  with	  the	  analytical	  column.	  	  A	  gradient	  of	  2-­‐50%	  
(v/v)	  ACN	  /	  0.1	  %	  formic	  acid	  over	  90	  mins	  was	  applied	  to	  the	  column	  at	  a	  flow	  rate	  
of	   300	   nl	   /	   min.	   The	   mass	   spectrometer	   was	   set	   to	   perform	   data	   acquisition	   in	  
positive	  ion	  mode,	  with	  survey	  scans	  of	  250	  ms,	  and	  with	  an	  MS/MS	  accumulation	  
time	  of	  100	  ms	  for	  the	  25	  most	  intense	  ions	  (total	  cycle	  time	  2.5	  s).	  A	  threshold	  for	  
triggering	   of	  MS/MS	   of	   100	   counts	   per	   second	  was	   used,	   together	  with	   dynamic	  
exclusion	  for	  12	  s	  and	  rolling	  collision	  energy,	  adjusted	  for	  the	  use	  of	  iTRAQ	  reagent	  
in	  the	  Analyst	  method.	  Information-­‐dependent	  acquisition	  was	  powered	  by	  Analyst	  
TF	   1.5.1	   software,	   using	  mass	   ranges	  of	   400–1600	  atomic	  mass	  unit	   (amu)	   in	  MS	  
and	  100–1400	   amu	   in	  MS/MS.	   The	   instrument	  was	   automatically	   calibrated	   after	  
every	  fifth	  sample	  using	  a	  beta-­‐galactosidase	  digest.155	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2.2.3.3 Protein	  identification	  and	  quantitation	  
Protein	   identification	  was	   carried	  out	  using	  ProteinPilot	   software	   (version	  4.2;	  AB	  
Sciex).	  The	  search	  was	  performed	  against	  the	  Uniprot	  Swiss-­‐Prot	  database	  (release	  
23/01/12)	   using	   the	   Paragon	   algorithm.	   The	   search	   parameters	   allowed	   MMTS-­‐
modification	   of	   cysteine	   residues	   and	   biological	   modifications	   predefined	   in	   the	  
software.	  Only	   those	  proteins	   identified	  with	  at	   least	  95%	  confidence	  were	   taken	  
into	  account.	  False	  discovery	  rate	  (FDR)	  was	  calculated	  as	  the	  percentage	  of	  decoy	  
proteins	  identified	  against	  the	  total	  protein	  identification	  database.	  Decoy	  proteins	  
were	   defined	   by	   searching	   against	   a	   reverse	   database,	   and	   the	   maximum	  
acceptable	   FDR	   value	  was	   set	   at	   1%.	   	   Relative	   protein	   quantification	   from	   iTRAQ	  
labelling	  used	  code	  written	  in	  the	  statistical	  program	  R,	  as	  previously	  described.149	  
2.2.4 Data	  analysis	  
All	   tumour	   samples	   were	   quantified	   relative	   to	   normal	   choroid.	   Supervised	   and	  
unsupervised	   hierarchical	   cluster	   analyses	   were	   performed	   using	   the	   statistical	  
program	  R.	  Outlier	  analysis	  based	  on	  box	  plots	  of	  fold	  changes	  was	  calculated	  using	  
the	   median	   absolute	   deviation	   (MAD)	   technique	   to	   identify	   commonly	   up-­‐	   and	  
down-­‐regulated	  protein	  expression.	  	  Data	  was	  log2	  transformed	  and	  the	  Z-­‐score	  for	  
each	  protein	  was	  calculated	  using	  the	  formula:	  	  
Z=	  0.6745*(x(i)-­‐xm)/MAD	  
where	  x(i)	  is	  the	  ‘ith’	  observation	  and	  ‘xm’	  is	  the	  median	  of	  the	  sample.	  
Outliers	   (Z	   >2	   or	   <-­‐2)	   represent	   proteins	   that	   are	   differentially	   expressed	   in	   each	  
tumour	  sample.	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Among	  these,	  proteins	  with	  known	  functions	   in	   tumour	  development/progression	  
and	   shown	   to	   be	   differentially	   expressed	   between	   HR	   and	   LR	   UM	   samples	   were	  
manually	   identified.	   A	   selection	   of	   these	   was	   validated	   in	   FFPE	   tissues	   by	  
immunohistochemistry	  (IHC).	  
2.2.5 Immunohistochemical	  analysis	  
All	  products	  used	  for	   IHC	  were	  supplied	  from	  Dako	  (Dako	  UK	  Lts,	  Cambridgeshire,	  
UK)	  unless	  otherwise	  specified.	  The	  same	  protocol	  was	  used	  for	  both	  whole	  tissue	  
section	  and	  TMA	  slides.	  
2.2.5.1 Selection	  of	  samples	  
For	   all	   antibodies,	   initial	   optimisation	   experiments	  were	   conducted	  on	   a	   panel	   of	  
FFPE	   slides	   of	   normal	   tissues	   (kidney,	   skin,	   testes,	   colon)	   known	   to	   express	   the	  
protein	  of	  interest	  in	  order	  to	  define	  the	  antibody	  concentration	  to	  be	  used.	  	  
4	  µm	  tumour	  sections	  from	  the	  corresponding	  FFPE	  blocks	  of	  the	  20	  UM	  (10	  HR	  and	  
10	   LR)	   used	   in	   the	   iTRAQ	   analysis	   underwent	   IHC	   using	   the	   optimised	   staining	  
conditions,	  in	  order	  to	  validate	  proteomics	  findings.	  	  
To	   verify	   the	   clinical	   relevance	   of	   those	   proteins	   showing	   differential	   expression	  
between	  HR	  and	  LR	  samples,	   IHC	  was	  performed	  on	  slides	  from	  a	  TMA	  containing	  
tumour	   tissues	   (3	  cores	  per	   tumour)	   from	  74	  primary	  UM	  patients	  with	  complete	  
clinical	  information,	  including	  at	  least	  7	  years	  of	  follow-­‐up.	  
2.2.5.2 Antigen	  Retrieval	  
Prior	  to	  IHC	  staining,	  all	  slides	  underwent	  de-­‐paraffinisation,	  rehydration	  and	  heat-­‐
induced	  epitope	  retrieval	  using	  the	  pre-­‐treatment	  module	  for	  tissue	  specimens	  (PT	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Link,	  Dako).	  Once	  the	  module	  was	  pre-­‐heated	  to	  65°C,	  the	  slides	  were	  placed	  in	  a	  
rack	   and	   incubated	   in	   a	   PT	   link	   tank	   containing	   1.5	   litres	   of	   high	   pH	   retrieval	  
solution	   (Target	  Retrieval	  Solution,	  pH9.0)	   for	  20	  mins	  at	  97°C.	  The	  sections	  were	  
allowed	   to	   cool	   in	   the	   PT	   Link	   for	   approximately	   50	   mins	   until	   it	   reached	   a	  
temperature	   of	   65°C.	   The	   slide	   rack	   was	   then	   removed	   from	   the	   tank	   and	  
immediately	   dipped	   into	   a	   container	   of	   1X	   EnvisionTM	   Flex	   Wash	   Buffer	   (Tris	  
buffered	  saline	  containing	  Tween-­‐20,	  pH	  7.6)	  at	  RT	  and	  left	  for	  5	  mins.	  	  
2.2.5.3 Staining	  	  
IHC	   staining	   was	   performed	   using	   the	   Dako	   Autostainer,	   which	   is	   an	   automated	  
slide	   processing	   system	   designed	   to	   automate	   manual	   staining	   methods.	   All	   the	  
reagents	  were	  part	  of	   the	  EnVision™	  FLEX,	  High	  pH	  kit,	  which	   is	  a	  high-­‐sensitivity	  
visualization	   system	   intended	   for	  use	   in	   IHC	   together	  with	   the	  autostainer.	   It	   is	   a	  
dual	   link	   system	  where	   the	   signal	   from	  the	  primary	  antibody	   (mouse	  or	   rabbit)	   is	  
amplified	   by	   adding	   a	   species-­‐specific	   detection	   reagent	   consisting	   of	   a	   dextran	  
backbone	   to	   which	   horseradish	   peroxidases	   (HRP)	   are	   bound	   coupled	   with	  
secondary	  antibody	  molecules.	  	  The	  reaction	  is	  then	  visualised	  through	  the	  addition	  
of	  a	  chromogenic	  substrate	  that	   reacts	  with	  HRP	   in	   the	  presence	  of	  peroxide.	  For	  
this	  work	  we	  used	  AEC	  (3-­‐amino-­‐9-­‐ethylcarbazole),	  which	   forms	  a	  red	  end-­‐colour,	  
rather	   than	   the	   classic	   DAB	   (3,3'-­‐diaminobenzidine	   tetrahydrochloride),	   which	  
forms	   a	   brown-­‐coloured	   product,	   as	   the	   red	   staining	   is	   more	   easily	   detected	   in	  
pigmented	  tumours.	  
Following	  a	  wash	  in	  distilled	  water,	  the	  slides	  were	  counterstained	  in	  freshly	  filtered	  
haematoxylin	   (VWR	   International,	   Leicestershire,	  UK)	   for	  30	   s	   and	  microscopically	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examined	  to	  assess	  the	  staining	  intensity.	  Haematoxylin	  stained	  nuclei	  were	  blued	  
using	   Scott’s	   Tap	  Water	   for	   30	   s	   to	   allow	   contrast	   with	   the	   red	   chromogen	   end	  
products.	  Slides	  were	  mounted	  using	  aqueous	  mounting	  medium	  (Merk,	  Millipore	  
UK	  Limited,	  Hertfordshire,	  UK).	  	  
Details	  of	   the	  primary	  antibodies	  used	   can	  be	   seen	   in	  Table	  2.1.	  A	  positive	  and	  a	  
negative	  control	  slide	  for	  each	  antibody	  were	  stained	  alongside	  the	  tumour	  slides.	  




Scoring	   of	   the	   stained	   slides	   was	   performed	   by	   two	   independent	   observers	   and	  
consisted	  of	  assessing	  the	  presence/absence	  of	  the	  stain	  and	  its	  cellular	  localisation	  
within	  the	  tumour	  tissue.	  The	  three	  antibodies	  used	  showed	  different	  localisation:	  
perinuclear,	  cytoplasmic,	  and	  both	  nuclear	  and	  cytoplasmic.	  
The	   percentage	   of	   tumour	   cells	   showing	   perinuclear,	   cytoplasmic	   or	   nuclear	  
staining	  was	   determined	   in	   four	   categories,	   and	   the	   intensity	   of	   the	   staining	  was	  
also	   assessed	   (Table	   2.2).	   The	   final	   score	   for	   each	   slide	   was	   calculated	   by	  
multiplying	   these	   two	   values,	   i.e.	   percentage	   tumour	   positivity	   and	   intensity.	   For	  
one	   antibody	   showing	   both	   nuclear	   and	   cytoplasmic	   staining,	   the	   final	   value	  was	  
calculated	  by	   adding	   the	   total	   cytoplasmic	   and	  nuclear	   scores.	   In	   the	   TMA	   slides,	  
three	   independent	  cores	  are	  present	   to	   represent	  each	  sample.	  An	  average	  score	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for	  both	  cytoplasmic	  and	  nuclear	   staining	  was	  calculated	   from	  the	  different	  cores	  
present	   on	   the	   TMA	   to	   determine	   the	   final	   result.	   If	   more	   than	   one	   core	   was	  
missing	  or	  not	  assessable	  the	  sample	  was	  dismissed	  from	  the	  final	  analysis.	  
Table	  2.2	  IHC	  scoring	  criteria	  	  
	  
*	  Perinuclear	  staining	  was	  scored	  in	  the	  same	  way	  as	  cytoplasmic	  staining	  
	  
2.2.5.5 Statistics	  
Correlations	  were	   drawn	   between	   the	   staining	   results	   of	   the	   TMA	   slides	   and	   the	  
clinical,	  histopathological	  and	  genetic	  data	  of	  the	  corresponding	  tumours,	  as	  well	  as	  
the	   clinical	   information	   about	   the	   patients,	   including	   survival	   at	   the	   end	   of	   the	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2.3 Results	  
2.3.1 Characteristics	  of	  tumour	  and	  choroid	  samples	  
Twenty	   primary	   UM	   tumours	   (10	   HR	   and	   10	   LR)	   were	   analysed	   following	   iTRAQ	  
labelling.	  The	  clinical,	  histopathological	  and	  genetic	  characteristics	  of	  the	  samples,	  
used	  to	  determine	  the	  risk	  categories,	  are	  shown	  in	  Table	  2.3.	  During	  the	  three-­‐year	  
follow-­‐up	   period,	   six	   out	   of	   10	   patients	   defined	   as	   HR	   developed	   subsequent	  
metastases	  in	  the	  liver,	  whereas	  all	  10	  LR	  cases	  were	  disease	  free	  at	  this	  time.	  This	  
is	   in	  line	  with	  the	  predictions	  made	  by	  the	  prognostication	  algorithm	  (please	  refer	  
to	  Chapter	  1	  for	  further	  details).	  
As	  described	  above,	  non-­‐involved	  choroid	  was	  harvested	  from	  19	  eyes,	  enucleated	  
because	   of	   UM.	   Meticulous	   care	   was	   taken	   when	   collecting	   the	   specimens	   to	  
ensure	   that	   they	  were	   from	   a	  macro-­‐	   and	  microscopically	   disease-­‐free	   area.	   The	  
weight	   of	   these	   samples	   ranged	   from	   7μg	   to	   35μg,	   therefore	   a	   large	   number	   of	  
samples	  had	  to	  be	  pooled	  in	  order	  to	  achieve	  a	  concentration	  of	  at	  least	  5	  mg/ml	  of	  
extracted	  proteins	  following	  homogenization.	  	  
Where	  the	  choroid	  sample	  was	  large	  enough,	  part	  of	  it	  was	  used	  for	  DNA	  extraction	  
and	  MLPA	  analysis,	  to	  compare	  the	  genetic	  profile	  of	  what	  was	  considered	  normal	  
tissue	  to	  that	  of	  the	  tumour	  in	  the	  eye.	  This	  was	  possible	  in	  six	  cases,	  all	  of	  which	  
showed	  a	  normal	  profile	  for	  the	  chromosomes	  tested,	   in	  contrast	  to	  the	  tumours,	  
as	  shown	  in	  Table	  2.4.	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Table	  2.3	  Clinical,	  histopathological	  and	  genetic	  characteristics	  of	  the	  UM	  tumours	  used	  for	  
iTRAQ	  analysis	  
	  
F:	   female;	  M:	  male;	  Y:	   yes;	  N:	  no;	   LBD:	   largest	  basal	  diameter;	  HT:	   tumour	   thickness;	  CB:	  
ciliary	  body	   involvement;	  EOE:	  extraocular	  extension;	  Cell	  type:	  spindle,	  mixed,	  epithelioid;	  
HR:	   high	   risk;	   LR:	   low	   risk	   of	   developing	   metastases;	   genetic	   (chromosomal	   alteration	  
determined	   by	   MLPA):	   N-­‐normal,	   L-­‐loss,	   G-­‐gain,	   U-­‐unclassified.	   *Indicates	   patients	   who	  
have	  developed	  metastatic	  disease	  during	  the	  follow-­‐up	  period.	  
	  
	  	   	  
Sample'No.' Age' Sex' LBD' HT' CB' EOE' Cell'type' Loops' Mitosis' Risk' Genetic'
S042%11' 65' F' 20.5' 11.4' N' N' SPIN' N' 2' LR' 3N,'8N'
S061%11' 39' M' 19.6' 12.9' N' N' SPIN' N' 3' HR*' 3L,'8G'
S067%11' 62' F' 17.2' 10.7' Y' N' SPIN' N' 9' HR*' 3L,'8G'
S159%11' 22' M' 15.9' 8.5' N' N' MIX' Y' 12' LR' 3N,'8G'
S165%11' 73' F' 20.8' 15.4' N' N' MIX' N' 4' HR*' 3L,'8G'
S166%11' 53' F' 17.8' 12.9' Y' N' MIX' Y' 21' HR*' 3L,'8G'
S196%11' 71' F' 14.5' 6.8' N' N' SPIN' N' 7' LR' 3N,'8G'
S228%11' 48' F' 17.1' 15.3' N' N' EPI' Y' 17' HR*' 3L,'8G'
S065%12' 74' F' 20.3' 11.2' N' N' MIX' Y' 10' HR*' 3L,'8G'
S070%12' 57' M' 16.7' 7.3' N' N' SPIN' Y' 4' LR' 3N,'8N'
S113%12' 58' M' 17.9' 10.7' N' N' MIX' Y' 5' LR' 3N,'8N'
S116%12' 59' F' 16.8' 5.2' Y' N' SPIN' Y' 7' HR' 3L,'8G'
S124%12' 74' F' 16.2' 7.2' N' N' SPIN' N' 6' LR' 3N,'8N'
S140%12' 69' M' 17.6' 11' N' Y' MIX' N' 5' HR' 3L,'8G'
S147%12' 62' M' 16.3' 8.6' N' N' MIX' Y' 5' LR' 3N,'8G'
S163%12' 46' M' 16.4' 5.9' N' N' SPIN' N' 8' LR' 3N,'8G'
S194%12' 42' M' 12.7' 11.6' N' N' MIX' N' 3' LR' 3N,'8N'
S195%12' 77' F' 14.7' 5.7' N' N' EPI' N' 7' HR' 3L,'8G'
S197%12' 71' F' 13.6' 8' N' N' MIX' Y' 6' HR' 3L,'8U'
S204%12' 48' M' 12.7' 10.5' N' N' SPIN' N' 3' LR' 3N,'8N'












	  Table	   2.4	  MLPA	  analysis	   of	  matched	   choroid	  
and	   tumour	   samples	   from	   the	   same	   eye,	  
showing	   lack	   of	   chromosomal	   alterations	   in	  
the	  normal	  choroid	  for	  chromosomes	  3	  and	  8.	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2.3.2 iTRAQ	  results	  
2.3.3 Protein	  identification	  
The	  samples	  were	  analysed	  in	  three	  non-­‐consecutive	  MS	  runs	  performed	  between	  
June	  and	  October	  2012.	  Each	  run	  included	  a	  mixture	  of	  high-­‐	  and	  low-­‐	  risk	  samples	  
as	  well	  as	  one	  aliquot	  from	  the	  choroid	  pool,	  which	  remained	  constant	  (Table	  2.5).	  	  
Table	  2.5	  Allocation	  of	  samples	  to	  different	  MS	  runs	  
	  
	  
Overall,	   3022	   unique	   proteins	   were	   identified:	   1896	   (63%)	   were	   common	   to	   all	  
runs,	  while	  2428	  (80%)	  were	  detected	  in	  at	  least	  two	  runs.	  The	  number	  of	  identified	  
proteins	  differed	  among	  runs,	  with	  run	   ‘A’	  being	  optimal	   in	  terms	  of	  quantity	  and	  
Run$no.$ iTRAQ$label$ Sample$ Patient$ID$ Risk$
A$ 113$ 1$ S065=12$ HR$
A$ 114$ 2$ S042=11$ LR$
A$ 115$ 3$ S166=11$ HR$
A$ 116$ 4$ S159=11$ LR$
A$ 117$ 5A$ S067=11$ HR$
A$ 118$ 5B$ S067=11$ HR$
A$ 119$ 6$ S196=11$ LR$
A$ 121$ Ch$ Choroid$pool$ Normal$
B$ 115$ 7$ S147=12$ LR$
B$ 121$ 8$ S124=12$ LR$
B$ 119$ 10$ S165=11$ HR$
B$ 114$ 11$ S070=12$ LR$
B$ 118$ 12$ S061=11$ HR$
B$ 113$ 13$ S228=11$ HR$
B$ 117$ 14$ S194=12$ LR$
B$ 116$ Ch$ Choroid$pool$ Normal$
C$ 118$ 15$ S195=12$ HR$
C$ 114$ 16$ S197=12$ HR$
C$ 117$ 17$ S216=12$ HR$
C$ 113$ 18$ S116=12$ HR$
C$ 121$ 19$ S113=12$ LR$
C$ 115$ 20$ S163=12$ LR$
C$ 116$ 21$ S204=12$ LR$
C$ 119$ Ch$ Choroid$pool$ Normal$
$
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quality	  (based	  on	  number	  of	  peptides)	  of	   identified	  proteins.	  Details	   for	  each	  run,	  
including:	  protein	  ID,	  accession	  number,	  number	  of	  peptides	  identified	  with	  at	  least	  
95%	  confidence	  and	  percentage	  of	  sequence	  coverage	  can	  be	  seen	  in	  Appendix	  1.	  	  
2.3.3.1 Protein	  quantification	  
Relative	   quantification	   based	   on	   the	   iTRAQ	   labelling	   was	   calculated	   using	   the	  
pooled	  choroid	  sample	  as	  a	  denominator	  in	  all	  cases,	  as	  this	  sample	  was	  present	  in	  
all	  runs.	  	  
Unsupervised	  hierarchical	  clustering	  (UHC)	  of	  the	  samples	  in	  Run	  A	  showed	  a	  nice	  
separation	   between	   high-­‐	   (T1,	   T3,	   T5,	  with	   5A	   and	   5B	   being	   technical	   replicates)	  
and	   low-­‐	   (T2,	   T4,	   T6)	   risk	   samples.	   This	   would	   remain	   true	   whether	   using	   as	  
common	  denominator	  a	  tumour	  sample	  (in	  this	  case,	  T5B),	  or	  the	  normal	  choroid	  
pool	  (Figure	  2.3).	  	  
	  
Figure	   2.3	   Unsupervised	   hierarchical	   clustering	   of	   samples	   in	   Run	   A,	   showing	   a	   nice	  
separation	   between	   risk	   categories	   when	   using	   a	   tumour	   sample	   (T5B)	   as	   common	  
denominator	  (A),	  as	  well	  as	  when	  using	  the	  choroid	  pool	  (norm)	  as	  denominator	  (B).	  
A	   B	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However,	   the	   quality	   and	  quantity	   of	   proteins	   quantified	   progressively	   decreased	  
with	  runs.	  Moreover,	  using	  the	  choroid	  pool	  as	  common	  reference	  could	  no	  longer	  
distinguish	  the	   low-­‐	  and	  high-­‐	  risk	  samples	  upon	  UHC,	  whereas	  this	  would	  remain	  
true	  when	  using	  a	  tumour	  sample	  as	  common	  denominator	  (Figure	  2.4).	  	  
	  
	  
Figure	   2.4	   Unsupervised	   hierarchical	   clustering	   of	   samples	   in	   Run	   B,	   showing	   a	   nice	  
separation	   between	   risk	   categories	   when	   using	   a	   tumour	   sample	   (11L)	   as	   common	  
denominator	  (B),	  but	  now	  when	  using	  the	  choroid	  pool	  (A).	  L:	  low-­‐risk,	  H:	  high-­‐risk;	  norm:	  
choroid	  pool.	  
This	  indicates	  that	  the	  most	  likely	  source	  of	  problem	  was	  the	  choroid	  pool.	  Indeed,	  
the	  protein	  concentration	  of	  the	  pooled	  stock,	  which	  should	  have	  remained	  stable,	  
did	  change	  over	  time	  (Table	  2.6).	  This	  could	  be	  due	  to	  protein	  degradation	  and	  may	  
explain	  the	  deterioration	  of	  the	  iTRAQ	  results.	  
Table	   2.6	   Protein	   concentration	   (assessed	   by	   Bradford	   assay)	   of	   the	   choroid	   pool	   at	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However,	   the	  choroid	  pool	  was	  the	  only	  sample	   in	  common	  between	  runs,	  so	  we	  
still	  used	  it	  as	  a	  common	  denominator	  to	  perform	  a	  cumulative	  analysis	  of	  the	  10	  
HR	  versus	  10	  LR	  samples.	  When	  merged,	  821	  unique	  proteins	  were	  quantified	  in	  all	  
three	  runs.	  Data	  were	  scaled	  to	  adjust	  for	  protein	  loading	  differences	  between	  runs	  
before	   performing	   cluster	   analysis,	   but	   nevertheless	   UHC	   only	   separated	   the	  
samples	  into	  run	  (not	  HR	  vs	  LR).	  	  
2.3.3.2 Selection	  of	  relevant	  proteins	  
iTRAQ	  Run	  ‘A’	  was	  identified	  as	  the	  optimal	  run	  both	  in	  terms	  of	  the	  internal	  control	  
and	  the	  identification/quantification	  of	  proteins	  and	  was	  used	  to	  select	  proteins	  for	  
further	   validation.	   A	   median	   expression	   value	   (using	   the	   normal	   choroid	   as	   the	  
denominator)	  was	  calculated	   for	   the	   three	  HR	  samples	  and	  the	  three	  LR	  samples.	  
For	   sample	   S067-­‐11,	   which	   was	   run	   in	   duplicate,	   the	   average	   of	   the	   values	   was	  
used.	  
All	   1960	   unique	   accessions	   were	   subsequently	   ranked	   according	   to	   the	   median	  
value	   for	   HR	   (from	   lowest	   to	   highest),	   highlighting	   those	   with	   differing	   median	  
values	   between	   HR	   and	   LR	   tumours	   (n=81).	   These	   proteins	   were	   manually	  
examined	   in	  the	  complete	  spreadsheet	  containing	  the	  merged	  data	  from	  all	   three	  
the	   iTRAQ	   runs:	   of	   the	   81	   selected	   proteins,	   16	   showed	   difference	   in	   expression	  
between	  HR	  and	  LR	  across	  most	  samples.	  These	  are	  detailed	  in	  Table	  2.7.	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Table	  2.7	  List	  of	  proteins	  showing	  differential	  expression	  between	  HR	  and	  LR	  tumours	  
	  
	  
After	   studying	   their	   function,	   localization	   and	   potential	   role	   in	   cancer	   using	  
UniProtKB	  and	  Genecard,	   three	  proteins	  were	   selected	   for	   further	   IHC	  validation:	  
nesprin	   2,	   S100	   A6	   and	   programmed	   cell	   death	   protein	   4	   (PDCD4).	   The	   first	   two	  
proteins	  showed	  a	  relatively	  higher	  abundance	  in	  the	  HR	  samples,	  whereas	  PDCD4	  
was	  more	  abundant	   in	   the	   LR	   samples.	  Detailed	  values	  are	   shown	   in	  Appendix	  2.
Expression! Accession,! Name! Gene,
LR!>HR! P61225! Ras-related!protein!Rap-2b! RAP2B!
LR!>HR! P07108! Acyl-CoA-binding!protein! DBI!
LR!>HR! Q96N67! Dedicator!of!cytokinesis!protein!7! DOCK7!





LR!>HR! Q8NBS9! Thioredoxin!domain-containing!protein!5! TXNDC5!
LR!>HR! P37840! Alpha-synuclein! SNCA!
LR!>HR! P50453! Serpin!B9! SERPINB9!
LR!>HR! P11216! Glycogen!phosphorylase,!brain!form! PYGB!
LR!>HR! Q96RF0! Sorting!nexin-18! SNX18!
LR!>HR! Q53EL6! Programmed!cell!death!protein!4! PDCD4!
LR!>HR! Q09666! Neuroblast!differentiation-associated!protein!AHNAK! AHNAK!
HR!>LR! P06865! Beta-hexosaminidase!subunit!alpha! HEXA!
HR!>LR! P06703! Protein!S100-A6! S100A6!
HR!>LR! Q15155! Nodal!modulator!1! NOMO1!
HR!>LR! Q8WXH0! Nesprin-2! SYNE2!
!
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2.3.4 Protein	  expression	  in	  tissue	  sections	  
Matched	   FFPE	   slides	   were	   available	   for	   all	   20	   tumours	   used	   in	   the	   iTRAQ	  
experiments;	   however	   in	   one	   case	   (S165-­‐11)	   the	   residual	   tumour	   was	   mainly	  
necrotic,	   hence	   the	   IHC	   staining	   could	   not	   be	   assessed.	   In	   all	   other	   cases,	   IHC	  
confirmed	  the	  presence	  of	   the	  proteins	   in	   the	   tissues	  and	  their	  different	   levels	  of	  
expression	  between	  the	  HR	  and	  LR	  samples	  (Appendix	  2).	  	  
Nesprin	   was	   expressed	   on	   the	   perinuclear	   membrane,	   S100A6	   in	   the	   cytoplasm,	  
and	   PDCD4	   in	   the	   nucleus	   and/or	   cytoplasm.	   Nesprin	   expression	   showed	   a	   high	  
degree	  of	  heterogeneity	  across	   the	   tissue	  section,	   such	   that	  positive	   tumour	  cells	  
were	   limited	   to	   one	   region	   of	   the	   tumour	   (generally	   the	   edge),	   while	   protein	  
expression	  was	  not	  detected	  in	  the	  rest	  of	  the	  tumour	  section	  (Figure	  2.5).	  For	  this	  
reason,	   assessing	   Nesprin	   expression	   in	   small	   TMA	   cores	   would	   be	   not	  
representative,	  as	  the	  positive-­‐staining	  areas	  could	  be	  over-­‐	  or	  under-­‐represented;	  
hence	  only	  PDCD4	  and	  S100A6	  were	   selected	   for	   further	   clinical	   validation	   in	   the	  
TMA.	  
	   	  
Figure	  2.5	   Immunohistochemical	  staining	  of	  Nesprin	  2	  in	  a	  pigmented	  UM	  specimen	  (20x).	  
The	  protein	  of	   interest	   is	   expressed	  on	   the	  perinuclear	  membrane	  of	  UM	  cells,	   visible	  as	  
red	  circles	  around	  the	  blue	  nuclei.	  The	  large	  dark	  brown	  cells	  are	  melanomacrophages.	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Figure	   2.6	   Immunohistochemical	   staining	   for	   PDCD4	   (right)	   and	   S100A6	   (left)	   proteins	   in	  
UM	   TMA.	   A)	   PDCD4	   is	   expressed	   in	   the	   nucleus	   but	   not	   in	   the	   cytoplasm;	   B)	   PDCD4	   is	  
expressed	   in	   the	   cytoplasm	  but	  not	   in	   the	  nucleus;	  C)	  positive	  PDCD4	  expression	  both	   in	  
the	   nucleus	   and	   in	   the	   cytoplasm.	   S100A6	   is	   strictly	   cytoplasmic,	   but	   its	   expression	   has	  
been	  defined	  as:	  D)	  weak;	  E)	  moderate;	  F)	  strong.	  (Image	  magnification	  20x	  and	  40x)	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2.3.5 Validation	  of	  PDCD4	  and	  S100A6	  expression	  in	  an	  independent	  
cohort	  of	  primary	  UM	  tissues	  	  
The	   TMA	   comprised	   UM	   from	   42	   males	   and	   32	   females,	   with	   a	   mean	   age	   at	  
diagnosis	   of	   62	   years	   (median,	   61yrs;	   range,	   39-­‐89yrs).	   The	   tumours	   had	   a	  mean	  
largest	   basal	   diameter	   of	   16.7	   mm	   (median,	   17.0	   mm;	   range,	   8.8-­‐23.6mm).	  
Histological	   examination	   previously	   performed	   on	   full	   tumour	   sections	   as	   part	   of	  
the	   routine	   diagnostic	   work-­‐up,	   identified	   epithelioid	   cells	   in	   42	   tumours.	   Closed	  
PAS	  positive	  loops	  were	  found	  in	  48	  UM,	  and	  the	  mitotic	  count	  exceeded	  5	  per	  40	  
high	   power	   fields	   in	   23	   tumours.	   Genetic	   analysis	   of	   all	   UM	   examined	   by	  MLPA	  
classified	  44	  of	  these	  tumours	  as	  D3,	  and	  29	  as	  M3.	  In	  one	  patient,	  the	  chromosome	  
3	  status	  was	  not	  known.	  Follow-­‐up	  information	  was	  available	  for	  72	  patients	  at	  the	  
close	  of	  study,	  in	  June	  2014:	  40	  patients	  were	  still	  alive;	  28	  had	  died	  of	  metastatic	  
melanoma;	  and	  four	  had	  died	  of	  other	  causes.	  After	  excluding	  these	  four	  patients,	  
the	  mean	  survival	  time	  was	  6.7	  years	  (median	  7.0	  years;	  range	  0.4-­‐14.0	  years).	  
2.3.5.1 Expression	  of	  PDCD4	  
PDCD4	   protein	   expression	  was	   assessable	   in	   67/74	   tumours	   because	   some	   cores	  
were	   missing	   or	   damaged.	   PDCD4	   staining	   was	   localised	   to	   the	   cytoplasm	   and	  
nucleus	   of	   tumour	   cells	   in	   62/67	   (92%)	   and	   25/67	   (37%)	   of	   primary	   UM	   cases,	  
respectively	   (Figure	  2.6	  A,B,C).	   For	   all	   cases	   in	   the	  TMA,	   the	   staining	   score	   in	   the	  
individual	   cores	   of	   each	   case	   did	   not	   differ	   by	   more	   than	   10%,	   indicating	   no	  
significant	  heterogeneity	   in	   the	  presence	  or	  absence	  of	  PDCD4	  protein	  expression	  
across	   any	   individual	   tumour.	  Nuclear	   expression	   of	   PDCD4	  protein	  was	   found	   in	  
the	   presence	   of	   cytoplasmic	   PDCD4	   staining	   in	   23/25	   (92%)	   cases,	   with	   the	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hypothesis	  being	  that	  PDCD4	  protein	  dynamically	  shuttles	  in	  and	  out	  of	  the	  nucleus	  
from	   the	   cytoplasm.156	   Thus	  Receiver	  Operating	  Characteristic	   (ROC)	   analysis	  was	  
performed	   on	   the	   PDCD4	   cytoplasmic	   staining	   data	   only.	   ROC	   curve	   analysis	  
identified	  an	  optimal	  threshold	  for	  PDCD4	  staining	  scores,	  of	  ≤4,	  giving	  a	  sensitivity	  
of	  79%	  and	  specificity	  of	  70%.	  For	  all	  further	  statistical	  analyses,	  PDCD4	  cytoplasmic	  
protein	  expression	  ≤4	  was	  considered	  as	  negative	  and	  all	  other	  values	  as	  positive.	  	  
2.3.5.2 Expression	  of	  S100A6	  
S100A6	  protein	  expression	  was	   assessable	   in	   68/74	   tumours	  because	   some	   cores	  
were	   missing	   or	   damaged.	   S100A6	   staining	   was	   localised	   to	   the	   cytoplasm	   of	  
tumour	  cells	  in	  42/68	  (62%)	  cases	  of	  primary	  UM	  (Figure	  2.6	  D,E;F).	  For	  all	  cases	  in	  
the	  TMA,	   the	   staining	   score	   in	   the	   individual	   cores	  of	   each	   case	  did	  not	  differ	  by	  
more	  than	  10%,	  indicating	  no	  significant	  heterogeneity	  in	  the	  presence	  or	  absence	  
of	   S100A6	   protein	   expression	   across	   any	   individual	   tumour.	   ROC	   curve	   analysis	  
identified	  an	  optimal	  threshold	  for	  S100A6	  staining	  scores	  of	  ≤1,	  giving	  a	  sensitivity	  
of	   79%	   and	   specificity	   of	   55%.	   For	   all	   further	   statistical	   analyses,	   S100A6	   protein	  
expression	  ≤1	  was	  considered	  as	  negative	  and	  all	  other	  values	  as	  positive.	  
	  
2.3.5.3 Correlation	   of	   protein	   expression	   with	   clinicopathological	   and	  
genetic	  features	  of	  metastatic	  risk	  
Univariate	  analysis	  of	  all	  cases	  demonstrated	  that	  the	  presence	  of	  S100A6	  protein	  
expression	  was	  strongly	  associated	  with	  clinicopathological	  and	  genetic	  features	  of	  
increased	  metastatic	  risk,	  namely:	  increased	  age	  at	  primary	  management	  (p=0.010);	  
presence	  of	  PAS+	  closed	  connective	  tissue	  loops	  (p=0.088);	  presence	  of	  epithelioid	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cells	   (p=0.004);	   a	   high	   mitotic	   count	   (p=0.028);	   and	   monosomy	   3	   (p=0.002).	  
Importantly,	  an	  absence	  of	  PDCD4	  protein	  expression	  was	  also	  associated	  with	  the	  
following	   clinicopathological	   and	   genetic	   features	   of	   increased	   metastatic	   risk:	  
increased	   age	   at	   primary	  management	   (p=0.032);	   a	   high	  mitotic	   count	   (p=0.054);	  
and	  monosomy	  3	  (p=0.014)	  (Table	  2.8).	  
	  
Table	   2.8	  Association	  of	  S100A6	  and	  PDCD4	  protein	  expression	  with	  clinical,	  pathological	  
and	  genetic	  risk	  factors	  in	  UM	  















Age$(years)$ ! ! ! ! ! !
Mean%
$
57.6% 65.1% 0.010( 69.5% 61.0% 0.032(
Gender$ $ $ $ $ $ $
Female% 10%(31%)% 22%(69%)% 0.160% 5%(16%)% 27%(84%)% 0.678%
Male% 20%(48%)% 22%(52%)% % 5%(12%)% 36%(88%)% %
LBD$(mm)$ % % % % % %
Mean$ 16.2% 17.1% 0.224% 17.8% 16.5% 0.245%
Height$(mm)$
%
% % % % % %
Mean%
%
9.4% 9.0% 0.591% 9.4% 9.2% 0.834%
Epithelioid$ cells$
present$
% % % % % %
Yes% 11%(26%)% 31%(74%)% 0.004( 6%(15%)% 35%(85%)% 0.796%




% % % % % %
Yes% 16%(33%)% 32%(67%)% 0.088( 7%(15%)% 40%(85%)% 0.695%
No% 14%(54%)% 12%(46%)% % 3%(11%)% 23%(89%)% %
Mitotic$count$$
per$40$HPF$
% % % % % %
Mean% 3.7% 7.1% 0.028( 10.6% 5.0% 0.054(
Monosomy$3$ % % % % % %
Yes% 5%(17%)% 24%(83%)% 0.002( 8%(29%)% 20%(71%)% 0.014(
No% 25%(57%)% 19%(43%)% % 2%(4%)% 42%(96%)% %
Not%available% 0%% 1% % 0% 1% %
%
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2.3.5.4 S100A6	  and	  PDCD4	  as	  prognostic	  factors	  of	  metastatic	  disease	  	  
Kaplan-­‐Meier	  survival	  analysis	  showed	  that	  patients	  whose	  primary	  UM	  expressed	  
S100A6	  had	  a	  significantly	  shorter	  survival	  time	  than	  those	  patients	  whose	  primary	  




Figure	   2.7	  Kaplan-­‐Meier	   survival	   analysis	   showing	  a	   significantly	   shorter	   survival	   time	   for	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Conversely,	   patients	   whose	   primary	   UM	   was	   classified	   as	   positive	   for	   PDCD4	  
expression	   had	   a	   significantly	   longer	   survival	   time	   than	   those	   patients	   whose	  
primary	  UM	  was	  classified	  as	  negative	   for	  PDCD4	  expression	   (Log	  Rank,	  p=0.001).	  
(Figure	  2.8)	  
	  
Figure	   2.8	  Kaplan-­‐Meier	   survival	   analysis	   showing	  a	   significantly	   shorter	   survival	   time	   for	  
UM	  not	  expressing	  PDCD4.	  
	  
A	   combined	   analysis	   for	   expression	   of	   PDCD4	   and	   S100A6	   in	   the	   same	   tumours	  
showed	  that	   those	  patients	  whose	  primary	  UM	  expressed	  PDCD4	  but	  not	  S100A6	  
achieved	   the	   longest	   survival	   time	   (Figure	   2.9).	   The	   Mantel-­‐Cox	   test	   for	   overall	  
PDCD4 -ve 
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comparisons	  showed	  a	  significant	  difference	   (p=0.001)	   in	  survival	  distributions	   for	  
the	  different	  combinations	  of	  PDCD4/S100A6	  expression.	  
	  	  
	  
Figure	   2.9	  Combined	  Kaplan-­‐Meier	   survival	   analysis	   for	   PDCD4	  and	   S100A6,	   showing	   the	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2.4 Discussion	  
By	  performing	  comparative	  proteomic	  analysis	  of	  a	  cohort	  of	  HR	  versus	  LR	  UM,	  we	  
have	   identified	   a	   number	   of	   differentially	   expressed	   proteins,	   two	   of	  which	   have	  
been	  further	  validated	  and	  shown	  to	  be	  of	  prognostic	  value.	  	  
The	   main	   limitation	   of	   this	   work	   is	   the	   lack	   of	   reproducibility	   between	   iTRAQ	  
experiments,	  which	  did	  not	  allow	  us	  to	  merge	  the	  data	  from	  the	  different	  runs	  and	  
perform	   the	   solid	   data	   mining	   analyses	   that	   had	   been	   planned.	   The	   most	   likely	  
explanation	   for	   this	   are	   the	   technical	   difficulties	   encountered	   during	   sample	  
preparation.	  Extracting	  proteins	  from	  small	  UM	  tissues	  samples	  has	  proven	  difficult;	  
therefore	  we	  applied	  a	  quite	  “aggressive”	  method,	  based	  on	  mechanical	  as	  well	  as	  
chemical	  denaturation.	  On	  retrospective,	   this	  may	  have	  caused	  nuclear	  disruption	  
with	  DNA	  precipitation	   as	  well.	   Such	   contamination	   is	   likely	   to	   have	   affected	   the	  
quality	  of	  the	  protein	  determination,	  hence	  all	  downstream	  analyses.	  In	  particular,	  
iTRAQ	  labelling	  requires	  a	  precise	  peptide	  to	  label	  ratio,	  hence	  it	  is	  likely	  that	  some	  
peptides	  loaded	  in	  the	  MS	  were	  not	  labelled	  properly.	  Moreover,	  the	  protein	  load	  
in	  each	  MS	  run	  may	  have	  been	  different,	  hence	  the	  impossibility	  to	  reliably	  merge	  
the	   runs.	   Another	   technical	   aspect	   that	   may	   have	   affected	   the	   quality	   of	   the	  
experiments	   is	   that	   the	   protein	   lysates	   have	   been	   prepared	   and	   then	   stored	   for	  
over	  a	  year	  without	  protease	  inhibitors	  before	  being	  analysed	  in	  the	  MS.	  
Despite	   these	   limitations,	   however,	   we	   managed	   to	   identify	   and	   validate	   two	  
promising	   proteins,	   S100A6	   and	   PDCD4.	   Interestingly,	   these	   two	   had	   been	  
previously	   identified	   in	   UM	  by	   gene	   expression	   profiling.	   In	   the	   original	   study	   by	  
Onken	   et	   al.,80	   these	   two	   factors	   were	   among	   the	   62	   genes	   that	   discriminated	  
	  
	   85	  
between	  class	  1	  and	  class	  2	  tumours.	  The	  mRNA	  expression	  levels	  were	  concordant	  
with	  our	  proteomic	  finding:	  PDCD4	  is	  overexpressed	  in	  class	  1	  (LR)	  tumours,	  while	  
S100A6	  is	  overexpressed	  in	  class	  2	  (HR)	  ones.	  The	  authors,	  however,	  subsequently	  
selected	  only	  15	  of	   the	  62	   genes	   to	   limit	   the	   size	  of	   the	  assay	   and	  develop	   it	   for	  
clinical	  use,157	  and	  neither	  S100A6	  nor	  PDCD4	  were	  among	  these.	  S100A6,	  but	  not	  
PDCD4,	   have	   been	   previously	   reported	   in	   the	   global	   proteomic	   analysis	   of	   UM	  
cells.108	  	  
Our	   IHC	   study	   in	   an	   independent	   cohort	   of	   UM	   samples	  with	   long	   follow-­‐up	   has	  
shown	   the	   prognostic	   value	   of	   these	   proteins,	   which	   had	   not	   previously	   been	  
described	  in	  UM.	  
2.4.1 S100A6	  
S100A6,	  also	  known	  as	  calcyclin,	   is	  a	  member	  of	  the	  S100	  calcium-­‐binding	  protein	  
family.	   This	   is	   a	  multi-­‐gene	   family	   clustering	  on	   chromosome	  1q21,	   comprising	  at	  
least	  20	  known	  members,	  each	  coded	  by	  a	  different	  gene.158	  It	  is	  well	  documented	  
that	  S100	  proteins	  have	  a	  broad	  range	  of	   intracellular	  and	  extracellular	   functions.	  
These	   have	   been	   implicated	   in	   establishing	   the	  metastatic	   phenotypes	   of	   various	  
cancers	  types,	  including	  UM.159	  It	  has	  long	  been	  known	  that	  the	  vast	  majority	  of	  UM	  
express	   some	   members	   of	   the	   S100	   family,	   which	   can	   be	   determined	   by	   IHC	  
staining	   using	   a	   rabbit	   polyclonal	   antibody	   which	   binds	   all	   isoforms.160	   However,	  
further	   studies	   with	   isoform-­‐specific	   monoclonal	   antibodies	   showed	   marked	  
differences	  between	  particular	  isoform	  expression.161-­‐163	  In	  particular,	  Van	  Ginkel	  et	  
al.162	   performed	  western	   blot	   analysis	   and	   immunofluorescence	  microscopy	   on	   a	  
panel	  of	  cells,	  namely:	  normal	  choroidal	  melanocytes,	  a	  primary	  UM	  sample,	   	   the	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OCM-­‐1	   (spindle)	   and	   OCM-­‐3	   (epithelioid)	   UM	   cell	   lines	   and	   the	   M7	   cutaneous	  
melanoma	  cell	   line.	  	  They	  compared	  the	  expression	  level	  of	  seven	  calcium-­‐binding	  
proteins,	   and	   concluded	   that	   S100A6	   was	   more	   highly	   expressed	   in	   UM	   than	  
normal	  melanocytes,	  and	  hence	  may	  correlate	  with	  the	  malignant	  properties	  of	  the	  
tumour.	  No	  further	  studies	  to	  validate	  these	  findings	  have	  been	  published	  to	  date.	  	  
Given	   that	   cutaneous	   melanoma	   cells	   are	   known	   to	   secrete	   a	   soluble	   form	   of	  
S100,164	  Cochran	  et	  al.165	  investigated	  the	  levels	  of	  S100	  protein	  in	  ocular	  fluids,	  but	  
found	   the	  quantification	   to	  be	  of	   limited	  use	  as	  a	  diagnostic	   tool	   in	  UM	  patients.	  
Studies	  in	  cutaneous	  melanoma	  patients,	  on	  the	  contrary,	  have	  shown	  that	  serum	  
levels	   of	   S100β	   correlate	   with	   clinical	   stage,	   prognosis	   and	   survival,	   making	   it	   a	  
valuable	  biomarker.97	  As	  discussed	  in	  Chapter	  1,	  serum	  levels	  of	  S100β	  are	  also	  of	  
some	  value	  in	  UM	  patients.102	  	  
However,	   the	   question	   arising	   from	   our	   current	   discovery	   is	  whether	   the	  marker	  
that	  should	  be	   investigated	   in	  UM	  patients	   is	  not	  rather	  S100A6,	  given	  that	   it	  can	  
also	  be	  detected	  in	  the	  serum,	  as	  recently	  demonstrated	  in	  gastric	  cancer.166	  
2.4.2 PDCD4	  
Programmed	   cell	   death	   4	   was	   originally	   identified	   as	   an	   inhibitor	   of	   tumour	  
promoter-­‐induced	  neoplastic	  transformation	  in	  a	  murine	  model.167	  Its	  loss	  or	  down-­‐
regulation	  has	  subsequently	  been	  described	  to	  correlate	  with	   tumour	  progression	  
and	  prognosis	  in	  a	  number	  of	  human	  cancers,	  including	  lung,168	  renal,169	  breast,170	  
colorectal,171	   and	   ovarian	   carcinoma.172	   Loss	   of	   PDCD4	   causes	   more	   aggressive	  
tumour	   behaviour	   through	   increased	   proliferation,	   cell	   motility	   and	   invasion,	  
resistance	   to	  apoptosis,	   and	   resistance	   to	   chemotherapeutic	  agents.173	  Therefore,	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there	   has	   been	   great	   interest	   in	   targeting	  molecular	   pathways	   that	   cause	   PDCD4	  
depletion	   and	   in	   identifying	   small	  molecules	   that	  would	   act	   to	   stabilize	   PDCD4	   in	  
cancer	  cells.174	  PDCD4	  is	  regulated	  by	  multiple	  mechanisms	  at	  the	  different	   levels,	  
including	   proteosomal	   degradation,175	  mRNA	   decay	   and	   translational	   suppression	  
mediated	  by	  microRNAs	  (in	  particular	  miR-­‐21),176	  as	  well	  as	  promoter	  methylation-­‐
dependent	   suppression	   of	   transcription.177	   A	  main	   player	   in	   PDCD4	   repression	   is	  
mammalian	   target	   of	   rapamycin	   (mTOR),	   which	   has	   long	   been	   known	   to	   cause	  
proteasomal	  degradation	  via	  the	  S6K1	  pathway,178	  but	  which	  has	  also	  very	  recently	  
been	   identified	   as	   being	   responsible	   for	   transcriptional	   repression	   in	   lung	   cancer	  
cells.179	  This	   is	  very	   interesting	   for	  UM,	  where	  the	  mTOR	  pathway	   is	  known	  to	  be	  
activated	  in	  most	  cell	   lines	   independent	  of	  AKT	  signalling	  and	  is	  becoming	  a	  novel	  
therapeutic	  target.180	  	  
To	  date,	  there	  are	  no	  studies	  on	  the	  role	  of	  PDCD4	  in	  UM,	  whereas	  there	  are	  some	  
encouraging	  data	  in	  cutaneous	  melanoma.	  Wang	  et	  al.181	  established	  clones	  of	  the	  
human	   melanoma	   cell	   line	   B16	   with	   expression	   of	   different	   PDCD4	   fragments,	  
providing	   “direct	   evidence	   for	   an	   essential	   role	   of	   the	   PDCD4	   in	   melanoma”.	  
Indeed,	  upregulation	  of	  PDCD4	  expression	  in	  the	  cell	  line	  (by	  transfection	  of	  cDNA)	  
resulted	  in	  decreased	  proliferation,	  increased	  apoptosis	  and	  diminished	  migration.	  
Furthermore,	   they	   provided	   evidence	   that	   PDCD4	   could	   inhibit	   mobility	   of	   these	  
cells	  by	  down-­‐regulating	  the	  expression	  of	   the	  chemokine	  receptor	  CXCR4.181	  This	  
protein	  is	  also	  of	  interest	  in	  UM:	  please	  refer	  to	  Chapter	  4.	  	  
A	  recent	  study	  examined	  the	  expression	  of	  PDCD4	  by	  western	  blot	   in	  23	  cell	   lines	  
derived	   from	   metastatic	   lesions	   of	   stage	   IV	   cutaneous	   melanoma	   patients	   and	  	  
detected	  variable	  levels	  of	  the	  protein.	  PDCD4	  expression	  was	  completely	  absent	  in	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25%	  of	   the	   cell	   lines.182	   The	  authors	   then	   tested	   the	  effect	  of	   treating	   these	   cells	  
with	  mTOR,	   PI3K	   and	  MEK	  1/2	   inhibitors,	   concluding	   that	   although	  PDCD4	   loss	   is	  
not	  a	  common	  event	  in	  melanoma,	  it	  can	  be	  reversed	  by	  treatment	  with	  inhibitors	  
of	  AKT	  signalling.	  Therefore,	  PDCD4	  up-­‐regulation	  might	  be	  contributing	  to	  the	  anti-­‐
tumour	   effect	   of	   AKT	   pathway	   inhibitors,	   which	   are	   also	   being	   investigated	   as	  
therapeutic	  tools	  for	  metastatic	  UM	  patients.88	  
PDCD4	   regulation	   by	   the	   MAPK	   pathway	   via	   members	   of	   the	   p90	   ribosomal	   S6	  
kinase	   (RSK)	   family	   of	   proteins	   has	   also	   been	   described	   recently	   in	   melanoma	  
cells.183	   This	   study	   demonstrated	   that	   RSK	   inhibitors	   promote	   PDCD4	   stability	   in	  
melanoma	   cells,	   suggesting	   that	   this	   could	   be	   exploited	   in	   other	   cancers	  
characterized	   by	   the	   hyperactivation	   of	   the	   MAPK	   pathway.	   This	   is	   of	   particular	  
relevance	   for	  UM,	  where	  GNAQ/11	  mutations	  cause	  constitutive	  activation	  of	   the	  
MAPK	  pathway	  in	  the	  vast	  majority	  of	  patients.184	  
	  
In	   summary,	   although	   there	   have	   been	   some	   issues	   with	   the	   quantification	   of	  
proteins	  in	  our	  samples,	  proteomic	  analysis	  and	  IHC	  validation	  of	  UM	  tumour	  tissue	  
from	  HR	  and	  LR	  samples	  has	   led	  to	  the	   identification	  of	  two	  novel	  prognostic	  and	  
potentially	   therapeutic	   targets.	   We	   plan	   to	   assess	   these	   two	   proteins	   further:	  
S100A6	  as	  prognostic	  biomarker	  in	  the	  peripheral	  blood	  of	  UM	  patients,	  and	  PDCD4	  
as	   potential	   therapeutic	   target.	   In	   particular,	   we	   will	   assess	   the	   expression	   of	  
PDCD4	  by	  IHC	  in	  a	  TMA	  of	  metastatic	  UM,	  and	  by	  Western	  Blot	  in	  a	  variety	  of	  well-­‐
phenotyped	   cell	   lines	   derived	   from	   primary	   and	   metastatic	   UM.	   Our	   lab	   has	  
recently	   acquired	   a	   panel	   of	   newly	   characterised	   UM	   cell	   lines	   that	   show	  mTOR	  
pathway	   activation	   independent	   of	   AKT	   signalling	   and	   whose	   viability	   can	   be	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inhibited	   with	   the	   mTOR	   inhibitor	   Everolimus:180	   these	   will	   be	   the	   ideal	   tool	   to	  
study	  the	  relationship	  between	  PDCD4/SK61/PDCD4	  in	  UM.	  	  
	  In	   conclusion,	   proteomic	   analysis	   of	   UM	   tissues	   has	   been	   instrumental	   to	   the	  
identification	   of	   potentially	   very	   interesting	   proteins	   that	   have	   not	   yet	   been	   fully	  
investigated	  in	  UM,	  opening	  new	  avenues	  for	  collaborative	  research.	  Unfortunately,	  
the	   issues	   encountered	   with	   the	   iTRAQ	   labelling	   and	   samples	   degradation	   has	  
precluded	   the	   possibility	   to	   merge	   all	   the	   data	   and	   perform	   a	   systems	   biology	  
analysis	  of	  the	  large	  dataset	  from	  all	  the	  tumours.	  Moreover,	  although	  S100A6	  will	  
be	  investigated	  a	  serum	  biomarker,	   it	   is	  reasonable	  to	  speculate	  that	  a	  number	  of	  
potentially	   interesting	   secreted	   proteins	   could	   not	   be	   detected	   in	   the	   tumour	  
tissue.	   To	   overcome	   these	   limitations,	   we	   have	   then	   performed	   label-­‐free	  
comparative	   proteomic	   analysis	   of	   the	   secretome	   from	  HR	   versus	   LR	  UM	   cells	   in	  
short-­‐term	  cultures,	  as	  detailed	  in	  the	  next	  chapter.	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Chapter	  3 	  
Quantitative	  proteomic	  analysis	  of	  the	  secretome	  from	  
cultured	  primary	  uveal	  melanoma	  cells	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3.1 Introduction	  
Cancer	  biomarkers	  provide	  diagnostic,	  prognostic	  and	  therapeutic	  information	  and	  
are	  of	  increasing	  importance	  for	  early	  detection	  of	  disseminated	  disease.101	  Cancer	  
proteomics	  is	  a	  rapidly	  expanding	  field,	  which	  has	  increasing	  potential	  in	  biomarker	  
discovery.185	  Blood	   is	  a	   logical	  choice	   for	  biomarker	  application	  as	   its	  constituents	  
change	   rapidly	   in	   response	   to	   pathological	   states,	   and	   its	   sampling	   is	   easy	   and	  
comparatively	   less	   invasive.	   Accordingly,	   plasma	   and	   serum	  have	   been	   the	  major	  
targets	   of	   proteomic	   studies	   aimed	   at	   identifying	   potential	   cancer	   biomarkers.186	  
However,	  these	  studies	  have	  faced	  major	  technical	  limitations,	  due	  to	  the	  fact	  that	  
blood	  is	  a	  very	  complex	  fluid,	  comprising	  an	  enormous	  diversity	  of	  proteins	  with	  a	  
high	  dynamic	  range	  of	  concentrations.	  Essentially,	  a	  few	  high-­‐abundance	  proteins,	  
such	   as	   albumin	   and	   immunoglobulins,	   make	   the	   detection	   of	   low-­‐abundance	  
proteins	  extremely	  difficult,	  mainly	  because	  the	  disease-­‐specific	  biomarkers	  are	  at	  
low	   concentrations.	   A	   number	   of	   depletion	   techniques	   have	   been	   developed	   to	  
remove	  the	  more	  abundant	  proteins	  for	  proteomic	  analysis;	  however	  it	  is	  a	  labour-­‐
intensive	   process	   that	   may	   also	   indiscriminately	   remove	   the	   desired	   proteins	   by	  
nonspecific	   binding.187	   As	   a	   result,	   additional	   methods	   for	   cancer	   biomarker	  
discovery	   are	   being	   explored,	   such	   as	   analysing	   other	   accessible	   biological	   fluids,	  
and,	  in	  particular,	  the	  secretome.	  	  
The	   term	   “secretome”	   was	   originally	   introduced	   in	   a	   genome-­‐wide	   study	   of	  
secreted	   proteins	   in	   bacteria.188	   It	   is	   now	   commonly	   used	   to	   describe	   the	   total	  
proteins	  that	  are	  released	  by	  cells,	  tissues	  or	  organisms	  through	  different	  secretion	  
mechanisms,	   including	  classical	  secretion,	  non-­‐classical	  secretion	  and	  secretion	  via	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microvesicles.189	  It	  can	  also	  be	  broadly	  used	  to	  indicate	  the	  conditioned	  medium	  of	  
cells	   in	   culture,	   which	   contains	   proteins	   that	   are	   secreted,	   shed	   from	   the	   cell	  
surface	   and	   intracellular	   proteins	   released	   due	   to	   apoptosis,	   lysis	   or	   necrosis.190	  
Because	   the	   limited	   complexity	   of	   such	   samples	   enhances	   identification	   of	   less	  
abundant,	  disease-­‐specific	  proteins,	  secretome	  profiling	  of	  cancer	  cell	  lines	  is	  seen	  
as	  promising	  strategy	  for	  cancer	  biomarker	  discovery.191	  
A	  pioneer	  study	  by	  Pardo	  et	  al.	  successfully	  characterised	  the	  secretome	  of	  a	  panel	  
of	   UM	   cell	   lines	   (SP6.5,	   UW-­‐1,	   92.1,	   OCM-­‐1)	   and	   one	   short-­‐term	   primary	   UM	  
culture	   (UM-­‐A)	   by	   2DE	   and	   MS,	   and	   further	   validated	   the	   presence	   of	   two	  
candidate	   biomarkers	   (gp100	   and	   cathepsin	   D)	   in	   UM	   patients’	   sera.110	  
Interestingly,	  the	  authors	  pointed	  out	  that	  the	  variety	  and	  diversity	  of	  the	  proteins	  
identified	  in	  the	  short-­‐term	  primary	  UM	  culture	  (UM-­‐A)	  was	  much	  greater	  than	  in	  
the	   cell	   lines.	   Since	   the	   above-­‐mentioned	   publication,	   great	   progress	   has	   been	  
made	   in	  MS-­‐based	  analysis	  of	   clinical	   tissues	  and	  biofluids,	  with	   the	   identification	  
and	  quantification	  of	  thousands	  of	  proteins	  now	  becoming	  increasingly	  routine.192	  	  
Secretome	  analysis,	  however,	  does	  face	  analytical	  challenges	  that	  interfere	  with	  the	  
search	   for	   true	   secreted	   tumour	   biomarkers.	   In	   particular,	   it	   is	   important	   to	  
optimise	  experimental	  conditions,	  in	  order	  to	  minimise	  the	  contamination	  of	  serum	  
proteins	   in	   the	   conditioned	  medium.193	   However,	   at	   the	   same	   time,	   it	   is	   also	   as	  
important	   to	   monitor	   cell	   viability	   during	   secretome	   production	   if	   using	   ‘serum	  
starvation’.194	  
Based	   on	   the	   points	   above,	   the	   present	   study	   examined	   the	   secretome	  
(conditioned	  media)	   of	   a	   panel	   of	   heterogeneous	   primary	  UM	   cells	   in	   short-­‐term	  
culture,	  using	  a	  nanoLC-­‐MS/MS-­‐based	  label-­‐free	  quantitative	  proteomics	  approach,	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which	  had	  previously	  been	  used	  for	  colorectal	  cancer	  samples.185	  The	  aims	  of	  this	  
study	   were	   to	   increase	   our	   understanding	   of	   the	   metastatic	   process	   in	   UM	   and	  
possibly	   to	   identify	  a	  secreted	  biomarker	  of	  metastatic	  disease	  for	   these	  patients.	  
To	  achieve	  this,	  a	  comparative	  analysis	  of	  secretome	  samples	  from	  UM	  patients	  at	  
HR	   versus	   LR	   of	   developing	   metastatic	   disease,	   as	   well	   as	   normal	   choroidal	  
melanocytes	  from	  post-­‐mortem	  human	  eyes	  was	  performed.	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3.2 Methods	  
3.2.1 Establishment	  of	  primary	  UM	  cell	  cultures	  	  
3.2.1.1 Choice	  of	  culture	  medium	  
UM	  cells	  are	  notably	  hard	  to	  culture,	  and	  even	  when	  they	  do	  adhere	  to	  the	  bottom	  
of	  the	  flask,	  they	  grow	  slowly,	  with	  a	  doubling	  time	  of	  several	  days.	  Since	  it	  was	  our	  
intention	   to	  preserve	   the	  unique	   features	  and	   the	  heterogeneity	  of	  cells	   in	   short-­‐
term	   for	   secretome	   production,	   a	   culture	   medium	   was	   selected	   that	   favoured	  
enhanced	  plating	  efficiency	  and	  proliferation.	  Three	  media	  were	  compared	  (all	  cell	  
culture	   media,	   unless	   otherwise	   indicated,	   were	   supplied	   by	   Gibco,	   Life	  
Technologies,	  Paisley,	  UK):	  
i)	   “Standard”	   or	   Roswell	   Park	   Memorial	   Institute	   (RPMI)	   1640-­‐based:	   RPMI	   with	  
10%	   foetal	   bovine	   serum	   (FBS),	   antibiotics	   (penicillin	   50	   IU/ml,	   streptomycin	   500	  
µg/ml),	   and	   200	   mM	   L-­‐Glutamine.	   This	   is	   the	   medium	   most	   commonly	   used	   to	  
culture	  uveal	  melanoma	  cell	  lines.	  
ii)	  	  “Basal”	  or	  DMEM-­‐based:	  1:1	  Dulbecco’s	  modified	  Eagle’s	  medium	  (DMEM)	  high	  
glucose	   and	   Ham’s	   F12,	   1	   x	   B27	   supplement,	   20	   ng/ml	   epidermal	   growth	   factor	  
(EGF),	  1%	  FBS,	  plus	  antibiotics	  and	  L-­‐Glutamine	  as	  above.	  	  
iii)	  “Primary”	  or	  αMEM-­‐based:	  1:1	  Minimum	  Essential	  Medium,	  alpha	  modification	  
(αMEM)	  and	  Quantum	  3-­‐21,	   (PAA	  Laboratories	  Ltd,	  UK),	  10%	  FBS,	  plus	  antibiotics	  
and	   L-­‐Glutamine	  as	   above.	   This	   is	   a	   very	   rich	  medium,	   as	   the	  Quantum	  3-­‐21	  was	  
developed	  as	  a	  substitute	  for	  amniotic	   liquid	  to	  culture	  amniotic	  villi	   for	  antenatal	  
screening.	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Cells	  from	  two	  primary	  tumours	  (one	  M3,	  one	  D3)	  and	  two	  cell	   lines	  (Mel270	  and	  
OMM	  2.5)	  were	  seeded	  at	  a	  density	  of	  5000	  cells/well	  in	  a	  96-­‐well	  plate,	  in	  each	  of	  
the	  three	  different	  media.	  Cell	  number	  was	  assessed	  at	  day	  0,	  2,	  5	  and	  7	  using	  the	  
sulforhodamine-­‐B	   (SRB;	   Sigma)	   method	   with	   0.4%	   SRB	   dye.195	   This	   colourimetric	  
assay	  relies	  on	  the	  ability	  of	  the	  SRB	  dye	  to	  bind	  in	  a	  stoichiometric	  manner	  to	  basic	  
amino-­‐acid	  residues	  of	  cells	  that	  have	  been	  fixed	  by	  trichloroacetic	  acid	  (TCA).	  The	  
dye	   dissociates	   under	   basic	   conditions,	   and	   the	   intensity	   of	   the	   colour,	   which	   is	  
proportional	   to	   the	   cell	  mass,	   can	   be	   assessed	  with	   a	   plate	   reader.	   As	   there	   is	   a	  
linear	   relationship	   between	   the	   absorbance	   reading	   and	   the	   cell	   number,	   this	  
technique	   allows	   assessing	   and	   comparing	   the	   number	   of	   cells	   in	   the	   different	  
plates.	  
At	   various	   time	  points	   the	  medium	  was	   removed	   from	   the	  96	  well	   plate	   and	   the	  
cells	  were	  fixed	  with	  100µl	  10%	  TCA	  (Sigma)	  for	  1	  hour	  at	  4°C.	  The	  plates	  were	  then	  
washed	  with	  distilled	  water	  and	  allowed	  to	  air	  dry.	  100µl	  0.4%	  SRB	  in	  1%	  acetic	  acid	  
was	  then	  added	  to	  each	  well	  of	  the	  plate	  and	  incubated	  for	  1	  hour	  at	  RT.	  Unbound	  
SRB	   was	   removed	   by	   rinsing	   the	   plate	   in	   1%	   acetic	   acid	   prior	   to	   solubilising	   the	  
bound	   dye	   with	   10mM	   Tris	   base	   solution.	   Absorbance	   readings	   were	   made	   at	  
570nm	  on	  a	  microplate	   reader	   (ELx	  800,	  BioTek)	   and	   the	  background	  absorbance	  
measured	  at	  650nm	  subtracted	  from	  these	  values.	  All	  data	  were	  analysed	  in	  Excel.	  	  
To	  corroborate	  the	   findings	  and	  for	   their	  use	   in	   the	  experiments	  described	  within	  
this	  chapter,	  this	  same	  experiment	  was	  repeated	  with	  three	  UM	  primary	  samples.	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3.2.1.2 Samples	  
Following	  approvals	   from	   the	   local	  and	  national	  ethics	   committees	   (NRES	  Ref	  No.	  
11/NW/0568),	   fresh	   UM	   specimens	   were	   acquired	   via	   the	   LOOB	   from	   patients	  
undergoing	  enucleation	  or	  transcleral	  local	  resection	  as	  their	  primary	  treatment	  for	  
UM.	   Clinical,	   histopathological	   and	   genetic	   information	   for	   each	   sample	   were	  
available	   for	   each	   specimen,	   so	   that	   the	   risk	   category	   for	   developing	   metastatic	  
disease	  could	  be	  determined,	  as	  explained	  in	  Chapter	  1.	  
3.2.1.3 Isolation	  and	  culture	  of	  primary	  UM	  cells	  	  
A	  small	  sample	  of	  fresh	  UM	  tissue	  (approximately	  3	  mm3,	  depending	  on	  the	  size	  of	  
the	  tumour)	  was	  collected	  within	  an	  hour	  of	  surgical	  removal,	  and	  placed	  in	  RPMI	  
containing	   antibiotics.	   All	   subsequent	   procedures	   were	   performed	   under	   sterile	  
conditions	   in	   a	   Class	   II	   Biological	   Safety	   Cabinet.	   A	   single	   cell	   suspension	   was	  
obtained	   by	   finely	   mincing	   the	   sample	   with	   a	   sterile	   scalpel	   blade,	   and	   then	  
subsequently	  digesting	  the	  clumps	  with	  5	  ml	  of	  type	  I	  collagenase	  (Sigma)	  at	  37°C	  
for	  approximately	  1	  hour,	  with	  occasional	  agitation	  of	  the	  solution.	  The	  presence	  of	  
single	   cells	   was	   assessed	   by	   examining	   a	   10	   μl	   aliquot	   on	   the	   haemocytometer.	  
When	   digestion	   was	   considered	   complete,	   FBS	   was	   added	   to	   a	   concentration	   of	  
10%.	  The	  single	  cells	   in	  the	  solution	  were	  then	  recovered	  by	  gentle	  centrifugation	  
(1800	   rpm	   for	   2	   minutes)	   and	   re-­‐suspended	   in	   primary	   medium.	   The	   cells	   were	  
counted	  under	  the	  haemocytometer	  and	  seeded	  into	  two	  T75	  vented	  tissue	  culture	  
flasks	  (Falcon,	  VWR	  international,	  Leicestershire,	  UK)	  at	  a	  density	  of	  1.5x106	  cells	  in	  
10	  ml	   of	  medium.	   The	   flasks	  were	   kept	   at	   37°C	   in	   a	   humidified	   95%	   air,	   5%	   CO2	  
incubator	  and	  grown	  to	  approximately	  75-­‐80%	  confluence.	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3.2.2 Characterisation	  of	  cells	  in	  culture	  
Particular	  attention	  was	  paid	  to	  document	  the	  characteristics	  of	  each	  primary	  UM	  
cell	  culture,	  and	  to	  determine	  its	  similarity	  with	  the	  original	  tumour,	  so	  that	  results	  
from	   downstream	   analyses	   could	   be	   related	   to	   its	   clinical	   features.	   Data	   were	  
recorded	  in	  a	  template	  designed	  ad	  hoc	  to	  summarise	  all	  the	  available	  information	  
from	   the	  original	   tumour,	   as	  well	   as	   tracking	   the	  processing	  of	   the	   cultured	   cells.	  
Observations	   of	   the	   characteristics	   of	   each	   culture	   used	   for	   production	   of	  
secretome	  were	  also	  recorded	  in	  a	  systematic	  manner	  using	  a	  template.	  
3.2.2.1 Cellular	  morphology	  
The	  morphology	  of	  the	  cells	  in	  culture	  was	  observed	  using	  an	  inverted	  microscope	  
and	  documented	  by	  digital	   images.	  Primary	  UM	  cells	   can	  grow	  as	  a	  monolayer	  of	  
spindle	  cells	   creating	  a	  neural-­‐like	  network	  or	  as	  a	  carpet	  of	  more	  epithelioid-­‐like	  
cells.	   Occasionally,	   clumps	   or	   small	   spheres	   of	   cells	   formed,	   which	   were	   then	  
spontaneously	  shed	   into	   the	  culture	  medium.	  These	  different	  phenotypes	  are	  not	  
mutually	  exclusive	  as	   they	   reflected	   the	  variety	  of	  UM	  cells	   in	   the	  primary	   tissue.	  
The	  degree	  of	  pigmentation	  was	  also	  variable	  and	  can	  be	  best	  appreciated	  in	  bright	  
field	   microscopy.	   The	   presence	   of	   other	   cells,	   classified	   as	   fibroblasts	   or	  
mesenchymal	   -­‐like	   cells	   was	   also	   recorded.	   Both	   overgrowth	   by	   fibroblasts	   or	  
suspicion	  of	  infection	  were	  strict	  exclusion	  criteria	  for	  collection	  of	  the	  secretome.	  
3.2.2.2 Immunofluorescence	  
From	  each	  primary	  UM,	   cells	  were	  also	   seeded	  at	  50,000	   cells/well	   in	   two	  8-­‐well	  
glass	  chamber	  slides	  (Fisher	  Scientific,	  UK)	  and	  grown	  to	  70-­‐80%	  confluence	  before	  
being	  fixed	  with	  3.7%	  formaldehyde	  in	  phosphate	  buffered	  saline	  (PBS)	  for	  10	  mins.	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This	  was	  performed	  in	  order	  to	  determine	  the	  proportion	  and	  characteristics	  of	  UM	  
cells	   in	   the	   culture,	   using	   a	   panel	   of	   antibodies	   known	   to	   characterise	   the	  
melanocytic	  lineage,	  as	  previously	  shown	  in	  UM	  cell	  lines	  (Table	  3.1).196	  In	  order	  to	  
allow	   for	   the	  detection	  of	  nuclear	  antigens,	  permeabilisation	  was	  performed	  with	  
0.2%	  Triton	  X-­‐100	  for	  5	  mins	  at	  RT,	  followed	  rinsing	  in	  PBS.	  Blocking	  was	  achieved	  
by	  incubating	  the	  cells	  with	  10%	  normal	  goat	  serum	  in	  PBS	  containing	  1%	  BSA	  for	  1	  
hour	   at	   RT.	   Incubation	  with	   primary	   antibodies	   was	   performed	   overnight	   at	   4°C,	  
followed	  by	  appropriate	  rinsing	  in	  PBS	  before	  addition	  of	  the	  appropriate	  secondary	  
antibody:	   goat	   anti-­‐rabbit	   Alexa	   Fluor®	   555	   or	   goat	   anti-­‐mouse	   Alexa	   Fluor®	   488	  
(both	  from	  Molecular	  Probes,	  Life	  Technologies,	  Paisley,	  UK).	  Slides	  were	  incubated	  
for	   1	   hour	   at	   RT	   in	   the	  dark,	   and	   subsequently	   rinsed	   in	   PBS.	   Finally,	   Vectashield	  
(Vector	   Laboratories,	   Peterborough,	   UK)	   mounting	   medium	   with	   DAPI	   (4',6-­‐
diamidino-­‐2-­‐phenylindole)	   was	   applied	   to	   counterstain	   the	   nuclei,	   prevent	  
photobleaching	  and	  drying	  of	  the	  slide	  under	  the	  coverslip.	  
	  
Table	   3.1	   Details	   of	   the	   antibodies	   used	   to	   characterise	   primary	   UM	   cells	   in	   short-­‐term	  
cultures	  
	  
Antibody) Full)name) Species) Isotype) Dilution) Supplier)
HMB45& Melanocyte&lineage1specific&antigen& Mouse& IgG1k& 1:200& Dako&
Ki67& Ki67& Mouse) IgG1k& 1:200& Leica&
MelanA& Melan1A&/&MART1& Mouse& IgG1k& 1:100& Dako&





VIM& Vimentin& Mouse& IgG2a& 1:200& Dako&
&
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3.2.2.3 Genetic	  profiling	  of	  cells	  in	  culture	  
Following	   incubation	   of	   the	   cells	   in	   serum-­‐free	   medium	   (SFM)	   for	   secretome	  
production	   (see	   below),	   primary	   UM	   cells	   were	   harvested	   and	   split	   into	   two	   cell	  
pellets:	  one	  cell	  pellet	  was	  stored	  for	  further	  protein	  analyses,	  the	  other	  was	  lysed	  
in	  180μl	  of	  ATL	  buffer	   (Qiagen)	   and	   stored	  at	   -­‐20°C	   for	  DNA	  extraction.	  When	  all	  
cultures	  had	  been	  completed,	  samples	  were	  retrieved	  and	  DNA	  was	  extracted	  and	  
quantified.	   Depending	   on	   the	   DNA	   concentration	   obtained,	   either	  MSA	   or	  MLPA	  
was	  performed,	  and	  compared	  to	  the	  genetic	  profile	  of	  the	  primary	  UM	  specimen.	  
All	   of	   the	   above-­‐mentioned	   procedures	   were	   performed	   following	   the	   same	  
protocols	  used	  for	  clinical	  samples.197	  Please	  refer	  to	  Chapter	  5	   for	   further	  details	  
on	  these	  techniques.	  
3.2.3 Establishment	  of	  choroidal	  melanocytes	  in	  culture	  
3.2.3.1 Samples	  
Human	  choroidal	  melanocytes	  were	   isolated	   from	  post-­‐mortem	  eyes	  with	  a	  delay	  
of	   less	  of	  8	  hours,	  obtained	  with	  consent	  from	  the	  Lions	  New	  South	  Wales	  (NSW)	  
Eye	  Bank,	  by	  our	  collaborator	  Dr	  Michele	  Madigan	   in	  Sydney,	  Australia.	  The	  study	  
was	  performed	  according	  to	  the	  Declaration	  of	  Helsinki	  and	  with	  approval	  from	  the	  
University	  of	  Sydney	  Human	  Research	  Ethics	  Committee.	  	  
3.2.3.2 Isolation	  and	  culture	  of	  human	  choroidal	  melanocytes	  
All	   chemicals,	   unless	  otherwise	   indicated,	  where	   supplied	  by	   Sigma	  Chemical	  Co.,	  
St.	   Louis,	   MO	   (USA).	   Melanocytes	   were	   isolated	   and	   grown	   as	   previously	  
described198	   with	   minor	   modifications.	   Briefly,	   the	   anterior	   segment	   and	   the	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vitreous	  were	  removed.	  The	  retina	  was	  gently	  separated	  from	  the	  ora	  serrata,	  and	  
then	  cut	  at	  the	  optic	  nerve	  head	  and	  removed	  from	  the	  eyecup,	  leaving	  the	  retinal	  
pigment	  epithelium	  (RPE)	  and	  underlying	  choroid	  and	  sclera.	  The	  eyecup	  was	  filled	  
with	  warm	  0.25%	  trypsin	  /	  0.1%	  EDTA	  (ethylene-­‐diamine-­‐tetra-­‐acetic	  acid)	   in	  PBS,	  
and	   incubated	  at	  37°C	  for	  45	  minutes,	   then	  the	  RPE	  removed	  by	  gentle	  pipetting.	  
The	   eyecup	   was	   rinsed	   with	   warm	   PBS	   several	   times	   and	   the	   choroid	   finally	  
removed	   from	   the	   underlying	   sclera,	   being	   careful	   to	   avoid	   the	   optic	   nerve	   head	  
tissue.	   The	   choroid	   was	   then	   dissected	   into	   pieces	   approximately	   5mm	   x	   5mm,	  
further	  rinsed	  in	  PBS,	  then	  incubated	  overnight	  (approximately	  18	  hours)	  in	  0.25%	  
trypsin	  /	  0.1%	  EDTA	  at	  4°C	  with	  gentle	  shaking.	  	  
Following	  this,	  the	  choroid	  pieces	  were	  incubated	  for	  60	  minutes	  at	  37°C,	  and	  then	  
10	   ml	   warm	   Ham’s	   F12	   /	   10%	   FBS	   medium	   was	   added.	   Cells	   were	   collected	   by	  
centrifugation	   (290	  x	  g	   for	  5	  minutes	  at	  20°C)	  and	  plated	   into	  a	  6	  well	  plate.	  The	  
choroid	  pieces	  were	  then	  further	   incubated	   in	   two	  changes	  of	  1.2	  U/ml	  dispase	   II	  
and	  0.5mg/ml	   collagenase	  at	  37°C	   for	  1	  hour,	   after	  which	   cells	  were	   collected	  by	  
centrifugation	  (290	  x	  g	  for	  5	  mins	  at	  20°C)	  and	  plated	  into	  subsequent	  wells	  of	  the	  6	  
well	  plate.	  
Isolated	  cells	  were	  maintained	  at	  37°C	  and	  5%	  CO₂	  and	  initially	  washed	  with	  warm	  
PBS	  at	  3	  to	  4	  days	  after	  plating	  to	  remove	  unattached	  cells.	  	  Cells	  were	  then	  grown	  
for	  a	  further	  2	  weeks	  in	  melanocyte	  growth	  medium	  (MGM),	  with	  growth	  medium	  
changes	  twice	  weekly.	  The	  MGM	  was	  composed	  of:	  Ham’s	  F12	  supplemented	  with	  
10%	   heat	   inactivated	   FBS,	   2	   mM	   L-­‐glutamine,	   50	   IU/ml	   penicillin/50	   μg/ml	  
streptomycin	  and	  10	  ng/ml	  cholera	   toxin,	  100	  nM	  PMA	  (phorbol	  12-­‐myristate	  13-­‐
acetate)	  and	  0.1	  mM	  isobutylmethylxanthine	  (IBMX).	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Cells	  were	  detached	  using	  0.25%	  trypsin/0.1%	  EDTA	  for	  2	  mins	  and	  centrifuged	  (163	  
x	  g	  for	  5	  mins	  at	  20°C),	  resuspended	  in	  MGM	  and	  subcultured	  in	  35mm	  dishes,	  25	  
cm2	   flasks	   or	   in	   8-­‐well	   chamber	   slides	   for	   immunocytochemistry	   (see	   below).	  
Passage	  1–3	  melanocytes	  were	  used	  for	  all	  experiments.	  Cells	  were	  maintained	  in	  a	  
humidified	  incubator	  at	  37°C	  and	  5%	  CO2.	  
3.2.3.3 Characterisation	  by	  immunocytochemistry	  	  
Immunostaining	   was	   performed	   on	   primary	  melanocytes	   as	   follows.	   Sterile	   glass	  
coverslips	  or	  8-­‐well	  chamber	  slides	  were	  seeded	  with	  2.5	  to	  3	  ×	  104	  cells	   in	  MGM	  
and	   incubated	   at	   37°C	   for	   3	   to	   5	   days.	   Cells	   in	   chamber	   slides	   were	   fixed	   in	   2%	  
paraformaldehyde	   in	   PBS	   (pH	   7.4)	   for	   20	  minutes	   at	   RT,	   then	   rinsed	   in	   PBS	   and	  
blocked	  in	  5%	  BSA	  for	  30	  mins	  to	  reduce	  non-­‐specific	  binding.	  	  
Primary	  antibodies	  (all	  from	  Thermo	  Fisher	  Scientific	  Australia	  Pty	  Ltd,	  Scoresby	  Vic)	  
used	   to	   assess	   the	   melanocyte	   cultures	   included	   Mel	   Ab-­‐3	   (HMB45+HMB50)	  
Tyrosinase	  (T311),	  TRYP1	  (TA99),	  MART-­‐1	  Ab-­‐3,	  gp-­‐100	  and	  vimentin.	  	  
Cells	  were	  incubated	  with	  primary	  antibodies	  overnight	  at	  4°C,	  rinsed	  in	  PBS	  three	  
times,	   followed	   by	   incubation	   in	   the	   appropriate	   species-­‐specific	   Alexa-­‐488	  
conjugated	  secondary	  antibody	  (1:1000,	  Molecular	  Probes,	  USA)	  for	  1	  h	  at	  RT.	  Cells	  
were	   then	   further	   rinsed	   in	   PBS,	   nuclei	   stained	   with	   either	   DAPI	   (1:10,000)	   or	  
propidium	  iodide	  (1:10,000)	  for	  5	  mins,	  then	  rinsed,	  and	  finally	  chamber	  slide	  wells	  
removed	  and	  the	  slide	  cover-­‐slipped	   in	  glycerol	  and	  sealed	  with	  nail	  varnish.	  Cells	  
were	  viewed	  with	  an	  Olympus	  DP70	  fluorescence	  microscope	  (Olympus,	  Japan)	  or	  a	  
Zeiss	   LSM510	   confocal	   microscope.	   Immunofluorescence	   images	   were	   collected	  
with	  either	  Olympus	  DP70	  Manager	  Software	  or	  Zeiss	  ZEN	  software.	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3.2.4 Secretome	  sample	  preparation	  and	  collection	  
Secretome	   analysis	   is	   usually	   performed	   by	   incubating	   cells	   in	   SFM,	   in	   order	   to	  
avoid	  contamination	  and	  any	  masking	  of	  secreted	  proteins	  by	  serum	  proteins	  from	  
the	  cell	  culture	  media.199	  Moreover,	   the	  cell	  monolayer	  requires	  rinsing	  to	  ensure	  
removal	  of	  adherent	  serum	  proteins	  prior	  to	  incubation	  in	  SFM.193	  Please	  note	  that	  
from	  this	  point	  onwards,	  SFM	  indicates	  phenol-­‐red	  free	  αMEM	  (Gibco),	  without	  any	  
other	  supplement.	  
Preliminary	   optimization	   experiments	   (Appendix	   3)	   demonstrated	   that	   the	   most	  
effective	  way	  to	  remove	  albumin	  and	  other	  serum	  proteins	  from	  UM	  cells	  in	  culture	  
was	  to	  follow	  the	  protocol	  originally	  developed	  for	  glioblastoma	  cells.200	  Briefly,	  the	  
cell	  monolayer	  was	  gently	  rinsed	  three	  times	  with	  10	  ml	  of	  PBS,	  incubated	  with	  10	  
ml	   of	   SFM	   for	   1	   hour,	   and	   rinsed	   once	   again	   with	   fresh	   SFM.	   Cells	   were	  
subsequently	   incubated	   with	   8	   ml	   of	   SFM	   for	   48	   hours,	   and	   the	   conditioned	  
medium	  at	  the	  end	  of	  the	  incubation	  period	  was	  defined	  as	  the	  secretome.	  
3.2.4.1 Secretome	  collection	  
At	   the	   end	   of	   the	   incubation	   period,	   the	   secretome	   from	   both	   T75	   flasks	   of	   the	  
same	   patient	   was	   pooled	   into	   a	   30	  ml	   universal	   tube,	   and	   gently	   centrifuged	   at	  
1660	  rpm	  x	  5	  mins	  at	  4°C	  to	  pellet	  any	  floating	  cells.	  The	  supernatant	  was	  aliquoted	  
in	  1	  ml	  units	  and	  stored	  at	  -­‐80°C.	  	  
3.2.4.2 Cell	  viability	  assay	  
The	  cell	  monolayer	  was	  rinsed	  with	  Hanks's	  Balanced	  Salt	  Solution	  without	  calcium	  
and	   magnesium	   (Gibco),	   covered	   with	   3	   ml	   of	   non-­‐enzymatic	   cell	   dissociation	  
solution	  (Sigma)	  and	  incubated	  at	  37°C	  for	  5-­‐10	  mins.	  When	  the	  cells	  had	  detached,	  
	  
	   103	  
they	  were	  collected	   in	   the	   same	  universal	   tube	  used	  previously,	   so	   that	  adherent	  
and	   non-­‐adherent	   cells	   were	   combined	   and	   viability	   assessed	   by	   Trypan	   Blue	  
exclusion	  test.201	  Trypan	  blue	  dye	  in	  PBS	  (10	  μl	  of	  0.4%	  w/v)	  was	  mixed	  with	  10	  μl	  of	  
cell	  suspension	  and	  observed	  under	  the	  microscope.	  Cell	  viability	  was	  expressed	  as	  
the	  ratio	  of	  total	  viable	  cells	  to	  the	  sum	  of	  total	  viable	  and	  dead	  (i.e.	  blue)	  cells.	  
The	  residual	  cell	  suspension	  was	  split	  into	  two	  and	  centrifuged	  at	  2000g	  x	  10	  mins:	  
one	  part	  was	  used	  for	  DNA	  extraction	  as	  explained	  above,	  the	  rest	  was	  stored	  ‘dry’	  
at	  -­‐80°C.	  	  
The	   same	   protocol	   was	   adopted	   for	   secretome	   production	   from	   choroidal	  
melanocytes	   in	   culture,	  with	  a	  difference	  only	   in	   the	   volume	  of	  medium	  used,	   as	  
these	  cells	  were	  cultured	  in	  35	  mm	  dishes.	  The	  final	  volume	  of	  secretome	  for	  each	  
sample	  was	  1.4	  ml,	  which	  was	  aliquoted	  (700	  μl	  per	  vial)	  and	  stored	  at	  -­‐80°C	  until	  
further	  analysis.	  	  
The	  cell	  monolayer	  was	  harvested	  as	  described	  above,	  cell	  viability	  was	  also	  tested	  
by	  Trypan	  blue,	  and	  the	  whole	  cell	  pellet	  was	  stored	  for	  future	  protein	  analysis	  (i.e.,	  
no	  DNA	  extraction	  was	  performed).	  
3.2.5 Secretome	  analysis	  
3.2.5.1 Protein	  quantification	  and	  digestion	  
All	  proteomic	  analyses	  were	  conducted	  only	  once	  the	  prospective	  collection	  of	  all	  
secretome	  samples	  had	  been	  completed.	  
Protein	   concentration	   was	   determined	   for	   all	   UM	   secretome	   samples	   using	   a	  
Bradford	   assay	   reagent	   (Pierce	   Coomassie	   Plus,	   Thermo	   Scientific)	   as	   previously	  
described	   in	   Chapter	   2.	   Samples	   were	   diluted	   two-­‐and	   four-­‐fold	   and	   after	   the	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addition	  of	  reagent,	  samples	  were	  read	  at	  595	  nm	  in	  a	  plate	  reader	  (Multiskan	  FC,	  
Thermo	   Scientific)	   and	   protein	   amounts	   interpolated	   from	   a	   BSA	   standard	   curve.	  
For	   each	   sample,	   a	   volume	   equivalent	   to	   15	   µg/ml	   was	   added	   to	   a	   low	   bind	  
microfuge	   tube	   containing	   10	   µl	   of	   StrataClean	   resin	   (Agilent	   Technologies	   Ltd,	  
Oxfordshire,	  UK)	  (B1).	   	  Samples	  were	  vortexed	  for	  1	  min,	  centrifuged	  at	  2000	  rpm	  
for	   2	   mins,	   and	   the	   supernatant	   aspirated	   and	   transferred	   to	   a	   second	   tube	  
containing	   10	   µl	   of	   beads	   (B2).	   After	   vortexing	   for	   1	  min,	   the	   beads	   and	   sample	  
were	  transferred	  to	  the	  first	  tube	  containing	  B1	  and	  the	  sample	  centrifuged	  and	  the	  
supernatant	   discarded.	   The	   beads	   were	   washed	   twice	   with	   1	   ml	   of	   25	   mM	  
ammonium	  bicarbonate	  (hereafter	  termed	  ‘ambic’)	  (not	  pH	  adjusted).	  For	  on-­‐bead	  
digestion,	   the	  beads	  were	   re-­‐suspended	   in	  80	  µl	  of	  25	  mM	  ambic	  and	  5	  µl	  of	  1%	  
(w/v)	  Rapigest	  (Waters	  Limited,	  Hertfordshire,	  UK)	  in	  100	  mM	  ambic.	  The	  samples	  
were	  heated	  at	  80°C	  for	  10	  mins.	  Samples	  were	  reduced	  by	  the	  addition	  of	  5	  µl	  of	  
dithiothreitol	   (DTT,	   9.2	  mg/ml	   in	   25	  mM	  ambic)	   and	  heated	   at	   60°C	   for	   10	  mins.	  
Following	   cooling,	   5	  µl	   of	   iodoacetamide	   (33	  mg/ml	   in	  25	  mM	  ambic)	  was	   added	  
and	  the	  samples	   incubated	  at	  RT	   for	  30	  mins	   in	   the	  dark.	  Trypsin	   (Porcine	  trypsin	  
sequencing	  grade,	  Sigma)	  (1µg)	  was	  added	  and	  the	  sample	  was	   incubated	  at	  37°C	  
overnight	  on	  a	  rotary	  mixer.	  
The	   digests	  were	   acidified	   by	   the	   addition	   of	   1	   µl	   of	   trifluoracetic	   acid	   (TFA)	   and	  
incubated	  at	  37°C	  for	  45	  mins.	  Samples	  were	  then	  centrifuged	  at	  17,000	  x	  g	  for	  30	  
mins	   and	   supernatants	   transferred	   to	   0.5	   ml	   low-­‐binding	   tubes.	   Samples	   were	  
centrifuged	  for	  a	  further	  30	  mins	  and	  10	  µl	  transferred	  to	  total	  recovery	  vials	  for	  LC-­‐
MS	   analysis.	   The	   pre	   and	   post-­‐acidification	   digest	  were	   analysed	   by	   SDS-­‐PAGE	   to	  
check	  for	  the	  absence	  of	  protein	  and	  hence	  complete	  digestion.	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3.2.5.2 Liquid	  chromatography	  
All	   peptide	   separations	  were	   carried	  out	  using	   an	  Ultimate	  3000	  Nano	   LC	   system	  
(Dionex,	  Thermo	  Fisher	  Scientific).	  For	  each	  analysis	  the	  sample	  was	  loaded	  onto	  a	  
trap	  column	  (Acclaim	  PepMap	  100,	  2	  cm	  x	  75	  µm	  inner	  diameter,	  C18,	  3	  µm,	  100Å)	  
at	   5	   ml/min	   with	   an	   aqueous	   solution	   containing	   0.1%	   (v/v)	   TFA	   and	   2%	   (v/v)	  
acetonitrile.	  After	  3	  mins,	  the	  trap	  column	  was	  set	  on-­‐line	  with	  an	  analytical	  column	  
(Easy-­‐Spray	   PepMap®	   RSLC	   15	   cm	   x	   75	   µm	   inner	   diameter,	   C18,	   2	   µm,	   100Å)	  
(Dionex).	  Peptide	  elution	  was	  performed	  by	  applying	  a	  mixture	  of	  solvents	  A	  and	  B.	  
Solvent	   A	  was	   HPLC	   grade	  water	  with	   0.1%	   (v/v)	   formic	   acid,	   and	   solvent	   B	  was	  
HPLC	   grade	   acetonitrile	   80%	   (v/v)	   with	   0.1%	   (v/v)	   formic.	   Separations	   were	  
performed	  by	  applying	  a	   linear	  gradient	  of	  3.8%	  to	  50%	  solvent	  B	  over	  95	  min	  at	  
300	   nl/min	   followed	   by	   a	   washing	   step	   (5	   mins	   at	   99%	   solvent	   B)	   and	   an	  
equilibration	  step	  (15	  mins	  at	  3.8%	  solvent	  B).	  2	  µl	  of	  each	  sample	  was	  injected.	  	  
3.2.5.3 Mass	   spectrometry	   analyses	   on	   a	   Quadrupole-­‐Orbitrap	  
instrument	  	  
The	  Q	  ExactiveTM	  (Thermo	  Fisher)	  instrument	  was	  operated	  in	  the	  ‘data	  dependent	  
mode’	  to	  automatically	  switch	  between	  full	  scan	  MS	  and	  MS/MS	  acquisition.	  Survey	  
full	   scan	   MS	   spectra	   (m/z	   300-­‐2000)	   were	   acquired	   in	   the	   Orbitrap	   with	   70,000	  
resolution	   (m/z	   200)	   after	   accumulation	   of	   ions	   to	   1x106	   target	   value	   based	   on	  
predictive	  automatic	  gain	  control	  (AGC)	  values	  from	  the	  previous	  full	  scan.	  Dynamic	  
exclusion	  was	  set	  to	  20	  s.	  The	  10	  most	   intense	  multiply	  charged	   ions	  (z	  ≥	  2)	  were	  
sequentially	  isolated	  and	  fragmented	  in	  the	  octopole	  collision	  cell	  by	  ‘higher	  energy	  
collisional	   dissociation’	   (HCD)	   with	   a	   fixed	   injection	   time	   of	   100	  ms	   and	   17,500x	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resolution.	  Typical	  MS	  conditions	  were	  as	  follows:	  spray	  voltage,	  1.9kV,	  no	  sheath	  
and	   auxillary	   gas	   flow;	   heated	   capillary	   temperature,	   275°C;	   normalised	   HCD	  
collision	  energy	  30%.	  The	  MS/MS	  ion	  selection	  threshold	  was	  set	  to	  1	  x	  104	  counts.	  
A	  2Da	  isolation	  width	  was	  set.	  
3.2.5.4 Database	  search	  and	  protein	  identification	  	  
Raw	  data	   files	  were	  uploaded	   into	  Proteome	  Discoverer	  1.3	  and	  searched	  against	  
the	   human	   UniProt	   database	   using	   the	   Mascot	   search	   engine	   (version	   2.4.1).	   A	  
precursor	   ion	   tolerance	  of	  10	  ppm	  and	  a	   fragment	   ion	   tolerance	  of	  0.01	  Da	  were	  
used	  with	   carbamidomethyl	   cysteine	   set	   as	   a	   fixed	  modification	   and	   oxidation	   of	  
methionine	  as	  a	  variable	  modification.	  The	  FDR	  against	  a	  decoy	  database	  was	  1-­‐5%.	  	  
The	   data	   set	   was	   analysed	   using	   Progenesis®	   4.1	   (Nonlinear	   Dynamics	   Limited,	  
Newcastle	  upon	  Tyne,	  UK)	  label-­‐free	  quantification	  software,	  where	  detection	  and	  
quantification	   of	   all	   peptide	   ions	   is	   followed	   by	   expression	   analysis	   and	  
identification	   of	   the	   proteins	   from	   which	   they	   originate.	   Protein	   abundance	   is	  
calculated	   from	   the	   sum	   of	   all	   unique	   normalised	   peptide	   ion	   abundances	   for	   a	  
specific	   protein	   on	   each	   run.	   Alignment	   and	   co-­‐detection	   of	   features	   means	   the	  
same	  number	  of	  identified	  peptides	  is	  quantified	  on	  all	  runs	  so	  that	  it	  is	  possible	  to	  
compare	   the	   sum	  of	   ion	   abundances	   between	   groups.	   The	   top	   5	  MS/MS	   spectra	  
were	  exported	   from	   the	  Progenesis®	   software	   as	   a	  Mascot	   generic	   file	   (mgf)	   and	  
used	   for	   peptide	   identification	   using	   the	   above	   settings.	   The	   search	   results	  were	  
adjusted	  to	  a	  FDR	  of	  1%	  and	  imported	  into	  Progenesis®.	  When	  comparing	  different	  
groups	   (i.e.	   normal	   versus	   tumour,	   or	   HR	   versus	   LR),	   a	   protein	   was	   defined	   as	  
differentially	  expressed	  if	  the	  fold	  change	  was	  at	  least	  2,	  with	  Anova	  set	  at	  p≤0.01.	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3.2.6 Bioinformatics	  	  
3.2.6.1 Prediction	  of	  secreted	  proteins	  
To	  determine	  how	  many	  of	  the	  proteins	  identified	  in	  our	  secretome	  were	  actually	  
secreted,	  we	  used	  a	  combination	  of	  bioinformatics	  tools,	  which	  are	  freely	  available	  
online,	  and	  which	  have	  been	  validated	  for	  prediction	  of	  secreted	  proteins.202	  	  
In	   particular,	   we	   used	   SignalP	   4.0	   to	   estimate	   the	   presence	   of	   secretory	   signal	  
peptide	   sequences	   (classical	   secretion	   pathway),203	   SecretomeP	   to	   deduce	   non-­‐
signal	   peptide-­‐triggered	   protein	   secretion	   (non-­‐classical	   secretion),204	   and	   the	  
transmembrane	   Hidden	   Markov	   model	   (TMHMM)	   to	   predict	   transmembrane	  
helices.205	  
3.2.6.2 Identification	   of	   protein	   signature	   discriminating	   between	   HR	  
and	  LR	  	  
Expression	   analysis	   and	   hierarchical	   clustering	   of	   peptide	  MS	   intensity	   data	   from	  
Progenesis®	  was	  performed	   in	  Partek®	  Genomics	  Suite®	  6.6	   (Partek	   Incorporated,	  
Missouri,	   USA)	   following	   data	   normalisation	   using	   the	   open-­‐source	   statistical	  
package	  R	   (version	  3.1.0).	   Peptides	  with	   identification	   confidence	   FDR	   values	   less	  
than	  1%	  were	  selected.	  MS	  intensity	  data	  were	  ‘floored’	  to	  0.001	  before	  a	  Shapiro-­‐
Wilks	  normality	  test	  was	  applied	  to	  log2	  transformed	  data.	  Those	  peptides	  with	  log	  
normal	  distribution	  were	  retained	  and	  these	  were	   filtered	  to	  retain	  peptides	  with	  
coefficient	  of	  variation	  <10%	  and	  interquartile	  range	  exceeding	  0.5	  across	  patients.	  	  
With	  the	  aim	  of	  identifying	  a	  protein	  signature	  that	  would	  discriminate	  between	  HR	  
and	   LR,	   we	   selected	   only	   those	   secretome	   samples	   with	   a	   well-­‐defined	   genetic	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profile.	  Hierarchical	   clustering	  of	   differentially	   expressed	   log	   transformed	  peptide	  
intensity	  data	  was	  performed	  over	  both	  peptides	  and	  patients	  using	  the	  Euclidean	  
distance	  and	  average	  linkage	  in	  both	  cases.	  Clustered	  peptide	  intensity	  values	  were	  
visualised	  by	   shifting	   the	   column	  mean	   to	   zero	  with	   standard	  deviation	   scaled	   to	  
one.	  
3.2.7 Validation	  of	  putative	  biomarkers	  by	  quantitative	  Western	  Blot	  
MS-­‐derived	   data	   have	   previously	   required	   validation	   by	   another	   technique,	   to	  
confirm	  the	  presence	  of	  the	  protein	  of	  interest	  in	  the	  sample.	  Typically,	  this	  would	  
have	   been	   performed	   with	   an	   antibody-­‐based	   assay,	   such	   as	   ELISA	   or	   Western	  
Blotting.	  We	  are	  of	  the	  opinion	  that	  with	  modern	  MS	  and	  associated	  identification	  
software,	   this	   is	   no	   longer	   necessary.	   It	   is	   recognised,	   however,	   that	   label-­‐free	  
protein	   quantification	   performed	   by	   Progenesis®	   software	   remains	   a	   relative	  
quantification,	   and	   therefore	   a	   low	   abundance	   protein	   may	   be	   difficult	   to	   be	  
correctly	   quantified	   in	   the	   original	   sample.	   MS-­‐based	   techniques	   for	   absolute	  
quantification	   are	   available206	   and	   have	   shown	   promising	   results	   in	   secretome	  
studies,207	  but	  they	  are	  expensive	  and	  time	  consuming.	  Simple	  Western™	  is	  a	  gel-­‐
free,	   blot-­‐free,	   automated	   capillary	   immunoassay	   system	   recently	   developed	   by	  
ProteinSimple®	   (Santa	   Clara,	   CA,	   USA),	   which	   has	   been	   successfully	   used	   for	  
absolute	  quantitation.208	  	  
We	  used	   the	  Wes	  system	  of	  Simple	  Western™,	  where	  up	   to	  25	   samples	  could	  be	  
run	   simultaneously,	   and	   followed	   the	   manufacturer’s	   instructions.	   In	   brief,	  
undiluted	  secretome	  samples	  and	  recombinant	  protein	  were	  mixed	  with	  the	  master	  
mix	   to	  a	   final	   concentration	  of	  1:1	   sample	  buffer	   to	   fluorescent	  molecular	  weight	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markers,	   and	   40	   mM	   DTT,	   and	   subsequently	   heated	   at	   95°C	   for	   5	   minutes.	   The	  
samples,	   blocking	   reagent,	   primary	   antibodies,	   HRP-­‐conjugated	   secondary	  
antibodies,	  chemiluminescent	  substrate,	  and	  separation	  and	  stacking	  matrices	  were	  
also	  dispensed	  to	  designated	  wells	  in	  the	  plate.	  After	  plate	  loading,	  the	  separation	  
electrophoresis	   and	   immunodetection	   steps	   took	   place	   in	   the	   fully	   automated	  
capillary	   system.	   Results	   were	   analysed	   using	   the	   Compass	   software	  
(ProteinSimple®).	  	  
Using	  the	  Wes	  system	  we	  verified	  the	  concentration	  in	  the	  secretome	  samples	  of	  β-­‐
2	  microglobulin	   (B2M),	   a	   putative	   secreted	  protein,	  which	  had	  been	   identified	   as	  
overexpressed	  in	  the	  secretome	  of	  our	  HR	  samples	  by	  label-­‐free	  proteomics.	  Both	  
the	  antibody	   (rabbit	  monoclonal),	   as	  well	   as	   the	   corresponding	  human	   full-­‐length	  
recombinant	  protein,	  were	  purchased	   from	  Abcam	  (Cambridge,	  UK).	  Optimization	  
experiments	   were	   conducted	   testing	   different	   concentrations	   of	   the	   primary	  
antibody	   (1:25	   to	   1:400),	   using	   the	   recombinant	   protein	   at	   1ng/µl	   as	   a	   positive	  
control.	  The	  working	  concentration	  was	  ultimately	  set	  at	  1:50.	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3.3 Results	  
3.3.1 Primary	  culture	  of	  UM	  cells	  
3.3.1.1 Choice	  of	  culture	  medium	  
The	  results	  of	  the	  SRB	  proliferation	  assays	  are	  shown	  in	  Figure	  3.1.	  The	  growth	  of	  
Mel270	   and	   Omm2.5	   cell	   lines	   (top)	   was	   not	   influenced	   by	   culture	   medium.	   D3	  
primary	  UM	  cells	  (bottom	  left)	  did	  not	  grow	  in	  the	  short-­‐term	  culture,	  irrespective	  
of	  the	  medium	  used.	   In	  contrast,	  M3	  primary	  UM	  cells	  (bottom	  right)	  showed	  the	  
greatest	   increase	   in	   cell	   number	   over	   time	   in	   αMEM-­‐based	   “primary”	   medium.	  
Three	   further	   experiments	   using	   primary	   UM	   cells	   confirmed	   that	   the	   primary	  
promoted	   proliferation	   of	   the	   cells	   in	   culture.	   This	   was	   evident	   even	   with	   light	  
microscopy,	  as	  shown	  in	  Figure	  3.2.	  
The	  primary	  medium	  was	  therefore	  used	  for	  all	  subsequent	  short-­‐term	  cultures	  of	  
isolated	  primary	  UM	  cells.	  
	   	  
Figure	  3.1	  Assessment	  of	  cell	  proliferation	  in	  different	  media	  using	  sulforhodamine-­‐B.	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Figure	  3.2	  Light	  microscopy	  images	  of	  the	  same	  primary	  tumour	  (S171-­‐10)	  grown	  for	  5	  days	  
in	   three	   different	   media:	   A)	   RPMI-­‐based;	   B)	   DMEM-­‐based;	   C)	   αMEM-­‐based.	   (40x	  
magnification)	  
	  
3.3.1.2 Clinical	  samples	  
Between	  May	   and	  December	   2012,	   32	  UM	   samples	  were	   placed	   into	   culture:	   21	  
(66%)	   successfully	   proliferated	   in	   vitro	   and	   were	   used	   for	   the	   preparation	   of	  
secretome.	   The	   clinical,	   histopathological	   and	   genetic	   characteristics	   of	   the	  
successfully	  cultured	  UM	  are	  shown	  in	  Table	  3.2.	  Within	  18	  months	  follow-­‐up	  time,	  
4/15	  HR	  (27%)	  patients	  developed	  metastatic	  disease.	  	  
Of	  note,	  only	  5/21	  (24%)	  cultures	  were	  established	  from	  LR	  tumours.	  The	  reasons	  
for	  this	  are	  discussed	  in	  detail	  below	  in	  the	  Discussion.	  
Three	  of	  the	  21	  samples	  were	  used	  for	  assay	  optimisation,	  hence	  a	  final	  cohort	  of	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Table	   3.2	   Clinical,	   histopathological	   and	   genetic	   characteristics	   of	   the	   UM	   tumours	  
successfully	  grown	  in	  culture	  and	  used	  for	  secretome	  production.	  
	   	  
LBD:	   largest	   basal	   diameter;	   HT:	   tumour	   thickness;	   CB:	   ciliary	   body	   involvement;	   EOE:	  
extraocular	   extension;	   cell	   type:	   spindle,	  mixed,	   epithelioid;	   HR:	   high	   risk;	   LR:	   low	   risk	   of	  
developing	  metastases;	   genetic	   (chromosomal	   alteration	   determined	   by	  MLPA,	   or	  MSA	   if	  
marked	  with	  §):	  N-­‐normal,	  L-­‐loss,	  G-­‐gain,	  U-­‐undetermined.	  	  
*	  indicates	  development	  of	  metastatic	  disease.	  
	  §	  indicates	  samples	  used	  for	  optimisation	  but	  not	  included	  in	  the	  final	  MS	  analysis.	  
3.3.1.3 Characterization	  of	  UM	  cell	  cultures	  
Morphological	   examination	   under	   light	   microscopy	   showed	   clear	   differences	  
between	  UM	  cells	  derived	  from	  the	  HR	  and	  LR	  tumours.	  UM	  cells	  from	  HR	  tumours	  
Sample'
No.'
Age' Sex' LBD' HT' CB' EOE' Cell'
type'
Loops' Mitosis' Risk' Genetic'
S116$12& 59& F& 15.7& 5.2& N& N& SPIN& Y& 7& HR& 3L,&8G&
S117$12°& 43& M& 11.3& 3& N& N& SPIN& Y& 4& HR& 3L,&8G&
S140$12& 58& M& 17.6& 11& N& Y& MIX& N& 5& HR& 3L,&8G&
S147$12& 61& M& 16.3& 8.6& N& N& MIX& Y& 5& LR& 3N,&8G&
S174$12& 81& F& 19.8& 2.5& N& Y& MIX& Y& 5& HR*& 3L§&
S175$12& 64& F& 17.4& 6.5& N& N& SPIN& N& 3& LR& 3N§&
S194$12& 41& M& 12.7& 11.6& N& N& MIX& N& 3& LR& 3N,&8N&
S195$12& 77& F& 14.7& 5.7& N& N& EPI& N& 7& HR*& 3L,&8G&
S197$12& 71& F& 13.6& 8& N& N& MIX& Y& 6& HR& 3L,&8G&
S216$12& 46& M& 19.9& 14.4& N& N& MIX& Y& 5& HR& 3L,&8U&
S220$12& 80& F& 18.2& 12.5& N& Y& MIX& N& 1& HR& 3L,&8G&
S221$12& 51& M& 16.2& 14.8& Y& N& SPIN& Y& 4& LR& 3N,&8N&
S223$12& 67& M& 18.7& 12.2& Y& N& MIX& N& 2& HR*& 3L,&8G&
S231$12°& 71& M& 13& 7.5& N& N& MIX& Y& 1& LR& 3U,&8N&
S235$12°& 77& F& 15.8& 8.2& Y& N& SPIN& Y& 3& HR& 3L,&8G&
S236$12& 71& M& 15.1& 18.3& Y& N& MIX& Y& 18& HR& 3L,&8G&
S248$12& 50& M& 17.9& 11.5& N& N& SPIN& N& 4& LR& 3U,&8N&
S265$12& 76& F& 15.4& 7.8& N& N& SPIN& N& 7& HR& 3L,&8G&
S281$12& 71& M& 13& 5.9& N& Y& MIX& N& 4& HR*& 3L,&8G&
S282$12& 65& M& 19.2& 16.8& Y& N& MIX& Y& 1& HR& 3L,&8G&
S285$12& 77& F& 15.2& 8.9& N& N& MIX& N& 4& HR& 3L,&8G&
&
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had	  a	  higher	  plating	  efficiency	  and	  commenced	  proliferation	  more	  readily	  than	  UM	  
cells	   derived	   from	   LR	   tumours.	   Cells	   would	   often	   create	   neural-­‐like	   networks	   or	  
clumps	  (as	  shown	  in	  Figure	  3.2C).	  The	  predominant	  cellular	  phenotype	  was	  plump	  
spindle,	   but	   foci	   of	   epithelioid	   cells	   did	   develop	   in	   a	   limited	   number	   of	   cultures.	  
Overall,	  UM	  cells	  derived	  from	  HR	  tumours	  were	  highly	  heterogeneous	   in	  culture;	  
however,	  a	  common	  feature	  was	  their	  relatively	  rapid	  proliferation.	  In	  contrast,	  UM	  
cells	  from	  LR	  tumours	  would	  often	  fail	  to	  adhere	  and	  survive,	  and	  when	  they	  did	  ‘sit	  
down’,	   the	   cells	   grew	   slowly.	   The	   morphology	   was	   typically	   spindle,	   and	   was	  
relatively	   similar	   between	   cell	   cultures.	   Immunofluorescence	   staining	   highlighted	  
such	  differences,	  as	  shown	  in	  Figures	  3.3	  and	  Figure	  3.4.	  
	   	  
Figure	  3.3	  Cultured	  cells	  (CC)	  from	  a	  D3	  UM,	  showing	  low	  proliferative	  capacity	  in	  culture	  
(Ki67),	  high	  expression	  of	  melanoma	  specific	  antigens	   (HMB45,	  MelanA,	  Vimentin,	  MITF),	  
small	  number	  of	  cells	  positive	  for	  the	  myofibroblast	  marker	  αSMA,	  but	  no	  positive	  staining	  
for	   Oil	   Red	   O.	   Please	   note	   that	   the	   red	   fluorochrome	   is	   C-­‐Kit	   while	   the	   green	   nuclear	  
fluorochrome	  is	  MITF	  in	  the	  combined	  slide.	  
	  
	   114	  
	   	  
Figure	  3.4	  Cultured	  cells	  (CC)	  from	  a	  M3	  UM,	  showing	  high	  proliferative	  capacity	  in	  culture	  
(Ki67),	  expression	  of	  melanoma	  specific	  antigens	  (HMB45,	  MelanA,	  Vimentin,	  MITF),	   large	  
number	  of	   cells	  positive	   for	   the	  myofibroblast	  marker	  αSMA	  and	  positive	   staining	   for	  Oil	  
Red	  O.	  Please	  note	  that	  the	  red	  fluorochrome	  is	  C-­‐Kit	  while	  the	  green	  nuclear	  fluorochrome	  
is	  MITF	  in	  the	  combined	  slide.	  
	  
3.3.1.4 Genetic	  profile	  of	  cultured	  cells	  as	  compared	  to	  original	  UM	  
DNA	   was	   successfully	   extracted	   and	   quantified	   from	   16/18	   cultures	   used	   for	  
secretome	  analysis,	  as	  two	  vials	  were	  misplaced.	  The	  amount	  of	  purified	  DNA	  was	  
>100	  ng	   in	  12/16	   cases,	  which	  were	  analysed	  by	  MLPA,	  while	   the	   remaining	   four	  
with	  <100	  ng	  DNA	  were	  analysed	  by	  MSA.	  The	  metastatic	  risk	  classification	  of	  the	  
patient	  was	  concordant	  with	  the	  data	  obtained	  from	  the	  short	  term	  cultures	  of	  the	  
primary	  UM	  cells	  in	  all	  but	  two	  cases	  (shown	  in	  Table	  3.3).	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Table	   3.3	  Comparison	  between	   genetic	   profile	   /	   risk	   category	  of	   the	  original	  UM	   sample	  











Test	  type	   Result	   Notes	  
S116-­‐12	   HR	   22.06.2012	   Yes	   MLPA	   HR	   	  
S140-­‐12	   HR	   22.06.2012	   Yes	   MLPA	   HR	   	  
S147-­‐12	   LR	   20.06.2012	   Yes	   MLPA	   LR	   	  
S174-­‐12	   HR	   08.08.2012	   No	   none	   N/A	   No	  DNA,§	  
S175-­‐12	   LR	   10.08.2012	   Yes	   MLPA	   LR	   	  
S194-­‐12	   LR	   31.08.2012	   Yes	   MLPA	   LR	   	  
S195-­‐12	   HR	   30.08.2012	   Yes	   MLPA	   HR	   	  
S197-­‐12	   HR	   02.09.2012	   Yes	   MSA	   HR	   	  




S220-­‐12	   HR	   10.10.2012	   Yes	   MLPA	   HR	   	  
S221-­‐12	   LR	   17.10.2012	   No	   none	   	  N/A	   No	  DNA	  
S223-­‐12	   HR	   26.10.2012	   Yes	   MSA	   HR	   	  
S236-­‐12	   HR	   02.11.2012	   Yes	   MLPA	   HR	   §	  
S248-­‐12	   U	   08.11.2012	   Yes	   MLPA	   LR	   Unclassifi
able,	  §	  	  
S265-­‐12	   HR	   30.11.2012	   Yes	   MLPA	   HR	   	  
S281-­‐12	   HR	   12.12.2012	   Yes	   MSA	   HR	   	  
S282-­‐12	   HR	   12.12.2012	   Yes	   MSA	   HR	   	  
S285-­‐12	   HR	   20.12.2012	   Yes	   MLPA	   HR	   	  
LR:	   low	   risk	   of	   developing	   metastatic	   disease;	   HR:	   high	   risk;	   U:	   undetermined;	   MLPA:	  
multiplex	   ligation-­‐dependent	   probe	   amplification;	   MSA:	   microsatellite	   analysis;	   M3:	  
monosomy	  of	  chromosome	  3;	  D3:	  disomy	  3.	  
§:	  sample	  excluded	  from	  HR	  vs	  LR	  differential	  analysis	  
	  
3.3.2 Culture	  of	  normal	  uveal	  melanocytes	  
3.3.2.1 Characterisation	  of	  choroidal	  melanocytes	  in	  culture	  
Five	   healthy	   post-­‐mortem	   eyes	   were	   used	   for	   harvesting	   choroidal	   melanocytes.	  
The	  clinical	  details	  of	  the	  donors	  are	  shown	  in	  Table	  3.4.	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Table	  3.4	  Clinical	  features	  of	  the	  donor	  eyes	  used	  for	  culture	  of	  choroidal	  melanocytes	  
	  
F:	  female;	  M:	  male	  
	  
Uveal	   melanocytes	   in	   culture	   show	   mainly	   spindle	   morphology,	   with	   evident	  
pigmentation	  due	  to	  melanin	  granules	   in	   the	  cytoplasm.	   Incubation	   in	  SFM	  for	  48	  
hours	   did	   not	   alter	   the	   morphological	   appearance	   of	   the	   cells,	   nor	   caused	   a	  
significant	  increase	  of	  cell	  death,	  as	  judged	  by	  Trypan	  blue.	  (Figure	  3.5).	  
	  
Figure	  3.5	  Light	  microscopy	  appearance	  of	  choroidal	  melanocytes	   in	  culture.	  A)	   In	  normal	  
culture	  medium;	  B)	  after	  48	  hours	  in	  serum	  free	  medium.	  (Courtesy	  Dr	  M.	  Madigan).	  
	  
As	   shown	   in	  Figure	  3.6,	   the	  uveal	  melanocytes	  expressed	   the	  classical	  markers	  of	  
the	   melanocytic	   lineage,	   i.e.	   MART-­‐1	   /	   MelanA,	   HMB45	   and	   gp100.	   They	   also	  
expressed	  the	  proteins	  tyrosinase	  and	  tyrosinase-­‐related	  protein	  1	  (TYRP1),	  which	  
are	  specific	  to	  melanin	  synthesis.	  
Sample'
No.' Age' Sex' Cause'of'death' Other'history'




10057$ 39$ M$ Cardiac$arrest$ Nil$
10135$ 52$ M$ Pancreatic$cancer$ NonAinsulin$dependent$diabetes$
10205$ 55$ M$ Cardiac$arrest$ Nil$
13635$ 17$ M$ Motor$vehicle$accident$ Nil$
$
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Figure	   3.6	   Immunophenotypical	   characterisation	   of	   cultured	   choroidal	   melanocytes,	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3.3.3 Secretome	  profiling	  by	  LC-­‐MS/MS	  
Eighteen	   UM	   (4	   LR	   and	   14	   HR)	   and	   5	   normal	   (N)	   samples	   were	   analysed	   in	  
consecutive	   MS	   runs,	   interspaced	   by	   inter-­‐sample	   blanks.	   A	   total	   of	   1917	   non-­‐
redundant	   proteins	   were	   identified	   using	   the	   above-­‐described	   criteria	   and	   a	   1%	  
FDR.	  Among	  these,	  1857	  proteins	  were	  quantified	  in	  all	  three	  subgroups.	  There	  was	  
a	   clear	   distinction	   in	   the	   proteome	  profile	   of	  N	   versus	  UM	   secretomes,	  with	   947	  
proteins	  being	  differentially	  expressed	  with	  a	  fold	  change	  ≥2	  	  (Figure	  3.7).	  
	  
Figure	  3.7	  Principal	  component	  analysis	  (PCA)	  showing	  the	  segregation	  of	  947	  differentially	  
expressed	   proteins	   between	   normal	   versus	   tumour	   secretome	   (Anova	   p≤0.01,	   Max-­‐fold	  
≥2).	  
When	   analyzing	   only	   the	   UM	   secretomes,	   67	   proteins	   were	   identified	   as	  
differentially	  expressed	  ≥2	  fold	  between	  the	  HR	  and	  LR	  samples.	  (Figure	  3.8)	  
	   	  
Figure	  3.8	  PCA	  showing	  the	  segregation	  of	  67	  differentially	  expressed	  proteins	  between	  LR	  
versus	  HR	  UM	  secretome	  (Anova	  p≤0.01,	  Max-­‐fold	  ≥2)	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3.3.4 Prediction	  of	  secreted	  proteins	  
The	   secretory	   routes	   of	   the	   identified	   proteins	   were	   predicted	   based	   on	   their	  
protein	   sequences.	   The	   SignalP	   program	   predicted	   that	   341	   (out	   of	   1857,	   18%)	  
proteins	  were	  released	  through	  the	  classical	  secretion	  pathway	  (SignalP	  probability	  
≥0.8).	  244	  proteins	  (13%)	  were	  predicted	  to	  be	  secreted	  via	  non-­‐classical	  secretion	  
pathways	   (SecretomeP	   score	   ≥0.5).	   Among	   the	   proteins	   that	   could	   not	   be	  
categorized	   into	   either	   secretion	   pathway,	   42	   (2%)	   were	   predicted	   to	   have	  
transmembrane	   helixes	   and	   thus	   could	   be	   released	   via	   membrane	   shedding	  
(TMHMM	  PredHel	  ≤1).	  Taken	  together,	  these	  results	  predict	  that	  627	  (34%)	  of	  the	  
identified	  proteins	  in	  the	  SFM	  were	  likely	  to	  have	  been	  secreted.	  
3.3.4.1 Exosomal	  proteins	  
The	   list	   of	   proteins	   identified	   in	   the	   secretome	   of	   normal	   choroidal	  melanocytes	  
and	  UM	  cells	  was	  cross-­‐referenced	  with	  the	  online	  database	  of	  exosomal	  proteins	  
(www.exocarta.org),	  and	  554/1857	  (30%)	  were	  identified	  as	  having	  been	  previously	  
reported	  in	  exosomes.	  Of	  the	  554	  exosomal	  proteins,	  108	  were	  upregulated	  ≥2	  fold	  
with	   a	   p	   value	   ≤0.05	   in	   UM	   versus	   normal	   melanocytes,	   while	   190	   were	  
downregulated	  ≥2	  fold	  with	  a	  p	  value	  ≤0.05	  in	  UM	  versus	  N.	  
	  
3.3.5 Protein	  signature	  discriminating	  between	  HR	  and	  LR	  
To	   identify	   proteins	   that	   could	   be	   investigated	   in	   the	   serum	   of	   UM	   patients	   as	  
biomarkers	  for	  the	  early	  detection	  of	  metastatic	  disease,	  we	  selected	  a	  subset	  of	  10	  
out	  of	  the	  14	  HR	  samples	  to	  compare	  with	  the	  four	  LR	  samples.	  Four	  samples	  were	  
excluded	   for	   the	   following	   reasons:	   lack	   of	   post-­‐culture	   DNA	   profiling	   due	   to	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missing	  vial	  (S174-­‐12);	  change	  of	  genetic	  profile	  in	  culture	  as	  compared	  to	  primary	  
tumour	  (S216-­‐12);	  unclassified	  chromosome	  3	  profile	  of	  the	  primary	  tumour	  (S248-­‐
12);	  abnormal	  MS	  peaks,	  making	  quantification	  unreliable	  (S236-­‐12).	  
An	  analysis	  of	  the	  MS	  data	  from	  these	  14	  samples	  was	  performed	  with	  Progenesis®,	  
leading	   to	   the	  quantification	  of	  1577	  proteins.	   The	  Shapiro-­‐Wilk	   test	  of	  normality	  
showed	  that	  88.8%	  of	   these	  proteins	  could	  be	  considered	  as	  normally	  distributed	  
once	   log-­‐transformed	   (log2).	   Further	   to	   log2	   transformation,	   normalization	   and	  
ANOVA	   filtering	   at	   a	   FDR=1%,	   842	   proteins	  were	   used	   for	   downstream	   statistical	  
analyses	   using	   the	   Partek®	   software.	   Figure	   3.9	   clearly	   illustrates	   the	   segregation	  
between	   LR	   (to	   the	   left)	   and	  HR	   samples	   on	   principal	   component	   analysis	   (PCA).	  
Interestingly,	   all	   LR	   samples	   mapped	   closely,	   whereas	   within	   the	   HR	   samples	   a	  
wider	  distribution	  was	  observed,	   in	   line	  with	  the	  varied	  phenotypical	  appearances	  
noticed	  in	  vitro	  and	  the	  known	  increased	  biological	  heterogeneity	  of	  HR	  UM	  in	  vivo.	  
Noticeably,	   the	   clearly	   defined	   outlier	   in	   the	   HR	   group	   (S281-­‐12,	   red	   polyhedral	  
intersecting	  the	  X-­‐axis)	  corresponds	  to	  the	  secretome	  from	  the	  only	  patient	  in	  this	  
series	  with	  manifest	  metastatic	  disease.	  
Unsupervised	  two-­‐way	  hierarchical	  clustering	  was	  performed	  according	  to	  Pearson	  
similarity	  and	  Ward’s	  linkage	  method,	  and	  the	  resulting	  plot	  can	  be	  seen	  in	  Figure	  
3.10.	   A	   signature	   of	   18	   proteins	   that	   discriminated	   between	   HR	   (top)	   and	   LR	  
(bottom)	  samples	  was	   identified.	   It	   is	  again	   interesting	   to	  note	  the	  close	  mapping	  
for	  these	  proteins	  of	  the	  LR	  samples	  as	  compared	  with	  the	  HR	  profile.	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Figure	   3.9	   Principal	   component	   analysis	   (PCA)	   map	   for	   the	   first	   three	   eigenvectors,	  
representing	   the	   percent	   variation	   accounted	   by	   each	   principal	   component.	   A	   clear	  
segregation	  can	  be	  appreciated	  between	  LR	  and	  HR	  samples	  and	  the	  overall	  PCA	  mapping	  
(82.9%)	  is	  excellent.	  
	  
Figure	   3.10	   Hierarchical	   clustering	   shows	   an	   18	   protein	   signature	   that	   discriminated	  
between	  HR	  and	  LR	  secretome	  samples.	  Samples	  are	  shown	  in	  the	  rows	  (colour-­‐coded	  as	  
per	   the	   legend),	   and	   proteins	   (UniProt	   accession	   numbers)	   are	   shown	   in	   the	   columns.
3.3.6 Validation	  by	  quantitative	  Western	  Blotting	  
B2M	   is	   a	   secreted	   protein	   that	   has	   been	   previously	   quantified	   in	   the	   peripheral	  
blood	   of	   cancer	   patients,	   including	   those	   from	   patients	   with	   UM.209	   B2M	   was	  
identified	  as	  a	  key	  protein	   in	  the	  18	  protein	  signature	  that	  discriminated	  between	  
the	  HR	  and	  LR	  samples.	  The	  presence	  of	  B2M	  was	  validated	  in	  matched	  undiluted	  
secretome	   aliquots	   from	   the	   same	   samples	   using	   the	   Wes	   system	   of	   Simple	  
Western™.	   By	   spiking	   with	   known	   concentrations	   of	   recombinant	   B2M	   protein	  
relative	   quantitative	   results	   (in	   the	   order	   of	   fentomoles)	   were	   obtained	   (Figure	  
3.11).	  	  
As	   demonstrated	   in	   Figure	   3.12,	   B2M	   was	   detected	   in	   all	   secretome	   samples;	  
secretomes	   from	   LR	   UM	   had	   consistently	   low	   levels	   of	   B2M,	   whereas	   the	  
secretomes	   from	   HR	   UM	  were	  more	   variable	   in	   their	   expression	   of	   this	   protein.	  
Although	   there	   was	   no	   exact	   correspondence	   between	   the	   MS	   and	   Wes	   data,	  
overall	  B2M	  was	  most	  highly	  expressed	  in	  secretomes	  from	  HR	  UM.	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Figure	   3.11	   Lane	   view	   (top)	   and	   peak	   view	   (bottom)	   of	   beta2	   microglobulin	   protein	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Figure	  3.12	  Relative	  quantification	  of	  Beta-­‐2	  microglobulin	  protein	  expression	  determined	  
by	  mass	  spectrometry	  (A)	  and	  Wes	  (in	  fmol/µl)	  (B).	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3.4 Discussion	  
The	   study	   of	   the	   cell	   secretome	   has	   been	   proposed	   as	   a	   feasible	   strategy,	   in	   a	  
number	   of	   cancers,	   to	   identify	   putative	   biomarkers	   that	   are	   more	   likely	   to	   be	  
detected	   in	   body	   fluids.210	   To	   date,	   a	   single	   secretome	   study	   published	   for	   UM	  
cells110	   concluded	   that	  primary	   cell	   cultures	  would	  be	  more	   informative	   than	  UM	  
cell	  lines	  for	  biologically	  relevant	  studies.	  	  
In	  the	  current	  study	  we	  analysed	  the	  secretome	  from	  a	  panel	  of	  primary	  UM	  cells	  
and	  choroidal	  melanocytes	  in	  short-­‐term	  culture,	  with	  the	  aim	  of	  recapitulating	  the	  
multiform	   biological	   landscape	   of	   UM.	   To	   ensure	   that	   variability	   would	   be	   truly	  
biological	   and	   not	   technical,	   we	   adopted	   an	   accurate,	   sensitive	   and	   robust	  
approach,	   keeping	   sample	   handling	   to	   a	   minimum.	   In	   particular,	   we	   avoided	   all	  
filtration	  and	  concentration	  steps,	  and	  introduced	  an	  innovative	  method	  for	  protein	  
extraction	   and	   digestion	   using	   magnetic	   beads.	   We	   prospectively	   collected	   all	  
samples	   and	   then	   processed	   them	   in	   a	   single	   MS	   experiment,	   normalising	   peak	  
intensities	   for	   semi	  quantitative	  analysis.192	   Finally,	  we	  used	  a	   recently	  developed	  
automated	   capillary	   immunoassay	   system	   to	   validate	   and	   quantify	   one	   of	   the	  
proteins	   identified	   by	   MS.	   As	   a	   result	   of	   these	   steps,	   we	   could	   demonstrate	  
differential	  protein	  expression	  between	  the	  secretomes	  of	  normal	  melanocytes	  and	  
choroidal	   UM	   cells,	   as	   well	   as	   between	   those	   of	   HR	   and	   LR	   UM.	   Moreover,	  
hierarchical	   clustering	   analyses	   revealed	   that	   a	   panel	   of	   18	   proteins	   could	  
discriminate	  HR	  UM	   from	   LR	  UM.	  Of	   the	   18	   proteins	   identified,	   some	  have	   been	  
previously	   identified	   in	   plasma.	   Moreover,	   several	   of	   the	   identified	   proteins	   are	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related	   to	   immune-­‐surveillance,	   which	   is	   extremely	   interesting	   given	   that	  
immunotherapy	  is	  a	  promising	  therapeutic	  option	  for	  UM	  patients.211	  
Two	   proteins	   in	   particular	   have	   been	   previously	   implicated	   in	   UM:	   B2M	   and	  
macrophage	  migration	   inhibitory	   factor	   (MIF).	   B2M	   is	   a	   light	   chain	   of	   the	   major	  
histocompatibility	   complex	   (MHC)	   class	   I	  molecule	   that	   is	   associated	  with	  antigen	  
presentation	   to	   cytotoxic	   T	   lymphocytes.212	   Cancer	   cells	   are	   believed	   to	   avoid	  
immune	   surveillance	   by	   down-­‐regulating	   the	   expression	   of	   MHC	   class	   I	   via	   the	  
secretion	  of	  free	  B2M.213	  At	  the	  same	  time,	  there	  is	  convincing	  evidence	  that	  B2M	  
may	   act	   as	   a	   growth-­‐promoting	   factor	   and	   signal	   molecule,	   as	   increased	   levels	  
positively	  correlate	  with	  advanced-­‐stage	  tumours.214	  	  
In	   UM,	   expression	   of	   B2M,	   as	   determined	   by	   IHC	   on	   tumour	   sections,	   has	   been	  
associated	  with	  development	  of	  metastasis.215	  Moreover,	   increased	  plasma	   levels	  
of	  B2M	  have	  been	  correlated	  with	  high	  metastatic	  risk	  M3	  UM	  in	  a	  study	  by	  Triozzi	  
et	   al.209	   In	   this	   study,	   ELISA	  was	   used	   to	   assess	   the	   concentration	   of	   B2M	   in	   the	  
plasma	  of	  76	  UM	  patients	  with	  known	  chromosome	  3	  status	  (determined	  by	  FISH).	  
Using	   a	   recursive	   partitioning	   algorithm,	   a	   cut-­‐off	   point	   of	   3000	   pg/ml	   (normal	  
blood	  range	  for	  B2M	  is	  1100-­‐2600	  pg/ml)	  was	  established.	  Based	  on	  this	  threshold,	  
33%	  of	  M3	  versus	  5%	  of	  D3	  patients	  (p=0.002)	  where	  considered	  to	  have	  elevated	  
B2M	   levels.	   An	   independent	   association	   of	   elevated	   plasma	   B2M	   levels	   and	  M3	  
status	  of	  the	  tumour	  was	  confirmed	  in	  multivariate	  analysis.	  The	  authors	  concluded	  
that	  plasma	  levels	  of	  B2M	  may	  become	  a	  prognostic	  biomarker	  of	  HR	  UM	  patients.	  
The	   fact	   that	   we	   also	   identified	   B2M	   as	   potential	   biomarker	   based	   on	   our	  
secretome	  studies	  is	  a	  proof	  of	  the	  validity	  of	  our	  experimental	  design.	  Moreover,	  
the	  variable	   levels	  of	  B2M	  protein	  expression	   in	  the	   individual	  secretome	  samples	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(Figure	   3.12)	   shows	   that	   our	   approach	   is	   able	   to	   preserve	   the	   known	   biological	  
variability	  occurring	  in	  vivo.	  	  
MIF	  is	  a	  pleiotropic	  cytokine	  that,	  among	  other	  functions,	  inhibits	  natural	  killer	  (NK)	  
cell-­‐mediated	  cytolysis,	  and	  is	  well	  known	  to	  contribute	  to	  the	  immune	  privilege	  of	  
the	  eye.216	   The	  presence	  of	  MIF	   in	   intraocular	   fluids	  protects	   tumours	  against	  NK	  
cell-­‐mediated	  surveillance	  and	  promotes	  their	  growth.217	  The	  liver	  is	  an	  organ	  with	  
exceptionally	   high	   levels	   of	   NK	   activity.	   The	   importance	   of	   NK	   cells	   in	   controlling	  
UM	   systemic	   metastases	   has	   been	   shown	   in	   a	   mouse	   model	   of	   intraocular	  
melanoma,	   where	   multiple	   systemic	   metastases	   developed	   following	   in	   vivo	  
depletion	  of	  NK	  cells	  with	  anti-­‐asialo-­‐GM1	  Ab.218	  Repp	  et	  al.	  have	  shown	  that	  UM	  
cells	   can	   produce	   MIF,	   with	   cell	   lines	   derived	   from	   UM	   metastasis	   producing	  
approximately	   twice	   as	   much	   biologically	   active	   MIF	   as	   cultures	   derived	   from	   a	  
primary	   UM.219	   Very	   recently,	   Costa-­‐Silva	   et	   al.	   have	   demonstrated	   in	   murine	  
models	   of	   pancreatic	   carcinoma	   that	   MIF	   is	   highly	   expressed	   in	   tumour-­‐derived	  
exosomes	   and	   that	   it	   is	   responsible	   for	   pre-­‐metastatic	   niche	   formation	   in	   the	  
liver.220	  Moreover,	  high	  exosomal	  MIF	  levels	  were	  present	  in	  the	  plasma	  of	  patients	  
who	   later	   on	   developed	   metastatic	   disease,	   indicating	   the	   potential	   prognostic	  
value	  of	  MIF	  as	  a	  biomarker.	  This	  corroborates	  our	  interest	  for	  MIF	  in	  UM	  as	  both	  a	  
biomarker	  and	  a	  potential	  therapeutic	  target,	  and	  we	  will	  investigate	  its	  expression	  
in	  UM-­‐derived	  exosomes.	  
3.4.1 Strengths	  of	  our	  work	  
Cell	   lines	   have	   been	   widely	   used	   for	   secretome	   studies	   because	   they	   are	   easily	  
accessible,	   grow	   well	   in	   culture,	   and	   can	   be	   used	   for	   multiple	   experiments	   with	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minimal	   inter-­‐sample	   variability.	   This	   homogeneity,	   however,	   is	   also	   a	   major	  
limitation	  from	  the	  translational	  point	  of	  view,	  as	   it	  does	  not	  reflect	  the	  biological	  
variability	  seen	   in	  patients.	  Moreover,	  there	   is	   increasing	  scepticism	  regarding	  the	  
use	  of	   long-­‐standing	  cell	   lines,	  as	  their	  genetic	  and	  phenotypic	  characteristics	  may	  
significantly	   differ	   from	   the	   original	   tumour,	   and	   many	   cell	   lines	   have	   been	  
misclassified	   over	   time.221	   More	   specifically	   for	   UM	   cell	   lines,	   many	   previously	  
believed	   to	   be	   distinct	   were	   actually	   derived	   from	   the	   same	   patients	   (OCM1	   =	  
MUM2C,	   OCM3	   =	   OCM8,	   and	   M619	   =	   C918	   =	   MUM2B)	   and	   for	   some,	   BRAF	  
mutations	  were	  identified,	  bringing	  into	  question	  their	  uveal	  origin.222	  
In	   this	   study	  we	   used	   short-­‐term	   primary	   UM	   cultures	   that,	   although	   difficult	   to	  
obtain,	   more	   closely	   represent	   the	   tumours	   seen	   in	   vivo.	   From	   32	   UM	   tumour	  
samples	  grown	  in	  culture,	  only	  four	  were	  obtained	  from	  LR	  UM	  samples.	  This	  can	  
be	  attributed	  to	  two	  main	  reasons:	  1)	  sample	  selection,	  as	  only	  very	  large	  tumours	  
would	  provide	  enough	  spare	  tissue	  to	  be	  used	  for	  culture,	  and	  large	  tumour	  size	  is	  
an	   established	   risk	   factor	   for	   development	   of	   metastatic	   disease;223	   2)	   the	   low	  
survival	  rate	  of	  D3	  cells	   in	  vitro.	  These	  cells	  seem	  more	  “fragile”	  and	  often	  do	  not	  
survive	  the	  first	  24	  hours	  in	  culture.	  Moreover,	  they	  grow	  so	  slowly	  that	  the	  culture	  
flask	  can	  be	  overgrown	  by	  fibroblast/mesenchymal-­‐like	  cells.	  	  
One	   of	   the	   potential	   drawbacks	   regarding	   the	   use	   of	   primary	   cultures	   is	   the	  
necessity	   to	   phenotype	   the	   cells	   grown	   in	   culture.	   We	   performed	   rigorous	  
phenotypic	  characterisation	  of	  our	  cells	  by	  immunofluorescence,	  as	  well	  as	  genetic	  
analysis	   to	   compare	   the	   genetic	   profile	   to	   that	   of	   the	   original	   tumour.	   MLPA	  
analysis	  demonstrated	  a	  discordant	  chromosome	  3	  result	  between	  the	  tumour	  and	  
the	  cultured	  cells	  in	  only	  1/	  21	  (4%)	  cases	  analysed.	  This	  may	  have	  been	  due	  to	  the	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outgrowth	   of	   non-­‐tumour	   cells.	   The	   corresponding	   secretome	   sample	   was	  
discarded	  from	  the	  analysis	  leading	  to	  the	  18-­‐protein	  signature.	  	  
As	   expected,	   the	   primary	   UM	   cultures	   demonstrated	   inter-­‐sample	   phenotypic	  
heterogeneity,	  especially	  among	   the	  HR	   tumours,	  which	  was	  also	   reflected	   in	   the	  
protein	  composition	  of	  the	  secretome	  samples.	  	  
Another	  unique	  aspect	  of	   this	  work	   is	   the	  production	  of	   secretome	   from	  primary	  
human	  normal	  uveal	  melanocytes,	  which	   to	   the	  best	  of	  our	  knowledge	  has	  never	  
been	  done	  before.	  Human	  choroidal	  melanocytes	  are	  difficult	  to	  obtain,	  as	  there	  is	  
a	  tight	  time	  limit	  (8	  hours	  post	  mortem)	  within	  which	  their	  viability	  can	  be	  ensured.	  
In	  collaboration	  with	  Dr	  Michele	  Madigan	  from	  Sidney,	  the	  protocol	  for	  secretome	  
production,	   established	   in	   our	   laboratory	   was	   reproduced	   for	   normal	   choroidal	  
melanocytes	  and	  the	  samples	  were	  then	  shipped	  to	  Liverpool	  on	  dry	  ice.	  Proteomic	  
analysis	   was	   performed	   together	   with	   the	   UM	   secretome	   samples.	   Detailed	  
analyses	  of	  the	  protein	  profile	  of	  normal	  melanocytes	  versus	  that	  of	  UM	  cells	  were	  
outside	   the	   remit	   of	   the	   current	   study,	   but	   will	   be	   performed	   as	   part	   of	   further	  
studies	   aimed	   to	   increase	   our	   understanding	   of	   the	   biological	   process	   of	   UM	  
development	  within	  the	  eye.	  
Another	  strength	  of	  this	  study	  is	  the	  quality	  of	  the	  proteomic	  analysis.	  The	  protein	  
content	   of	   the	   SFM	   was	   preserved	   by	   keeping	   handling	   to	   a	   minimum	   and	   by	  
avoiding	   enrichment	   steps	   such	   as	   ultrafiltration.	   The	   extraction	  of	   proteins	   from	  
such	  a	  diluted	  sample	  was	  possible	  due	  to	  the	  innovative	  use	  of	  StrataClean	  beads,	  
followed	  by	  on-­‐bead	  digestion.	  	  
A	   label-­‐free	   MS	   approach	   was	   also	   preferred	   since	   it	   provides	   a	   wide	   range	   of	  
benefits	  when	  compared	  to	  other	  proteomic	  techniques,	  such	  as	  iTRAQ,	  including:	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reduced	   protein	   loading;	   no	   labelling	   reagent	   costs;	   reduced	   fractionation	   and	  
sample	   handling;	   increased	   sequence	   coverage	   per	   protein;	   increased	   overall	  
proteome	   coverage;	   ability	   to	   compare	   more	   conditions	   within	   a	   single	  
experiment.126	   The	   equipment	   used	   (Q	   ExactiveTM)	   is	   a	   “state	   of	   the	   art”	   LC-­‐
MS/MS	   system	   which	   combines	   quadruple	   precursor	   ion	   selection	   with	   high-­‐
resolution,	   accurate-­‐mass	   Orbitrap	   detection	   to	   deliver	   exceptional	   performance	  
and	   versatility.	   Peptide	   identification	   and	   quantification	   was	   performed	   using	  
Progenesis®,	   a	   software	   that	   uses	   the	   ion	   intensities	   recorded	   in	   the	  MS	   data	   to	  
provide	   reliable	   measurements	   of	   peptides	   and	   is	   therefore	  more	   accurate	   than	  
spectral	  count.	  	  
3.4.2 Limitations	  of	  our	  work	  and	  future	  perspectives	  
Although	   short-­‐term	   primary	   UM	   cell	   cultures	   preserve	   the	   genetic	   and	  
immunophenotypical	   characteristics	   of	   the	   original	   tumour,	   we	   know	   that	   a	   2D	  
environment	   is	   still	   far	   from	   ideal.	   There	   has	   been	   a	   recent	   move	   from	   2D	   cell	  
monolayers	  to	  three-­‐dimensional	  (3D)	  cultures,	  motivated	  by	  the	  need	  to	  work	  with	  
cellular	  models	   that	  mimic	   the	   functions	   of	   living	   tissues.	   Other	  members	   of	   our	  
team	  are	  currently	  working	  on	  these	  aspects,	  by	  culturing	  cells	  on	  matrices,	  or	  as	  
3D	  spheroids,	  and	   in	  co-­‐cultures	  with	  other	  cell	   types	  such	  as	  macrophages.	  Once	  
such	  model	  systems	  have	  been	  optimised,	  secretome	  collection	  and	  analysis	   from	  
3D	  culture	  will	  no	  doubt	  provide	  further	  novel	  insight	  into	  UM	  biology.	  
Another	   limitation	   of	   our	   model	   is	   the	   need	   to	   use	   SFM	   to	   avoid	   albumin	  
interference	  with	   the	   detection	   of	   smaller	   proteins.	   Differing	   depletion	   protocols	  
and	  incubation	  times	  were	  assessed	  during	  the	  course	  of	  this	  study	  and	  although	  48	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hours	   was	   selected	   for	   secretome	   analysis	   there	   is	   always	   the	   possibility	   that	  
differences	   in	   the	   secretome	  produced	   at	   other	   time	   points	   i.e.	   12	   and	   24	   hours	  
may	   occur.	   In	   future,	   FACS	   analysis	   of	   the	   cells	   at	   different	   incubation	   points	   to	  
assess	  early	  apoptotic	  signs	  might	  be	  preferable	  as	  compared	  to	  count	  of	  dead	  cells	  
with	  trypan	  blue	  and	  incubation	  time	  in	  SFM	  might	  then	  be	  adjusted	  accordingly.	  
Cell	   death	   with	   release	   of	   intracellular	   proteins	   may	   explain	   the	   relatively	   low	  
percentage	  (34%)	  of	  putative	  secreted	  proteins	  identified	  in	  our	  samples	  using	  the	  
available	  bioinformatics	  tools	  (SecretomeP,	  Protein	  IP,	  TMHMM).	  Further	  analyses	  
with	   software	   such	   as	   Ingenuity®	   Pathway	   Analysis	   (IPA)	   will	   be	   performed	   to	  
investigate	  the	  nature	  of	  biological	  pathways	  activated	  or	  inhibited	  in	  our	  samples	  
and	  aid	  interpreting	  these	  results.	  	  
Should	   cellular	   debris	   be	   an	   issue,	   lectin	   affinity	   capture	   prior	   to	   MS	   could	   be	  
performed,	   in	   order	   to	   enrich	   secreted	   proteins,	   based	   on	   the	   assumption	   that	  
secreted	   proteins	   are	   usually	   glycosylated.	   This	   approach	  was	   adopted	   by	   Yao	   et	  
al.224	   for	  colorectal	  cancer	  ex	  vivo	  explants	   incubated	   in	  SFM	  and	  demonstrated	  a	  
significant	  increase	  in	  the	  detection	  efficiency	  of	  secreted	  proteins,	  evidenced	  by	  an	  
increased	  percentage	  of	  spectral	  counts	  belonging	  to	  the	  secreted	  proteins	  as	  well	  
as	  an	  increase	  in	  the	  number	  of	  secreted	  proteins	  detected.	  	  
Another	   possible	   explanation	   for	   the	   presence	   of	   membrane	   and	   intracellular	  
proteins	  in	  our	  secretome	  samples	  is	  that	  these	  are	  related	  to	  exosomes	  and	  other	  
extracellular	   microvesicles	   secreted	   by	   UM	   cells,	   as	   previously	   suggested.134	  
Exosomes	  are	  fascinating	  entities	  that	  are	  increasingly	  thought	  to	  play	  an	  important	  
role	   in	  many	  of	   the	  biological	  processes	   regulating	   tumour	  progression,	  especially	  
because	  of	  their	  ability	  to	  horizontally	  transport	  genetic	  and	  /or	  protein	  molecules	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and	   for	   their	   proposed	   role	   in	   preparing	   the	   metastatic	   niche.225	   Indeed,	   the	  
discovery	   that	  such	  a	  high	  percentage	  of	  exosomal	  proteins	  could	  be	   identified	   in	  
our	   secretome	   samples	   has	   led	   to	   a	   further	   project	   within	   our	   research	   group,	  
which	   aims	   to	   identify	   and	   characterise	   exosomes	   produced	   by	   UM	   cells	   and	   to	  
compare	  the	  proteomic	  profiles	  of	  these	  with	  the	  current	  proteomic	  dataset.	  	  
Future	  avenues	  opened	  by	  this	  work	  also	  include	  further	  analyses	  of	  the	  proteomic	  
data	  with	  software	  such	  as	  IPA	  to	  investigate	  the	  biological	  pathways	  up	  or	  down-­‐
regulated	  in	  these	  tumours	  in	  more	  detail	  and	  as	  compared	  with	  normal	  choroidal	  
melanocytes	   in	   order	   to	   understand	   the	   biological	   processes	   in	   addition	   to	  
searching	  for	  a	  biomarker	  of	  metastatic	  progression.	  
3.4.3 Conclusions	  
The	   aim	  of	   this	   current	  work	  was	   to	   identify	   one	   or	  more	   secreted	   proteins	   that	  
could	  be	  used	  as	  a	  blood-­‐borne	  biomarker	  of	  metastatic	  disease	  in	  UM	  patients.	  We	  
identified	  a	  panel	  of	  18	  proteins	  that	  could	  discriminate	  between	  patients	  at	  a	  high	  
or	   low	  risk	  of	  developing	  metastatic	  disease,	  which	  now	  require	  further	  validation	  
by	  ELISA	  based	  methods	   in	  the	  associated	  remaining	  secretome	  prior	  to	  testing	   in	  
patient	  blood	  samples.	   	   In	  addition,	  performing	  proteomic	  analyses	  has	   taught	  us	  
about	   the	   importance	  of	   sample	   collection	   and	   storage,	   therefore	  we	  are	  now	   in	  
the	   process	   of	   standardising	   our	   blood	   collection	   procedure	   to	  minimise	   protein	  
loss.	  Further	  analysis	  of	  the	  protein	  dataset	  will	  be	  performed	  using	  IPA.	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Chapter	  4 	  
Detection	  of	  circulating	  tumour	  cells	  in	  uveal	  melanoma	  
patients	  using	  the	  CellSearch®	  system	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4.1 Introduction	  
Circulating	  tumour	  cells	  (CTC)	  were	  first	  described	  in	  1869	  by	  Thomas	  Ashworth	  in	  a	  
man	   with	   metastatic	   cancer	   as	   “cells	   similar	   to	   those	   in	   the	   tumors	   seen	   in	   the	  
blood”.226	   Investigations	   into	   the	   clinical	   significance	   of	   CTC,	   however,	   only	   really	  
began	   in	   the	   1990’s,	   with	   the	   description	   of	   a	   polymerase	   chain	   reaction	   (PCR)-­‐
based	  methods	  to	  detect	  tyrosinase	  mRNA,	  a	  key	  enzyme	  in	  melanin	  synthesis,	   in	  
patients	  with	  cutaneous	  melanoma.227	  	  
Further,	   the	   introduction	   of	   immunocytochemical	   techniques	   for	   the	   isolation	   of	  
cancer	   cells	   from	   the	   circulation	   has	   enabled	   researchers	   to	   investigate	   the	  
biological	   relevance	   and	   clinical	   significance	   of	   CTC.228	   For	   example	   in	   breast	  
carcinomas,	   the	   presence	   of	   CTC	   was	   included	   in	   the	   international	   AJCC	   tumour	  
staging	  system,229,	   230	  whilst	  the	  biological	  relevance	  of	  CTCs	   in	  most	  other	  cancer	  
types,	  including	  UM,	  remains	  unclear.231	  
The	  search	  for	  CTC	  in	  the	  blood	  of	  cancer	  patients	  generally	  includes	  an	  enrichment	  
step	  and	  a	  detection	  step.232	  The	  enrichment	  step	  is	  applied	  to	  compensate	  for	  the	  
rarity	  of	  CTC	  in	  the	  bloodstream,	  estimated	  as	  one	  in	  105-­‐106	  mononuclear	  cells.233	  
Enrichment	   can	   be	   achieved	   through	   positive	   selection	   methods	   based	   on	   the	  
physical	  or	  biological	  properties	  of	  CTC,	   for	  example	  by	  filtration,	  density	  gradient	  
centrifugation,	   immunomagnetic	   capture	   and	   immunoselection	   under	   low-­‐flow	  
conditions.234	   Alternatively,	   negative	   selection	   methods	   have	   been	   described,	  
where	  leucocytes	  and	  other	  “contaminating”	  mononuclear	  cells	  are	  detected	  using	  
antibodies	  directed	  at	  cell	  surface	  markers	  such	  as	  the	  pan-­‐leukocyte	  marker	  CD45	  
and	  discarded	  by	  immunoselection.235	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The	   detection	   step	   allows	   for	   confirmation	   and	   enumeration	   of	   CTC.	   This	   can	   be	  
achieved	  by	  flow	  cytometry,	  immunocytochemistry,	  PCR-­‐based	  analysis	  of	  tumour-­‐
cell-­‐associated	  DNA	  and	  RNA	  or	  FISH.234	  
Studies	  conducted	  in	  UM	  have	  mainly	  used	  reverse	  transcriptase	  (RT-­‐)	  PCR	  for	  the	  
detection	   of	  mRNA	   levels	   of	   tyrosinase,236-­‐239	   either	   alone	   or	   in	   conjunction	  with	  
melanoma	   antigen	   recognized	   by	   T-­‐cells	   1	   (MART-­‐1)233,	   240-­‐242	   and/or	   gp100	  
melanoma	  antigen,243	  as	  surrogate	  markers	  for	  the	  presence	  of	  CTC	  (Table	  4.1).	  In	  
one	  of	  these	  studies,	  Pinzani	  et	  al.241	  performed	  a	  direct	  comparison	  in	  16	  patients	  
between	  the	  results	  obtained	  by	  the	  tyrosinase	  qRT-­‐PCR	  assay	  and	  those	  obtained	  
using	   the	   isolation	   by	   size	   of	   epithelial	   tumour	   cells	   (ISET)	   platform,	   a	   filtration-­‐
based,	  marker-­‐independent	  method	   of	   CTC	   detection	   that	   relies	   on	   cell	   size	   and	  
morphology.	  CTC	  were	  detected	  by	  ISET	   in	  5	  of	  the	  16	  samples,	  which	  also	  tested	  
positive	  for	  tyrosinase	  levels,	  showing	  a	  direct	  correlation	  between	  the	  two	  tests.	  In	  
addition,	   tyrosinase	   levels	   in	   the	   11	   ISET-­‐negative	   patients	   were	   undetectable.	  
Despite	   this,	   mRNA	   analysis	   is	   renowned	   to	   be	   susceptible	   to	   false	   positives,	  
resulting	  from	  ‘illegitimate’	  transcription	  or	  contamination,244	  while	  ISET	  is	  a	  time-­‐
consuming	  operator-­‐dependent	  system	  not	  ideal	  for	  the	  clinical	  setting.	  
To	   overcome	   these	   limitations	   an	   alternative	   approach	   has	   been	   adopted:	  
immunomagnetic	   cell	   sorting	  with	   the	   anti-­‐melanoma	  antibody,	  which	   recognises	  
the	  melanoma-­‐associated	  chondroitin	   sulphate	  proteoglycan	   (MCSP)	  antigen,	  also	  
known	  as	  high-­‐molecular	  weight	  melanoma	  associated	  antigen	  (HMW-­‐MAA).245-­‐247	  
Ulmer	   et	   al.	   were	   the	   first	   to	   suggest	   this	   approach	   for	   UM	  patients,	   adopting	   a	  
technique	  previously	  used	  to	  examine	  for	  CTC	  in	  cutaneous	  melanoma	  patients.248	  
These	   authors	   examined	   whole	   blood	   from	   52	   UM	   patients	   without	   metastatic	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disease,	  and	  identified	  CTC	  (1-­‐5	  cells	  /	  50	  mL)	  in	  10	  of	  the	  samples	  (19%),	  showing	  a	  
positive	   relationship	   with	   established	   clinical	   prognostic	   factors	   associated	   with	  
increased	   risk	   of	   metastatic	   disease.245	   In	   contrast,	   a	   later	   study	   from	   the	   same	  
group	   on	   94	   patients	   tested	   before	   and	   after	   treatment	   of	   the	   ocular	   tumour	  
showed	  that	  CTC	  could	  only	  be	  detected	  in	  14%	  of	  patients,	  without	  any	  significant	  
association	  with	  established	  prognostic	  parameters.246	  
Taken	  together,	  data	  produced	  to	  date	  from	  the	  various	  CTC	  studies	  conducted	  in	  
UM	  (Table	  4.1)	  have	  been	  inconsistent,	  complicated	  mainly	  by	  variations	  in	  the	  test	  
procedures.	   As	   previously	   demonstrated	   in	   cutaneous	   melanoma,	   comparative	  
analyses	   of	   the	   same	   patient	   samples	   by	   different	   platforms/methodologies	   can	  
lead	   to	   dissimilar	   results,249	   hence	   the	   clinical	   and	   biological	   implications	   of	   CTC	  
enumeration	  largely	  depends	  on	  the	  technology	  applied.250	  The	  result	  of	  this	  is	  that	  
none	  of	  the	  above-­‐described	  techniques	  has	  as	  yet	  been	  adopted	  in	  clinical	  practice	  
for	  UM	  patients.	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Tyrosinase 0/36 (0) - 2/31 
Despite of a demonstrated sensitivity of 
1cell/ml, no CTC were found in UM nor 
advanced cutaneous melanoma patients 
El-Shabrawi             
et al.  
(1998) 
Tyrosinase 2/12 (17) - - 
During the 12-month follow-up, 1/2 CTC+ 





Tyrosinase 16/41 (39) - - 
Prospective, 5yrs follow-up. 11/16 CTC+ 
pts became CTC- after local treatment. 







3/21 (14) 12/17 (71) 
0/21 for tyrosinase. 
3/21 for MART-1  
17/21 for gp100 
 
2/3 CTC+ patients developed metastasis 








11/110 (10) - - 
CTC+ as independent prognostic  








29/30 (97) over 
multiple visits 
 
- 0/30 for both markers 
Prospective longitudinal study, multiple 
samples per patient. Pt enrolled at 
diagnosis (5/30) or after treatment, none 
with metastatic disease. CTC+ months 








Longitudinal study, 55-month f-up. CTC+ 
as independent prognostic  
factor for progression-free and overall 
survival  







- 43/68 (63) - 
CTC+ as independent prognostic factor 
for progression-free and overall survival 
in metastatic UM patients 




MCSP 10/52 (19) - 0/20 
CTC+ associated with clinicopathologic 
risk factors (LBD>14mm, CB 
involvement) 
 Suesskind 
  et al. 
  (2011) 
MCSP 13/94 (14) - - 
No changes in CTC level before and 
after ocular treatment. No correlation 




MCSP 4/ 249 (2) - - 
Prospective, 9-year long study. 
Bone marrow was also tested with 
98/328 (30%) positive results.  
CTC=	  circulating	  tumour	  cells;	  MART-­‐1=	  Melanoma	  antigen	  recognised	  by	  T-­‐cells-­‐1;	  MCSP=	  
Melanoma-­‐associated	   chondroitin	   sulphate	   proteoglycan;	   ISET=	   Isolation	   by	   size	   of	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In	   order	   to	   overcome	   test	   inconsistencies	   and	   to	   facilitate	   comprehensive	   CTC	  
analysis	  in	  rare	  cancers	  such	  as	  UM,	  where	  the	  samples	  are	  likely	  to	  be	  collected	  at	  
multiple	   clinical	   sites	   over	   time,	   an	   automated	   and	   standardised	   platform	   is	  
needed.	  To	  date,	  the	  only	  platform	  for	  CTC	  enumeration	  to	  gain	  U.S.	  Food	  and	  Drug	  
Administration	   (FDA)	   approval	   for	   prognostication	   in	   metastatic	   breast,250	  
colorectal,251	  and	  prostate	  carcinoma252	  is	  the	  CellSearch®	  System	  (Veridex	  LLC,	  NJ).	  
More	  recently,	  CTC	  detection	  by	  CellSearch®	  has	  also	  been	  demonstrated	  to	  be	  of	  
prognostic	   significance	   in	   lung	   carcinoma253	   and	   cutaneous	   melanoma.254	   At	   the	  
time	   of	   commencing	   this	   study	   in	   September	   2011,	   no	   data	   existed	   for	   the	  
detection	  of	  CTC	  in	  UM	  patients	  using	  this	  platform.	  
The	  overall	  goal	  of	   this	  study	  was	  to	  evaluate	  the	  prevalence,	  clinical	  significance,	  
and	  biomarker	  potential	  of	  CTCs	  using	  the	  CellSearch®	  technology	  in	  UM	  patients	  at	  
different	   stages	   of	   the	   disease.	   To	   achieve	   this,	   we	   investigated	   whether	   the	  
presence	   of	   CTC	   in	   blood	   samples	   from	   UM	   patients	   could	   be	   detected	   and	  
enumerated	  by	  the	  CellSearch®	  system	  using	  the	  CellTracks®	  circulating	  melanoma	  
cell	  (CMC)	  kit	  (previously	  developed	  for	  cutaneous	  melanoma)	  and	  correlated	  with	  
known	  clinical,	  histopathological	  and	  genetic	  features	  of	  increased	  metastatic	  risk.	  	  
The	   CMC	   kit	   enriches	   CTC	   using	   ferromagnetic	   beads	   coated	   in	   melanoma	   cell	  
adhesion	   molecule	   (MelCAM	   or	   CD146)	   and	   defines	   them	   according	   to	  
morphological	   characteristics,	   positive	   expression	   of	   MCSP,	   and	   absence	   of	   the	  
leukocyte	  marker	  CD45.	   In	   addition,	   it	   contains	  a	  4th	   channel	   that	   can	  be	   loaded	  
with	  a	  customised	  antibody.	  An	  exploratory	  endpoint	  of	  this	  study	  was	  to	  validate	  
the	  expression	  of	  the	  enrichment	  (CD146)	  and	  detection	  (MSCP)	  antigens	  present	  in	  
the	  CMC	  kit,	  using	  UM	  cell	  lines	  grown	  as	  adherent	  and	  non-­‐adherent	  cultures.	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We	  also	  investigated	  the	  expression	  of	  an	  additional	  cell	  surface	  antigen	  that	  could	  
be	  used	  in	  the	  4th	  channel:	  CD184,	  also	  known	  as	  C-­‐X-­‐C	  chemokine	  receptor	  type	  4	  
(CXCR-­‐4)	   or	   fusin,	   a	   G-­‐protein-­‐coupled	   chemokine	   receptor	   specific	   for	   stromal-­‐
derived-­‐factor-­‐1.	  CD184	  was	  initially	  recognised	  for	  its	  involvement	  in	  HIV	  entry	  and	  
leukocyte	   trafficking,	   but	   it	   is	   now	   also	   accepted	   as	   an	   important	   player	   in	   the	  
development	  of	  metastatic	  disease	  in	  multiple	  cancer	  types.255	  In	  particular,	  CD184	  
expression	   has	   been	   detected	   by	   flow	   cytometry	   on	   almost	   80%	   of	   CTC	   isolated	  
from	  the	  peripheral	  blood	  of	  metastatic	  cutaneous	  melanoma	  patients.256	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4.2 Patients	  and	  methods	  
4.2.1 Patient	  population	  
4.2.1.1 Inclusion	  criteria	  
Consenting	  patients	  were	  entered	  into	  this	  study	  if	  they	  had	  received	  treatment	  for	  
their	  primary	  UM	  at	   the	  Liverpool	  Ocular	  Oncology	  Centre	   (LOOC)	  or	   if	   they	  were	  
diagnosed	  with	  metastatic	  UM	  at	   the	  Clatterbridge	  Cancer	  Centre	   (CCC)	  between	  
October	  2011	  and	  March	  2012.	  All	  patient	  samples	  were	  pseudo-­‐anonymised	  prior	  
to	   release	   from	   the	   OOB.	   Project	   specific	   ethical	   approval	   for	   this	   study	   was	  
obtained	  from	  the	  National	  Research	  Ethics	  Service	  (NRES	  Ref	  No.	  11/NW/0568).	  
Patients	  affected	  by	  metastatic	  UM	  and	  treated	  at	  the	  Christie	  Hospital	  NHS	  Trust	  in	  
Manchester	  during	  the	  same	  time	  period	  were	  also	   included	   in	  this	  study.	  Patient	  
consent	  and	  ethical	  approval	  for	  this	  part	  of	  the	  study	  formed	  part	  of	  the	  CEP144	  
project,	  Clinical	  and	  Experimental	  Pharmacology	  (CEP)	  Group,	  Cancer	  Research	  UK,	  
Manchester	  Institute.	  
4.2.1.2 Exclusion	  criteria	  
Samples	  from	  patients	  affected	  at	  any	  time	  by	  another	  malignancy	  were	  excluded.	  	  
4.2.1.3 Metastatic	  risk	  stratification	  
Patients	   with	   a	   primary	   UM	   and	   without	   evidence	   of	   metastatic	   disease	   were	  
classified	  as	  being	  at	  either	  at	  HR	  or	  LR	  of	  developing	  metastatic	  disease	  using	  the	  
LUMPO,	  as	  detailed	  in	  Chapter	  1.	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Details	   about	   the	   clinical,	   histopathological	   and	   genetic	   characteristics	   of	   the	  
tumour,	   as	   well	   as	   follow-­‐up	   information	   about	   the	   patient,	   were	   provided	   in	   a	  
pseudo-­‐anonymised	  manner	  by	  the	  custodian	  of	  the	  OOB.	  
To	  avoid	  possible	  bias,	   sample	  analysis	  was	  performed	  without	  any	  knowledge	  of	  
the	  risk	  stratification	  of	  the	  patient.	  
4.2.2 Sample	  collection	  and	  analysis	  	  
4.2.2.1 Sample	  collection	  	  
For	  each	  patient,	  a	  10ml	  blood	  sample	  was	  drawn	  by	  venepuncture	  directly	  into	  a	  
CellSave®	  tube	  (Veridex	  LLC,	  NJ),	  containing	  ethylenediaminetetraacetic	  acid	  (EDTA)	  
and	  a	  custom	  preservative,	  allowing	  sample	  preservation	  at	  room	  temperature	  for	  
up	   to	  96	  hours.	  Samples	  collected	  at	   the	  LOOC	  and	  CCC	  were	  shipped	  to	   the	  CEP	  
group	   using	   the	   Royal	   Mail	   Safebox™,	   with	   Special	   Delivery™	   Next	   Day	   postage.	  
Samples	   collected	   at	   the	   Christie	   Hospital	  were	   transferred	   to	   the	   CEP	   group	   via	  
internal	  porters.	  
Each	   sample	  was	  assigned	  a	  unique	   study	   code	   (linked	   to	   the	  pseudoanonymised	  
OOB	  code)	  and	  entered	  onto	  a	  database	  prior	  to	  processing.	  
Samples	   from	   metastatic	   patients	   were	   collected	   prior	   to	   beginning	   any	  
chemotherapy.	  
4.2.2.2 Sample	  analysis	  using	  the	  CellSearch®	  platform	  
The	   CellSearch®	   System	   (Veridex	   LLC,	   NJ)	   comprises	   the	   CellTracks®	   Autoprep	  
system,	   the	  CellSearch®	  CMC	  Kit	   and	   the	  CellTracks®	  Analyser	   II	   (Figure	   4.1).	   The	  
	  
	   142	  
Autoprep	  system	  is	  semi-­‐automated	  for	  CTC	  enrichment.	  The	  CMC	  kit	  contains	  the	  
following	  reagents:	  
•	   ferrofluid	  consisting	  of	   iron	  nanoparticles	  coated	  with	  a	  polymer	   layer	  and	  
conjugated	  to	  the	  MelCAM	  (CD146)	  antibody	  for	  CTC	  enrichment	  
•	   phycoerythrin	  (PE)-­‐conjugated	  mouse	  monoclonal	  antibody	  to	  MCSP	  for	  CTC	  
detection	  
•	   allophycocyanin	   (APC)-­‐conjugated	   mouse	   antibody	   to	   CD45	   and	   CD34	   for	  
detection	  and	  negative	  selection	  of	  blood	  components	  
•	   4,6-­‐diamidino-­‐2-­‐phenylindole	  (DAPI)	  to	  stain	  the	  nucleus	  
•	   a	  proprietary	  buffer	  to	  wash,	  permeabilise	  and	  re-­‐suspend	  the	  cells.	  	  
The	  CMC	  kit	  also	  comprises	  a	  4th	  channel	  that	  can	  be	  customised	  with	  user-­‐defined	  
antibodies.	  
	  
Figure	  4.1	  Schematic	  highlighting	  the	  processes	  undertaken	   in	  the	  detection	  of	  CTC	  using	  
the	  CellSearch®	  system	  and	  the	  CellTracks®	  CMC	  kit.	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For	  each	  sample,	  7.5ml	  blood	  was	  transferred	  to	  a	  15ml	  conical	  tube	  and	  6.5ml	  of	  
CMC	  kit	  dilution	  buffer	  was	  added.	  The	  samples	  were	  mixed	  by	  inverting	  five	  times	  
and	  then	  centrifuged	  at	  800xg	  for	  10	  minutes	  to	  separate	  the	  plasma	  layer	  from	  the	  
cellular	  pellet.	  Samples	  were	  loaded	  onto	  the	  CellTracks®	  Autoprep	  system	  and	  the	  
automated	   process	   performed	   whereby	   the	   plasma	   was	   aspirated	   and	   the	  
ferrofluid	   containing	  CD146	  was	   added	   to	   the	   cellular	   pellet.	   Captured	   cells	  were	  
then	  drawn	  to	  the	  sides	  of	  the	  column	  by	  a	  magnetic	  field	  and	  unattached	  cells	  and	  
blood	   were	   aspirated.	   Captured	   cells	   were	   re-­‐suspended	   in	   buffer	   and	  
permeabilising	   agent	   applied	   prior	   to	   staining	   with	   the	   fluorochrome	   conjugated	  
antibodies	   detailed	   above.	   Magnetic	   separation	   was	   again	   applied	   to	   aspirate	  
excess	   reagent	   and	   the	   enriched	   sample	   was	   resuspended	   and	   placed	   into	   a	  
MagNest®	   presentation	   device.	   The	  MagNest®	   presentation	   device	   is	   a	   cartridge	  
located	   between	   two	   magnets	   that	   draw	   the	   cells	   to	   the	   cartridge	   surface	   thus	  
enabling	  scanning	  by	  the	  CellTracks®	  Analyser	  II	  system.	  The	  MagNest®	  was	  rested	  
in	  the	  dark	  for	  a	  minimum	  of	  20	  minutes	  prior	  to	  scanning.	  
The	  CellTracks®	  Analyser	  II	  is	  a	  four-­‐colour	  fluorescence	  microscope.	  The	  MagNest®	  
was	   placed	   in	   the	   analyser	   and	   scanned	   for	   each	   of	   the	   four	   fluorescent	   probes.	  
Cells	  stained	  with	  MCSP/endothelial	  markers	  and	  DAPI	  were	  presented	  for	  analysis.	  
Melanoma	   CTC	   were	   defined	   as	   MCSP	   and	   DAPI	   positive,	   and	   CD45	   and	   CD34	  
negative	   (MCSP+,	   DAPI+,	   CD45-­‐,	   CD34-­‐).	   White	   blood	   cells	   and	   endothelial	   cells	  
were	   CD45,	   CD34	   and	   DAPI	   positive,	   but	   MCSP	   negative	   (CD45+,	   CD34+,	   DAPI+,	  
MCSP-­‐).	  The	  total	  number	  of	  CTC	  present	  in	  each	  sample	  was	  recorded.	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4.2.2.3 Data	  analysis	  
Correlations	  were	  drawn	  between	  the	  number	  of	  CTC	  identified	  in	  each	  sample	  and	  
the	   clinical,	   histopathological	   and	   genetic	   data	   of	   the	   corresponding	   primary	  
tumour,	   as	  well	   as	   the	   survival	   data	   at	   study	   completion.	   All	   data	  were	   analysed	  
using	  the	  statistics	  software	  SPSS.	  
As	   this	  was	  an	  exploratory	  pilot	   study,	  no	   formal	  power	  calculation	   to	  set	   sample	  
size	  was	  performed	  to	  detect	  clinical	  significance.	  
4.2.3 Assessment	  of	  antigen	  expression	  on	  uveal	  melanoma	  cells	  
4.2.3.1 Cell	  culture	  
Five	   cell	   lines	   established	   from	   primary	   (Mel	   270257	   and	   92.1258)	   and	   metastatic	  
(Omm1259,	   Omm2.3257,	   Omm2.5257)	   UMs,	   kindly	   provided	   by	   Dr	  M	   Jager	   (Leiden,	  
The	  Netherlands),	  were	  grown	  in	  adherent	  and	  non-­‐adherent	  culture	  conditions	  as	  
previously	   described.196	   All	   cells	  were	   grown	   in	   RPMI	  medium	   (PAA	   Laboratories,	  
Somerset,	  UK)	  supplemented	  with	  10%	  FBS	  (PAA	  Laboratories),	  2	  mM	  L-­‐glutamine	  
(Sigma,	   Dorset,	   UK),	   and	   antibiotics	   and	   incubated	   at	   37°C	   with	   5%	   CO2.	   For	  
adherent	   cultures,	   1x106	   cells	   were	   seeded	   in	   a	   25-­‐cm2	   flask	   and	   grown	   to	   85%	  
confluence.	  	  
For	   non-­‐adherent	   cultures,	   1x106	   cells	   were	   seeded	   in	   a	   25-­‐cm2	   flask	   previously	  
coated	  with	  poly	  2-­‐hydroxyethyl	  methacrylate	   (poly-­‐HEMA;	  Sigma)	   to	  prevent	  cell	  
attachment.	  Cells	  were	  grown	   in	  suspension	   for	  48	  hours	  only,	  as	   the	  aim	  was	   to	  
measure	  cell	  surface	  antigen	  expression,	  not	  to	  facilitate	  3D	  spheroid	  induction.	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As	   an	   exploratory	   endpoint,	   cells	   from	   one	   primary	   short-­‐term	   UM	   cell	   culture	  
(S156-­‐13	  p1),	  established	  as	  described	   in	  Chapter	  3,	  were	  also	  grown	   in	  adherent	  
and	   suspension	   conditions	   and	   stained	   using	   the	   same	   protocol	   as	   per	   cell	   lines	  
(below).	  
4.2.3.2 Multicolour	  flow	  cytometry	  
Single	   cells	   were	   collected	   using	   non-­‐enzymatic	   cell	   dissociation	   solution	   (Sigma	  
Aldrich	  C5789),	  counted	  and	  resuspended	  at	  2x106/ml	  in	  FACS	  buffer	  (1%	  BSA,	  0.1%	  
NaN3	  in	  PBS).	  Cells	  were	  stained	  at	  4°C	  for	  15	  min	  with	  the	  following	  fluorochrome	  
conjugated	   anti-­‐human	   monoclonal	   antibodies:	   CD146-­‐fluorescein	   isothiocyanate	  
(FITC),	  MCSP-­‐phycoerythrin	   (PE)	   (both	  Miltenyi	   Biotech,	   Germany)	   and	   CD184-­‐PE	  
cyanine	  dye	  7	  (PE-­‐Cy7)	  (BD	  Pharmingen,	  Germany).	  Isotype-­‐matched	  IgG	  antibodies	  
were	  used	  as	  controls.	  Fixable	  Viability	  Dye	  eFluor®	  450	  (eBioscience	  Ltd,	  Hatfield,	  
UK)	  was	  used	  to	  assess	  cellular	  viability.	  Stained	  cells	  were	  kept	  on	  ice,	  in	  the	  dark,	  
and	  immediately	  analysed,	  without	  adding	  any	  fixative.	  	  
Samples	  were	  measured	  with	  the	  LSRFortessa,	  using	  BDTM	  CompBeads	  to	  optimise	  
compensation	   settings	   for	   multicolour	   flow	   cytometric	   analyses.	   Data	   were	  
analysed	  with	  Diva	  7.0	  software	  (all	  BD	  Biosciences).	  Single	  live	  UM	  cells	  positive	  for	  
the	  markers	  above	  were	  identified	  by	  gating	  out	  dead	  cells	  (stained	  by	  the	  viability	  
dye),	  and	  determining	  the	  negative	  population	  using	  isotype	  controls.	  Experiments	  
were	  repeated	  three	  times	  with	  cells	  at	  different	  passage	  numbers.	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4.3 Results	  	  
4.3.1 Detection	  of	  CTC	  in	  patient	  samples	  
A	  total	  of	  37	  patients	  were	   included	   in	  the	  study:	  22	  affected	  by	  primary	  UM	  and	  
treated	  at	   the	   LOOC;	  5	  diagnosed	  with	  metastatic	  UM	  at	   the	  CCC;	  10	   treated	   for	  
metastatic	   UM	   at	   the	   Christie	   Hospital,	  Manchester.	   Four	   of	   these	   samples	   (two	  
from	   LOOC	   and	   two	   from	   CCC)	   could	   not	   be	   analysed	   because	   of	   a	   temporary	  
shortage	   of	   reagents.	   Hence,	   33	   samples	   were	   successfully	   analysed	   by	   the	  
CellSearch	   platform	   for	   CTC	   detection	   and	   enumeration.	   The	   number	   of	   CTC	  
identified	  ranged	  between	  0	  and	  510	  (Figure	  4.2).	  CTC	  were	  detected	  in	  seven	  out	  
of	  13	  metastatic	  patients	  (range	  1-­‐510),	  in	  five	  out	  of	  14	  HR	  UM	  patients	  (range	  1-­‐
2).	  No	  CTC	  were	  detected	  in	  the	  six	  LR	  UM	  patients.	  	  
	   	  
Figure	  4.2	  Number	  of	  CTC	  identified	  in	  UM	  patients	  at	  different	  stages	  of	  the	  disease	  using	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4.3.1.1 Correlation	  between	  CTC	  number	  and	  metastatic	  risk	  	  
In	   patients	   with	   primary	   UM,	   the	   presence	   of	   1	   or	   more	   CTC	   was	   significantly	  
correlated	  with	   the	   presence	   of	  monosomy	   3	   in	   the	   tumour	   (Chi-­‐square,	   p<0.01)	  
detected	   using	  MLPA	  or	  MSA	  but	   not	  with	   any	   other	   clinical	   or	   histopathological	  
prognostic	  factor	  (Table	  4.2)	  	  
During	   the	   2-­‐year	   follow-­‐up	   period,	   three	   out	   of	   the	   14	   HR	   patients	   developed	  
metastatic	  disease.	  CTC	  had	  been	  detected	  at	  the	  time	  of	  ocular	  treatment	  in	  one	  
of	  these	  patients,	  whereas	  no	  CTC	  had	  been	  identified	  in	  the	  other	  two	  individuals.	  
	  
Table	  4.2	  CTC	  count	  in	  patients	  with	  primary	  UM	  prior	  to	  ocular	  treatment	  
	  LBD	  =	  largest	  basal	  diameter;	  CBI	  =	  ciliary	  body	  invasion;	  EOE	  =	  extra-­‐ocular	  extension;	  	  
MD	  =	  metastatic	   disease;	  HR	  =	  high	   risk;	   LR	  =	   low	   risk;	  M	  =	  male;	   F	  =	   female;	  N/A	  =	  not	  
available.	  §=	  patient	  deceased.	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4.3.1.2 Correlation	  between	  CTC	  numbers	  and	  overall	  survival	  
Of	   the	   13	   samples	   from	   UM	   patients	   with	   overt	   metastatic	   disease	   successfully	  
analysed,	   CTC	  were	   identified	   in	   eight	   samples	   (61%).	   The	   blood	   sample	   for	   CTC	  
analysis	  was	  collected	  before	  the	  start	  of	  chemotherapy	  in	  all	  cases,	  but	  one	  patient	  
(M4)	   had	   undergone	   surgical	   liver	   resection	   of	   isolated	   metastases	   two	   years	  
before.	  Details	  of	  the	  systemic	  treatment	  received	  by	  each	  patient	  are	  outlined	   in	  
Table	  4.3.	  	  
During	   the	   18	  months	   of	   follow-­‐up,	   12	  of	   13	  patients	   died	  of	  metastatic	   disease.	  
The	   data	   would	   suggest	   that	   patients	   with	   ≥1	   CTC	   have	   a	   shorter	   mean	   overall	  
survival	  time	  as	  compared	  with	  those	  patients	  in	  whom	  no	  CTC	  were	  detectable	  (72	  
vs	  318	  days).	  However,	  given	  the	  overall	  small	  number	  of	  patients	  in	  our	  series	  and	  
the	   fact	   that	   the	   two	   groups	   (CTC	   positive	   vs	   CTC	   negative)	   included	   a	   different	  
number	   of	   patients,	   there	   were	   insufficient	   numbers	   to	   do	   formal	   statistic.	  
Moreover,	   the	  patients	  were	   included	   independently	  of	   their	  performance	  status,	  
tumour	  burden,	  or	  hepatic	  function.	  Since	  all	  of	  these	  factors	  play	  a	  role	  in	  survival,	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Table	  4.3	  CTC	  count	  in	  patients	  with	  metastatic	  UM	  
Patient	  
No.	  




Sex	   Time	   to	  
mets	  
(years)	  
Metastatic	  sites	   Systemic	  
treatment	  
Time	   to	  
death	  
(days)	  
M1	   510	   48	   M	   1	   liver	  	   DTIC	   40	  
M2	   5	   60	   M	   2	   liver,adrenal	  gland	   DTIC	   173	  
M3	   0	   67	   F	   2	   liver	   DTIC	   397	  
M4	   0	   64	   M	   18	   liver	   DTIC*	   495	  
M5	   39	   82	   F	   2	   liver	   None	   112	  
M6	   1	   71	   M	   12	   liver,	  kidney	   None	   43	  
M7	   4	   77	   M	   2	   liver	   DTIC	   102	  
M8	   10	   74	   F	   4	   liver	   None	   63	  
M9	   1	   74	   M	   2	   liver	   None	   4	  
M10	   0	   62	   F	   5	   liver,pancreas,lung	   None	   60	  
M11	   9	   67	   M	   0§	   liver	   None	   42	  
M12	   0	   25	   M	   3	   spine	   Surgery	   Alive	  
M13	   0	   64	   M	   2	   liver	   DTIC	   102	  
§=	   metastatic	   disease	   diagnosed	   at	   the	   same	   time	   as	   the	   ocular	   tumour;	   DTIC	   =	  
Dacarbazine;	  *=	  this	  patient	  had	  liver	  resection	  of	  an	  isolated	  metastasis	  two	  years	  earlier	  
	  
4.3.2 Cell	  surface	  antigen	  expression	  in	  UM	  cells	  
4.3.2.1 Expression	  in	  UM	  cell	  lines	  
The	  CD146	   antigen,	   used	   for	   positive	   enrichment	   in	   the	  CellSearch	  platform,	  was	  
detected	  in	  >	  99%	  of	  live	  cells	  in	  all	  five	  cell	  lines,	  irrespective	  of	  whether	  they	  were	  
grown	   in	   adherent	   or	   non-­‐adherent	   culture	   conditions.	   In	   contrast,	   expression	   of	  
the	  MCSP	  antigen,	  used	  for	  detection	  in	  the	  CMC	  kit,	  demonstrated	  heterogeneous	  
levels	  of	   expression	  both	  within	   and	  between	   cell	   lines.	   The	   strongest	   expression	  
was	  detected	  in	  the	  Mel270	  cell	  line,	  where	  there	  appear	  to	  be	  two	  populations	  of	  
cells,	  one	  negative	  and	  one	  positive	  for	  MCSP.	  The	  chemokine	  receptor	  CD184	  was	  
detectable	  in	  all	  UM	  cell	  lines,	  but	  only	  in	  a	  very	  low	  percentage	  of	  the	  cells.	  (Table	  
4.4).	   The	   type	   of	   culture	   conditions,	   i.e.	   adherent	   or	   non-­‐adherent,	   did	   not	  
significantly	  influence	  protein	  expression.	  (Figure	  4.3)	  
	  
	   150	  
Table	   4.4	   Percentage	   of	   UM	   cells	   positive	   for	   CD146,	   MCSP,	   CD184	   measured	   by	  
multicolour	   flow	   cytometry.	   Percentages	   refer	   only	   to	   the	   live	   cell	   population,	   as	  
determined	  by	  viability	  dye	  exclusion	  
Adh	  =	  adherent	  culture;	  Susp	  =	  suspension	  culture	  	  
	  
Figure	  4.3	  Representative	  images	  of	  cell	  surface	  antigen	  expression	  in	  the	  Mel	  270	  cell	  line	  
grown	  in	  adherent	  (A)	  and	  suspension	  (B)	  conditions	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4.3.2.2 Expression	  in	  one	  UM	  short-­‐term	  primary	  culture	  
Primary	   cells	   grew	  well	   in	   both	   conditions,	   forming	   spontaneous	   large	   clumps	   in	  
both	  adherent	  and	  suspension	  cultures	   (Figure	  4.4).	  The	  cells	  were	  harvested	  and	  
underwent	  the	  same	  staining	  protocol	  as	  for	  the	  cell	  lines.	  Difficulties	  in	  obtaining	  a	  
single	   cell	   suspension	   and	   the	   multiple	   centrifugation	   wash	   steps	   during	   the	  
protocol,	   resulted	   in	   a	   reduction	   in	   the	   percentage	   of	   viable	   cells	   for	   flow	  
cytometric	   analysis	   to	  33.4%	  and	  41.8%	   in	   the	  adherent	  and	   suspension	   cultures,	  
respectively	  (Figure	  4.5).	  	  
	  
	  
Figure	   4.4	  Primary	  UM	  cells	   (S156-­‐13)	   in	   short	   term	  culture	  under	  adherent	   (A,	  10X)	  and	  
suspension	  (B,	  40X)	  conditions.	  
	  
Flow	  cytometric	  analysis	  of	  the	  viable	  single	  cell	  populations	  demonstrated	  antigen	  
expression	   in	   adherent	   and	   suspension	   cells,	   respectively,	   as	   follows:	  MCSP,	   98%	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4.4 Discussion	  
In	   this	  Chapter,	  we	  report	   the	  prevalence	  and	  prognostic	  value	  of	  CTC	   in	  patients	  
with	   primary	   UM	   as	   well	   as	   those	   with	   overt	   metastatic	   disease	   using	   the	   FDA	  
approved	  CellSearch®	  platform	  and	  CMC	  kit.	  	  This	  is	  currently	  the	  only	  system	  that	  
would	  be	  suitable	   to	  be	  used	   in	  multicentre	  clinical	   trials,	  which	  are	  the	   future	  of	  
rare	  diseases,	  such	  as	  UM.	  	  
The	   main	   use	   of	   the	   CellSearch®	   platform	   in	   other	   cancers	   has	   been	   in	   the	  
metastatic	  setting,	  for	  prognostic	  purposes	  and	  to	  monitor	  response	  to	  treatment.	  
In	  this	  study	  patients	  with	  only	  primary	  UM	  were	  also	  included	  in	  the	  hope	  that	  CTC	  
could	   provide	  more	   information	  on	   the	  development	  of	  metastatic	   disease	   in	  HR	  
patients.	  At	  the	  time	  of	  initiating	  this	  study,	  there	  were	  no	  data	  available	  regarding	  
the	  utility	  of	  this	  platform	  in	  UM	  patients.	  	  
4.4.1 Prognostic	  value	  of	  CTC	  in	  patients	  with	  only	  ocular	  disease	  
Our	  data	  demonstrate	   that	  at	   the	  diagnosis	  of	  patients	  with	  primary	  UM,	  ≥1	  CTC	  
were	   detectable	   in	   25%	   of	   individuals.	   The	   presence	   of	   one	   or	   more	   CTC	   in	   the	  
peripheral	  blood	  was	  more	  frequently	  associated	  with	  M3	   in	  the	  primary	  tumour.	  
None	  of	   the	   six	   LR	  patients	  had	  detectable	  CTC	   in	   their	  peripheral	  blood.	  Despite	  
this,	   there	  was	  no	  correlation	  between	  other	  clinical	  or	  histopathological	   features	  
of	  the	  primary	  tumour	  and	  the	  presence	  of	  CTC	   in	  the	  peripheral	  blood.	  This	   is	   in	  
line	   with	   previous	   reports,	   where	   the	   presence	   of	   CTC	   determined	   by	   PCR	   for	  
tyrosinase	  and	  Melan	  A	  showed	  no	  correlation	  with	  established	  clinico-­‐pathological	  
prognostic	  factors.233,	  239,	  240,	  246	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To	  validate	  the	  prognostic	  value	  of	  CTC	  in	  terms	  of	  predicting	  the	  development	  of	  
metastatic	  disease,	   it	   is	  necessary	  to	   follow	  the	  patient	   for	  at	   least	  10	  years.260	   In	  
the	   two-­‐year	   follow-­‐up	   period	   for	   this	   study,	   three	   out	   of	   20	   patients	   developed	  
metastases:	  all	  patients	  were	  classified	  as	  HR,	  but	  only	  one	  of	  them	  had	  detectable	  
CTC.	  No	  conclusions	  can	  therefore	  be	  drawn	  at	  this	  point.	  
4.4.2 Prognostic	  value	  of	  CTC	  in	  metastatic	  UM	  patients	  
Using	  the	  CMC	  Kit	  in	  the	  CellSearch®	  system,	  one	  or	  more	  CTC	  were	  detected	  in	  the	  
peripheral	  blood	  of	  61%	  of	  the	  metastatic	  patients	  in	  this	  study,	  all	  of	  whom	  were	  
tested	  prior	  to	  any	  chemotherapeutic	  treatment.	  	  
In	   a	   similar	   study	   of	   40	  metastatic	   UM	   patients	   using	   this	   platform	   just	   recently	  
published,261	  CTC	  were	  detected	   in	  only	  30%	  of	  cases,	  with	  a	  range	  of	  1-­‐20	  cells	  /	  
7.5	  ml	  of	  blood.	  It	  should	  be	  noted,	  however,	  that	  all	  patients	  were	  either	  on	  first-­‐
line	  treatment	  or	  had	  received	  previous	  multiple	  treatments	  prior	  to	  CTC	  analysis,	  
which	  may	  have	  had	  an	  impact	  on	  the	  number	  of	  detectable	  CTCs	  in	  the	  peripheral	  
blood.	  This	  is	  in	  contrast	  to	  our	  study,	  where	  the	  blood	  sample	  for	  CTC	  analysis	  was	  
taken	  prior	  to	  beginning	  any	  systemic	  therapy.	  In	  the	  above-­‐mentioned	  study,	  CTC	  
positivity	   was	   strongly	   associated	   with	   a	   reduced	   progression	   free	   survival	   and	  
overall	  survival	  time	  by	  univariate	  analysis.	  However,	  in	  a	  multivariate	  analysis	  time	  
to	  first	  metastatic	  relapse,	  performance	  status,	  and	  tumour	  volume	  were	  the	  only	  
independent	  prognostic	  indicators	  of	  reduced	  overall	  survival.	  	  
It	   should	   be	   recognised	   that	   in	   both	   the	   published	   work	   and	   our	   current	   study,	  
heterogeneity	   of	   the	   clinical	   cohort	   analysed	   highlights	   the	   importance	   of	  
comprehensive	   clinical	   information	   and	   the	   ability	   to	   recruit	   a	   large	   number	   of	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patients	   is	   needed	   to	   be	   able	   to	   create	   comparable	   groups	   with	   similar	  
characteristics,	   which	   is	   only	   possible	   through	  multicentre	   studies	   in	   such	   a	   rare	  
tumour	  as	  UM.	  
4.4.3 Validation	   of	   cell	   surface	   antigens	   used	   by	   the	   CellSearch®	  
Melanoma	  Kit	  
The	   number	   of	   CTC	   detected	   by	   the	   CellSearch®	   system	   in	   UM	   patients,	   was	  
surprisingly	   low	   as	   compared	   with	   the	   cutoff	   used	   for	   prognostic	   significance	   in	  
other	   cancers:	   50	   CTC	   for	   small	   cell	   lung	   cancer;	   5	   CTC	   for	   breast,	   prostate,	   and	  
non–small	   cell	   lung	   cancer;	   and	   3	   CTC	   for	   colorectal	   cancer.	   	   One	   possible	  
explanation	   for	   the	   low	   numbers	   of	   CTC	   detected	   is	   that	   the	   antigens	   used	   for	  
enrichment	   and	   detection	   are	   suboptimal	   for	   this	   cancer	   type,	   resulting	   in	   false-­‐
negative	  results.	  	  
The	   enrichment	   antigen,	   CD146,	   also	   known	   as	   MelCAM	   or	   MUC18,	   is	   a	   cell	  
adhesion	  molecule,	  which	  has	  been	  demonstrated	  previously	   in	  UM	  cells	  and	  cell	  
lines	  by	  proteomics,109	  and	  RT-­‐PCR,	  immunoblotting,	  and	  immunocytochemistry.262	  
Variations	   in	   the	   expression	   levels	   of	   MUC18	   between	   the	   UM	   cell	   lines	   are	  
reported	  in	  both	  studies.	  	  
The	  detection	  antigen	  MCSP,	  also	  known	  as	  HMW-­‐MAA,	  which	  is	  recognised	  by	  the	  
monoclonal	  antibody	  9.2.27,263	  has	  been	  used	  previously	   for	  CTC	  detection	   in	  UM	  
using	  immunomagnetic	  methods.245-­‐247	  Selection	  of	  this	  antigen	  is	  based	  on	  a	  single	  
paper	  showing	  moderate	  immunohistochemical	  expression	  in	  18/19	  FFPE	  choroidal	  
melanoma	  sections.264	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We	  hypothesised	  that	  expression	  of	  these	  two	  antigens	  could	  be	  influenced	  by	  their	  
growth	   in	   anchorage	   dependent	   and	   independent	   conditions,	   the	   latter	   more	  
closely	  mimicking	  UM	  cells	  circulating	   in	  the	  blood.	   	  Based	  on	  our	  analysis,	  CD146	  
was	  widely	  expressed	  in	  all	  cell	  lines	  in	  both	  adherent	  and	  non-­‐adherent	  conditions	  
suggesting	   good	   performance	   of	   the	   enrichment	   step.	   In	   contrast,	   the	   detection	  
antibody	  MCSP	  was	   expressed	  only	   by	   a	   limited	  number	  of	   cells	   both	  within	   and	  
between	   the	   UM	   cell	   lines,	   perhaps	   explaining	   the	   absence/low	   levels	   of	   CTC	  
detection	   in	   many	   UM	   patient	   samples.	   In	   contrast,	   cells	   isolated	   from	   a	   single	  
primary	   UM	   specimen	   and	   grown	   in	   short	   term	   culture	   showed	   low	   numbers	   of	  
CD146	   positive	   cells,	   particularly	   when	   grown	   in	   suspension,	   while	   expression	   of	  
MCSP	  was	  detected	  in	  almost	  every	  cell	  analysed.	  Of	  further	  interest	  was	  the	  more	  
widespread	  expression	  of	  CD184.	  These	  data	  highlight	  the	  need	  for	  further	  studies	  
using	  UM	  cells	  isolated	  from	  patient	  specimens.	  In	  this	  respect,	  magnetic-­‐activated	  
cell	   sorting	   (MACS),	   could	   be	   preferable	   over	   FACS,	   as	   it	   requires	   less	   sample	  
handling	   (in	   particular	   rinse/centrifugation	   steps)	   and	   allows	   for	   large	   input	  
volumes.265	  
	  In	   a	   recently	   published	   paper,	   similar	   concerns	   about	   the	   use	   of	   MCSP	   for	   CTC	  
detection	   in	   UM	   were	   raised.266	   The	   authors	   went	   on	   to	   apply	   a	   dual	   immune-­‐
magnetic	   enriched	   assay	   using	   antibodies	   against	   two	   melanoma	   markers:	  
NKI/beteb	   (analogue	   to	   CD146)	   and	  NKI/C3	   (analogue	   to	   CD63),	  which	   had	   been	  
previously	  tested	  in	  UM	  cell	  lines.267	  Using	  an	  indirect	  labelling	  approach,	  in	  which	  
the	  mononuclear	   cell	   fraction	  was	   first	   incubated	  with	   the	   antibody	   cocktail	   and	  
then	  added	  to	  the	  immunobeads,	  a	  detection	  sensitivity	  of	  2	  tumour	  cells/	  10ml	  of	  
blood,	  as	  shown	  by	  spiking	  experiments	  with	  the	  92.1	  cell	  line,	  was	  achieved.	  Using	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this	  method,	  CTC	  were	  detected	  in	  29	  out	  of	  31	  (93.5%)	  patients	  with	  primary	  non-­‐
metastatic	  UM,	  with	  a	  median	  count	  of	  3.5	  cells	  /	  10	  ml	  of	  blood	  (range:	  0-­‐10	  cells).	  
However,	   as	   reported	   in	   the	  previous	   studies,	   no	   correlation	  was	   found	  between	  
the	  number	  of	  CTC	  and	  any	  clinical	  prognostic	  factors.	  Furthermore,	  there	  was	  no	  
follow-­‐up	   information	   to	   draw	   conclusions	   about	   survival.	   The	   most	   interesting	  
aspect	   of	   this	   approach	   is	   that	   intact	   and	   viable	   CTC	   could	   be	   identified	   and	  
successfully	   cultured	   for	   the	   majority	   of	   UM	   patients.	   This	   opens	   the	   avenue	   to	  
further	  molecular	  characterization	  of	  CTC	  as	  well	  as	  enhancing	  our	  understanding	  
of	  the	  biology	  of	  these	  cells	  and	  elements	  of	  the	  metastatic	  process.	  
4.4.4 CTC	  and	  cancer	  stem	  cells	  	  
Recent	  data	  have	  suggested	  an	  interesting	  functional	  confluence	  between	  CTC	  and	  
cancer	  stem	  cells	  (CSC),	  as	  different	  functional	  statuses	  of	  the	  same	  subpopulation	  
of	  cancer	  cells.268	  The	  concept	  of	  dynamic	  phenotype	  and	  heterogeneity	  amongst	  
CTC	  has	  led	  to	  the	  development	  of	  a	  hypothetical	  model	  with	  three	  types	  of	  CTC:	  a)	  
bystander	  CTC;	  b)	  pathogenically	  active	  CTC;	  and	  c)	  migrating	  CSC.269	  	  
Bystander	   CTC	   are	   more	   differentiated	   cancer	   cells	   that	   have	   no	   proliferative	  
potential	   and	   have	   entered	   the	   circulation	   by	   a	   passive	   mechanism	   such	   as	  
inflammation	  at	  the	  site	  of	  the	  primary	  cancer.	  Enumeration	  of	  this	  subpopulation	  
would	  be	  of	  no	  clinical	  value.	  
Pathogenically	   active	   CTC	   are	   those	   that	   play	   a	   role	   in	   cancer	   dissemination	   and	  
metastasis.	   Characterization	   and	   enumeration	   of	   this	   subpopulation	   over	   time	  
would	  provide	  useful	  diagnostic	  and	  prognostic	  information.	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Migrating	   CSC	   are	   characterised	   by	   peculiar	   genotypic	   and	   phenotypic	   plasticity,	  
being	   able	   to	   assume	   stem	   cell-­‐like	   characteristics	   as	   well	   as	   undergo	   epithelial-­‐
mesenchymal	   transition	   (EMT).	   This	   would	   be	   the	   subpopulation	   of	   greatest	  
pathogenic	   value	   in	   terms	   of	   cancer	   aggressiveness	   and	   resistance	   to	   therapy.	  
However,	  the	  currently	  used	  detection	  methods	  for	  CTC	  are	  not	  efficient	  enough	  to	  
identify	  this	  CTC	  subpopulation.270	  	  
For	   this	   reason,	  we	   simultaneously	   tested	   the	   expression	   of	   the	   two	   cell	   surface	  
markers	  used	  for	  enrichment	  (CD146)	  and	  detection	  (MCSP)	  of	  CTC	  as	  well	  as	  that	  
of	   a	   putative	   stem	   cell	   marker,	   CD184,	   which	   had	   previously	   been	   shown	   to	   be	  
expressed	   on	   the	   surface	   of	   CTC	   in	   metastatic	   cutaneous	   melanoma.256	   In	   both	  
adherent	   and	   suspension	  UM	  cell	   lines,	   the	   expression	  of	   CD184	  was	  minimal,	   in	  
line	  with	  one	  previous	  report,271	  and	  did	  not	  correlate	  with	  MCSP	  status.	  In	  the	  one	  
primary	   sample,	   on	   the	   contrary,	   22%	   of	   cells	   were	   positive	   for	   this	   marker.	   	   It	  
should	  be	  noted	  that	  detection	  of	  the	  CD184	  chemokine	  receptor	  is	   influenced	  by	  
microenvironmental	  conditions	  leading	  to	  its	  internalisation.	  Hence	  caution	  should	  
be	  taken	  when	  assaying	  this	  cell	  surface	  marker	  in	  the	  laboratory,	  and	  once	  again,	  
studies	  on	  a	  larger	  series	  of	  primary	  samples	  are	  very	  much	  needed.	  
4.4.5 Conclusions	  and	  future	  directions	  
The	  heterogeneity	  and	  intriguing	  plasticity	  of	  CTC	  in	  the	  bloodstream,	  essential	  for	  
their	  high	  adaptability	  to	  the	  changing	  microenvironment,	  makes	  the	  discovery	  of	  a	  
specific	  and	  sensible	  assay	  for	  CTC	  detection	  very	  difficult.269	  Our	  study	  shows	  that	  
the	   CellSearch®	   platform	   with	   the	   current	   CMC	   kit	   does	   not	   seem	   suitable	   for	  
enumeration	  of	  CTC	  in	  UM	  patients	  at	  any	  stage	  of	  disease.	  However,	  our	  work	  also	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shows	  that	  determining	  which	  antibody	  may	  be	  most	  suitable	  remains	  difficult,	  as	  
studies	   of	   surface	   antigen	   expression	   on	   cell	   lines	   are	   not	   truly	   representative.	  
Advances	  in	  the	  characterization	  of	  primary	  UM	  samples	  are	  warranted	  and	  could	  
lead	  to	  the	   identification	  of	  alternative	  cell	  markers	  for	  the	  development	  of	  a	  UM	  
customised	  kit.	  
In	   the	   meanwhile,	   other	   groups	   have	   focused	   on	   the	   detection	   of	   circulating	  
tumour	  DNA	  (ctDNA)272	  or	  cell-­‐free	  DNA	  (cfDNA),273	  rather	  than	  CTC,	  in	  the	  search	  
for	   a	   solid	   and	   reproducible	   technique	   that	   can	   overcome	   antibody-­‐based	  
limitations.	   This	   is	   based	   on	   the	   knowledge	   that	   approximately	   80%	   of	   UM	   bear	  
mutually	   exclusive	   somatic	  mutations	   in	   the	   GNAQ	   or	   GNA11	   genes.	   One	   recent	  
study	  investigated	  the	  presence	  of	  CTC	  (using	  the	  CellSearch®	  platform)	  and	  ctDNA	  
(using	  bidirectional	  pyrophosphorolysis-­‐activated	  polymerization)	  in	  a	  cohort	  of	  40	  
metastatic	  UM	  patients	   and	   showed	   that	   ctDNA	   is	  more	   frequently	  detected	  and	  
has	   greater	   prognostic	   value	   in	  multivariate	   analysis	   than	   CTC	   enumeration.261	   In	  
addition,	  ctDNA	  is	  more	  promising	  as	  clinical	  tool	  because	  it	  has	  a	  dynamic	  range	  of	  
values,	  and	  therefore	  could	  be	  used	  to	  monitor	  treatment	  response.	  To	  date,	  there	  
is	  no	   information	  about	   the	  presence	  or	  not	  of	   ctDNA	   in	  primary	  UM	  patients.	   In	  
metastatic	  patients,	  a	  strong	  correlation	  has	  been	  shown	  between	  tumour	  burden	  
and	   ctDNA	   levels,	   with	   low	   tumour	   burden	   being	   the	   only	   clear	   limit	   to	   ctDNA	  
detection.272	  It	  is	  therefore	  not	  clear	  whether	  ctDNA	  could	  be	  used	  as	  a	  biomarker	  
for	  monitoring	  the	  development	  of	  metastasis	  in	  HR	  patients;	  however,	  this	  is	  also	  
worth	  investigating	  in	  the	  future.	  
In	  conclusion,	  the	  analysis	  of	  CTC	  in	  the	  peripheral	  blood	  of	  UM	  patients	  is	  still	  far	  
from	   being	   clinically	   useful,	   but	   it	   requires	   pursuit	   in	   terms	   of	   CTC	   capture	   and	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characterisation	  (rather	  than	  enumeration),	  as	  it	  could	  provide	  unparalleled	  means	  
to	  understand	  metastatic	  biology	  and	  identify	  relevant	  therapeutic	  targets.	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Chapter	  5 	  
Choroidal	  tumour	  biopsies	  for	  risk	  stratification	  in	  	  
uveal	  melanoma	  patients	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5.1 Introduction	  
As	   discussed	   in	   Chapter	   1,	   almost	   50%	   of	   patients	   with	   choroidal	   melanoma	  
develop	  metastatic	  disease,	  which	  is	  only	  rarely	  clinically	  detectable	  at	  the	  time	  of	  
diagnosis	   of	   the	   ocular	   tumour	   and	   which	   may	   develop	   months	   to	   years	   after	  
apparent	  good	  health.	  Metastatic	  disease	  almost	  always	  involves	  the	  liver	  initially,	  
and	   usually	   has	   a	   fatal	   outcome.274	   However,	   there	   are	   increasing	   therapeutic	  
options,	   such	   as	   hepatic	   tumour	   resection,89	   intra-­‐hepatic	   chemotherapy,275	   and	  
immunotherapy	  with	  agents	  such	  as	  ipilimumab.211	  The	  best	  results	  are	  obtained	  in	  
patients	  when	  metastases	   have	   been	   identified	   early	  within	   the	   liver,	   are	   few	   in	  
number,	   and	   are	   potentially	   surgically	   resectable.78,	   89,	   90	   To	   identify	   UM	   patients	  
with	  increased	  metastatic	  risk	  and	  who	  thus	  require	  more	  intensive	  liver	  screening,	  
chromosomal	   aberrations	   or	   GEP	   of	   the	   primary	   tumour	   is	   assessed	   and	  
incorporated	   into	   risk	   stratification	   at	   many	   oncology	   centres.	   At	   the	   LOOC	   a	  
computerized	  neural	  network276	  was	  developed	  and	  validated	   to	  produce	  survival	  
estimates	   that	   are	   relevant	   to	   individual	   patients	   (i.e.,	   ‘personalized	  
prognostication’)277	  based	  on	  affordable	  molecular	  and	  histopathological	  analyses,	  
financed	  by	  the	  National	  Health	  Service	  (NHS)	  England,	  and	  which	  is	  routinely	  used	  
to	  guide	  the	  screening	  protocol	  for	  metastatic	  disease.90	  
Between	  1999	  and	  2007,	  such	  prognostic	  tests	  were	  offered	  to	  consented	  patients	  
treated	   by	   local	   resection	   or	   enucleation,	   in	   whom	   tumour	   tissue	   was	   readily	  
available.278	   Advances	   in	   survival	   prediction	   and	   in	   the	   treatment	   of	   metastases	  
prompted	  LOOC	  to	  start	  offering	  prognostic	  tumour	  biopsy	  to	  as	  many	  patients	  as	  
possible,	   including	   those	   treated	   by	   brachytherapy	   or	   PBR.76	   Intraocular	   tumour	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biopsies	   have	   been	   performed	   in	   Liverpool	   since	   1993	   mainly	   for	   diagnostic	  
purposes,279,	  280	  hence	   the	  surgical	  expertise	  was	  already	   there.	   Indeed,	   the	  LOOC	  
was	  the	  first	  to	  describe	  a	  trans-­‐retinal	  (TR)	  approach	  using	  a	  25G	  vitreous	  cutter281	  
and	  have	  since	  developed	  a	  variety	  of	  approaches	  for	  trans-­‐retinal	  and	  trans-­‐scleral	  
(TS)	  tumour	  sampling,	  depending	  on	  size	  and	  location.	  
To	  facilitate	  the	  processing	  of	  prognostic	  samples,	  in	  November	  2010,	  the	  Liverpool	  
Ocular	   Oncology	   Molecular	   Pathology	   Service	   was	   established	   in	   the	   accredited	  
laboratory	   of	   the	   Department	   of	   Cellular	   Pathology,	   Royal	   Liverpool	   University	  
Hospital	   NHS	   Trust.	   This	   has	   allowed	   all	   prognostic	   testing,	   including	   molecular	  
genetic	   analyses	   by	   MLPA	   or	   MSA,	   to	   be	   performed	   ‘in	   house’,	   with	   close	  
collaboration	  between	  the	  Department	  of	  Cellular	  Pathology	  and	  the	  LOOC	  clinical	  
team.	  
Nevertheless,	  prognostic	   intraocular	  biopsies	  are	  not	  always	   successful,	   especially	  
for	   thin	   tumours	   (<3	  mm	   thick)282	   and	   the	   procedures	   themselves	   bear	   potential	  
risks,	   including:	   tumour	   dissemination;	   surgical	   complications,	   such	   as	   vitreous	  
haemorrhage	  or	  retinal	  detachment;	  endophthalmitis;	  and	  failure	  to	  obtain	  a	  result.	  
The	   issue	   of	   tumour	   dissemination	   has	   been	   addressed	   in	   a	   number	   of	   previous	  
publications,	   which	   showed	   no	   clinical	   evidence	   of	   intraocular,	   extra	   ocular	   or	  
orbital	   spread	   following	   either	   trans-­‐scleral	   or	   trans-­‐retinal	   biopsy.283-­‐290	   The	   two	  
aspects	   that	  clinicians	  still	  need	   to	  consider	  and	  discuss	  with	  prospective	  patients	  
are	   the	   risk	   of	   developing	   vitreo-­‐retinal	   complications,	   with	   potential	   visual	   loss	  
and/or	   need	   for	   further	   surgery,279	   and	   the	   risk	   of	   not	   obtaining	   a	   result,	   either	  
because	  of	  inadequate	  sampling	  or	  laboratory	  processing.38	  The	  failure	  to	  obtain	  a	  
result	  is	  indeed	  an	  important	  aspect	  to	  consider	  because	  psychological	  studies	  have	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shown	   that	   patients	   find	   an	   uncertain	   prognosis	   more	   stressful	   than	   a	   poor	  
prognosis.291	  	  
Prognostic	  tumour	  biopsy	  and	  personalised	  prognostication	  in	  UM	  is	  also	  important	  
for	   translational	   research,	   as	   it	   provides	   essential	   information	   that	   allows	   for	  
segregation	   into	  HR	   versus	   LR	   of	   associated	  material,	   such	   as	   blood	   samples.	   For	  
example,	   the	   study	   on	   CTC	   described	   in	   Chapter	   4	   relied	   on	   tumour	   biopsies	   for	  
determination	   of	   metastatic	   risk	   in	   those	   patients	   treated	   conservatively.	   While	  
collecting	  this	  information,	  it	  became	  apparent	  that	  molecular	  genetic	  results	  could	  
not	  be	  obtained	  in	  some	  cases;	  therefore	  an	  audit	  of	  the	  prognostic	  biopsy	  process	  
was	  started.	  In	  particular,	  we	  were	  interested	  in	  understanding	  whether	  there	  was	  
room	  for	  improvement	  in	  the	  surgical	  techniques,	  in	  the	  sample	  handling,	  and	  in	  its	  
processing.	  
The	  aims	  of	  the	  study	  in	  this	  Chapter	  were	  to	  retrospectively	  evaluate	  the	  process	  
of	   choroidal	   melanoma	   biopsy	   conducted	   by	   LOOC	   over	   an	   18-­‐month	   period,	   to	  
assess	   the	   yield	   of	   prognostic	   information	   provided	   weighed	   against	   surgical	  
complications,	  to	  identify	  possible	  ‘pitfalls’	  in	  the	  process,	  to	  describe	  the	  change	  of	  
practice	  undertaken,	  and	  to	  re-­‐assess	  the	  results	  after	  a	  further	  12	  months.	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5.2 Patients	  and	  methods	  
5.2.1 Patients	  
Patients	   were	   included	   in	   this	   study	   if	   treated	   for	   choroidal	   melanoma	   with	  
Ruthenium-­‐106	  plaque	  brachytherapy	  or	  PBR	  at	   the	   LOOC	  between	   January	  2011	  
and	   June	   2013	   and	   if	   a	   prognostic	   biopsy	   was	   performed.	   The	   study	   population	  
comprised	   two	   groups:	   1)	   a	   retrospective	   cohort	   of	   patients	   treated	   between	  
January	   2011	   and	   June	   2012;	   and	   2)	   a	   prospective	   cohort	   of	   patients	   treated	  
between	  July	  2012	  and	  June	  2013	   in	  which	  the	   impact	  of	  the	  adopted	  changes	  to	  
procedure	  was	  assessed.	  	  
The	  inclusion/exclusion	  criteria,	  data	  collection,	  follow-­‐up	  protocols	  were	  identical	  
in	  both	  groups.	  On	  the	  contrary,	  the	  surgical	  technique	  and	  the	  sample	  processing	  
were	  modified	  as	  a	  result	  of	  the	  audit	  process,	  hence	  are	  different	  between	  the	  two	  
groups,	  as	  explained	  in	  Table	  5.1.	  
Table	  5.1	  Differences	  in	  practice	  between	  group	  1	  and	  group	  2.	  
	   Group	  1	   Group	  2	  
Time	  period	   01/2011	  –	  06/2012	   07/2012	  –	  06/2013	  
Biopsy	  techniques	  
(TR	  or	  TS	  approach	  
depending	  on	  
tumour	  location,	  
with	  TR	  being	  
preferred	  for	  post-­‐
equatorial	  UM)	  
For	   all	   tumours	   irrespective	   of	  
thickness	  
TR:	  25G	  vitreous	  cutter	  
TS:	  25G	  FNAB	  
	  
Tumours	  <3mm	  thick:	  
TR:	  “sideway	  approach”	  
TS:	  “flap	  biopsy”	  
Tumours	  >3mm	  thick:	  
TR:	  25G	  vitreous	  cutter	  
TS:	  25G	  FNAB	  
Blood	  sample	   From	  selected	  patients	   Collected	   in	  all	  cases	  and	  sent	  




3-­‐4	   cytospin	   slides	   prepared	  
for	   all	   biopsy	   samples;	  
remaining	   sample	   used	   for	  
genetic	  analyses	  
Only	  1	  cytospin	  slide	  prepared	  
for	  morphological	  
examination;	  majority	  of	  the	  
specimen	  preserved	  for	  
genetic	  analyses	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Patients	   were	   excluded	   if	   the	   tumour	   arose	   in	   the	   iris,	   and	   if	   the	   biopsy	   was	  
performed	   for	   diagnostic	   purposes.	   Clinical	   data	   were	   collected	   from	   patient	  
records	   and	   included:	   age,	   gender,	   affected	  eye,	   tumour	   characteristics	   (location,	  
largest	  basal	  diameter	  and	  thickness	  measured	  by	  B-­‐scan	  ultrasonography).	  Surgical	  
data	   included:	   type	   of	   treatment	   for	   uveal	   melanoma	   (plaque	   or	   PBR),	   type	   of	  
biopsy	   (trans-­‐scleral	   or	   trans-­‐retinal),	   time	   of	   biopsy	   compared	   to	   treatment	  
commencement,	  surgeon,	  intraoperative	  complications,	  follow-­‐up	  examination	  at	  1	  
day,	  1	  month,	  and	  any	  other	  further	  visit.	  
Tumours	  were	  biopsied	  either	   trans-­‐sclerally	  or	   trans-­‐retinally	  depending	  on	   their	  
size,	  location	  and	  treatment.	  Those	  treated	  with	  a	  ruthenium	  plaque	  were	  biopsied	  
either:	   (a)	   trans-­‐sclerally	   if	   they	   extended	   pre-­‐equatorially	   and	   if	   the	   tumour	  
thickness	   exceeded	   2mm;	   or	   (b)	   trans-­‐retinally,	   if	   the	   tumour	   was	   considered	  
inaccessible	   with	   this	   approach	   because	   it	   was	   small	   and/or	   posterior.	   Tumours	  
treated	  with	  PBR	  were	  biopsied	  trans-­‐retinally	  as	  soon	  as	  possible	  after	  completion	  
of	   the	   radiotherapy,	   i.e.,	   on	   the	   last	   day	   of	   the	   radiotherapy	   or,	   if	   this	   was	   not	  
possible,	  within	  a	  period	  of	  two	  weeks.	  	  
Written	  informed	  consent	  was	  obtained	  in	  all	  cases	  prior	  to	  performing	  the	  biopsy.	  
In	   addition	   to	   being	   advised	   of	   the	   possible	   risks	   associated	   with	   the	   surgery,	  
patients	  were	  informed	  of	  the	  screening/follow-­‐up	  procedures	  following	  prognostic	  
testing.	  Contra-­‐indications	  to	  biopsy	  were	  poor	  vision	  in	  the	  fellow	  eye	  and	  patients	  
on	  any	  anti-­‐coagulant	  therapy.	  	  
Generic	  consent	  for	  the	  use	  of	  data,	  tissues	  and	  images	  for	  research,	  teaching	  and	  
audit	   was	   obtained	   prospectively	   from	   all	   patients.	   Approval	   for	   this	   study	   was	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obtained	   from	   the	   Royal	   Liverpool	   University	   Hospital	   (project	   reference	   number	  
4031-­‐11/129).	  	  
5.2.2 Surgical	  Techniques	  
5.2.2.1 Trans-­‐retinal	  biopsies	  
Trans-­‐retinal	   biopsies	   were	   performed	   under	   local	   anaesthesia	   with	   a	   25-­‐gauge	  
vitreous	  cutter,	  using	  a	  3-­‐port	  sutureless	  vitrectomy	  kit,	  as	  previously	  described.281	  
Briefly,	  the	  vitreous	  cutter	  was	  advanced	  across	  the	  vitreous	  cavity	  and	  through	  the	  
retina	  into	  the	  centre	  of	  the	  tumour,	  avoiding	  any	  retinal	  blood	  vessels.	  To	  obtain	  
more	   tissue	   samples,	   the	   vitreous	   cutter	   was	   repeatedly	   inserted	   into	   and	  
withdrawn	   from	   the	   tumour,	  with	  maximum	   suction	   and	   low	   cutting	   rate	   (Figure	  
5.1).	  	  
	   	  
Figure	   5.1	   Schematic	   representation	  of	   the	   transretinal	   tumour	  biopsy	   technique	  using	   a	  
25G	   vitreous	   cutter	   introduced	   via	   pars-­‐plana	   through	   the	   vitreous	   cavity.	   The	   tumour	   is	  
visualised	   using	   a	   fundus	   lens	   (not	   shown)	   and	   a	   light	   pipe,	   shown	   in	   black	   on	   the	   right	  
hand	  side	  of	  the	  image	  (Courtesy	  of	  Mr	  C.	  Groenewald;	  vitreoretinal	  surgeon,	  LOOC).	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A	  modified	  technique	  has	  been	  developed	  for	  thinner	  choroidal	  tumours	  (i.e.,	   less	  
than	  3	  mm	   thick)	   and	  applied	   to	   study	  group	  2.	   In	   such	   tumours,	   the	   retinotomy	  
was	   placed	   near	   the	   tumour	   margin	   and	   the	   retina	   was	   lifted	   slightly	   away	   by	  
moving	   the	   cutter	   sideways	   towards	   the	   centre	   of	   the	   tumour.	   Raising	   the	  
intraocular	   pressure	   for	   about	   one	   minute	   controlled	   bleeding	   on	   removing	   the	  
cutter	   from	   the	   tumour.	   Vitrectomy,	   endo-­‐laser	   photocoagulation	   and	   internal	  
tamponade	  were	  not	  required	  in	  any	  case.	  The	  specimen	  was	  ejected	  through	  the	  
vitreous	  cutter	  into	  a	  sterile	  universal	  tube	  by	  flushing	  the	  line	  with	  BSS.	  
5.2.2.2 Trans-­‐scleral	  biopsies	  
Trans-­‐scleral	   fine-­‐needle	   aspiration	   biopsies	   (FNAB)	   were	   performed	   with	   a	   25-­‐
gauge	   needle,	   which	   was	   attached	   to	   a	   20ml	   syringe	   by	   flexible	   plastic	   tubing.	  
(Figure	  5.2).	  	  
	  
Figure	   5.2	   Schematic	   representation	   of	   the	   trans-­‐scleral	   fine-­‐needle	   aspiration	   biopsy	  
technique	  using	  a	  25G	  needle.	  (Courtesy	  of	  Mr	  C.	  Groenewald;	  vitreoretinal	  surgeon,	  LOOC).	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An	   ink-­‐mark	   was	   made	   on	   the	   needle	   at	   an	   appropriate	   distance	   from	   the	   tip	  
corresponding	  to	  the	  thickness	  of	  the	  tumour,	  plus	  1-­‐2	  mm	  extra,	  so	  that	  the	  mark	  
would	  not	  be	  wiped	  away	  by	  contact	  with	  the	  sclera.	  The	  needle	  was	  abraded	  with	  
artery	   forceps	   beforehand,	   in	   order	   to	   create	   a	   rough	   surface	   on	   which	   the	   ink	  
would	  stay.	  The	  needle	  was	  passed	  obliquely	  through	  the	  sclera	  for	  3-­‐4	  mm	  before	  
being	  adjusted,	  in	  order	  to	  enter	  the	  tumour.	  Traction	  was	  applied	  to	  the	  plunger	  of	  
the	  syringe	  while	   the	  needle	  tip	  was	  moved	  from	  side	  to	  side	  and	  backwards	  and	  
forwards.	  Immediately	  after	  removing	  the	  needle,	  the	  scleral	  track	  was	  compressed	  
with	   a	   cotton	   bud	   and	   diathermied	   with	   bipolar	   cautery	   to	   reduce	   any	   risk	   of	  
tumour	  seeding	  outside	  the	  eye.	  The	  specimen	  was	  collected	  by	  filling	  the	  syringe	  
with	  BSS	  and	  flushing	  the	  content	  of	  the	  tubing	  and	  needle	  into	  a	  sterile	  universal	  
tube.	  
The	  following	  modification	  to	  the	  procedure	  was	  adopted	  for	  all	  patients	  included	  
in	   study	   group	   2:	   a	   trans-­‐scleral	   incisional	   biopsy	   approach	   (“flap	   biopsy”)	   was	  
developed	  by	  Professor	  Damato,	   lead	  of	  the	  LOOC	  at	  the	  time,	  to	  sample	  anterior	  
tumours	   less	   than	   3	   mm	   thick	   being	   treated	   by	   brachytherapy	   (Figure	   5.3).	   A	  
partial-­‐thickness,	   lamellar	   scleral	   flap	  was	   created	   over	   the	   centre	   of	   the	   tumour	  
and	   hinged	   posteriorly.	   Essen	   forceps292	   were	   repeatedly	   introduced	   into	   the	  
tumour	   through	  a	  deep	  scleral	   incision,	   rinsing	   the	   forceps	  with	  BSS	   into	  a	   sterile	  
universal	   tube	   to	   collect	   the	   cell	   pellets	   (at	   least	   two).	   The	   superficial	   scleral	   flap	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Figure	   5.3	   The	   “flap	   biopsy”	   technique	   developed	   for	   thin	   anterior	   choroidal	   tumours.	   A	  
superficial,	   lamellar	   scleral	   flap	   is	   created	   (	   a	   );	   a	   deep	   scleral	   incision	   is	   made	   for	  
introduction	   of	   Essen	   forceps	   into	   the	   tumour	   (	   b	   );	   the	   specimens	   are	   collected	   onto	   a	  
tissue	  before	  transferring	  into	  a	  container	  (	  c	  );	  any	  pigment	  is	  treated	  with	  bipolar	  cautery	  
(	   d	   );	   the	   flap	   is	   closed	   with	   tissue	   glue	   (	   e	   );	   if	   necessary,	   sutures	   are	   placed	   (	   f	   );	   the	  
radioactive	   plaque	   is	   then	   inserted	   overlying	   the	   biopsy	   site.	   (Courtesy	   of	   Prof.	   B.	  
Damato293)	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Figure	  5.4	  Flow	  diagram	  illustrating	  the	  pathway	  designed	  for	  the	  optimal	  processing	  of	  
prognostic	  biopsy	  samples,	  depending	  on	  the	  surgical	  technique	  used	  (study	  group	  2).	  
Please	  note	  how	  cytomorphological	  evaluation	  of	  the	  sample	  is	  key	  in	  determining	  further	  
steps,	  including	  molecular	  genetic	  analyses.	  (Legend:	  BSS:	  balanced	  salt	  solution;	  MGG:	  
May-­‐Grünwald-­‐Giemsa;	  UM:	  uveal	  melanoma;	  H&E:	  haematoxylin	  and	  eosin)	  
	  
5.2.3 Sample	  processing	  
Specimens	   were	   transported	   immediately	   without	   fixative	   to	   the	   pathology	  
laboratory,	  where	  the	  sample	  was	  used	  as	  follows:	  	  
•	   Study	  group	  1:	  3	  to	  4	  cytospin	  slides	  were	  prepared	  for	  cytomorphological	  
analysis	   and	   immunocytochemistry;	   the	   remainder	   of	   the	   specimen	  was	   used	   for	  
DNA	  extraction	  and	  subsequent	  molecular	  genetic	  analyses.	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•	   Study	  group	  2:	   a	   single	   cytospin	   slide	  was	  prepared	   for	   cytomorphological	  
analysis	  allowing	  the	  preservation	  of	  the	  majority	  of	  the	  sample	  for	  DNA	  extraction	  
and	   subsequent	   molecular	   analyses.	   Moreover,	   two	   different	   pathways	   were	  
devised	  for	  handling	  of	  trans-­‐retinal	  and	  trans-­‐scleral	  FNAB	  versus	  trans-­‐scleral	  flap	  
biopsies,	   as	   the	   latter	   surgical	   technique	   yields	   small	   fragments	   of	   tumour	   rather	  
than	  cells	  (Figure	  5.4).	  	  
5.2.3.1 Molecular	  genetic	  analyses	  
Following	  morphological	  examination	  and	  confirmation	  of	  the	  presence	  of	  UM	  cells	  
in	  the	  sample	  by	  experienced	  ophthalmic	  pathologists,	  DNA	  was	  extracted	  from	  the	  
residual	  sample	  and	  used	  for	  molecular	  genetic	  analyses,	  either	  by	  MLPA	  or	  MSA,	  
depending	  on	  the	  DNA	  yield	  obtained,	  as	  detailed	  below.	  	  
For	   DNA	   extraction,	   tissues	   were	   incubated	   for	   16	   hours	   at	   56°C	   (Thermomixer	  
Comfort,	  Eppendorf,	  Stevenage,	  UK)	  in	  125	  µl	  of	  P-­‐buffer	  (50	  mM	  Tris-­‐HCl	  pH	  8.2,	  1	  
mM	   EDTA,	   100	   mM	   NaCl,	   0.5%	   Tween-­‐20,	   0.5%	   NP40,	   20	   mM	   dithiothreitol)	  
containing	   8.2	   mg	   of	   Proteinase	   K	   (Qiagen,	   Crawley,	   UK).	   Samples	   were	   further	  
incubated	  at	  37°C,	   following	   the	  addition	  of	  8.2	  mg	  of	  Proteinase	  K	   for	  24	  hours.	  
Genomic	  DNA	  was	  extracted	  using	   the	  DNeasy	  Blood	  and	  Tissue	   kit	   (Qiagen)	   and	  
the	   DNA	   eluted	   in	   15-­‐25	   µl	   of	   AE	   buffer.	   DNA	   concentration	   was	   quantified	   by	  
fluorometry	   (Qubit	   fluorometer	   and	   Broad	   Range	   DNA	   Quantification	   assay,	   Life	  
Technologies,	  Glasgow,	  UK)	  and	  its	  quality	  was	  assessed	  by	  multiplex	  PCR	  (adapted	  
from	  Dongen	  et	  al)294,	  as	  previously	  described	  by	  Dopierala	  et	  al.197	  
When	  at	  least	  100	  ng	  of	  amplifiable	  DNA	  was	  obtained,	  MLPA	  was	  performed	  with	  
the	  P027.B1	  assay	  produced	  by	  MRC-­‐Holland	   (Amsterdam,	  The	  Netherlands).	  This	  
	  
	   172	  
kit	   has	   been	   specifically	   designed	   for	   use	   in	   UM	   to	   determine	   copy	   number	  
alterations	  for	  gene	  loci	  on	  chromosomes	  1,	  3,	  6	  and	  8.	  The	  kit	  comprises	  a	  set	  of	  50	  
probes	   (12	   control,	   38	   test),	   each	   hybridizing	   to	   a	   specific	   genomic	   sequence.	   As	  
MLPA	   is	  a	  high-­‐resolution	  multiplex	  PCR-­‐based	  method,	   it	   is	  not	   target	  sequences	  
that	   are	   amplified	   in	   the	   reaction,	   but	  MLPA	   probes	   that	   hybridise	   to	   the	   target	  
sequence.	  In	  contrast	  to	  a	  standard	  multiplex	  PCR,	  a	  single	  pair	  of	  PCR	  primers	  are	  
used	  for	  DNA	  amplification.	  The	  resulting	  amplification	  products	  can	  be	  analysed	  by	  
capillary	   electrophoresis.	   By	   comparing	   the	   peak	   pattern	   of	   a	   tumour	   sample	   to	  
that	  of	  non-­‐tumour	   reference	   samples,	  gene	  dosage	  quotients	   (DQ)	   for	   individual	  
loci	  are	  determined.	  Six	  FFPE	  non-­‐tumour,	  normal	  choroid,	  control	   samples	  and	  a	  
negative	   (no	   template)	   control	   were	   analysed	   alongside	   the	   UM	   test	   samples	   in	  
each	   reaction.	   MLPA	   was	   performed	   in	   a	   G-­‐Storm	   GS1	   Thermal	   Cycler	   (Genetic	  
Research	   Instrumentation	   Ltd,	   Essex,	   UK)	   as	   per	   the	   manufacturers’	   instructions	  
and	   quantified	   using	   the	   3130XL	   Genetic	   Analyser	   and	   GeneMapper	   software	  
(Applied	   Biosystems,	   Paisley,	   UK).	   Peak	   heights	   were	   taken	   as	   a	   measure	   of	  
intensity.	   MLPA	   data	   were	   analyzed	   using	   an	   adapted	   version	   of	   the	   Excel	  
spreadsheet	   designed	  by	  Dr.	  Andrew	  Wallace	  of	   the	  National	  Genetics	   Reference	  
Laboratory	   (NGRL),	   Manchester,	   UK	   (http:/www.ngrl.org.uk/Manchester/).	   The	  
adapted	   analysis	   method	   allows	   for	   the	   removal	   of	   any	   control	   loci	   from	   an	  
individual	  MLPA	  assay	  if	  the	  DQ	  is	  not	  within	  the	  range	  for	  a	  normal	  (disomic)	  copy	  
number	  (0.85–1.14).	  MLPA	  data	  were	  considered	  reliable	  if	  the	  number	  of	  control	  
loci	  within	  the	  normal	  range	  was	  ≥6	  and	  if	  the	  standard	  deviation	  (SD)	  of	  their	  DQs	  
was	  <0.2.	  The	  DQ	  for	  each	  gene	  loci	  was	  categorized	  as	  suggested	  by	  the	  NGRL	  as	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follows:	  deletion	  (D),	  ≤0.65;	  borderline	  loss	  (E),	  0.65-­‐0.84;	  normal=diploid	  (N),	  0.85-­‐
1.14;	  borderline	  amplification	  (Q),	  1.15-­‐1.35;	  and	  amplification	  (A)	  >1.35.	  	  
	  
When	   the	   yield	   of	  DNA	  was	   <100	   ng,	  MSA	  was	   used	   to	   detect	   regions	   of	   loss	   of	  
heterozygosity	   on	   chromosome	   3.	  Microsatellites	   are	   small	   repeat	   regions	   of	   1-­‐6	  
base	   pairs	   generally	   found	   in	   the	   non-­‐coding	   regions	   of	   the	   genome.	   The	   region	  
containing	  the	  microsatellite	  is	  amplified	  by	  PCR	  using	  forward	  and	  reverse	  primers	  
that	  flank	  the	  microsatellite.	  The	  size	  of	  the	  DNA	  amplified	  can	  then	  be	  determined	  
by	  the	  number	  of	  repeats	  present	  in	  the	  microsatellite	  on	  that	  allele.	  One	  of	  each	  
primer	   pair	   is	   fluorescently	   tagged	   to	   allow	   quantitation	   by	   capillary	  
electrophoresis.	  A	  comparison	  of	  the	  peak	  area	  of	  tumour	  DNA	  (biopsy	  specimens)	  
and	  normal	  DNA	  (matched	  blood	  sample)	  allows	  the	  determination	  of	  allele	  ratio	  in	  
the	  tumour.	  
The	  protocol	  for	  MSA	  analysis	  of	  chromosome	  3	  (p	  and	  q	  arms)	  used	  in	  this	  study	  is	  
based	  on	  the	  validated	  method	  published	  by	  Dr	  Zeschnigk’s	  group.295	  
	  
5.2.3.2 Cytomorphological	  assessment	  
In	   an	   effort	   to	   understand	  whether	   examination	   of	   cytospin	   slides	   (which	   can	   be	  
done	   within	   a	   few	   hours)	   could	   predict	   the	   likelihood	   to	   obtain	   a	   genetic	   result	  
(process	   which	   requires	   several	   days),	   May-­‐Grünwald-­‐Giemsa	   (MGG)-­‐stained	  
cytospin	  slides	  for	  all	  patients	  in	  study	  group	  1	  were	  retrieved	  from	  the	  Pathology	  
archives,	   the	   pathology	   report	   reviewed,	   and	   the	   cytospins	   scored	   by	   three	  
independent	  observers	  in	  terms	  of	  the	  overall	  degree	  of	  cellularity	  (i.e.	  percentage	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of	   the	   cytospin	   area	   occupied	   by	   cells	   of	   any	   type).	   This	   percentage	   was	   then	  
broken	  down	  into	  the	  proportions	  occupied	  by;	  1)	  tumour	  cells,	  2)	  red	  blood	  cells,	  
3)	   white	   blood	   cells	   and	   4)	   other	   cells,	   such	   as	   macrophages.	   In	   the	   case	   of	  
discrepancy,	  slides	  were	  re-­‐assessed	  together	  with	  the	  reporting	  pathologist	  and	  a	  
consensus	   reached.	   Examples	   of	   this	   scoring	   system	   are	   given	   in	   Figure	   5.5.	  
Correlations	  were	  drawn	  between	  the	  score	  of	  tumour	  cellularity	  on	  the	  slide	  and	  
the	  amount	  of	  DNA	  extracted	  from	  the	  sample.	  
5.2.4 Data	  analysis	  
All	  patient	  data	  were	   retrieved	  and	  all	   samples	  analysed	  according	   to	   their	  ability	  
to:	   (1)	   yield	   cytomorphological	   information;	   and	   (2)	   provide	   chromosome	   3	  
classification.	   Secondary	   analyses	   included:	   intraoperative	   complications;	  
postoperative	  complications;	  tumour	  dissemination.	  	  
All	  statistical	  analyses	  were	  carried	  out	  using	  SPSS	  (IBM)	  version	  20	  (SPSS	  Science,	  
Chicago,	   IL)	   in	   collaboration	  with	  Prof	  Azzam	  Taktak,	   Consultant	   Clinical	   Scientist,	  
Department	  of	  Clinical	  Physics	  and	  Engineering,	  University	  of	  Liverpool.	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Figure	   5.5	   Scoring	   of	   choroidal	   melanoma	   biopsy	   content	   (cytospin	   slides	   stained	   with	  
MGG).	   The	   overall	   cellularity	   of	   the	   specimen	   is	   classified	   as:	   A)	   low	   –	   5%;	   B)	  medium	  –	  
50%;	   C)	   high	   -­‐100%.	   The	   presence	   of	   melanoma	   cells	   (as	   percentage	   of	   the	   overall	  
cellularity)	  is	  classified	  as:	  D)	  absent	  –	  0%;	  E)	  medium	  –	  30%;	  F)	  high	  –	  100%.	  The	  presence	  
of	  other	  cell	   types	   (as	  percentage	  of	   the	  overall	   cellularity)	   is	  also	  noted,	   for	  example:	  G)	  
erythrocytes-­‐	  80%,	  and	  macrophages	  –	  10%;	  H)	  leucocytes	  –	  5%.	  The	  use	  of	  Essen	  forceps	  
in	   trans-­‐scleral	   incisional	   biopsies	   allows	   for	   preservation	   of	   clumps	   of	   uveal	   melanoma	  
tissue,	  rather	  than	  loose	  cells,	  as	  shown	  in	  figure	  1I.	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5.3 Results	  
5.3.1 Clinical	  characteristics	  
Between	   January	   2011	   and	   June	   2013	   (i.e.	   18	   months),	   232	   consecutive	   UM	  
patients	   underwent	   prognostic	   tumour	   biopsy	   of	   a	   choroidal	   melanoma.	   The	  
patients	  (123	  male,	  109	  female)	  had	  a	  median	  age	  of	  59	  years	  (range,	  25	  –	  82).	  The	  
tumour	  was	  located	  in	  the	  right	  eye	  in	  111	  patients	  and	  in	  the	  left	  eye	  in	  121.	  The	  
site	  of	  origin	  was	  considered	  to	  be	  the	  choroid	   in	  190	  patients	  and	  ciliary	  body	   in	  
42.	   The	   tumours	   had	   a	   median	   LBD	   of	   11.4	   mm	   (range	   4.1-­‐20.8)	   and	   a	   median	  
thickness	   of	   3.4	   mm	   (range	   0.7-­‐10.3),	   with	   47%	   measuring	   less	   than	   3	   mm	   in	  
thickness.	  	  
As	  detailed	   in	  Table	  5.2,	   the	  clinical	  characteristics	  of	   the	  tumours	   in	  group	  1	  and	  
group	   2	   were	   not	   statistically	   significantly	   different.	   In	   particular,	   although	   the	  
number	  of	  patients	  differed	  between	  the	  two	  groups,	  the	  tumour	  size	  distribution	  
within	  the	  groups	  was	  comparable,	  as	  illustrated	  in	  Figure	  5.6.	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Table	  5.2	  Clinical	  characteristics	  of	  the	  study	  population	  
	  
SD:	  standard	  deviation;	  LBD:	  largest	  basal	  diameter;	  Ru:	  ruthenium-­‐106	  
*	  χ2	  test	  between	  the	  two	  groups;+	  Student’s	  t-­‐test;	  °	  Mann-­‐Whitney	  test	  
	  
	  
Figure	   5.6	   Scatterplot	   showing	   the	   size	   distribution	   of	   the	   tumors	   according	   to	   the	   TNM	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5.3.2 Surgical	  results	  
Treatment	  consisted	  of:	  Ruthenium	  plaque	  in	  151	  cases	  (65%)	  and	  PBR	  in	  81	  cases	  
(35%).	  The	  surgical	  treatment	  was	  similar	  in	  group	  1	  and	  group	  2	  (Student’s	  T	  test,	  
p=0.115).	  	  
Overall,	   the	   mean	   tumour	   thickness	   was	   significantly	   lower	   for	   trans-­‐retinal	  
biopsies	  (3.09±0.175	  mm)	  than	  for	  trans-­‐scleral	  biopsies	  (3.8±0.141	  mm)	  (T-­‐test,	  p	  =	  
0.003).	   The	   mean	   LBD	   was	   also	   significantly	   lower	   for	   trans-­‐retinal	   biopsies	  
(10.48±3.06	  mm)	  than	  for	  trans-­‐scleral	  biopsies	  (12.6±2.7	  mm)	  (T-­‐test,	  p	  <	  0.001).	  
Sixty-­‐one	  percent	   (86/142)	  of	   tumours	   in	  group	  1	  and	  50%	   (45/90)	  of	   tumours	   in	  
group	   2	   were	   biopsied	   trans-­‐retinally.	   For	   both	   groups,	   the	   biopsy	   technique	  
adopted	   for	   tumours	  of	  different	  height	   categories,	   as	   suggested	  by	  McCannel	  et	  
al.283,	   are	   detailed	   in	   Table	   5.3.	   Tumours	   <	   3	   mm	   in	   thickness	   are	   the	   most	  
challenging	   ones	   to	   safely	   biopsy.	   In	   group	   1,	   only	   22%	   (16/72)	   of	   these	   were	  
biopsied	   transclerally	   at	   the	   time	   of	   plaque	   insertion,	   whereas	   all	   other	   patients	  
required	  a	  separate	  surgical	  procedure	  for	  trans-­‐retinal	  biopsy.	  Changes	  in	  practice	  
and	  improvements	  in	  the	  biopsy	  technique	  (flap	  biopsy)	  adopted	  for	  cases	  in	  group	  
2	   resulted	   in	  an	   increase	   to	  37%	  (14/38)	  of	   thin	   tumours	  undergoing	   trans-­‐scleral	  
biopsy	  	  
5.3.2.1 Surgical	  complications	  	  
Group	  1	  
Trans-­‐scleral	  biopsy	  was	  without	  complication	  in	  71%	  (40/56)	  of	  cases.	  Thirteen	  out	  
of	  56	  patients	  experienced	   limited	  sub-­‐retinal	  or	   localised	  perilesional	  bleeding.	  A	  
single	   case	   had	   mild	   transient	   vitreous	   haemorrhage	   and	   in	   two	   cases,	   retinal	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perforation	  occurred:	  one	  patient	   required	   further	  surgery	   for	   retinal	  detachment	  
repair,	   whereas	   the	   other	   was	   successfully	   managed	   with	   pneumatic	   retinopexy	  
and	  laser.	  	  
Trans-­‐retinal	  biopsy	  was	  without	  complication	  in	  67%	  (58/86)	  of	  cases.	  Limited	  and	  
transient	   sub-­‐retinal	   bleeding	   occurred	   in	   three	   cases,	   perilesional	   bleeding	  
occurred	   in	   five	  cases	  and	  mild	  vitreous	  haemorrhage	  was	  noted	   in	  15.	  All	  of	   the	  
above	   resolved	   spontaneously	   during	   the	   follow-­‐up	   time.	   Further	   surgery	   was	  
needed	   in	   6%	   (5/86)	   of	   cases:	   to	   manage	   severe	   vitreous	   haemorrhage	   in	   four	  
patients,	  and	  to	  repair	  retinal	  detachment	  in	  one.	  
Group	  2	  
Peri-­‐lesional	  bleeding	  was	  noted	  in	  only	  one	  case	  (2%)	  among	  the	  45	  patients	  who	  
underwent	  trans-­‐scleral	  biopsy.	  With	  the	  newly	  introduced	  flap	  technique	  no	  cases	  
of	  retinal	  perforation	  or	  retinal	  detachment	  occurred;	  however,	  one	  patient	  needed	  
further	  surgery	  to	  repair	  a	  scleral	  wound	  dehiscence	  caused	  by	  poor	  suturing	  of	  the	  
conjunctiva	   over	   the	   flap	   after	   plaque	   removal.	   For	   patients	   undergoing	   trans-­‐
retinal	  biopsy,	  the	  rate	  of	  peri-­‐operative	  complications	  was	  similar	  to	  that	  in	  group	  
1	   (14/45,	   31%).	   In	   seven	   cases	   there	   was	   limited	   sub-­‐retinal	   or	   peri-­‐lesional	  
bleeding,	  which	  resolved	  spontaneously.	  Of	  seven	  patients	  who	  developed	  vitreous	  
haemorrhage:	   one	   needed	   vitrectomy;	   two	   decided	   to	   undergo	   enucleation	  
because	   of	   old	   age	   and	   poor	   visual	   acuity	   of	   the	   eye	   related	   to	   tumour	   size	   and	  
location;	   four	   were	   kept	   under	   observation	   and	   the	   haemorrhage	   resolved	  
spontaneously.	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Table	   5.3	   Morphological	   and	   genetic	   results,	   grouped	   by	   tumour	   height	   and	   biopsy	  
technique	  




Follow-­‐up	  information	  was	  available	  for	  213/232	  patients	  (92%),	  as	  the	  others	  were	  
overseas	   patients.	   Over	   a	  median	   follow-­‐up	   period	   of	   9	  months	   (range	   2-­‐32),	   no	  
case	  of	  endophthalmitis,	  orbital	  dissemination	  or	  local	  treatment	  failure	  was	  noted.	  	  
5.3.3.1 Metastatic	  disease	  
Overall,	  15/232	  (6%)	  UM	  patients	  developed	  metastatic	  disease	  during	  the	  follow-­‐
up	  time.	  The	  chromosome	  3	  status	  for	  these	  patients	  was:	  monosomy	  3	  in	  8	  cases,	  
allelic	  imbalance	  in	  2	  cases,	  disomy	  3	  in	  1	  case,	  indeterminate	  in	  1	  case.	  For	  3	  cases	  
no	  genetic	  information	  could	  be	  obtained,	  as	  the	  biopsy	  did	  not	  yield	  sufficient	  DNA	  
for	  genetic	  analyses.	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5.3.4 Cytomorphological	  results	  
In	  group	  1,	  cytospins	  stained	  with	  MGG	  were	  prepared	  for	   the	  cytomorphological	  
assessment	   of	   all	   biopsy	   specimens.	   Confirmation	   of	   the	   presence	   of	   melanoma	  
cells	   was	   possible	   in	   131/142	   (92%)	   biopsy	   samples.	   For	   11	   biopsies,	   the	   sample	  
provided	  was	  either	  completely	  acellular	  or	  devoid	  of	  tumour	  cells;	  2/86	  (2%)	  were	  
trans-­‐retinal	   biopsies	   and	   9/56	   (16%)	   trans-­‐scleral	   biopsies.	   The	   median	   overall	  
cellularity	   of	   the	   cytospin	   was	   50%	   (range	   1-­‐100%).	   Tumour	   thickness	   did	   not	  
influence	   the	   overall	   biopsy	   cellularity	   (Mann-­‐Whitney	   Z=-­‐0.146,	   p=0.884).	   The	  
median	  tumour	  cell	  component	  of	  the	  cytospin	  was	  20%	  (range	  0-­‐100%),	  with	  red	  
blood	   cells	   accounting	   for	   the	  majority	   of	   other	   cells.	   This	  was	   not	   influenced	  by	  
surgical	  technique.	  As	  expected,	  tumour	  cell	  composition	  of	  the	  cytospin	  showed	  a	  
strong	   positive	   correlation	   with	   the	   DNA	   yield	   (Spearman’s	   r=0.732,	   p<0.001).	  
Macrophages	  were	  present	   in	  16/142	   (11%)	  samples.	  White	  blood	  cells	  were	  also	  
present	  in	  23/142	  (16%)	  of	  samples,	  but	  only	  rarely	  contributed	  to	  more	  than	  5%	  of	  
overall	  biopsy	  cellularity.	  	  
Overall,	  biopsies	  provided	  cytopathological	   information	   in	  92%	  (131/142)	  of	  cases	  
in	   group	   1	   and	   99%	   (89/90)	   of	   cases	   in	   group	   2.	   Details	   of	   cytomorphological	  
classification	   were	   taken	   from	   the	   official	   report	   issued	   by	   the	   Ophthalmic	  
Pathologists	   and	  used	   in	   the	   prognostication	   algorithm	   for	   the	   individual	   patient.	  
UM	  cells	  were	  classified	  as	   (group	  1	  and	  group	  2,	   respectively):	   spindle	   in	  77/142	  
(54%)	   and	   47/90	   (52%);	   mixed	   in	   22/142	   (15%)	   and	   20/90	   (22%);	   epithelioid	   in	  
22/142	  (15%)	  and	  19/90	  (21%);	  definite	  UM	  cells	  but	  with	  ambiguous	  morphology	  
in	  10/142	  (7%)	  and	  3/90	  (3%).	  Details	  of	  the	  cytomorphology	  for	  biopsies	  grouped	  
by	  tumour	  thickness	  are	  shown	  in	  Table	  5.3.	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5.3.5 Genetic	  results	  
As	  mentioned,	  genetic	  studies	  were	  only	  performed	  on	  samples	  with	  confirmed	  UM	  
cellularity	   and	   a	   yield	   of	   amplifiable	   DNA	   ≥10ng.	   These	   guidelines	   reduced	   the	  
number	   of	   samples	   eligible	   for	   genetic	   analyses.	   A	   detailed	   explanation	   of	   the	  
attrition	  of	  specimens	  is	  provided	  in	  Figure	  5.7.	  
In	   group	   1,	   of	   the	   131	   cases	   for	   which	   cytomorphological	   confirmation	   for	   the	  
presence	   of	   melanoma	   cells	   was	   possible,	   27	   (21%)	   yielded	   insufficient	   DNA	   for	  
genetic	   analysis	   by	   either	  MLPA	   or	  MSA.	   The	   breakdown	   of	   these	   27	   cases	   is	   as	  
follows:	   17	   were	   trans-­‐retinal	   samples	   and	   10	   were	   trans-­‐scleral	   biopsies.	   There	  
was	  no	  significant	  difference	  in	  the	  tumour	  thickness	  between	  those	  cases	  yielding	  
sufficient	  DNA	  and	  those	  that	  did	  not	  (T-­‐test	  between	  mean	  heights,	  p	  =0.688)	  
Genetic	   testing	   was	   performed	   in	   98	   of	   the	   remaining	   104	   DNA	   samples;	   in	   six	  
cases,	  DNA	  was	  extracted;	  however,	  the	  concentration	  was	  below	  that	  required	  for	  
MLPA	  and	  matched	  bloods	  were	  not	  available	  with	  which	  to	  perform	  MSA.	  Of	  the	  
98	  cases,	  66	  were	  analysed	  by	  MSA	  and	  32	  by	  MLPA.	  Fifty-­‐one	  cases	  were	  reported	  
as	  disomy	  3	  and	  40	  cases	  as	  monosomy	  3.	  Three	  cases	  passed	  the	  quality	  control	  
assessment	   for	   MLPA	   data	   but	   could	   not	   be	   unequivocally	   classified	   as	   either	  
disomy	  3	  or	  monosomy	  3.	  Four	  cases,	  in	  which	  MSA	  was	  performed,	  showed	  allelic	  
imbalance.	  In	  conclusion,	  genetic	  analysis	  was	  performed	  in	  75%	  (98/131)	  of	  cases	  
in	   group	   1.	   Of	   the	   98	   cases	   for	   which	   genetic	   analyses	   were	   performed,	  
chromosome	  3	   classification,	   as	   either	   disomy	  3	  or	  monosomy	  3,	  was	  possible	   in	  
93%	   (91/98).	   Overall	   in	   group	   1	   genetic	   analysis	   successfully	   yielded	   a	   result	   for	  
chromosome	  3	  status	  in	  70%	  (91/131)	  of	  cases	  with	  confirmed	  UM	  cells.	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In	   group	   2,	   of	   the	   89	   cases	   for	   which	   cytomorphological	   confirmation	   for	   the	  
presence	   of	   melanoma	   cells	   was	   possible,	   six	   (7%)	   yielded	   insufficient	   DNA	   for	  
genetic	   analysis	   by	  either	  MLPA	  or	  MSA	   (Figure	  5.7).	   The	  breakdown	  of	   these	   six	  
cases	  is	  as	  follows:	  two	  cases	  were	  trans-­‐retinal	  samples	  and	  four	  were	  trans-­‐scleral	  
biopsies.	   There	   was	   no	   significant	   difference	   in	   the	   tumour	   thickness	   between	  
those	   cases	   yielding	   sufficient	  DNA	  and	   those	   that	  did	  not	   (T-­‐test	   between	  mean	  
heights,	  p	  =0.677).	  
Genetic	   testing	   was	   performed	   in	   all	   83	   remaining	   DNA	   samples	   in	   Group	   2:	   52	  
were	  analysed	  by	  MSA	  and	  31	  by	  MLPA.	  Fifty-­‐five	  cases	  were	  reported	  as	  disomy	  3	  
and	  24	  cases	  as	  monosomy	  3.	  Three	  cases,	   in	  which	  MSA	  was	  performed,	  showed	  
allelic	   imbalance.	   One	   case	   examined	   by	   MLPA	   could	   not	   be	   classified	   as	   either	  
disomy	   3	   or	   monosomy	   3.	   In	   conclusion,	   genetic	   analysis	   was	   possible	   in	   93%	  
(83/89)	   of	   cases	   in	   group	   2.	   Of	   the	   83	   cases	   in	   which	   genetic	   analyses	   were	  
performed,	  chromosome	  3	  classification,	  as	  either	  disomy	  3	  or	  monosomy	  3,	  was	  
possible	   in	  95%	   (79/83).	  Overall	   in	   group	  2	  genetic	   analysis	   successfully	   yielded	  a	  
result	  for	  chromosome	  3	  status	  in	  89%	  (79/89)	  of	  cases	  with	  confirmed	  UM	  cells.	  
Details	  of	  the	  genetic	  test	  performed	  for	  biopsies	  grouped	  by	  tumour	  thickness	  are	  
shown	  in	  Table	  5.3.	  Following	  introduction	  of	  the	  new	  procedures,	  an	  improvement	  
in	  the	  overall	  capacity	  to	  provide	  a	  chromosome	  3	  classification	  was	  achieved.	  This	  
was	  particularly	  evident	  in	  the	  very	  thin	  tumour	  group	  (<3	  mm),	  where	  the	  success	  
rate	   increased	   from	  69%	   (50/72)	   in	  group	  1	   to	  95%	   (36/38)	   in	  group	  2	   (Z-­‐test	   for	  
Binomial	  distribution,	  p	  <	  0.001).	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5.4 Discussion	  
We	  audited	  the	  results	  of	  prognostic	  biopsies	  for	  UM	  patients	  treated	  in	  LOOC	  over	  
an	   18-­‐month	   time	   period	   by	   retrospectively	   assessing	   the	   yield	   of	   prognostic	  
information	  provided	  weighed	   against	   surgical	   complications	   (study	   group	  1).	  We	  
identified	  possible	   ‘pitfalls’	   in	   the	  process	  and	   implemented	  a	   change	  of	  practice,	  
which	   was	   assessed	   prospectively	   over	   12	   months	   (study	   group	   2),	   showing	   an	  
improvement	   in	   the	   cytogenetic	   results	   obtained	   and	   a	   reduction	   in	   surgical	  
complications.	  
In	   contrast	   to	   previous	   studies,282,	   283,	   285,	   296,	   297	   we	   do	   not	   perform	   molecular	  
genetic	   analyses	  on	   the	   specimen	  without	   cytomorphological	   examination,	   as	   the	  
presence	   of	   macrophages	   or	   leucocytes	   (or	   indeed	   a	   different	   malignancy!)	   may	  
affect	  the	  results	  and	  provide	  false	  reassurance	  to	  the	  patients.298	  In	  this	  study,	  we	  
reviewed	  the	  cytospin	  slides	  for	  all	  tumours	  and	  assessed	  the	  presence	  of	  tumour	  
cells,	   showing	   a	   strong	   correlation	   with	   the	   amount	   of	   DNA	   extracted	   from	   the	  
specimen.	  Moreover,	   it	   is	  well	   known	   that	   the	  presence	  of	   epithelioid	  melanoma	  
cells	   is	   a	   poor	   prognostic	   factor,223	   hence	   cytomorphological	   examination	   adds	  
meaningful	   information	  to	  our	  predictive	  model	  even	   in	  the	  absence	  of	  molecular	  
genetic	   results.	   For	   all	   of	   the	   above	   reasons,	   we	   believe	   that	   cytomorphological	  
examination	  of	  a	  cytospin	  slide	   is	  essential,	  and	  should	  be	  performed	  prior	  to	  any	  
molecular	  genetic	  analysis	  in	  UM.	  	  
Monosomy	   3	   remains	   the	   strongest	   predictive	   factor	   for	   the	   development	   of	  
metastatic	   disease,72	   thus,	   the	   aim	   for	   all	   prognostic	   biopsies	   is	   that	   they	   should	  
yield	   enough	  DNA	  with	  which	   to	   perform	  molecular	   analyses.	   About	   50	  %	  of	   the	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tumours	   in	  our	  series	  were	  thinner	  than	  3	  mm,	  which	   is	  a	  notorious	  challenge	  for	  
obtaining	   meaningful	   samples.284	   In	   agreement	   with	   other	   authors,282,	   296,	   299	   we	  
found	   in	   the	   first	   phase	   of	   this	   study	   that	   trans-­‐scleral	   FNAB	   of	   small	   UM	   is	  
successful	   for	  molecular	   analysis	   only	   in	   about	   70%	   of	   cases;	   therefore	   we	   have	  
adopted	   alternative	   surgical	   techniques	   to	   obviate	   such	   problem.	   Through	   this	  
combination	   of	   techniques,	   the	   overall	   success	   of	   biopsy	   (i.e.	   giving	   the	   patient	  
cytomorphological	  and	  chromosome	  3	  information)	  in	  this	  series	  did	  not	  depend	  on	  
tumour	  thickness.	  Trans-­‐retinal	  biopsy	  using	  a	  25G	  vitreous	  cutter	  has	  been	  used	  in	  
60%	  of	  the	  cases	  in	  this	  series,	  providing	  successful	  specimens	  even	  in	  tumours	  less	  
than	  1	  mm	  in	  thickness.	  However,	  such	  a	  technique	  is	  associated	  with	  a	  higher	  rate	  
of	  local	  complications,	  mainly	  intravitreal	  bleeding.	  Therefore,	  the	  senior	  author	  has	  
developed	  a	  new	  trans-­‐scleral	  approach,	  creating	  a	  scleral	  flap	  and	  introducing	  the	  
Essen	  forceps	  through	  a	  small	  incision	  over	  the	  tumour.	  Such	  a	  technique,	  adopted	  
only	  since	  July	  2012,	   is	  now	  being	  routinely	  used	  for	  pre-­‐equatorial	  melanomas	  of	  
less	  than	  3	  mm	  in	  thickness.	  Further	  studies	  with	  a	  longer	  follow-­‐up	  are	  underway	  
and	  will	  be	  necessary	  to	  determine	  the	  long-­‐term	  risks	  and	  benefits	  associated	  with	  
such	  an	  approach.	  Preliminary	  results	  presented	  here,	  however,	  are	  promising	  for	  
the	  large	  size	  of	  the	  specimens	  obtained	  and	  the	  lack	  of	  complications	  when	  such	  
biopsy	   is	   performed	   at	   the	   time	   of	   plaque	   insertion,	   as	   long	   as	   care	   is	   taken	   in	  
properly	  closing	  the	  conjunctiva	  over	  the	  flap	  after	  plaque	  removal.	  
To	   enhance	   our	   capacity	   to	   provide	   genetic	   results	   to	   the	   patient,	   we	   have	  
introduced	  MSA	   for	   determination	   of	   chromosome	   3	   status,	   which	   requires	   only	  
10ng	   DNA	   as	   compared	  with	   a	  minimum	   of	   100ng	   for	  MLPA.	  MSA	  was	   used	   for	  
genetic	  testing	  in	  the	  majority	  of	  biopsies	  obtained	  from	  UM	  <3	  mm	  in	  thickness.	  
	  
	   187	  
At	  present,	  the	  other	  most	  widely	  utilised	  technique	  for	  analysis	  of	  small	  samples	  is	  
GEP.	  As	  detailed	  in	  Chapter	  1,	  this	  commercial	  platform	  has	  been	  developed	  using	  a	  
panel	   of	   15	   genes	   (12	   test	   genes	   and	   3	   control	   genes),	   the	   expression	   of	   which	  
assigns	  UM	  to	   two	  prognostic	   subgroups:	   class	  1	   (low	  metastatic	   risk)	  and	  class	  2	  
(high	  metastatic	  risk).	  A	  collaborative	  study	  on	  459	  patients	  reported	  a	  success	  rate	  
of	  providing	  a	  prognostic	  class	  in	  97%	  of	  cases.	  Although	  this	  figure	  is	  slightly	  higher	  
than	   that	   reported	   for	   Group	   2	   cases	   in	   our	   study,	   there	   is	   currently	   insufficient	  
follow-­‐up	  of	  these	  patients	  to	  determine	  the	  accuracy	  of	  these	  prognostic	  data	  for	  
patient	   survival.	   	   Moreover,	   GEP	   analysis	   is	   performed	   in	   a	   commercial	   setting	  
(Castle	  Biosciences,	  Inc.)	  with	  high	  costs	  that	  would	  not	  be	  covered	  by	  NHS	  England.	  
Many	   other	   European	   colleagues	   are	   faced	   with	   similar	   economic	   restraints;300	  
hence	   our	   efforts	   are	   to	   provide	   the	   best	   possible	   service	   at	   an	   affordable	   cost.	  
Moreover,	   GEP	   analysis	   is	   routinely	   performed	   without	   any	   matched	   cytological	  
analysis	  of	  the	  sample.	  A	  recent	  study	  of	  159	  patients	  with	  matched	  biopsies	  being	  
sent	   for	   cytological	   as	  well	   as	  GEP	  analysis	   showed	   that	   cytological	  diagnosis	  was	  
possible	   for	  only	  125/159	   (79%)	   samples	  whereas	  GEP	  gave	   results	   in	   all	   but	  one	  
(99%).297	   The	   authors	   interpret	   this	   as	   very	   positive,	   whereas	   we	   look	   at	   it	   with	  
concern	   and	   stress	   the	   importance	   of	   a	   cytological	   diagnosis	   to	   confirm	   the	  
presence	   of	   UM	   cells	   in	   the	   sample	   prior	   to	   DNA	   extraction,	   given	   that	   GEP	  
provided	   a	   prognostic	   result	   for	   a	   tumour	   subsequently	   identified	   as	   a	   choroidal	  
metastasis.298	   Augsburger	   et	   al.301	   have	   recently	   reported	   an	   11%	   discrepancy	   in	  
GEP	   classification	   of	   the	   same	   UM	   when	   biopsied	   (FNAB)	   at	   two	   different	   sites,	  
which	  were	   then	   tested	   independently.	  The	  authors	  conclude	   that	  “sampling	  of	  a	  
clinically	   diagnosed	   posterior	   uveal	  melanoma	   at	   a	   single	   site	   for	   prognostic	   GEP	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testing	   is	   associated	   with	   a	   substantial	   probability	   of	   misclassification”	   and	  
recommend	   two-­‐site	   sampling	   and	   independent	   GEP	   testing,	   making	   the	   whole	  
process	  even	  more	  expensive.	  
The	  issue	  of	  intratumoural	  genetic	  heterogeneity	  has	  been	  debated	  for	  a	  long	  time,	  
and	   one	   of	   the	   potential	   criticisms	   to	   any	   study	   of	   prognostic	   biopsies,	   is	   that	   a	  
single	   biopsy	   may	   be	   subject	   to	   sampling	   error	   for	   monosomy	   3.302	   We	   have	  
recently	  performed	  a	  retrospective	  analysis	  of	  genetic	  data	  from	  28	  cases	  for	  which	  
both	  a	  biopsy	  and	  a	  secondary	  tumour	  specimen	  from	  the	  same	  UM	  (enucleation	  or	  
endoresection)	   had	   been	   tested	   by	   MSA	   or	   MLPA.	   The	   data	   from	   this	   analysis	  
showed	  100%	  concordance	  between	   the	   chromosome	  3	   status	  of	   the	  biopsy	   and	  
the	  subsequent	  secondary	  tumour	  specimen	  (Coupland	  et	  al	  2015,	  ARVO	  abstract	  
2013;	   manuscript	   submitted).	   Nevertheless,	   we	   discuss	   the	   risk	   for	   tumour	  
heterogeneity	  with	  the	  patient	  and	  clearly	  state	  it	  on	  the	  report,	  which	  is	  written	  by	  
a	  dedicated	  Ophthalmic	  Pathologist	  who	  interprets	  the	  genetic	  data	  in	  the	  light	  of	  
the	   clinical	   and	   cytomorphological	   characteristics	   of	   each	   individual	   tumour.	   A	  
definitive	   answer	   on	   the	   accuracy	   of	   prognostication	   for	   biopsies	   samples	   as	  
described	  in	  this	  study	  will	  only	  be	  available	  after	  many	  years	  of	  follow-­‐up,	  but	  this	  
was	  not	  the	  aim	  of	  the	  current	  study.	  	  
Performing	  a	  prognostic	  biopsy	  may	  also	  be	  questioned	  due	  to	  the	  lack	  of	  current	  
effective	  treatment	  modalities	  for	  those	  patients	  who	  develop	  metastatic	  disease.	  
However,	  with	  the	  identification	  of	  new	  therapeutic	  targets	  and	  the	  introduction	  of	  
clinical	   trials	   for	   adjuvant	   systemic	   treatment,303	   prognostication	   is	   essential	   to	  
identify	   those	   patients	   who	   could	   benefit	   from	   such	   treatments	   before	   the	  
development	  of	  clinically	  evident,	  advanced	  metastatic	  disease,	  which	  is	  known	  to	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be	   refractory	   to	   therapy.	   Our	   studies	   also	   demonstrate	   that	   prognostication	   is	  
welcomed	  by	  the	  patients	  in	  order	  to	  help	  prepare	  themselves	  and	  their	  family	  for	  
any	   eventuality.291	  We	  have	   found	   that	   the	   unhappiest	   patients	   are	   those	  whose	  
biopsy	  has	  failed	  to	  yield	  a	  prognostic	  result.	  We	  therefore	  consider	  biopsy	  failure	  
to	  be	  a	  serious	  complication,	  which	  is	  why	  we	  have	  developed	  a	  variety	  of	  surgical	  
techniques	  and	  laboratory	  methods	  to	  address	  this	  problem.	  
Specific	  limitations	  of	  our	  study	  are	  linked	  mainly	  to	  the	  retrospective	  nature	  of	  the	  
audit,	   for	  example;	  biopsies	  being	  performed	  by	  different	   surgeons	  with	  different	  
techniques,	  lack	  of	  matched	  blood	  samples	  with	  which	  to	  perform	  MSA	  analyses	  in	  
a	   few	   cases.	   However,	   we	   believe	   that	   these	   reflect	   important	   “real	   life”	  
experiences	  that	  are	  useful	  to	  colleagues	  planning	  to	  establish	  prognostic	  testing	  in	  
their	  units.	  Performing	  and	  interpreting	  prognostic	  biopsies	  is	  a	  challenge	  both	  for	  
the	  clinical	  and	  the	   laboratory	  team	  and	  requires	  close	  collaboration	  between	  the	  
two.	  While	   performing	   this	   audit	  we	   identified	   and	   solved	   pitfalls	   in	   the	   process,	  
such	  as:	  clearly	  stating	  in	  the	  request	  form	  whether	  a	  biopsy	  was	  for	  diagnostic	  or	  
prognostic	   analyses,	   so	   that	  only	   a	  minimum	  number	  of	   cytospin	   slides	  would	  be	  
prepared,	  saving	  most	  of	  the	  specimen	  for	  DNA	  extraction;	  collecting	  a	  small	  blood	  
sample	  for	  all	  patients	  undergoing	  prognostic	  biopsy,	  so	  that	  baseline	  DNA	  could	  be	  
extracted	   for	   MSA	   analysis	   should	   the	   uveal	   specimen	   be	   too	   small	   for	   MLPA;	  
informing	   the	   clinical	   team	   if	   a	   transcleral	   FNAB	   specimen	   done	   at	   the	   time	   of	  
plaque	   insertion	   was	   acellular,	   so	   that	   another	   sample	   could	   be	   collected	   trans-­‐
retinally	  at	  the	  time	  of	  plaque	  removal.	  
In	  conclusion,	  prognostic	  biopsy	  is	  a	  safe	  procedure	  that	  can	  yield	  useful	  prognostic	  
information	  in	  over	  90%	  of	  cases	  (cytomorphology	  in	  99%,	  chromosome	  3	  status	  in	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93%).	   Using	   a	   combination	   of	   surgical	   techniques	   depending	   on	   the	   size	   and	  
location	  of	  the	  tumour	  improves	  the	  chances	  of	  getting	  an	  adequate	  specimen	  for	  
cytomorphological	  and	  molecular	  genetic	  analyses.	  Cytomorphological	  examination	  
of	  a	  cytospin	  from	  the	  specimen	  is	  essential	  to	  determine	  cellular	  composition	  and	  
thus	   reduce	   the	   risk	   of	   a	   falsely	   reassuring	   prognosis.	   Using	   a	   combination	   of	  
molecular	  prognostic	  techniques	  such	  as	  MLPA	  and	  MSA	  maximises	  the	  chance	  of	  
providing	  a	  genetic	  result	  from	  the	  biopsy	  specimen.	  A	  close	  collaboration	  between	  
the	  clinical	  and	  molecular	  pathology	  team	  is	  essential	  to	  optimise	  the	  success	  of	  the	  
overall	  process	  and	  provide	  the	  patient	  with	  meaningful	  information.	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6.1 Conclusions	  and	  future	  perspectives	  
Despite	  successful	  treatment	  of	  the	  primary	  tumour,	  UM	  remains	  a	  fatal	  disease	  in	  
those	   patients	   who	   develop	   metastatic	   disease.	   Survival	   is	   improved	   by	   early	  
detection	   of	   liver	   metastases,	   which	   can	   then	   be	   treated	   with	   locoregional	  
therapies.	  
	  
As	   discussed	   in	   Chapter	   1,	   previous	   work	   done	   by	   members	   of	   the	   LOORG	   has	  
focused	  on	  genetic	  analyses	  of	  UM,	  leading	  to	  the	  creation	  and	  clinical	  validation	  of	  
a	  prognostic	  tool	  to	  stratify	  patients	  as	  being	  at	  HR	  or	  LR	  of	  developing	  metastatic	  
disease.	  However,	  the	  mechanisms	  responsible	  for	  the	  development	  of	  metastatic	  
disease	   in	   UM	   are	   still	   largely	   unknown;	   therefore	   no	   adjuvant	   treatment	   is	  
currently	   offered	   to	  HR	   patients	   to	   prevent	   development	   of	   fatal	   disease.	   As	   the	  
time	   to	   discovery	   of	   clinically	   detectable	   metastases	   can	   range	   from	   months	   to	  
decades,	   a	   secreted	  biomarker(s)	   that	   could	  be	   routinely	   tested	   in	  blood	   is	  much	  
needed.	  	  	  
The	  scope	  of	  the	  work	  presented	  in	  this	  thesis	  was	  to	  use	  proteomics	  as	  a	  tool	  to	  
identify	   potential	   novel,	   UM-­‐specific	   biomarkers.	   Moreover,	   the	   proteomic	   data	  
acquired	  would	  complement	  our	  genomic	  and	  transcriptomic	  information,	  with	  the	  
ultimate	   aim	   of	   increasing	   our	   understanding	   of	   UM	   development	   and	  
dissemination.	  
	  
In	   Chapter	   2	   we	   described	   the	   use	   of	   iTRAQ	   labelling	   and	   MS	   to	   compare	   the	  
proteome	  of	  UM	  tissue	  samples	  at	  HR	  versus	  LR	  of	  developing	  metastatic	  disease.	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The	  quantification	  of	  proteins	   in	  our	   samples,	  proteomic	  analysis	   and	   further	   IHC	  
validation	   has	   led	   to	   the	   identification	   of	   two	   novel	   prognostic	   and	   potentially	  
therapeutic	   targets,	   S100A6	   and	   the	   tumour	   suppressor	   PDCD4.	   Further	  
examination	   of	   these	   two	   proteins	   will	   be	   undertaken;	   S100A6	   as	   prognostic	  
biomarker	   in	   the	   peripheral	   blood	   of	   UM	   patients,	   and	   PDCD4	   as	   potential	  
therapeutic	   target.	   In	  particular,	   immunoprecipitation	   studies	   in	   lung	   cancer	  have	  
shown	  that	  PDCD4	  is	  part	  of	  a	  molecular	  complex	  that	  also	  comprises	  the	  ribosomal	  
protein	   S6	   kinase	   2	   (S6K2)	   and	   the	   heterogeneous	   nuclear	   ribonucleoprotein	   A1	  
(hnRBNPA1).	   This	  mediates	   chemoresistance	   by	   promoting	   the	   translation	   of	   the	  
anti-­‐apoptotic	  proteins	  BCL-­‐XL	  and	  XIAP.304,	  305	  A	  collaboration	  has	  been	  established	  
with	  Prof.	  Michael	  Seckl	  and	  his	  group	  at	  Imperial	  College	  in	  London	  to	  investigate	  
the	   relationship	   between	   hnRNPA1/SK62/PDCD4	   in	   UM.	   Further	   studies	   to	  
investigate	   the	   relationship	   between	   PDCD4	   and	   its	   regulation	   by	   the	   oncogene	  
microRNA-­‐21	  as	  described	  for	  other	  tumours176,	  306,	  307	  are	  also	  warranted.	  
	  
In	   Chapter	   3	   we	   described	   another	   proteomic	   approach	   to	   identify	   potential	  
biomarkers	   of	   metastatic	   disease	   in	   UM:	   comparative	   proteomic	   analyses	   of	   the	  
secretome	   from	  short-­‐term	  primary	  cultures	  of	  HR	  and	  LR	  UM,	  as	  well	   as	  normal	  
choroidal	   melanocytes,	   using	   label-­‐free	   nanoLC-­‐MS/MS.	   This	   led	   to	   the	  
identification	   and	   quantitation	   of	   almost	   2000	   proteins,	   with	   more	   than	   30%	   of	  
these	   identified	  as	  secreted	  and/or	  previously	   identified	   in	  exosomes.	  Using	  these	  
data	   an	   18	   protein	   signature,	   able	   to	   discriminate	   between	   HR	   and	   LR	   UM	   was	  
identified..	  Further	  validation	  of	  the	  non-­‐exosomal	  secreted	  proteins	  within	  the	  18	  
protein	   signature	   will	   be	   necessary	   in	   secretome	   samples	   and	   in	   the	   peripheral	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blood	   of	   UM	   patients.	   This	   has	   the	   potential	   of	   being	   translated	   into	   a	   clinically	  
useful	   assay	   to	   detect	   early	   development	   of	   metastatic	   disease.	   Furthermore,	   in	  
view	   of	   the	   number	   of	   exosomal	   proteins	   identified	   in	   the	   secretome	   and	   the	  
current	   interest	   in	   the	   role	  of	   these	  extracellular	  microvesicles	   in	   tumour	  biology,	  
further	   work	   is	   now	   being	   undertaken	   within	   the	   LOORG	   to	   study	   the	   role	   of	  
exosomes	  in	  UM.	  In	  particular,	  analysis	  of	  their	  cargo	  and	  how	  this	  may	  aid	  tumour	  
progression	  will	  be	  conducted.	  
Further	  interrogation	  of	  proteomic	  data	  derived	  from	  both	  the	  secretome	  analysis	  
and	   iTRAQ	   run	   A	   will	   be	   performed	   using	   the	   IPA	   software	   to	   increase	   our	  
understanding	  of	   the	  differences	  between	  normal	   choroid,	   LR	  UM	  and	  HR	  UM	   in	  
terms	  of	  protein	  expression	  and	  pathway	  activation	  and	  this	   information	  fed	  back	  
into	  the	  ongoing	  analyses.	  	  	  
	  
In	   recent	   years,	   there	   has	   been	   a	   body	   of	   evidence	   across	   a	   number	   of	   tumour	  
types	  supporting	  the	  clinical	  utility	  of	  detecting	  and	  characterising	  CTC.	  As	  reported	  
in	  Chapter	  4,	  we	  conducted	  a	  pilot	  study	  on	  peripheral	  blood	  samples	  using	  the	  FDA	  
approved	  CellSearch®	  platform	  to	  enumerate	  CTC	  in	  UM	  patients	  at	  LR,	  HR	  or	  with	  
overt	  metastatic	  disease.	  CTC	  were	  detected	  in	  HR	  tumours	  and	  were	  not	  present	  
in	   LR	   UM,	   however,	   only	   two	   of	   the	   14	   HR	   UM	   displayed	   ≥2	   CTC.	   Although,	   the	  
number	   of	   CTCs	   detected	   in	   the	   patients	   with	   overt	   metastatic	   disease	   was	  
significantly	  higher	  it	  also	  varied	  widely,	  ranging	  from	  no	  CTC	  detected	  to	  510	  CTC	  
in	   a	   single	   patient.	   These	   data	   called	   into	   question	   the	   prognostic	   value	   of	   using	  
such	   a	   system	   for	   CTC	   detection	   in	   UM.	   We	   also	   conducted	   a	   small	   study	   to	  
examine	  expression	  of	  the	  chemokine	  receptor	  CD184	  in	  a	  panel	  of	  UM	  cell	  lines	  in	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the	   search	   of	   alternative	   surface	   markers	   for	   CTC.	   This	   work	   showed	   that	  
determining	  which	   antibody	  may	  be	  most	   suitable	   remains	   difficult,	   as	   studies	   of	  
surface	  antigen	  expression	  on	  cell	  lines	  may	  not	  be	  truly	  representative	  of	  primary	  
UM	  cells.	  Advances	  in	  the	  characterisation	  of	  primary	  UM	  samples	  are	  required	  and	  
could	  lead	  to	  the	  identification	  of	  alternative	  cell	  markers	  for	  the	  development	  of	  a	  
UM	   customised	   CTC	   detection	   kit.	   Moreover,	   CTC	   capture	   and	   characterisation	  
(rather	   than	   enumeration)	   is	   an	   important	   field	   of	   research	  worth	   pursuing,	   as	   it	  
could	   provide	   unparalleled	  means	   to	   understand	  metastatic	   biology	   and	   identify	  
relevant	  therapeutic	  targets.	  
	  
	  Chapter	  5	  describes	  an	  audit	  of	  the	  procedures	  undertaken	  during	  the	  acquisition	  
and	  processing	  of	  prognostic	  biopsies	  from	  UM	  tumours	  treated	  conservatively.	  In	  
this	   audit,	   pitfalls	   and	   limitations	   of	   procedures	   were	   identified	   leading	   to	   the	  
introduction	   of	   modifications	   to	   both	   the	   surgical	   technique	   and	   the	   specimen	  
handling	   and	   downstream	  analyses.	   By	   introducing	   revisions	   to	   both	   surgical	   and	  
pathological	   procedures	   the	   success	   rate	   for	   achieving	   cytomorphological	   and	  
genetic	  classification	  increased	  from	  69%	  to	  93%.	  This	  is	  an	  important	  improvement	  
in	  the	  ocular	  oncology	  service	  provision	  as	  more	  and	  more	  patients,	  who	  are	  being	  
treated	   by	   radiotherapy,	   wish	   to	   know	   their	   prognosis,	   and	   in	   particular	   their	  
chromosome	  3	  status.	  This	  would	  become	  even	  more	  important	  should	  an	  adjuvant	  
treatment	  be	  approved	  for	  HR	  UM	  patients,	  as	   those	  with	  an	  unsuccessful	  biopsy	  
and	  therefore	  incomplete	  risk	  stratification	  may	  be	  denied	  treatment.	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In	  conclusion,	  the	  work	  conducted	  throughout	  this	  PhD	  has	  provided	  further	  insight	  
into	   the	   molecular	   characteristics	   that	   can	   differentiate	   between	   the	   aggressive	  
high	  metastatic	   risk	  UM	  from	  those	  with	  a	   low	  metastatic	   risk.	  Unlike	   the	  genetic	  
code,	   measuring	   changes	   in	   protein	   expression	   allows	   us	   to	   monitor	   what	   is	  
happening	   in	  patients	   in	   “real-­‐time”,	   generating	  unique	   insight	   into	   the	  biological	  
processes	  occurring	  during	  tumour	  development	  and	  progression.	  Proteomics	  itself,	  
however,	  is	  not	  without	  its	  challenges,	  due	  to	  dynamic	  changes	  in	  expression,	  splice	  
variants	   and	   the	   influence	   of	   post-­‐translational	   modifications.	   Thus,	   the	   greatest	  
biological	  insight	  is	  likely	  to	  come	  from	  the	  integration	  of	  proteomic	  data	  with	  the	  
genomic	  and	  transcriptomic	  data	  already	  generated	  by	  LOORG.	  	  
	  
Finally,	  this	  PhD	  has	  been	  a	  unique	  learning	  experience	  for	  me	  personally,	  not	  only	  
in	  terms	  of	  laboratory	  techniques	  and	  scientific	  outputs,	  but	  also	  especially	  in	  terms	  
of	  independent	  thinking,	  problem	  solving	  and	  perseverance.	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Accession Name Peptides	  (95%) Coverage	  (95%) Peptides	  (95%) Coverage	  (95%) Peptides	  (95%) Coverage	  (95%)
A0AVT1 Ubiquitin-­‐like	  modifier-­‐activating	  enzyme	  6 10 11.69 2 1.24 2 2.19
A0FGR8 Extended	  synaptotagmin-­‐2 4 6.19 3 4.89 2 3.26
A0M8Q6 Ig	  lambda-­‐7	  chain	  C	  region 0 0.00 13 32.08 11 32.08
A1L0T0 Acetolactate	  synthase-­‐like	  protein 37 45.25 23 35.76 24 32.75
A2RTX5 Probable	  threonyl-­‐tRNA	  synthetase	  2,	  cytoplasmic 1 1.62 1 1.62 2 2.62
A4D1P6 WD	  repeat-­‐containing	  protein	  91 8 12.99 5 6.96 8 13.25
A5YKK6 CCR4-­‐NOT	  transcription	  complex	  subunit	  1 4 1.47 7 2.86 3 0.76
A6NCN2 Keratin-­‐81-­‐like	  protein 3 3.09 0 0.00 0 0.00
A6NDU8 UPF0600	  protein	  C5orf51 1 4.76 0 0.00 0 0.00
A6NHG4 D-­‐dopachrome	  decarboxylase-­‐like	  protein 8 40.30 4 23.88 3 17.91
A6NHR9 Structural	  maintenance	  of	  chromosomes	  flexible	  hinge	  domain-­‐containing	  protein	  1 2 1.15 2 0.55 3 1.25
A6NIZ1 Ras-­‐related	  protein	  Rap-­‐1b-­‐like	  protein 21 55.98 13 34.24 14 47.28
A6NL28 Putative	  tropomyosin	  alpha-­‐3	  chain-­‐like	  protein 18 23.77 9 16.59 11 16.59
A8MTJ3 Guanine	  nucleotide-­‐binding	  protein	  G(t)	  subunit	  alpha-­‐3 4 7.91 0 0.00 3 7.91
A8MWD9 Small	  nuclear	  ribonucleoprotein	  G-­‐like	  protein 3 15.79 0 0.00 3 15.79
A8MXV4 Nucleoside	  diphosphate-­‐linked	  moiety	  X	  motif	  19,	  mitochondrial 2 9.87 1 6.13 0 0.00
B2RPK0 Putative	  high	  mobility	  group	  protein	  B1-­‐like	  1 7 15.64 0 0.00 0 0.00
B9A064 Immunoglobulin	  lambda-­‐like	  polypeptide	  5 15 33.18 11 27.57 12 33.18
C4AMC7 Putative	  WAS	  protein	  family	  homolog	  3 2 7.34 1 3.02 1 3.02
C9JLW8 Protein	  FAM195B 3 29.90 0 0.00 1 11.34
O00115 Deoxyribonuclease-­‐2-­‐alpha 3 12.22 0 0.00 0 0.00
O00116 Alkyldihydroxyacetonephosphate	  synthase,	  peroxisomal 4 6.84 2 5.32 3 7.29
O00139 Kinesin-­‐like	  protein	  KIF2A 3 5.38 0 0.00 0 0.00
O00148 ATP-­‐dependent	  RNA	  helicase	  DDX39A 28 39.11 0 0.00 16 25.06
O00151 PDZ	  and	  LIM	  domain	  protein	  1 6 16.11 0 0.00 2 13.07
O00154 Cytosolic	  acyl	  coenzyme	  A	  thioester	  hydrolase 14 22.89 8 18.68 8 19.74
O00159 Myosin-­‐Ic 51 35.84 36 28.32 26 21.07
O00161 Synaptosomal-­‐associated	  protein	  23 3 12.80 0 0.00 0 0.00
O00170 AH	  receptor-­‐interacting	  protein 3 11.21 4 14.55 1 4.24
O00178 GTP-­‐binding	  protein	  1 2 4.78 0 0.00 0 0.00
O00186 Syntaxin-­‐binding	  protein	  3 4 9.29 0 0.00 0 0.00
O00192 Armadillo	  repeat	  protein	  deleted	  in	  velo-­‐cardio-­‐facial	  syndrome 2 2.60 0 0.00 0 0.00
O00193 Small	  acidic	  protein 2 12.57 0 0.00 0 0.00
O00203 AP-­‐3	  complex	  subunit	  beta-­‐1 12 12.98 3 3.66 9 8.13
O00217 NADH	  dehydrogenase	  [ubiquinone]	  iron-­‐sulfur	  protein	  8,	  mitochondrial 6 23.33 3 18.10 5 18.10
O00231 26S	  proteasome	  non-­‐ATPase	  regulatory	  subunit	  11 13 31.04 10 24.41 6 11.85
O00232 26S	  proteasome	  non-­‐ATPase	  regulatory	  subunit	  12 10 23.68 7 13.60 6 10.53
O00233 26S	  proteasome	  non-­‐ATPase	  regulatory	  subunit	  9 6 16.14 2 8.97 0 0.00
O00244 Copper	  transport	  protein	  ATOX1 2 25.00 1 25.00 1 25.00
O00255 Menin 1 2.28 0 0.00 0 0.00
O00264 Membrane-­‐associated	  progesterone	  receptor	  component	  1 11 31.79 6 12.31 3 7.69
O00273 DNA	  fragmentation	  factor	  subunit	  alpha 3 13.60 5 20.24 2 9.97
O00299 Chloride	  intracellular	  channel	  protein	  1 22 61.41 17 43.57 14 43.57
O00303 Eukaryotic	  translation	  initiation	  factor	  3	  subunit	  F 11 25.21 8 17.65 7 17.93
O00330 Pyruvate	  dehydrogenase	  protein	  X	  component,	  mitochondrial 2 4.59 2 4.79 0 0.00
O00399 Dynactin	  subunit	  6 1 7.37 0 0.00 0 0.00
O00401 Neural	  Wiskott-­‐Aldrich	  syndrome	  protein 1 1.58 0 0.00 0 0.00
O00410 Importin-­‐5 26 20.69 13 9.21 15 12.67
O00422 Histone	  deacetylase	  complex	  subunit	  SAP18 1 10.46 2 10.46 1 10.46
O00429 Dynamin-­‐1-­‐like	  protein 27 35.87 10 18.75 8 12.36
O00442 RNA	  3'-­‐terminal	  phosphate	  cyclase 3 7.65 0 0.00 4 10.38
O00468 Agrin 11 6.31 5 2.74 5 2.54
O00471 Exocyst	  complex	  component	  5 3 4.94 0 0.00 0 0.00
O00479 High	  mobility	  group	  nucleosome-­‐binding	  domain-­‐containing	  protein	  4 4 26.67 0 0.00 1 7.78
O00483 NADH	  dehydrogenase	  [ubiquinone]	  1	  alpha	  subcomplex	  subunit	  4 3 27.16 3 27.16 5 27.16
O00487 26S	  proteasome	  non-­‐ATPase	  regulatory	  subunit	  14 2 10.65 4 28.71 3 17.74
O00560 Syntenin-­‐1 42 55.03 27 46.31 32 51.01
O00567 Nucleolar	  protein	  56 33 39.73 21 33.00 19 31.99
O00571 ATP-­‐dependent	  RNA	  helicase	  DDX3X 14 25.53 15 21.90 15 21.30
O00584 Ribonuclease	  T2 2 9.77 0 0.00 1 3.91
O00625 Pirin 32 50.69 24 56.55 8 33.79
O00629 Importin	  subunit	  alpha-­‐4 9 17.47 5 11.32 4 4.80
O00754 Lysosomal	  alpha-­‐mannosidase 5 5.93 3 4.75 1 1.48
O00764 Pyridoxal	  kinase 12 29.17 8 28.21 6 16.67
O14556 Glyceraldehyde-­‐3-­‐phosphate	  dehydrogenase,	  testis-­‐specific 37 50.25 35 50.00 30 47.06
O14561 Acyl	  carrier	  protein,	  mitochondrial 14 28.21 8 17.95 6 17.95
O14579 Coatomer	  subunit	  epsilon 8 38.31 6 30.84 4 18.18
O14602 Eukaryotic	  translation	  initiation	  factor	  1A,	  Y-­‐chromosomal 4 14.58 0 0.00 2 14.58
O14617 AP-­‐3	  complex	  subunit	  delta-­‐1 18 15.18 11 10.67 13 10.49
O14618 Copper	  chaperone	  for	  superoxide	  dismutase 3 17.88 3 17.88 3 17.88
O14672 Disintegrin	  and	  metalloproteinase	  domain-­‐containing	  protein	  10 3 5.35 2 3.34 1 2.01
O14727 Apoptotic	  protease-­‐activating	  factor	  1 1 1.12 0 0.00 1 1.12
O14735 CDP-­‐diacylglycerol-­‐-­‐inositol	  3-­‐phosphatidyltransferase 4 10.80 1 6.10 3 6.10
O14737 Programmed	  cell	  death	  protein	  5 11 38.40 3 29.60 4 19.20
O14744 Protein	  arginine	  N-­‐methyltransferase	  5 4 6.12 0 0.00 0 0.00
O14745 Na(+)/H(+)	  exchange	  regulatory	  cofactor	  NHE-­‐RF1 6 17.32 6 19.83 5 17.32
O14773 Tripeptidyl-­‐peptidase	  1 57 36.94 35 36.94 31 36.94
O14776 Transcription	  elongation	  regulator	  1 5 4.28 4 3.10 4 3.10
O14787 Transportin-­‐2 4 4.68 3 4.13 3 4.46
Run	  A Run	  B Run	  C
Appendix	  1.	  Comparison	  of	  the	  proteins	  detected	  in	  the	  different	  iTRAQ	  runs
O14818 Proteasome	  subunit	  alpha	  type-­‐7 14 39.92 9 30.24 10 36.29
O14828 Secretory	  carrier-­‐associated	  membrane	  protein	  3 18 30.84 7 24.21 8 24.21
O14841 5-­‐oxoprolinase 17 17.86 8 9.86 8 9.32
O14874 [3-­‐methyl-­‐2-­‐oxobutanoate	  dehydrogenase	  [lipoamide]]	  kinase,	  mitochondrial 2 8.50 0 0.00 0 0.00
O14879 Interferon-­‐induced	  protein	  with	  tetratricopeptide	  repeats	  3 6 11.22 0 0.00 0 0.00
O14880 Microsomal	  glutathione	  S-­‐transferase	  3 23 33.55 11 33.55 7 32.24
O14907 Tax1-­‐binding	  protein	  3 2 13.71 0 0.00 0 0.00
O14908 PDZ	  domain-­‐containing	  protein	  GIPC1 2 14.11 0 0.00 0 0.00
O14949 Cytochrome	  b-­‐c1	  complex	  subunit	  8 3 15.85 0 0.00 2 15.85
O14950 Myosin	  regulatory	  light	  chain	  12B 22 68.02 12 34.88 13 36.05
O14964 Hepatocyte	  growth	  factor-­‐regulated	  tyrosine	  kinase	  substrate 7 10.81 5 6.56 2 3.09
O14972 Down	  syndrome	  critical	  region	  protein	  3 2 8.08 0 0.00 0 0.00
O14976 Cyclin-­‐G-­‐associated	  kinase 4 3.20 3 1.30 5 3.28
O14979 Heterogeneous	  nuclear	  ribonucleoprotein	  D-­‐like 17 21.19 16 17.86 10 17.38
O14980 Exportin-­‐1 29 24.84 23 22.04 14 15.78
O15020 Spectrin	  beta	  chain,	  brain	  2 12 5.98 0 0.00 0 0.00
O15027 Protein	  transport	  protein	  Sec16A 3 2.16 0 0.00 0 0.00
O15061 Synemin 3 2.24 6 4.41 4 3.20
O15067 Phosphoribosylformylglycinamidine	  synthase 20 16.74 7 6.58 10 7.02
O15083 ERC	  protein	  2 1 1.15 0 0.00 1 1.25
O15116 U6	  snRNA-­‐associated	  Sm-­‐like	  protein	  LSm1 3 12.03 3 26.32 4 15.79
O15118 Niemann-­‐Pick	  C1	  protein 3 2.82 1 0.94 2 1.88
O15126 Secretory	  carrier-­‐associated	  membrane	  protein	  1 3 10.95 0 0.00 0 0.00
O15127 Secretory	  carrier-­‐associated	  membrane	  protein	  2 4 13.07 0 0.00 2 6.08
O15131 Importin	  subunit	  alpha-­‐6 1 2.61 0 0.00 3 5.78
O15143 Actin-­‐related	  protein	  2/3	  complex	  subunit	  1B 7 20.16 1 4.84 2 4.84
O15144 Actin-­‐related	  protein	  2/3	  complex	  subunit	  2 9 30.00 3 10.33 6 17.33
O15145 Actin-­‐related	  protein	  2/3	  complex	  subunit	  3 8 35.39 4 14.61 4 13.48
O15160 DNA-­‐directed	  RNA	  polymerases	  I	  and	  III	  subunit	  RPAC1 3 11.27 0 0.00 3 15.90
O15173 Membrane-­‐associated	  progesterone	  receptor	  component	  2 10 33.18 6 28.70 6 28.70
O15198 Mothers	  against	  decapentaplegic	  homolog	  9 3 6.21 0 0.00 0 0.00
O15211 Ral	  guanine	  nucleotide	  dissociation	  stimulator-­‐like	  2 4 6.56 0 0.00 0 0.00
O15212 Prefoldin	  subunit	  6 7 27.91 4 20.16 3 20.16
O15226 NF-­‐kappa-­‐B-­‐repressing	  factor 1 1.88 0 0.00 0 0.00
O15230 Laminin	  subunit	  alpha-­‐5 25 9.77 13 3.98 9 3.90
O15234 Protein	  CASC3 1 1.28 0 0.00 0 0.00
O15260 Surfeit	  locus	  protein	  4 7 20.45 6 17.47 6 17.47
O15294 UDP-­‐N-­‐acetylglucosamine-­‐-­‐peptide	  N-­‐acetylglucosaminyltransferase	  110	  kDa	  subunit 1 1.05 1 1.05 1 1.05
O15355 Protein	  phosphatase	  1G 5 10.81 2 7.51 2 7.51
O15371 Eukaryotic	  translation	  initiation	  factor	  3	  subunit	  D 9 14.42 8 14.42 8 11.86
O15372 Eukaryotic	  translation	  initiation	  factor	  3	  subunit	  H 3 13.07 2 7.39 0 0.00
O15400 Syntaxin-­‐7 34 45.98 17 49.04 20 49.04
O15488 Glycogenin-­‐2 3 9.38 4 9.38 2 7.19
O15498 Synaptobrevin	  homolog	  YKT6 3 17.68 1 11.11 2 10.61
O15511 Actin-­‐related	  protein	  2/3	  complex	  subunit	  5 2 7.95 2 7.95 0 0.00
O15533 Tapasin 3 10.27 3 14.51 1 7.14
O43143 Putative	  pre-­‐mRNA-­‐splicing	  factor	  ATP-­‐dependent	  RNA	  helicase	  DHX15 19 23.02 13 17.48 9 13.96
O43149 Zinc	  finger	  ZZ-­‐type	  and	  EF-­‐hand	  domain-­‐containing	  protein	  1 5 1.35 0 0.00 4 1.69
O43156 TEL2-­‐interacting	  protein	  1	  homolog 2 1.74 1 1.74 1 1.74
O43169 Cytochrome	  b5	  type	  B 10 50.68 12 37.67 7 37.67
O43172 U4/U6	  small	  nuclear	  ribonucleoprotein	  Prp4 2 5.75 0 0.00 0 0.00
O43175 D-­‐3-­‐phosphoglycerate	  dehydrogenase 11 16.89 5 8.25 4 7.32
O43181 NADH	  dehydrogenase	  [ubiquinone]	  iron-­‐sulfur	  protein	  4,	  mitochondrial 8 28.57 2 13.71 3 22.86
O43237 Cytoplasmic	  dynein	  1	  light	  intermediate	  chain	  2 9 27.03 6 19.11 3 9.35
O43242 26S	  proteasome	  non-­‐ATPase	  regulatory	  subunit	  3 14 25.28 8 15.36 8 12.55
O43290 U4/U6.U5	  tri-­‐snRNP-­‐associated	  protein	  1 3 4.75 0 0.00 3 3.38
O43301 Heat	  shock	  70	  kDa	  protein	  12A 9 14.67 2 4.00 0 0.00
O43324 Eukaryotic	  translation	  elongation	  factor	  1	  epsilon-­‐1 3 11.49 3 20.11 0 0.00
O43390 Heterogeneous	  nuclear	  ribonucleoprotein	  R 27 28.59 24 23.85 17 22.12
O43396 Thioredoxin-­‐like	  protein	  1 11 36.33 4 15.57 6 24.57
O43399 Tumor	  protein	  D54 11 39.32 9 33.01 8 33.01
O43402 Neighbor	  of	  COX4 3 11.90 2 7.62 0 0.00
O43423 Acidic	  leucine-­‐rich	  nuclear	  phosphoprotein	  32	  family	  member	  C 3 9.40 3 4.70 0 0.00
O43447 Peptidyl-­‐prolyl	  cis-­‐trans	  isomerase	  H 2 9.04 2 9.04 0 0.00
O43464 Serine	  protease	  HTRA2,	  mitochondrial 9 24.89 4 12.23 0 0.00
O43488 Aflatoxin	  B1	  aldehyde	  reductase	  member	  2 14 22.28 8 15.32 10 17.55
O43491 Band	  4.1-­‐like	  protein	  2 15 17.21 4 5.47 12 15.92
O43592 Exportin-­‐T 1 1.04 0 0.00 2 2.49
O43598 Deoxyribonucleoside	  5'-­‐monophosphate	  N-­‐glycosidase 11 34.48 8 32.76 5 21.84
O43615 Mitochondrial	  import	  inner	  membrane	  translocase	  subunit	  TIM44 9 20.13 3 5.97 3 8.41
O43670 Zinc	  finger	  protein	  207 5 5.44 3 2.72 2 2.72
O43674 NADH	  dehydrogenase	  [ubiquinone]	  1	  beta	  subcomplex	  subunit	  5,	  mitochondrial 2 12.70 0 0.00 0 0.00
O43678 NADH	  dehydrogenase	  [ubiquinone]	  1	  alpha	  subcomplex	  subunit	  2 4 32.32 0 0.00 1 21.21
O43681 ATPase	  ASNA1 8 24.14 8 16.95 4 13.51
O43684 Mitotic	  checkpoint	  protein	  BUB3 2 9.15 0 0.00 3 9.15
O43707 Alpha-­‐actinin-­‐4 136 59.39 72 43.25 87 44.46
O43708 Maleylacetoacetate	  isomerase 3 6.48 0 0.00 0 0.00
O43747 AP-­‐1	  complex	  subunit	  gamma-­‐1 12 14.48 5 8.64 6 8.27
O43752 Syntaxin-­‐6 10 37.65 2 9.80 4 23.14
O43765 Small	  glutamine-­‐rich	  tetratricopeptide	  repeat-­‐containing	  protein	  alpha 10 19.81 4 11.50 5 10.86
O43776 Asparaginyl-­‐tRNA	  synthetase,	  cytoplasmic 30 33.94 17 28.28 18 26.46
O43790 Keratin,	  type	  II	  cuticular	  Hb6 3 3.09 0 0.00 0 0.00
O43795 Myosin-­‐Ib 7 7.57 6 6.51 6 5.90
O43809 Cleavage	  and	  polyadenylation	  specificity	  factor	  subunit	  5 2 15.86 3 10.57 1 6.61
O43813 LanC-­‐like	  protein	  1 7 8.52 5 8.52 4 8.52
O43819 Protein	  SCO2	  homolog,	  mitochondrial 2 9.40 0 0.00 0 0.00
O43823 A-­‐kinase	  anchor	  protein	  8 1 2.89 0 0.00 3 4.62
O43837 Isocitrate	  dehydrogenase	  [NAD]	  subunit	  beta,	  mitochondrial 6 15.32 2 4.16 3 11.69
O43852 Calumenin 18 42.22 16 36.19 10 26.98
O43865 Putative	  adenosylhomocysteinase	  2 4 6.23 5 6.79 4 8.30
O43920 NADH	  dehydrogenase	  [ubiquinone]	  iron-­‐sulfur	  protein	  5 4 23.58 2 23.58 2 23.58
O60216 Double-­‐strand-­‐break	  repair	  protein	  rad21	  homolog 3 6.97 1 3.17 2 4.91
O60220 Mitochondrial	  import	  inner	  membrane	  translocase	  subunit	  Tim8	  A 3 11.34 2 11.34 2 11.34
O60256 Phosphoribosyl	  pyrophosphate	  synthase-­‐associated	  protein	  2 6 27.10 0 0.00 7 22.76
O60262 Guanine	  nucleotide-­‐binding	  protein	  G(I)/G(S)/G(O)	  subunit	  gamma-­‐7 5 44.12 0 0.00 3 44.12
O60264 SWI/SNF-­‐related	  matrix-­‐associated	  actin-­‐dependent	  regulator	  of	  chromatin	  subfamily	  A	  member	  55 5.32 0 0.00 2 2.38
O60271 C-­‐Jun-­‐amino-­‐terminal	  kinase-­‐interacting	  protein	  4 6 4.32 5 4.54 9 9.69
O60287 Nucleolar	  pre-­‐ribosomal-­‐associated	  protein	  1 2 1.10 2 1.10 0 0.00
O60313 Dynamin-­‐like	  120	  kDa	  protein,	  mitochondrial 13 15.00 5 7.19 3 2.19
O60343 TBC1	  domain	  family	  member	  4 10 8.32 4 3.16 6 6.47
O60443 Non-­‐syndromic	  hearing	  impairment	  protein	  5 7 14.72 0 0.00 1 2.42
O60486 Plexin-­‐C1 13 8.04 4 4.34 8 6.70
O60493 Sorting	  nexin-­‐3 2 8.64 3 15.43 2 8.64
O60506 Heterogeneous	  nuclear	  ribonucleoprotein	  Q 37 29.53 31 32.58 25 27.77
O60547 GDP-­‐mannose	  4,6	  dehydratase 2 7.26 2 6.72 0 0.00
O60568 Procollagen-­‐lysine,2-­‐oxoglutarate	  5-­‐dioxygenase	  3 8 11.79 7 14.50 4 7.45
O60610 Protein	  diaphanous	  homolog	  1 5 3.38 2 2.12 1 0.86
O60613 15	  kDa	  selenoprotein 2 9.88 1 9.88 1 9.88
O60645 Exocyst	  complex	  component	  3 5 7.14 4 7.14 3 4.37
O60664 Perilipin-­‐3 32 60.83 19 49.31 17 43.32
O60684 Importin	  subunit	  alpha-­‐7 1 2.61 0 0.00 3 5.78
O60701 UDP-­‐glucose	  6-­‐dehydrogenase 7 14.17 0 0.00 4 10.73
O60716 Catenin	  delta-­‐1 37 26.03 18 17.56 19 19.32
O60739 Eukaryotic	  translation	  initiation	  factor	  1b 10 52.21 5 35.40 0 0.00
O60749 Sorting	  nexin-­‐2 13 20.81 3 5.20 5 12.72
O60762 Dolichol-­‐phosphate	  mannosyltransferase 5 8.46 4 8.46 2 8.46
O60763 General	  vesicular	  transport	  factor	  p115 13 11.85 8 10.29 6 6.76
O60784 Target	  of	  Myb	  protein	  1 6 15.85 5 12.40 3 8.54
O60814 Histone	  H2B	  type	  1-­‐K 61 67.46 61 62.70 43 57.94
O60825 6-­‐phosphofructo-­‐2-­‐kinase/fructose-­‐2,6-­‐biphosphatase	  2 4 7.13 0 0.00 0 0.00
O60826 Coiled-­‐coil	  domain-­‐containing	  protein	  22 10 14.99 7 16.75 8 18.50
O60831 PRA1	  family	  protein	  2 2 6.18 1 6.18 1 6.18
O60832 H/ACA	  ribonucleoprotein	  complex	  subunit	  4 14 25.68 4 12.65 1 2.53
O60841 Eukaryotic	  translation	  initiation	  factor	  5B 10 8.93 5 6.80 8 9.59
O60879 Protein	  diaphanous	  homolog	  2 2 2.72 1 0.82 0 0.00
O60888 Protein	  CutA 8 30.73 6 40.78 2 22.91
O60936 Nucleolar	  protein	  3 1 8.68 1 8.68 1 8.68
O75044 SLIT-­‐ROBO	  Rho	  GTPase-­‐activating	  protein	  2 3 2.43 3 1.12 0 0.00
O75083 WD	  repeat-­‐containing	  protein	  1 39 43.07 20 30.69 15 37.13
O75116 Rho-­‐associated	  protein	  kinase	  2 5 3.82 1 0.72 0 0.00
O75122 CLIP-­‐associating	  protein	  2 2 1.24 0 0.00 0 0.00
O75131 Copine-­‐3 14 12.29 6 8.38 6 6.70
O75165 DnaJ	  homolog	  subfamily	  C	  member	  13 16 6.78 10 4.90 14 5.08
O75208 Ubiquinone	  biosynthesis	  protein	  COQ9,	  mitochondrial 3 12.26 0 0.00 0 0.00
O75223 Gamma-­‐glutamylcyclotransferase 1 5.32 2 17.55 3 22.87
O75251 NADH	  dehydrogenase	  [ubiquinone]	  iron-­‐sulfur	  protein	  7,	  mitochondrial 2 4.22 2 4.22 2 10.80
O75306 NADH	  dehydrogenase	  [ubiquinone]	  iron-­‐sulfur	  protein	  2,	  mitochondrial 24 37.80 17 29.81 10 21.38
O75323 Protein	  NipSnap	  homolog	  2 7 16.78 2 6.99 0 0.00
O75340 Programmed	  cell	  death	  protein	  6 9 29.84 8 40.84 7 47.64
O75347 Tubulin-­‐specific	  chaperone	  A 8 27.78 7 18.52 4 10.19
O75348 V-­‐type	  proton	  ATPase	  subunit	  G	  1 6 27.97 4 27.97 4 20.34
O75351 Vacuolar	  protein	  sorting-­‐associated	  protein	  4B 7 14.86 3 4.28 0 0.00
O75352 Mannose-­‐P-­‐dolichol	  utilization	  defect	  1	  protein 2 9.72 1 5.67 1 5.67
O75367 Core	  histone	  macro-­‐H2A.1 32 42.74 27 38.98 22 36.56
O75368 SH3	  domain-­‐binding	  glutamic	  acid-­‐rich-­‐like	  protein 27 90.35 20 84.21 15 77.19
O75369 Filamin-­‐B 38 15.95 19 8.46 26 9.80
O75380 NADH	  dehydrogenase	  [ubiquinone]	  iron-­‐sulfur	  protein	  6,	  mitochondrial 1 17.74 1 17.74 1 17.74
O75390 Citrate	  synthase,	  mitochondrial 41 33.26 23 37.77 25 31.12
O75396 Vesicle-­‐trafficking	  protein	  SEC22b 11 45.12 7 34.42 11 34.42
O75400 Pre-­‐mRNA-­‐processing	  factor	  40	  homolog	  A 3 3.03 2 1.36 2 3.03
O75431 Metaxin-­‐2 3 13.31 2 8.37 1 4.94
O75436 Vacuolar	  protein	  sorting-­‐associated	  protein	  26A 4 9.79 0 0.00 1 2.14
O75439 Mitochondrial-­‐processing	  peptidase	  subunit	  beta 10 20.65 8 18.61 7 15.95
O75448 Mediator	  of	  RNA	  polymerase	  II	  transcription	  subunit	  24 1 1.42 0 0.00 0 0.00
O75477 Erlin-­‐1 4 8.38 0 0.00 5 16.18
O75489 NADH	  dehydrogenase	  [ubiquinone]	  iron-­‐sulfur	  protein	  3,	  mitochondrial 25 47.73 19 47.35 20 47.35
O75494 Serine/arginine-­‐rich	  splicing	  factor	  10 7 23.28 9 23.28 5 18.70
O75521 Enoyl-­‐CoA	  delta	  isomerase	  2,	  mitochondrial 6 13.71 0 0.00 3 7.87
O75531 Barrier-­‐to-­‐autointegration	  factor 16 48.31 12 40.45 7 40.45
O75533 Splicing	  factor	  3B	  subunit	  1 20 18.63 15 13.96 13 11.66
O75534 Cold	  shock	  domain-­‐containing	  protein	  E1 2 2.88 1 1.63 3 4.01
O75607 Nucleoplasmin-­‐3 3 27.53 2 21.35 2 21.35
O75608 Acyl-­‐protein	  thioesterase	  1 4 25.22 1 6.09 3 15.22
O75628 GTP-­‐binding	  protein	  REM	  1 1 3.69 0 0.00 0 0.00
O75629 Protein	  CREG1 4 9.54 0 0.00 2 9.54
O75643 U5	  small	  nuclear	  ribonucleoprotein	  200	  kDa	  helicase 33 15.64 25 11.47 20 10.96
O75688 Protein	  phosphatase	  1B 4 8.14 1 3.76 1 3.76
O75694 Nuclear	  pore	  complex	  protein	  Nup155 11 7.26 10 7.76 8 5.97
O75746 Calcium-­‐binding	  mitochondrial	  carrier	  protein	  Aralar1 15 19.91 11 14.75 7 10.03
O75781 Paralemmin-­‐1 2 7.49 1 4.91 2 7.49
O75792 Ribonuclease	  H2	  subunit	  A 2 7.36 1 2.68 0 0.00
O75817 Ribonuclease	  P	  protein	  subunit	  p20 1 10.71 0 0.00 0 0.00
O75821 Eukaryotic	  translation	  initiation	  factor	  3	  subunit	  G 13 26.88 3 10.31 3 7.50
O75822 Eukaryotic	  translation	  initiation	  factor	  3	  subunit	  J 3 8.53 0 0.00 0 0.00
O75843 AP-­‐1	  complex	  subunit	  gamma-­‐like	  2 2 4.08 0 0.00 1 1.15
O75874 Isocitrate	  dehydrogenase	  [NADP]	  cytoplasmic 18 39.61 10 23.19 13 31.40
O75891 Cytosolic	  10-­‐formyltetrahydrofolate	  dehydrogenase 5 5.99 5 6.32 3 4.10
O75915 PRA1	  family	  protein	  3 10 20.21 7 16.49 10 16.49
O75923 Dysferlin 8 4.90 1 0.91 0 0.00
O75937 DnaJ	  homolog	  subfamily	  C	  member	  8 4 25.69 2 7.51 1 3.16
O75947 ATP	  synthase	  subunit	  d,	  mitochondrial 21 71.43 8 47.83 10 47.83
O75955 Flotillin-­‐1 17 35.13 15 27.40 12 23.65
O75964 ATP	  synthase	  subunit	  g,	  mitochondrial 10 52.43 4 35.92 3 25.24
O76003 Glutaredoxin-­‐3 6 15.82 3 12.24 3 8.36
O76021 Ribosomal	  L1	  domain-­‐containing	  protein	  1 5 12.24 8 17.55 4 11.22
O76024 Wolframin 5 4.49 2 2.14 2 2.70
O76031 ATP-­‐dependent	  Clp	  protease	  ATP-­‐binding	  subunit	  clpX-­‐like,	  mitochondrial 2 3.79 0 0.00 0 0.00
O76054 SEC14-­‐like	  protein	  2 1 2.73 2 4.96 1 4.96
O76094 Signal	  recognition	  particle	  72	  kDa	  protein 5 5.22 6 6.56 6 14.16
O94760 N(G),N(G)-­‐dimethylarginine	  dimethylaminohydrolase	  1 2 7.72 0 0.00 0 0.00
O94766 Galactosylgalactosylxylosylprotein	  3-­‐beta-­‐glucuronosyltransferase	  3 2 7.16 0 0.00 0 0.00
O94804 Serine/threonine-­‐protein	  kinase	  10 11 9.92 6 5.37 5 6.40
O94826 Mitochondrial	  import	  receptor	  subunit	  TOM70 9 15.79 3 4.93 1 3.95
O94832 Myosin-­‐Id 49 28.13 21 16.40 26 23.06
O94874 E3	  UFM1-­‐protein	  ligase	  1 10 13.10 3 6.42 4 6.93
O94875 Sorbin	  and	  SH3	  domain-­‐containing	  protein	  2 1 1.82 0 0.00 0 0.00
O94886 Transmembrane	  protein	  63A 2 3.72 0 0.00 2 3.72
O94901 SUN	  domain-­‐containing	  protein	  1 4 5.05 0 0.00 4 5.67
O94905 Erlin-­‐2 8 22.12 7 18.88 12 34.81
O94915 Protein	  furry	  homolog-­‐like 1 0.60 0 0.00 0 0.00
O94919 Endonuclease	  domain-­‐containing	  1	  protein 6 7.40 2 2.60 6 11.60
O94925 Glutaminase	  kidney	  isoform,	  mitochondrial 3 6.13 0 0.00 0 0.00
O94973 AP-­‐2	  complex	  subunit	  alpha-­‐2 13 15.87 13 18.64 11 12.57
O94979 Protein	  transport	  protein	  Sec31A 9 7.62 6 6.64 6 4.02
O95071 E3	  ubiquitin-­‐protein	  ligase	  UBR5 2 1.25 2 0.68 0 0.00
O95155 Ubiquitin	  conjugation	  factor	  E4	  B 4 3.00 0 0.00 0 0.00
O95168 NADH	  dehydrogenase	  [ubiquinone]	  1	  beta	  subcomplex	  subunit	  4 3 16.28 2 21.71 0 0.00
O95169 NADH	  dehydrogenase	  [ubiquinone]	  1	  beta	  subcomplex	  subunit	  8,	  mitochondrial 4 21.51 0 0.00 3 22.58
O95182 NADH	  dehydrogenase	  [ubiquinone]	  1	  alpha	  subcomplex	  subunit	  7 2 17.70 2 18.58 0 0.00
O95197 Reticulon-­‐3 2 1.07 2 1.07 0 0.00
O95202 LETM1	  and	  EF-­‐hand	  domain-­‐containing	  protein	  1,	  mitochondrial 16 18.00 2 4.87 2 3.79
O95208 Epsin-­‐2 2 1.56 1 1.56 1 1.56
O95219 Sorting	  nexin-­‐4 3 4.89 0 0.00 0 0.00
O95232 Luc7-­‐like	  protein	  3 3 6.25 4 6.25 4 9.49
O95260 Arginyl-­‐tRNA-­‐-­‐protein	  transferase	  1 2 5.60 2 5.60 0 0.00
O95292 Vesicle-­‐associated	  membrane	  protein-­‐associated	  protein	  B/C 5 15.64 0 0.00 4 10.70
O95299 NADH	  dehydrogenase	  [ubiquinone]	  1	  alpha	  subcomplex	  subunit	  10,	  mitochondrial 11 26.20 8 19.72 2 6.20
O95302 Peptidyl-­‐prolyl	  cis-­‐trans	  isomerase	  FKBP9 4 8.42 3 5.61 0 0.00
O95336 6-­‐phosphogluconolactonase 20 48.06 14 54.65 11 39.92
O95372 Acyl-­‐protein	  thioesterase	  2 4 19.05 6 19.05 1 7.79
O95373 Importin-­‐7 11 9.73 6 5.78 7 8.09
O95379 Tumor	  necrosis	  factor	  alpha-­‐induced	  protein	  8 1 10.10 1 10.10 0 0.00
O95394 Phosphoacetylglucosamine	  mutase 1 3.14 0 0.00 0 0.00
O95428 Papilin 1 1.57 1 1.57 0 0.00
O95433 Activator	  of	  90	  kDa	  heat	  shock	  protein	  ATPase	  homolog	  1 7 15.68 7 15.68 6 10.06
O95456 Proteasome	  assembly	  chaperone	  1 2 10.42 0 0.00 0 0.00
O95470 Sphingosine-­‐1-­‐phosphate	  lyase	  1 1 2.64 1 2.64 0 0.00
O95479 GDH/6PGL	  endoplasmic	  bifunctional	  protein 8 9.35 6 6.70 5 7.33
O95486 Protein	  transport	  protein	  Sec24A 2 2.75 2 2.75 2 2.75
O95487 Protein	  transport	  protein	  Sec24B 7 3.78 5 3.23 3 1.73
O95571 Protein	  ETHE1,	  mitochondrial 5 22.05 3 23.23 3 12.20
O95573 Long-­‐chain-­‐fatty-­‐acid-­‐-­‐CoA	  ligase	  3 4 7.64 3 6.39 4 8.19
O95671 N-­‐acetylserotonin	  O-­‐methyltransferase-­‐like	  protein 2 6.92 0 0.00 1 2.74
O95674 Phosphatidate	  cytidylyltransferase	  2 5 15.06 3 11.69 4 10.79
O95678 Keratin,	  type	  II	  cytoskeletal	  75 3 2.90 0 0.00 0 0.00
O95716 Ras-­‐related	  protein	  Rab-­‐3D 10 26.03 6 27.40 6 15.53
O95721 Synaptosomal-­‐associated	  protein	  29 6 18.22 2 8.91 0 0.00
O95747 Serine/threonine-­‐protein	  kinase	  OSR1 5 9.49 4 12.14 0 0.00
O95777 N-­‐alpha-­‐acetyltransferase	  38,	  NatC	  auxiliary	  subunit 5 41.67 8 52.08 7 52.08
O95782 AP-­‐2	  complex	  subunit	  alpha-­‐1 11 10.95 9 10.13 9 9.01
O95817 BAG	  family	  molecular	  chaperone	  regulator	  3 1 2.61 0 0.00 2 6.96
O95822 Malonyl-­‐CoA	  decarboxylase,	  mitochondrial 5 15.21 2 4.06 1 4.06
O95831 Apoptosis-­‐inducing	  factor	  1,	  mitochondrial 14 21.53 11 18.92 9 14.19
O95834 Echinoderm	  microtubule-­‐associated	  protein-­‐like	  2 6 12.48 7 15.25 10 18.03
O95861 3'(2'),5'-­‐bisphosphate	  nucleotidase	  1 4 20.13 3 16.56 2 12.66
O95865 N(G),N(G)-­‐dimethylarginine	  dimethylaminohydrolase	  2 8 43.86 5 19.30 3 15.44
O95870 Abhydrolase	  domain-­‐containing	  protein	  16A 3 3.58 1 1.97 1 1.97
O95881 Thioredoxin	  domain-­‐containing	  protein	  12 3 17.44 0 0.00 0 0.00
O96000 NADH	  dehydrogenase	  [ubiquinone]	  1	  beta	  subcomplex	  subunit	  10 6 20.93 2 14.53 1 8.14
O96008 Mitochondrial	  import	  receptor	  subunit	  TOM40	  homolog 14 21.33 10 18.28 0 0.00
O96013 Serine/threonine-­‐protein	  kinase	  PAK	  4 1 1.86 1 2.20 2 8.80
O96019 Actin-­‐like	  protein	  6A 2 7.46 0 0.00 0 0.00
P00167 Cytochrome	  b5 3 25.37 2 15.67 3 25.37
P00338 L-­‐lactate	  dehydrogenase	  A	  chain 79 68.67 65 58.73 59 46.08
P00352 Retinal	  dehydrogenase	  1 10 16.57 11 18.96 10 24.75
P00367 Glutamate	  dehydrogenase	  1,	  mitochondrial 46 47.67 17 29.39 18 31.54
P00387 NADH-­‐cytochrome	  b5	  reductase	  3 37 64.12 23 53.82 14 46.51
P00390 Glutathione	  reductase,	  mitochondrial 8 11.11 5 8.81 4 8.81
P00403 Cytochrome	  c	  oxidase	  subunit	  2 7 35.24 4 17.18 6 26.43
P00441 Superoxide	  dismutase	  [Cu-­‐Zn] 30 46.10 23 46.10 15 32.47
P00450 Ceruloplasmin 32 25.54 30 20.09 20 12.30
P00488 Coagulation	  factor	  XIII	  A	  chain 11 16.26 10 14.62 12 16.26
P00505 Aspartate	  aminotransferase,	  mitochondrial 31 45.58 18 41.16 18 28.60
P00558 Phosphoglycerate	  kinase	  1 94 75.30 77 67.63 66 62.11
P00568 Adenylate	  kinase	  isoenzyme	  1 9 35.57 6 37.11 6 36.08
P00734 Prothrombin 14 15.27 7 12.70 6 10.93
P00738 Haptoglobin 13 18.72 17 32.27 12 14.04
P00747 Plasminogen 9 10.74 6 6.05 6 7.04
P00748 Coagulation	  factor	  XII 2 2.93 0 0.00 0 0.00
P00751 Complement	  factor	  B 11 11.13 11 12.96 7 8.25
P00846 ATP	  synthase	  subunit	  a 3 4.43 0 0.00 0 0.00
P00915 Carbonic	  anhydrase	  1 12 27.59 25 40.23 25 43.68
P00918 Carbonic	  anhydrase	  2 14 26.15 11 21.54 14 28.46
P00973 2'-­‐5'-­‐oligoadenylate	  synthase	  1 1 5.25 0 0.00 0 0.00
P01008 Antithrombin-­‐III 8 15.73 10 18.97 2 5.82
P01009 Alpha-­‐1-­‐antitrypsin 60 63.64 57 54.55 47 43.30
P01011 Alpha-­‐1-­‐antichymotrypsin 15 27.19 13 30.97 15 28.61
P01019 Angiotensinogen 9 17.32 9 23.51 7 18.35
P01023 Alpha-­‐2-­‐macroglobulin 57 30.80 81 38.20 47 28.83
P01024 Complement	  C3 114 46.90 115 42.15 98 44.62
P01034 Cystatin-­‐C 1 7.53 0 0.00 2 21.92
P01042 Kininogen-­‐1 8 8.70 5 7.45 4 7.45
P01111 GTPase	  NRas 8 25.40 7 25.40 4 17.46
P01112 GTPase	  HRas 9 30.16 7 25.40 4 17.46
P01593 Ig	  kappa	  chain	  V-­‐I	  region	  AG 5 16.67 7 31.48 18 31.48
P01594 Ig	  kappa	  chain	  V-­‐I	  region	  AU 5 16.67 6 16.67 8 16.67
P01599 Ig	  kappa	  chain	  V-­‐I	  region	  Gal 5 16.67 6 16.67 8 16.67
P01600 Ig	  kappa	  chain	  V-­‐I	  region	  Hau 5 16.67 6 16.67 9 22.22
P01601 Ig	  kappa	  chain	  V-­‐I	  region	  HK101	  (Fragment) 7 25.64 6 15.38 9 20.51
P01607 Ig	  kappa	  chain	  V-­‐I	  region	  Rei 5 16.67 6 16.67 8 16.67
P01608 Ig	  kappa	  chain	  V-­‐I	  region	  Roy 5 16.67 6 16.67 8 16.67
P01610 Ig	  kappa	  chain	  V-­‐I	  region	  WEA 5 16.67 6 16.67 9 22.22
P01611 Ig	  kappa	  chain	  V-­‐I	  region	  Wes 2 16.67 0 0.00 3 22.22
P01617 Ig	  kappa	  chain	  V-­‐II	  region	  TEW 1 21.24 0 0.00 0 0.00
P01620 Ig	  kappa	  chain	  V-­‐III	  region	  SIE 5 39.45 9 31.19 9 39.45
P01622 Ig	  kappa	  chain	  V-­‐III	  region	  Ti 4 31.19 9 31.19 8 31.19
P01623 Ig	  kappa	  chain	  V-­‐III	  region	  WOL 5 39.45 9 31.19 9 39.45
P01625 Ig	  kappa	  chain	  V-­‐IV	  region	  Len 4 23.68 3 23.68 4 23.68
P01701 Ig	  lambda	  chain	  V-­‐I	  region	  NEW 2 7.21 1 7.21 0 0.00
P01702 Ig	  lambda	  chain	  V-­‐I	  region	  NIG-­‐64 2 7.21 1 7.21 0 0.00
P01714 Ig	  lambda	  chain	  V-­‐III	  region	  SH 2 7.41 1 7.41 0 0.00
P01715 Ig	  lambda	  chain	  V-­‐IV	  region	  Bau 1 7.55 0 0.00 0 0.00
P01764 Ig	  heavy	  chain	  V-­‐III	  region	  VH26 2 25.64 2 25.64 3 25.64
P01765 Ig	  heavy	  chain	  V-­‐III	  region	  TIL 1 16.52 2 26.09 3 26.09
P01766 Ig	  heavy	  chain	  V-­‐III	  region	  BRO 6 25.00 6 25.00 2 25.00
P01774 Ig	  heavy	  chain	  V-­‐III	  region	  POM 1 15.97 1 15.97 2 15.97
P01776 Ig	  heavy	  chain	  V-­‐III	  region	  WAS 1 16.24 1 16.24 2 16.24
P01777 Ig	  heavy	  chain	  V-­‐III	  region	  TEI 4 15.97 5 15.97 1 15.97
P01779 Ig	  heavy	  chain	  V-­‐III	  region	  TUR 1 16.38 1 16.38 2 16.38
P01834 Ig	  kappa	  chain	  C	  region 55 80.19 44 80.19 61 80.19
P01857 Ig	  gamma-­‐1	  chain	  C	  region 95 51.21 90 57.58 76 59.09
P01859 Ig	  gamma-­‐2	  chain	  C	  region 50 42.64 49 44.48 43 46.01
P01860 Ig	  gamma-­‐3	  chain	  C	  region 35 38.46 31 37.40 24 35.81
P01861 Ig	  gamma-­‐4	  chain	  C	  region 65 34.56 64 49.54 57 48.62
P01871 Ig	  mu	  chain	  C	  region 8 15.49 14 25.00 4 12.61
P01876 Ig	  alpha-­‐1	  chain	  C	  region 22 33.99 12 23.51 14 26.06
P01880 Ig	  delta	  chain	  C	  region 2 6.51 0 0.00 0 0.00
P01889 HLA	  class	  I	  histocompatibility	  antigen,	  B-­‐7	  alpha	  chain 18 29.01 6 14.09 13 25.97
P01891 HLA	  class	  I	  histocompatibility	  antigen,	  A-­‐68	  alpha	  chain 15 23.84 0 0.00 9 16.71
P01892 HLA	  class	  I	  histocompatibility	  antigen,	  A-­‐2	  alpha	  chain 19 29.59 8 18.08 10 17.53
P01903 HLA	  class	  II	  histocompatibility	  antigen,	  DR	  alpha	  chain 9 29.13 5 24.41 3 17.72
P02042 Hemoglobin	  subunit	  delta 122 91.16 137 85.03 120 74.83
P02452 Collagen	  alpha-­‐1(I)	  chain 73 42.90 92 42.83 21 19.74
P02458 Collagen	  alpha-­‐1(II)	  chain 58 29.05 3 3.16 0 0.00
P02489 Alpha-­‐crystallin	  A	  chain 10 30.06 7 24.86 3 17.34
P02511 Alpha-­‐crystallin	  B	  chain 27 60.57 12 41.71 12 45.71
P02538 Keratin,	  type	  II	  cytoskeletal	  6A 2 1.24 0 0.00 0 0.00
P02545 Prelamin-­‐A/C 227 68.98 158 58.13 142 56.93
P02647 Apolipoprotein	  A-­‐I 83 65.54 67 58.05 56 49.81
P02649 Apolipoprotein	  E 20 49.53 14 37.54 13 35.96
P02652 Apolipoprotein	  A-­‐II 15 41.00 10 37.00 6 39.00
P02654 Apolipoprotein	  C-­‐I 1 10.84 0 0.00 0 0.00
P02656 Apolipoprotein	  C-­‐III 2 27.27 2 27.27 1 16.16
P02671 Fibrinogen	  alpha	  chain 20 15.01 12 10.85 17 13.63
P02675 Fibrinogen	  beta	  chain 25 32.18 32 37.68 28 36.46
P02679 Fibrinogen	  gamma	  chain 12 17.00 11 12.58 13 18.76
P02730 Band	  3	  anion	  transport	  protein 12 15.48 26 21.19 22 16.03
P02743 Serum	  amyloid	  P-­‐component 6 20.63 3 14.80 3 9.87
P02748 Complement	  component	  C9 10 10.38 7 11.27 7 7.51
P02749 Beta-­‐2-­‐glycoprotein	  1 4 8.41 5 6.67 5 10.72
P02750 Leucine-­‐rich	  alpha-­‐2-­‐glycoprotein 3 15.85 5 12.68 2 10.95
P02751 Fibronectin 15 7.67 18 10.85 17 11.48
P02760 Protein	  AMBP 3 10.23 3 8.52 5 20.17
P02763 Alpha-­‐1-­‐acid	  glycoprotein	  1 16 33.33 15 32.84 14 33.33
P02765 Alpha-­‐2-­‐HS-­‐glycoprotein 12 21.25 13 30.52 7 24.25
P02766 Transthyretin 14 70.07 17 70.07 9 40.82
P02768 Serum	  albumin 475 76.35 363 75.04 296 76.68
P02774 Vitamin	  D-­‐binding	  protein 22 28.06 20 23.21 19 23.21
P02786 Transferrin	  receptor	  protein	  1 3 5.40 4 5.40 0 0.00
P02787 Serotransferrin 124 51.72 104 48.57 71 37.25
P02790 Hemopexin 31 37.01 24 26.19 22 32.25
P02792 Ferritin	  light	  chain 2 17.14 0 0.00 2 17.14
P03989 HLA	  class	  I	  histocompatibility	  antigen,	  B-­‐27	  alpha	  chain 14 26.24 4 14.09 7 19.89
P04004 Vitronectin 10 12.97 8 14.85 6 8.79
P04040 Catalase 25 40.99 20 28.65 14 26.38
P04062 Glucosylceramidase 2 8.02 2 4.10 1 5.04
P04066 Tissue	  alpha-­‐L-­‐fucosidase 4 6.01 3 6.01 1 2.36
P04075 Fructose-­‐bisphosphate	  aldolase	  A 101 72.53 68 71.43 57 74.73
P04080 Cystatin-­‐B 8 57.14 3 55.10 0 0.00
P04083 Annexin	  A1 22 39.60 21 29.77 22 37.28
P04114 Apolipoprotein	  B-­‐100 9 2.28 15 4.41 6 1.78
P04179 Superoxide	  dismutase	  [Mn],	  mitochondrial 16 32.88 8 16.22 13 16.22
P04181 Ornithine	  aminotransferase,	  mitochondrial 4 10.02 0 0.00 0 0.00
P04196 Histidine-­‐rich	  glycoprotein 14 19.43 14 17.90 9 15.81
P04206 Ig	  kappa	  chain	  V-­‐III	  region	  GOL 4 31.19 10 37.61 8 31.19
P04217 Alpha-­‐1B-­‐glycoprotein 14 41.62 10 24.85 7 15.35
P04222 HLA	  class	  I	  histocompatibility	  antigen,	  Cw-­‐3	  alpha	  chain 23 36.34 0 0.00 20 19.67
P04229 HLA	  class	  II	  histocompatibility	  antigen,	  DRB1-­‐1	  beta	  chain 8 21.80 4 13.53 4 18.42
P04259 Keratin,	  type	  II	  cytoskeletal	  6B 4 3.01 0 0.00 0 0.00
P04264 Keratin,	  type	  II	  cytoskeletal	  1 28 37.89 26 19.72 10 10.56
P04271 Protein	  S100-­‐B 10 48.91 10 40.22 4 32.61
P04275 von	  Willebrand	  factor 5 2.74 2 1.42 3 1.88
P04350 Tubulin	  beta-­‐4A	  chain 152 76.80 108 75.00 87 71.85
P04406 Glyceraldehyde-­‐3-­‐phosphate	  dehydrogenase 147 73.43 129 69.55 80 61.79
P04431 Ig	  kappa	  chain	  V-­‐I	  region	  Walker 5 13.95 6 13.95 9 18.60
P04432 Ig	  kappa	  chain	  V-­‐I	  region	  Daudi 5 13.95 6 13.95 10 22.48
P04433 Ig	  kappa	  chain	  V-­‐III	  region	  VG	  (Fragment) 4 23.48 0 0.00 0 0.00
P04632 Calpain	  small	  subunit	  1 13 57.84 11 30.22 10 30.22
P04792 Heat	  shock	  protein	  beta-­‐1 50 78.05 50 84.88 43 78.05
P04839 Cytochrome	  b-­‐245	  heavy	  chain 1 2.98 0 0.00 1 2.98
P04843 Dolichyl-­‐diphosphooligosaccharide-­‐-­‐protein	  glycosyltransferase	  subunit	  1 44 48.11 31 37.23 31 31.47
P04844 Dolichyl-­‐diphosphooligosaccharide-­‐-­‐protein	  glycosyltransferase	  subunit	  2 37 33.76 33 29.00 31 33.28
P04899 Guanine	  nucleotide-­‐binding	  protein	  G(i)	  subunit	  alpha-­‐2 12 30.70 8 15.49 7 18.87
P05023 Sodium/potassium-­‐transporting	  ATPase	  subunit	  alpha-­‐1 62 33.82 41 29.52 35 27.86
P05091 Aldehyde	  dehydrogenase,	  mitochondrial 11 18.38 10 20.70 11 18.38
P05109 Protein	  S100-­‐A8 4 32.26 7 32.26 9 33.33
P05114 Non-­‐histone	  chromosomal	  protein	  HMG-­‐14 8 41.00 6 40.00 1 13.00
P05141 ADP/ATP	  translocase	  2 59 52.68 43 53.69 35 51.68
P05155 Plasma	  protease	  C1	  inhibitor 16 21.80 8 12.20 12 18.40
P05156 Complement	  factor	  I 1 2.23 0 0.00 0 0.00
P05161 Ubiquitin-­‐like	  protein	  ISG15 12 25.45 1 7.88 1 12.12
P05165 Propionyl-­‐CoA	  carboxylase	  alpha	  chain,	  mitochondrial 7 12.64 1 2.06 2 3.43
P05166 Propionyl-­‐CoA	  carboxylase	  beta	  chain,	  mitochondrial 12 26.72 5 11.50 5 11.32
P05198 Eukaryotic	  translation	  initiation	  factor	  2	  subunit	  1 20 42.86 12 24.13 9 21.59
P05204 Non-­‐histone	  chromosomal	  protein	  HMG-­‐17 7 30.00 3 22.22 2 21.11
P05362 Intercellular	  adhesion	  molecule	  1 7 10.71 6 11.09 8 11.09
P05386 60S	  acidic	  ribosomal	  protein	  P1 18 67.54 14 67.54 11 51.75
P05387 60S	  acidic	  ribosomal	  protein	  P2 26 77.39 25 77.39 27 76.52
P05388 60S	  acidic	  ribosomal	  protein	  P0 30 56.78 29 56.78 30 55.84
P05413 Fatty	  acid-­‐binding	  protein,	  heart 8 34.59 7 27.82 5 34.59
P05455 Lupus	  La	  protein 26 35.29 12 18.63 11 24.51
P05534 HLA	  class	  I	  histocompatibility	  antigen,	  A-­‐24	  alpha	  chain 16 20.00 0 0.00 3 7.40
P05546 Heparin	  cofactor	  2 4 5.81 4 7.01 2 4.01
P05549 Transcription	  factor	  AP-­‐2-­‐alpha 3 6.64 3 6.64 3 6.64
P05556 Integrin	  beta-­‐1 7 8.15 5 4.64 4 6.64
P05783 Keratin,	  type	  I	  cytoskeletal	  18 10 26.28 0 0.00 0 0.00
P05787 Keratin,	  type	  II	  cytoskeletal	  8 17 18.01 14 12.84 11 14.91
P06132 Uroporphyrinogen	  decarboxylase 3 13.08 0 0.00 0 0.00
P06241 Tyrosine-­‐protein	  kinase	  Fyn 4 4.84 2 3.35 0 0.00
P06280 Alpha-­‐galactosidase	  A 2 6.76 0 0.00 2 6.76
P06309 Ig	  kappa	  chain	  V-­‐II	  region	  GM607	  (Fragment) 1 20.51 0 0.00 0 0.00
P06312 Ig	  kappa	  chain	  V-­‐IV	  region	  (Fragment) 4 22.31 3 22.31 4 22.31
P06313 Ig	  kappa	  chain	  V-­‐IV	  region	  JI 4 20.30 3 20.30 4 20.30
P06314 Ig	  kappa	  chain	  V-­‐IV	  region	  B17 4 20.15 3 20.15 4 20.15
P06316 Ig	  lambda	  chain	  V-­‐I	  region	  BL2 2 6.15 1 6.15 0 0.00
P06396 Gelsolin 69 42.33 50 33.25 39 29.28
P06454 Prothymosin	  alpha 23 29.73 13 27.03 6 26.13
P06576 ATP	  synthase	  subunit	  beta,	  mitochondrial 148 73.53 108 72.40 93 67.86
P06681 Complement	  C2 3 3.72 1 1.60 1 1.60
P06702 Protein	  S100-­‐A9 6 37.72 11 49.12 16 49.12
P06703 Protein	  S100-­‐A6 5 35.56 1 8.89 2 8.89
P06727 Apolipoprotein	  A-­‐IV 23 34.34 11 18.18 11 17.42
P06733 Alpha-­‐enolase 177 77.65 168 72.58 107 60.83
P06737 Glycogen	  phosphorylase,	  liver	  form 90 41.20 71 40.85 96 39.32
P06744 Glucose-­‐6-­‐phosphate	  isomerase 47 44.09 32 40.32 25 28.49
P06748 Nucleophosmin 58 44.56 41 41.50 41 38.78
P06753 Tropomyosin	  alpha-­‐3	  chain 28 26.41 23 20.77 19 17.61
P06756 Integrin	  alpha-­‐V 15 15.08 9 8.87 5 6.30
P06865 Beta-­‐hexosaminidase	  subunit	  alpha 25 25.90 22 25.33 19 27.22
P06888 Ig	  lambda	  chain	  V-­‐I	  region	  EPS 2 7.34 1 7.34 0 0.00
P06899 Histone	  H2B	  type	  1-­‐J 59 67.46 60 62.70 41 57.14
P07093 Glia-­‐derived	  nexin 4 13.82 3 10.55 4 10.55
P07099 Epoxide	  hydrolase	  1 16 24.40 8 15.38 11 12.09
P07108 Acyl-­‐CoA-­‐binding	  protein 5 32.18 0 0.00 0 0.00
P07195 L-­‐lactate	  dehydrogenase	  B	  chain 64 56.89 36 53.59 42 47.01
P07203 Glutathione	  peroxidase	  1 10 56.65 4 26.60 7 40.89
P07205 Phosphoglycerate	  kinase	  2 25 25.90 28 25.66 21 19.66
P07237 Protein	  disulfide-­‐isomerase 60 52.36 39 37.99 41 38.58
P07305 Histone	  H1.0 6 20.62 4 15.46 3 11.34
P07339 Cathepsin	  D 50 46.60 30 36.41 43 44.66
P07355 Annexin	  A2 94 69.03 67 64.31 61 57.23
P07357 Complement	  component	  C8	  alpha	  chain 2 3.08 0 0.00 0 0.00
P07384 Calpain-­‐1	  catalytic	  subunit 18 18.07 13 15.83 10 12.32
P07437 Tubulin	  beta	  chain 193 75.90 133 74.32 123 73.87
P07602 Proactivator	  polypeptide 35 15.08 10 10.31 13 13.17
P07686 Beta-­‐hexosaminidase	  subunit	  beta 43 34.17 11 14.57 22 17.99
P07711 Cathepsin	  L1 5 14.71 0 0.00 0 0.00
P07737 Profilin-­‐1 28 72.14 21 57.14 22 50.00
P07738 Bisphosphoglycerate	  mutase 1 5.02 2 12.36 0 0.00
P07741 Adenine	  phosphoribosyltransferase 15 37.22 12 48.33 12 46.11
P07814 Bifunctional	  aminoacyl-­‐tRNA	  synthetase 24 19.05 17 10.98 10 4.63
P07858 Cathepsin	  B 27 35.69 13 19.47 14 23.89
P07900 Heat	  shock	  protein	  HSP	  90-­‐alpha 148 51.91 97 39.62 86 36.61
P07902 Galactose-­‐1-­‐phosphate	  uridylyltransferase 5 10.03 2 6.60 3 9.50
P07910 Heterogeneous	  nuclear	  ribonucleoproteins	  C1/C2 34 43.46 23 37.58 20 42.16
P07919 Cytochrome	  b-­‐c1	  complex	  subunit	  6,	  mitochondrial 8 56.04 9 64.84 5 57.14
P07947 Tyrosine-­‐protein	  kinase	  Yes 4 4.79 2 3.31 0 0.00
P07948 Tyrosine-­‐protein	  kinase	  Lyn 3 3.13 0 0.00 0 0.00
P07954 Fumarate	  hydratase,	  mitochondrial 31 45.49 17 42.35 12 29.02
P08107 Heat	  shock	  70	  kDa	  protein	  1A/1B 102 53.98 72 46.65 58 42.12
P08123 Collagen	  alpha-­‐2(I)	  chain 60 37.85 70 41.29 26 22.55
P08133 Annexin	  A6 91 55.42 72 46.95 64 43.24
P08134 Rho-­‐related	  GTP-­‐binding	  protein	  RhoC 26 51.30 0 0.00 16 51.30
P08195 4F2	  cell-­‐surface	  antigen	  heavy	  chain 60 40.16 34 30.32 30 37.30
P08236 Beta-­‐glucuronidase 8 16.13 0 0.00 3 2.77
P08237 6-­‐phosphofructokinase,	  muscle	  type 24 30.77 13 17.82 14 13.33
P08238 Heat	  shock	  protein	  HSP	  90-­‐beta 121 50.83 81 44.61 63 38.95
P08240 Signal	  recognition	  particle	  receptor	  subunit	  alpha 3 4.86 0 0.00 0 0.00
P08294 Extracellular	  superoxide	  dismutase	  [Cu-­‐Zn] 6 15.42 3 13.33 0 0.00
P08397 Porphobilinogen	  deaminase 6 16.07 6 16.90 5 10.80
P08473 Neprilysin 2 1.47 0 0.00 4 4.67
P08559 Pyruvate	  dehydrogenase	  E1	  component	  subunit	  alpha,	  somatic	  form,	  mitochondrial 13 33.59 8 17.69 5 13.08
P08574 Cytochrome	  c1,	  heme	  protein,	  mitochondrial 23 36.62 17 36.62 11 29.54
P08581 Hepatocyte	  growth	  factor	  receptor 3 2.45 0 0.00 0 0.00
P08582 Melanotransferrin 2 2.17 0 0.00 0 0.00
P08603 Complement	  factor	  H 8 6.90 4 2.27 1 0.97
P08621 U1	  small	  nuclear	  ribonucleoprotein	  70	  kDa 5 5.03 5 5.03 3 5.03
P08631 Tyrosine-­‐protein	  kinase	  HCK 3 3.04 0 0.00 0 0.00
P08670 Vimentin 344 83.05 220 83.69 237 78.33
P08697 Alpha-­‐2-­‐antiplasmin 3 6.72 3 8.76 0 0.00
P08708 40S	  ribosomal	  protein	  S17 21 48.89 20 48.89 20 41.48
P08729 Keratin,	  type	  II	  cytoskeletal	  7 8 5.54 0 0.00 0 0.00
P08758 Annexin	  A5 168 79.69 153 81.88 114 73.75
P08865 40S	  ribosomal	  protein	  SA 39 56.61 35 53.90 31 53.90
P08962 CD63	  antigen 5 6.72 0 0.00 0 0.00
P09012 U1	  small	  nuclear	  ribonucleoprotein	  A 2 6.38 6 15.25 0 0.00
P09104 Gamma-­‐enolase 40 51.15 37 55.53 29 44.70
P09110 3-­‐ketoacyl-­‐CoA	  thiolase,	  peroxisomal 2 9.67 1 3.07 2 7.07
P09211 Glutathione	  S-­‐transferase	  P 101 68.57 64 60.95 83 62.38
P09234 U1	  small	  nuclear	  ribonucleoprotein	  C 2 11.32 0 0.00 0 0.00
P09382 Galectin-­‐1 33 62.96 16 57.04 21 57.04
P09417 Dihydropteridine	  reductase 10 32.79 3 16.39 3 14.34
P09429 High	  mobility	  group	  protein	  B1 9 21.40 7 21.86 1 5.58
P09455 Retinol-­‐binding	  protein	  1 12 45.19 6 33.33 7 24.44
P09467 Fructose-­‐1,6-­‐bisphosphatase	  1 2 8.88 0 0.00 2 9.17
P09486 SPARC 4 12.54 0 0.00 0 0.00
P09488 Glutathione	  S-­‐transferase	  Mu	  1 8 29.82 4 22.48 0 0.00
P09493 Tropomyosin	  alpha-­‐1	  chain 24 24.30 17 17.96 14 15.14
P09496 Clathrin	  light	  chain	  A 5 18.95 0 0.00 4 12.10
P09497 Clathrin	  light	  chain	  B 2 6.11 0 0.00 0 0.00
P09525 Annexin	  A4 35 54.23 22 36.68 17 38.87
P09543 2',3'-­‐cyclic-­‐nucleotide	  3'-­‐phosphodiesterase 15 25.42 8 13.54 7 14.96
P09622 Dihydrolipoyl	  dehydrogenase,	  mitochondrial 21 35.56 18 30.06 17 31.63
P09651 Heterogeneous	  nuclear	  ribonucleoprotein	  A1 45 33.87 39 37.37 24 30.38
P09661 U2	  small	  nuclear	  ribonucleoprotein	  A' 7 24.71 4 16.47 3 12.16
P09669 Cytochrome	  c	  oxidase	  subunit	  6C 3 32.00 3 32.00 0 0.00
P09769 Tyrosine-­‐protein	  kinase	  Fgr 3 3.02 0 0.00 0 0.00
P09874 Poly	  [ADP-­‐ribose]	  polymerase	  1 26 20.12 16 14.40 9 8.88
P09914 Interferon-­‐induced	  protein	  with	  tetratricopeptide	  repeats	  1 7 13.81 0 0.00 2 5.23
P09936 Ubiquitin	  carboxyl-­‐terminal	  hydrolase	  isozyme	  L1 4 8.07 0 0.00 0 0.00
P09960 Leukotriene	  A-­‐4	  hydrolase 15 20.13 9 11.29 9 14.40
P09972 Fructose-­‐bisphosphate	  aldolase	  C 35 40.93 20 36.81 18 29.95
P0C0L4 Complement	  C4-­‐A 56 25.57 41 20.76 42 24.14
P0C0L5 Complement	  C4-­‐B 58 27.12 42 22.31 43 25.69
P0C0S5 Histone	  H2A.Z 17 45.31 17 49.22 7 28.91
P0C0S8 Histone	  H2A	  type	  1 54 47.69 55 37.69 35 37.69
P0C263 Serine/threonine-­‐protein	  kinase	  SBK2 1 4.60 0 0.00 0 0.00
P0C7P4 Putative	  cytochrome	  b-­‐c1	  complex	  subunit	  Rieske-­‐like	  protein	  1 11 34.28 0 0.00 0 0.00
P0C870 JmjC	  domain-­‐containing	  protein	  7 1 4.43 0 0.00 0 0.00
P0CB43 Protein	  FAM203B 7 32.82 4 21.79 5 25.13
P0CG05 Ig	  lambda-­‐2	  chain	  C	  regions 23 75.47 20 55.66 15 59.43
P0CG06 Ig	  lambda-­‐3	  chain	  C	  regions 22 68.87 20 55.66 15 59.43
P0CG38 POTE	  ankyrin	  domain	  family	  member	  I 49 8.84 0 0.00 31 7.72
P0CW22 40S	  ribosomal	  protein	  S17-­‐like 21 48.89 20 48.89 20 41.48
P10155 60	  kDa	  SS-­‐A/Ro	  ribonucleoprotein 11 16.73 4 10.78 7 16.36
P10253 Lysosomal	  alpha-­‐glucosidase 18 21.01 11 13.87 12 15.97
P10301 Ras-­‐related	  protein	  R-­‐Ras 4 16.51 4 16.51 3 5.51
P10412 Histone	  H1.4 44 49.32 29 45.21 19 27.85
P10415 Apoptosis	  regulator	  Bcl-­‐2 3 4.18 3 16.74 4 16.74
P10515 Dihydrolipoyllysine-­‐residue	  acetyltransferase	  component	  of	  pyruvate	  dehydrogenase	  complex,	  mitochondrial14 16.23 6 6.80 9 11.90
P10523 S-­‐arrestin 21 40.74 12 26.91 11 20.74
P10599 Thioredoxin 12 48.57 12 40.00 10 31.43
P10606 Cytochrome	  c	  oxidase	  subunit	  5B,	  mitochondrial 13 38.76 8 31.78 5 37.21
P10619 Lysosomal	  protective	  protein 5 10.63 3 6.88 0 0.00
P10644 cAMP-­‐dependent	  protein	  kinase	  type	  I-­‐alpha	  regulatory	  subunit 16 31.76 13 31.23 9 19.42
P10721 Mast/stem	  cell	  growth	  factor	  receptor	  Kit 2 1.64 1 1.03 1 1.13
P10745 Retinol-­‐binding	  protein	  3 56 38.01 31 28.87 37 31.19
P10768 S-­‐formylglutathione	  hydrolase 20 61.70 13 39.72 15 37.59
P10809 60	  kDa	  heat	  shock	  protein,	  mitochondrial 152 69.46 113 65.62 95 67.19
P10909 Clusterin 20 30.07 17 25.39 17 22.49
P11021 78	  kDa	  glucose-­‐regulated	  protein 99 49.69 76 47.55 72 40.52
P11047 Laminin	  subunit	  gamma-­‐1 10 7.52 4 3.23 7 5.16
P11137 Microtubule-­‐associated	  protein	  2 12 6.62 2 1.42 1 0.77
P11142 Heat	  shock	  cognate	  71	  kDa	  protein 145 54.95 96 46.59 87 43.65
P11166 Solute	  carrier	  family	  2,	  facilitated	  glucose	  transporter	  member	  1 7 6.50 4 4.47 4 3.86
P11172 Uridine	  5'-­‐monophosphate	  synthase 4 10.42 3 8.12 2 5.62
P11177 Pyruvate	  dehydrogenase	  E1	  component	  subunit	  beta,	  mitochondrial 25 40.95 16 33.43 7 17.27
P11182 Lipoamide	  acyltransferase	  component	  of	  branched-­‐chain	  alpha-­‐keto	  acid	  dehydrogenase	  complex,	  mitochondrial3 8.30 0 0.00 0 0.00
P11216 Glycogen	  phosphorylase,	  brain	  form 111 44.72 66 39.62 80 40.81
P11277 Spectrin	  beta	  chain,	  erythrocyte 9 5.62 15 9.83 15 7.49
P11279 Lysosome-­‐associated	  membrane	  glycoprotein	  1 4 8.63 3 6.00 3 6.00
P11310 Medium-­‐chain	  specific	  acyl-­‐CoA	  dehydrogenase,	  mitochondrial 8 17.81 10 20.67 5 15.68
P11387 DNA	  topoisomerase	  1 4 3.40 2 3.27 4 5.49
P11413 Glucose-­‐6-­‐phosphate	  1-­‐dehydrogenase 10 20.97 10 20.58 10 18.06
P11586 C-­‐1-­‐tetrahydrofolate	  synthase,	  cytoplasmic 25 25.45 18 20.75 17 20.43
P11717 Cation-­‐independent	  mannose-­‐6-­‐phosphate	  receptor 6 1.85 1 0.44 0 0.00
P11766 Alcohol	  dehydrogenase	  class-­‐3 12 20.86 9 20.86 7 20.32
P11940 Polyadenylate-­‐binding	  protein	  1 31 38.21 15 17.77 13 15.72
P12004 Proliferating	  cell	  nuclear	  antigen 4 18.01 4 13.03 5 22.99
P12034 Fibroblast	  growth	  factor	  5 1 4.85 0 0.00 0 0.00
P12035 Keratin,	  type	  II	  cytoskeletal	  3 2 1.11 0 0.00 0 0.00
P12081 Histidyl-­‐tRNA	  synthetase,	  cytoplasmic 9 17.29 2 3.34 3 5.50
P12109 Collagen	  alpha-­‐1(VI)	  chain 16 17.90 20 13.42 17 16.05
P12110 Collagen	  alpha-­‐2(VI)	  chain 7 9.32 8 8.44 7 8.64
P12111 Collagen	  alpha-­‐3(VI)	  chain 40 15.36 50 15.68 34 12.12
P12235 ADP/ATP	  translocase	  1 44 53.36 36 46.64 26 49.66
P12236 ADP/ATP	  translocase	  3 49 54.70 37 48.66 31 51.68
P12268 Inosine-­‐5'-­‐monophosphate	  dehydrogenase	  2 7 10.89 5 6.23 4 7.98
P12270 Nucleoprotein	  TPR 21 9.40 11 5.20 14 5.67
P12271 Retinaldehyde-­‐binding	  protein	  1 18 41.96 13 35.02 13 21.77
P12277 Creatine	  kinase	  B-­‐type 25 49.34 20 37.80 20 48.03
P12694 2-­‐oxoisovalerate	  dehydrogenase	  subunit	  alpha,	  mitochondrial 4 12.36 4 11.01 2 8.99
P12814 Alpha-­‐actinin-­‐1 88 44.62 51 32.74 57 38.12
P12830 Cadherin-­‐1 12 14.40 5 8.05 8 12.59
P12931 Proto-­‐oncogene	  tyrosine-­‐protein	  kinase	  Src 3 3.36 2 3.36 0 0.00
P12955 Xaa-­‐Pro	  dipeptidase 31 41.78 20 31.24 20 25.56
P12956 X-­‐ray	  repair	  cross-­‐complementing	  protein	  6 61 43.02 55 42.69 46 40.72
P13010 X-­‐ray	  repair	  cross-­‐complementing	  protein	  5 46 39.48 41 43.58 38 36.89
P13073 Cytochrome	  c	  oxidase	  subunit	  4	  isoform	  1,	  mitochondrial 5 17.16 4 17.16 1 5.92
P13164 Interferon-­‐induced	  transmembrane	  protein	  1 4 27.20 0 0.00 0 0.00
P13473 Lysosome-­‐associated	  membrane	  glycoprotein	  2 4 4.88 6 4.88 4 7.32
P13489 Ribonuclease	  inhibitor 31 45.99 18 30.37 24 34.06
P13639 Elongation	  factor	  2 104 46.62 64 43.47 60 36.60
P13645 Keratin,	  type	  I	  cytoskeletal	  10 3 6.51 17 23.29 0 0.00
P13647 Keratin,	  type	  II	  cytoskeletal	  5 2 1.19 0 0.00 0 0.00
P13667 Protein	  disulfide-­‐isomerase	  A4 28 33.95 18 25.43 15 26.36
P13671 Complement	  component	  C6 1 1.93 1 1.93 1 1.93
P13674 Prolyl	  4-­‐hydroxylase	  subunit	  alpha-­‐1 5 13.86 5 14.04 5 15.73
P13686 Tartrate-­‐resistant	  acid	  phosphatase	  type	  5 6 13.85 4 9.54 4 9.54
P13693 Translationally-­‐controlled	  tumor	  protein 9 51.74 5 28.49 4 15.70
P13716 Delta-­‐aminolevulinic	  acid	  dehydratase 6 19.70 7 15.45 5 11.52
P13760 HLA	  class	  II	  histocompatibility	  antigen,	  DRB1-­‐4	  beta	  chain 6 12.03 3 4.89 2 4.89
P13761 HLA	  class	  II	  histocompatibility	  antigen,	  DRB1-­‐7	  beta	  chain 6 13.16 3 4.89 4 13.53
P13796 Plastin-­‐2 23 26.00 18 25.20 22 30.62
P13797 Plastin-­‐3 41 35.40 23 26.03 29 21.59
P13798 Acylamino-­‐acid-­‐releasing	  enzyme 8 13.11 8 10.11 7 7.10
P13804 Electron	  transfer	  flavoprotein	  subunit	  alpha,	  mitochondrial 33 54.05 19 35.44 18 31.53
P13807 Glycogen	  [starch]	  synthase,	  muscle 14 17.50 14 15.88 9 14.65
P13861 cAMP-­‐dependent	  protein	  kinase	  type	  II-­‐alpha	  regulatory	  subunit 19 32.18 11 29.46 12 25.74
P13929 Beta-­‐enolase 31 38.94 22 28.80 0 0.00
P13987 CD59	  glycoprotein 10 17.19 4 15.63 7 15.63
P14136 Glial	  fibrillary	  acidic	  protein 24 22.69 19 16.67 0 0.00
P14174 Macrophage	  migration	  inhibitory	  factor 30 52.17 19 48.70 16 51.30
P14209 CD99	  antigen 4 7.57 2 7.57 0 0.00
P14314 Glucosidase	  2	  subunit	  beta 25 30.30 15 23.11 18 25.00
P14324 Farnesyl	  pyrophosphate	  synthase 5 7.16 3 7.16 3 7.16
P14406 Cytochrome	  c	  oxidase	  subunit	  7A2,	  mitochondrial 7 27.71 9 27.71 7 27.71
P14543 Nidogen-­‐1 2 2.33 3 2.41 0 0.00
P14550 Alcohol	  dehydrogenase	  [NADP+] 27 54.15 24 41.23 14 25.85
P14618 Pyruvate	  kinase	  isozymes	  M1/M2 101 71.56 83 65.35 74 59.51
P14625 Endoplasmin 76 41.34 49 33.37 44 30.01
P14672 Solute	  carrier	  family	  2,	  facilitated	  glucose	  transporter	  member	  4 2 5.11 0 0.00 0 0.00
P14678 Small	  nuclear	  ribonucleoprotein-­‐associated	  proteins	  B	  and	  B' 7 28.33 6 18.33 3 8.75
P14679 Tyrosinase 2 8.13 3 10.02 2 6.99
P14854 Cytochrome	  c	  oxidase	  subunit	  6B1 6 45.35 3 26.74 3 13.95
P14866 Heterogeneous	  nuclear	  ribonucleoprotein	  L 28 38.20 13 18.34 15 26.83
P14868 Aspartyl-­‐tRNA	  synthetase,	  cytoplasmic 27 37.52 19 27.35 14 21.96
P14927 Cytochrome	  b-­‐c1	  complex	  subunit	  7 10 30.63 10 30.63 4 20.72
P15104 Glutamine	  synthetase 2 9.92 5 9.65 4 9.65
P15121 Aldose	  reductase 13 30.38 5 18.35 5 17.41
P15153 Ras-­‐related	  C3	  botulinum	  toxin	  substrate	  2 4 15.10 4 19.79 5 23.96
P15289 Arylsulfatase	  A 1 3.35 4 6.51 2 3.35
P15311 Ezrin 32 34.47 23 28.67 25 28.50
P15531 Nucleoside	  diphosphate	  kinase	  A 26 63.16 19 58.55 12 46.05
P15559 NAD(P)H	  dehydrogenase	  [quinone]	  1 5 17.15 1 7.30 4 21.53
P15586 N-­‐acetylglucosamine-­‐6-­‐sulfatase 10 14.13 2 3.80 4 10.87
P15735 Phosphorylase	  b	  kinase	  gamma	  catalytic	  chain,	  testis/liver	  isoform 2 7.64 0 0.00 0 0.00
P15880 40S	  ribosomal	  protein	  S2 11 18.09 14 22.87 10 24.23
P15927 Replication	  protein	  A	  32	  kDa	  subunit 2 12.59 0 0.00 0 0.00
P16070 CD44	  antigen 29 12.13 16 9.43 11 6.87
P16083 Ribosyldihydronicotinamide	  dehydrogenase	  [quinone] 2 11.69 0 0.00 1 7.79
P16104 Histone	  H2A.x 58 41.96 61 37.06 41 37.06
P16152 Carbonyl	  reductase	  [NADPH]	  1 45 67.51 36 67.51 35 57.76
P16219 Short-­‐chain	  specific	  acyl-­‐CoA	  dehydrogenase,	  mitochondrial 14 35.19 10 25.49 10 24.03
P16278 Beta-­‐galactosidase 6 12.41 2 4.28 3 7.09
P16401 Histone	  H1.5 22 37.61 18 36.28 14 30.97
P16403 Histone	  H1.2 39 43.66 28 43.66 19 28.64
P16435 NADPH-­‐-­‐cytochrome	  P450	  reductase 10 17.87 4 10.64 4 7.24
P16615 Sarcoplasmic/endoplasmic	  reticulum	  calcium	  ATPase	  2 28 23.32 16 14.11 17 13.72
P16930 Fumarylacetoacetase 6 18.85 2 5.01 0 0.00
P16949 Stathmin 6 29.53 9 34.90 5 22.82
P16989 DNA-­‐binding	  protein	  A 8 18.82 7 20.70 8 19.62
P17066 Heat	  shock	  70	  kDa	  protein	  6 50 20.53 0 0.00 0 0.00
P17096 High	  mobility	  group	  protein	  HMG-­‐I/HMG-­‐Y 5 23.36 3 22.43 3 23.36
P17152 Transmembrane	  protein	  11,	  mitochondrial 3 12.50 2 8.33 1 8.33
P17174 Aspartate	  aminotransferase,	  cytoplasmic 21 38.01 18 27.12 15 24.94
P17480 Nucleolar	  transcription	  factor	  1 12 12.30 3 5.63 4 5.89
P17540 Creatine	  kinase	  S-­‐type,	  mitochondrial 9 30.07 0 0.00 3 12.41
P17568 NADH	  dehydrogenase	  [ubiquinone]	  1	  beta	  subcomplex	  subunit	  7 4 25.55 1 10.95 1 7.30
P17612 cAMP-­‐dependent	  protein	  kinase	  catalytic	  subunit	  alpha 3 12.25 0 0.00 3 9.69
P17643 5,6-­‐dihydroxyindole-­‐2-­‐carboxylic	  acid	  oxidase 24 27.56 7 11.36 23 24.39
P17655 Calpain-­‐2	  catalytic	  subunit 17 22.43 9 15.29 7 8.71
P17812 CTP	  synthase	  1 3 7.78 1 2.71 2 4.74
P17844 Probable	  ATP-­‐dependent	  RNA	  helicase	  DDX5 25 24.10 18 21.82 11 17.75
P17858 6-­‐phosphofructokinase,	  liver	  type 31 30.38 23 33.97 19 17.31
P17900 Ganglioside	  GM2	  activator 1 10.36 2 10.36 1 10.36
P17931 Galectin-­‐3 11 22.00 6 16.00 8 16.00
P17980 26S	  protease	  regulatory	  subunit	  6A 13 32.57 9 22.10 15 21.18
P17987 T-­‐complex	  protein	  1	  subunit	  alpha 39 45.32 26 33.81 25 42.81
P18031 Tyrosine-­‐protein	  phosphatase	  non-­‐receptor	  type	  1 5 17.24 0 0.00 3 12.64
P18077 60S	  ribosomal	  protein	  L35a 1 8.18 1 6.36 0 0.00
P18085 ADP-­‐ribosylation	  factor	  4 24 47.78 19 38.89 18 41.11
P18124 60S	  ribosomal	  protein	  L7 15 39.92 13 32.26 11 22.18
P18135 Ig	  kappa	  chain	  V-­‐III	  region	  HAH 5 33.33 9 26.36 9 33.33
P18136 Ig	  kappa	  chain	  V-­‐III	  region	  HIC 5 33.33 9 26.36 9 33.33
P18206 Vinculin 38 22.75 17 16.14 18 14.99
P18428 Lipopolysaccharide-­‐binding	  protein 1 3.95 0 0.00 0 0.00
P18463 HLA	  class	  I	  histocompatibility	  antigen,	  B-­‐37	  alpha	  chain 16 26.52 7 17.40 11 23.76
P18583 Protein	  SON 1 0.58 1 0.58 1 0.58
P18615 Negative	  elongation	  factor	  E 1 3.42 1 4.74 0 0.00
P18621 60S	  ribosomal	  protein	  L17 5 21.74 7 21.74 5 8.70
P18669 Phosphoglycerate	  mutase	  1 37 62.99 27 62.99 24 58.66
P18754 Regulator	  of	  chromosome	  condensation 9 27.08 4 15.44 7 16.86
P18858 DNA	  ligase	  1 2 1.52 0 0.00 1 1.52
P18859 ATP	  synthase-­‐coupling	  factor	  6,	  mitochondrial 4 40.74 0 0.00 0 0.00
P19013 Keratin,	  type	  II	  cytoskeletal	  4 4 3.18 0 0.00 0 0.00
P19105 Myosin	  regulatory	  light	  chain	  12A 22 68.42 12 35.09 13 36.26
P19174 1-­‐phosphatidylinositol-­‐4,5-­‐bisphosphate	  phosphodiesterase	  gamma-­‐1 3 3.02 0 0.00 0 0.00
P19320 Vascular	  cell	  adhesion	  protein	  1 1 2.44 0 0.00 0 0.00
P19338 Nucleolin 71 32.54 62 28.87 54 23.38
P19367 Hexokinase-­‐1 37 25.19 30 19.63 26 15.70
P19388 DNA-­‐directed	  RNA	  polymerases	  I,	  II,	  and	  III	  subunit	  RPABC1 2 8.09 0 0.00 0 0.00
P19404 NADH	  dehydrogenase	  [ubiquinone]	  flavoprotein	  2,	  mitochondrial 10 17.67 6 13.25 5 9.24
P19447 TFIIH	  basal	  transcription	  factor	  complex	  helicase	  XPB	  subunit 2 4.22 0 0.00 0 0.00
P19525 Interferon-­‐induced,	  double-­‐stranded	  RNA-­‐activated	  protein	  kinase 5 6.53 1 2.18 1 2.18
P19623 Spermidine	  synthase 4 10.26 5 17.55 3 7.62
P19634 Sodium/hydrogen	  exchanger	  1 3 3.44 0 0.00 1 1.59
P19652 Alpha-­‐1-­‐acid	  glycoprotein	  2 7 22.89 0 0.00 0 0.00
P19784 Casein	  kinase	  II	  subunit	  alpha' 3 7.14 0 0.00 2 8.86
P19823 Inter-­‐alpha-­‐trypsin	  inhibitor	  heavy	  chain	  H2 9 11.21 9 7.72 1 1.59
P19827 Inter-­‐alpha-­‐trypsin	  inhibitor	  heavy	  chain	  H1 7 8.67 11 10.43 9 10.43
P19838 Nuclear	  factor	  NF-­‐kappa-­‐B	  p105	  subunit 2 3.82 2 3.82 4 5.16
P19971 Thymidine	  phosphorylase 22 32.16 16 26.14 15 23.86
P20020 Plasma	  membrane	  calcium-­‐transporting	  ATPase	  1 4 4.69 0 0.00 4 4.05
P20039 HLA	  class	  II	  histocompatibility	  antigen,	  DRB1-­‐11	  beta	  chain 8 22.18 5 16.92 4 18.42
P20042 Eukaryotic	  translation	  initiation	  factor	  2	  subunit	  2 9 23.72 6 20.12 5 13.51
P20073 Annexin	  A7 13 18.44 4 8.20 7 12.30
P20231 Tryptase	  beta-­‐2 6 13.09 3 9.82 2 7.64
P20290 Transcription	  factor	  BTF3 2 22.82 6 32.04 5 22.82
P20338 Ras-­‐related	  protein	  Rab-­‐4A 5 20.66 0 0.00 0 0.00
P20340 Ras-­‐related	  protein	  Rab-­‐6A 9 33.17 4 23.08 4 16.35
P20591 Interferon-­‐induced	  GTP-­‐binding	  protein	  Mx1 57 47.13 5 11.78 1 2.27
P20618 Proteasome	  subunit	  beta	  type-­‐1 13 32.37 10 35.27 12 31.54
P20645 Cation-­‐dependent	  mannose-­‐6-­‐phosphate	  receptor 9 26.35 4 12.64 6 19.13
P20674 Cytochrome	  c	  oxidase	  subunit	  5A,	  mitochondrial 26 65.33 22 65.33 6 36.00
P20700 Lamin-­‐B1 38 40.61 25 29.69 16 21.84
P20774 Mimecan 5 20.47 7 20.47 4 13.09
P20810 Calpastatin 11 18.36 9 11.16 9 10.45
P20936 Ras	  GTPase-­‐activating	  protein	  1 5 5.64 0 0.00 0 0.00
P20962 Parathymosin 11 22.55 9 22.55 3 21.57
P21266 Glutathione	  S-­‐transferase	  Mu	  3 17 35.56 17 35.11 14 39.11
P21281 V-­‐type	  proton	  ATPase	  subunit	  B,	  brain	  isoform 43 53.03 36 57.34 37 50.88
P21283 V-­‐type	  proton	  ATPase	  subunit	  C	  1 13 21.20 7 21.20 7 19.90
P21291 Cysteine	  and	  glycine-­‐rich	  protein	  1 12 36.79 9 35.75 5 32.12
P21333 Filamin-­‐A 169 43.18 98 33.62 124 35.59
P21359 Neurofibromin 5 2.61 3 1.16 3 1.62
P21399 Cytoplasmic	  aconitate	  hydratase 14 19.69 13 20.92 13 19.57
P21589 5'-­‐nucleotidase 8 20.38 4 10.80 0 0.00
P21796 Voltage-­‐dependent	  anion-­‐selective	  channel	  protein	  1 40 75.27 28 75.27 26 51.59
P21810 Biglycan 11 19.57 16 17.12 9 17.12
P21912 Succinate	  dehydrogenase	  [ubiquinone]	  iron-­‐sulfur	  subunit,	  mitochondrial 11 23.93 9 18.57 3 12.50
P21953 2-­‐oxoisovalerate	  dehydrogenase	  subunit	  beta,	  mitochondrial 3 10.46 2 7.14 3 10.46
P21964 Catechol	  O-­‐methyltransferase 31 61.25 19 44.65 20 48.71
P21980 Protein-­‐glutamine	  gamma-­‐glutamyltransferase	  2 17 17.03 16 14.99 15 16.89
P22033 Methylmalonyl-­‐CoA	  mutase,	  mitochondrial 1 1.47 3 5.33 1 2.13
P22059 Oxysterol-­‐binding	  protein	  1 3 5.20 3 5.20 2 5.20
P22061 Protein-­‐L-­‐isoaspartate(D-­‐aspartate)	  O-­‐methyltransferase 14 54.63 6 35.68 4 24.23
P22087 rRNA	  2'-­‐O-­‐methyltransferase	  fibrillarin 15 49.84 16 53.89 6 24.92
P22102 Trifunctional	  purine	  biosynthetic	  protein	  adenosine-­‐3 25 25.05 16 16.63 11 14.75
P22234 Multifunctional	  protein	  ADE2 10 22.35 6 16.24 10 16.00
P22314 Ubiquitin-­‐like	  modifier-­‐activating	  enzyme	  1 61 39.32 57 33.08 48 29.96
P22392 Nucleoside	  diphosphate	  kinase	  B 30 75.00 25 70.39 14 63.82
P22570 NADPH:adrenodoxin	  oxidoreductase,	  mitochondrial 17 30.14 5 14.46 5 12.22
P22626 Heterogeneous	  nuclear	  ribonucleoproteins	  A2/B1 63 52.97 46 52.69 38 48.44
P22695 Cytochrome	  b-­‐c1	  complex	  subunit	  2,	  mitochondrial 33 44.15 27 38.41 19 34.44
P22914 Beta-­‐crystallin	  S 1 6.18 0 0.00 0 0.00
P23246 Splicing	  factor,	  proline-­‐	  and	  glutamine-­‐rich 38 27.02 26 17.82 21 16.27
P23258 Tubulin	  gamma-­‐1	  chain 13 25.50 8 28.38 8 26.39
P23284 Peptidyl-­‐prolyl	  cis-­‐trans	  isomerase	  B 25 47.22 18 39.81 16 36.57
P23297 Protein	  S100-­‐A1 35 45.74 26 45.74 16 38.30
P23368 NAD-­‐dependent	  malic	  enzyme,	  mitochondrial 10 15.41 3 6.16 0 0.00
P23381 Tryptophanyl-­‐tRNA	  synthetase,	  cytoplasmic 81 66.03 34 43.31 34 42.68
P23396 40S	  ribosomal	  protein	  S3 25 48.56 24 46.91 24 41.56
P23497 Nuclear	  autoantigen	  Sp-­‐100 5 7.51 2 2.27 2 2.96
P23526 Adenosylhomocysteinase 43 36.34 28 29.63 25 23.38
P23527 Histone	  H2B	  type	  1-­‐O 59 67.46 60 62.70 41 57.14
P23528 Cofilin-­‐1 53 61.45 46 56.02 40 50.60
P23588 Eukaryotic	  translation	  initiation	  factor	  4B 8 6.22 0 0.00 2 2.13
P23610 Factor	  VIII	  intron	  22	  protein 2 9.97 0 0.00 1 6.20
P23634 Plasma	  membrane	  calcium-­‐transporting	  ATPase	  4 17 15.87 9 11.76 9 8.06
P23786 Carnitine	  O-­‐palmitoyltransferase	  2,	  mitochondrial 6 13.22 6 12.92 1 1.52
P24534 Elongation	  factor	  1-­‐beta 17 42.22 5 28.00 5 12.44
P24539 ATP	  synthase	  subunit	  b,	  mitochondrial 13 31.64 4 13.67 4 13.67
P24666 Low	  molecular	  weight	  phosphotyrosine	  protein	  phosphatase 5 32.28 4 24.68 4 32.28
P24752 Acetyl-­‐CoA	  acetyltransferase,	  mitochondrial 30 48.71 26 43.09 17 38.17
P24844 Myosin	  regulatory	  light	  polypeptide	  9 12 44.19 8 34.30 0 0.00
P24941 Cyclin-­‐dependent	  kinase	  2 9 20.47 4 12.08 5 12.08
P25311 Zinc-­‐alpha-­‐2-­‐glycoprotein 15 32.89 12 32.89 13 23.15
P25325 3-­‐mercaptopyruvate	  sulfurtransferase 10 32.32 13 40.40 7 34.68
P25398 40S	  ribosomal	  protein	  S12 18 45.45 8 32.58 7 39.39
P25685 DnaJ	  homolog	  subfamily	  B	  member	  1 6 15.59 2 3.82 1 3.82
P25705 ATP	  synthase	  subunit	  alpha,	  mitochondrial 134 58.59 91 49.01 88 48.82
P25786 Proteasome	  subunit	  alpha	  type-­‐1 17 45.25 16 50.95 9 36.50
P25787 Proteasome	  subunit	  alpha	  type-­‐2 17 48.29 14 38.89 13 38.46
P25788 Proteasome	  subunit	  alpha	  type-­‐3 9 24.31 7 14.12 6 14.12
P25789 Proteasome	  subunit	  alpha	  type-­‐4 7 19.16 6 19.54 4 16.09
P26006 Integrin	  alpha-­‐3 6 4.76 2 1.90 0 0.00
P26038 Moesin 64 52.34 43 44.54 46 41.77
P26196 Probable	  ATP-­‐dependent	  RNA	  helicase	  DDX6 10 21.33 5 7.66 6 9.73
P26358 DNA	  (cytosine-­‐5)-­‐methyltransferase	  1 1 0.87 0 0.00 0 0.00
P26368 Splicing	  factor	  U2AF	  65	  kDa	  subunit 9 23.37 6 20.00 5 11.58
P26373 60S	  ribosomal	  protein	  L13 12 41.71 3 13.74 7 22.27
P26440 Isovaleryl-­‐CoA	  dehydrogenase,	  mitochondrial 18 28.61 6 18.20 7 15.60
P26447 Protein	  S100-­‐A4 4 27.72 0 0.00 0 0.00
P26572 Alpha-­‐1,3-­‐mannosyl-­‐glycoprotein	  2-­‐beta-­‐N-­‐acetylglucosaminyltransferase 5 17.30 0 0.00 3 5.62
P26599 Polypyrimidine	  tract-­‐binding	  protein	  1 30 37.48 34 33.90 21 22.79
P26639 Threonyl-­‐tRNA	  synthetase,	  cytoplasmic 11 7.61 4 3.04 6 7.88
P26640 Valyl-­‐tRNA	  synthetase 57 32.91 39 24.21 32 20.81
P26641 Elongation	  factor	  1-­‐gamma 32 32.27 19 26.54 17 24.71
P26885 Peptidyl-­‐prolyl	  cis-­‐trans	  isomerase	  FKBP2 7 38.73 5 9.16 8 54.23
P27105 Erythrocyte	  band	  7	  integral	  membrane	  protein 15 40.97 8 34.72 9 35.42
P27144 Adenylate	  kinase	  isoenzyme	  4,	  mitochondrial 2 21.08 2 9.87 0 0.00
P27169 Serum	  paraoxonase/arylesterase	  1 2 11.27 2 11.27 1 6.76
P27348 14-­‐3-­‐3	  protein	  theta 50 55.92 35 40.00 37 47.35
P27635 60S	  ribosomal	  protein	  L10 12 33.18 11 33.18 10 27.57
P27694 Replication	  protein	  A	  70	  kDa	  DNA-­‐binding	  subunit 7 16.07 5 12.99 4 7.30
P27695 DNA-­‐(apurinic	  or	  apyrimidinic	  site)	  lyase 39 66.04 23 45.28 15 39.94
P27701 CD82	  antigen 2 10.49 0 0.00 0 0.00
P27708 CAD	  protein 17 7.64 15 7.55 16 9.53
P27797 Calreticulin 31 45.08 18 29.26 14 25.66
P27816 Microtubule-­‐associated	  protein	  4 19 16.32 13 15.63 11 11.11
P27824 Calnexin 44 30.41 25 16.89 24 20.61
P27987 Inositol-­‐trisphosphate	  3-­‐kinase	  B 6 10.04 0 0.00 0 0.00
P28062 Proteasome	  subunit	  beta	  type-­‐8 11 21.38 7 16.30 3 5.07
P28065 Proteasome	  subunit	  beta	  type-­‐9 3 14.16 0 0.00 0 0.00
P28066 Proteasome	  subunit	  alpha	  type-­‐5 17 30.71 13 29.88 10 26.56
P28070 Proteasome	  subunit	  beta	  type-­‐4 10 26.89 5 15.15 8 23.11
P28072 Proteasome	  subunit	  beta	  type-­‐6 3 8.79 0 0.00 0 0.00
P28074 Proteasome	  subunit	  beta	  type-­‐5 7 25.10 6 21.29 1 6.08
P28161 Glutathione	  S-­‐transferase	  Mu	  2 8 37.61 6 24.31 5 18.35
P28288 ATP-­‐binding	  cassette	  sub-­‐family	  D	  member	  3 2 4.40 3 7.89 4 10.02
P28289 Tropomodulin-­‐1 2 10.58 1 4.74 2 10.58
P28331 NADH-­‐ubiquinone	  oxidoreductase	  75	  kDa	  subunit,	  mitochondrial 34 40.72 23 29.44 24 30.54
P28340 DNA	  polymerase	  delta	  catalytic	  subunit 2 2.62 1 1.26 1 1.26
P28482 Mitogen-­‐activated	  protein	  kinase	  1 15 27.78 5 15.28 8 22.50
P28827 Receptor-­‐type	  tyrosine-­‐protein	  phosphatase	  mu 2 1.93 0 0.00 2 2.20
P28838 Cytosol	  aminopeptidase 52 52.99 26 36.99 23 34.30
P29144 Tripeptidyl-­‐peptidase	  2 2 1.92 4 5.93 2 2.08
P29218 Inositol	  monophosphatase	  1 13 37.91 6 22.38 6 18.05
P29401 Transketolase 54 49.44 51 38.04 39 29.21
P29590 Protein	  PML 14 13.15 4 5.33 6 6.80
P29692 Elongation	  factor	  1-­‐delta 33 49.47 15 36.30 15 35.59
P29728 2'-­‐5'-­‐oligoadenylate	  synthase	  2 3 5.29 0 0.00 0 0.00
P29762 Cellular	  retinoic	  acid-­‐binding	  protein	  1 3 34.31 2 24.09 0 0.00
P29966 Myristoylated	  alanine-­‐rich	  C-­‐kinase	  substrate 36 47.89 22 43.37 20 40.06
P29992 Guanine	  nucleotide-­‐binding	  protein	  subunit	  alpha-­‐11 6 25.07 5 18.94 5 18.66
P30038 Delta-­‐1-­‐pyrroline-­‐5-­‐carboxylate	  dehydrogenase,	  mitochondrial 11 14.39 8 8.88 5 7.28
P30040 Endoplasmic	  reticulum	  resident	  protein	  29 18 37.93 14 37.93 10 27.20
P30041 Peroxiredoxin-­‐6 38 68.30 23 57.59 24 58.04
P30042 ES1	  protein	  homolog,	  mitochondrial 28 49.25 18 41.42 13 35.07
P30043 Flavin	  reductase	  (NADPH) 15 39.32 18 50.00 15 46.60
P30044 Peroxiredoxin-­‐5,	  mitochondrial 35 39.72 25 39.25 23 45.79
P30046 D-­‐dopachrome	  decarboxylase 11 55.08 5 36.44 4 29.66
P30048 Thioredoxin-­‐dependent	  peroxide	  reductase,	  mitochondrial 40 47.66 19 44.53 19 32.42
P30049 ATP	  synthase	  subunit	  delta,	  mitochondrial 13 36.90 9 28.57 7 28.57
P30050 60S	  ribosomal	  protein	  L12 22 50.30 19 45.45 10 45.45
P30084 Enoyl-­‐CoA	  hydratase,	  mitochondrial 18 45.17 11 33.79 13 43.45
P30085 UMP-­‐CMP	  kinase 16 46.43 12 27.55 7 24.49
P30086 Phosphatidylethanolamine-­‐binding	  protein	  1 67 78.07 39 68.45 36 68.45
P30101 Protein	  disulfide-­‐isomerase	  A3 98 59.01 72 53.07 60 51.88
P30153 Serine/threonine-­‐protein	  phosphatase	  2A	  65	  kDa	  regulatory	  subunit	  A	  alpha	  isoform 37 41.43 25 22.41 23 28.18
P30405 Peptidyl-­‐prolyl	  cis-­‐trans	  isomerase	  F,	  mitochondrial 3 21.74 1 14.01 0 0.00
P30419 Glycylpeptide	  N-­‐tetradecanoyltransferase	  1 5 11.49 5 10.28 4 7.66
P30447 HLA	  class	  I	  histocompatibility	  antigen,	  A-­‐23	  alpha	  chain 16 20.00 0 0.00 3 7.40
P30460 HLA	  class	  I	  histocompatibility	  antigen,	  B-­‐8	  alpha	  chain 21 32.32 8 17.40 14 23.76
P30462 HLA	  class	  I	  histocompatibility	  antigen,	  B-­‐14	  alpha	  chain 18 29.56 7 17.40 12 25.97
P30475 HLA	  class	  I	  histocompatibility	  antigen,	  B-­‐39	  alpha	  chain 15 26.24 5 14.09 9 22.65
P30479 HLA	  class	  I	  histocompatibility	  antigen,	  B-­‐41	  alpha	  chain 19 29.83 7 17.40 11 17.40
P30480 HLA	  class	  I	  histocompatibility	  antigen,	  B-­‐42	  alpha	  chain 21 32.32 8 17.40 30 25.97
P30481 HLA	  class	  I	  histocompatibility	  antigen,	  B-­‐44	  alpha	  chain 13 23.76 4 14.09 5 14.09
P30483 HLA	  class	  I	  histocompatibility	  antigen,	  B-­‐45	  alpha	  chain 11 20.72 4 14.09 5 14.09
P30485 HLA	  class	  I	  histocompatibility	  antigen,	  B-­‐47	  alpha	  chain 12 23.76 4 14.09 6 17.40
P30486 HLA	  class	  I	  histocompatibility	  antigen,	  B-­‐48	  alpha	  chain 13 25.41 4 6.63 12 22.38
P30487 HLA	  class	  I	  histocompatibility	  antigen,	  B-­‐49	  alpha	  chain 13 24.03 4 14.09 12 17.40
P30488 HLA	  class	  I	  histocompatibility	  antigen,	  B-­‐50	  alpha	  chain 13 24.03 4 14.09 12 17.40
P30519 Heme	  oxygenase	  2 8 21.20 4 17.72 4 21.84
P30520 Adenylosuccinate	  synthetase	  isozyme	  2 5 17.54 4 15.13 1 3.07
P30533 Alpha-­‐2-­‐macroglobulin	  receptor-­‐associated	  protein 11 13.45 4 8.12 5 8.12
P30536 Translocator	  protein 3 13.61 3 18.34 0 0.00
P30566 Adenylosuccinate	  lyase 6 16.12 0 0.00 0 0.00
P30622 CAP-­‐Gly	  domain-­‐containing	  linker	  protein	  1 6 4.31 0 0.00 2 2.02
P30626 Sorcin 7 27.78 4 18.69 5 24.24
P30711 Glutathione	  S-­‐transferase	  theta-­‐1 11 30.83 4 20.00 5 30.83
P30740 Leukocyte	  elastase	  inhibitor 9 14.78 7 25.59 6 14.78
P30837 Aldehyde	  dehydrogenase	  X,	  mitochondrial 45 46.23 37 36.56 31 32.88
P31040 Succinate	  dehydrogenase	  [ubiquinone]	  flavoprotein	  subunit,	  mitochondrial 34 34.94 17 27.26 14 18.98
P31146 Coronin-­‐1A 2 3.47 0 0.00 2 3.47
P31150 Rab	  GDP	  dissociation	  inhibitor	  alpha 18 28.86 0 0.00 12 26.40
P31153 S-­‐adenosylmethionine	  synthase	  isoform	  type-­‐2 12 24.05 6 18.99 7 14.68
P31689 DnaJ	  homolog	  subfamily	  A	  member	  1 8 24.94 0 0.00 0 0.00
P31930 Cytochrome	  b-­‐c1	  complex	  subunit	  1,	  mitochondrial 40 47.92 37 47.92 21 33.75
P31937 3-­‐hydroxyisobutyrate	  dehydrogenase,	  mitochondrial 32 46.43 24 38.69 28 38.99
P31939 Bifunctional	  purine	  biosynthesis	  protein	  PURH 47 44.93 29 35.30 36 43.92
P31942 Heterogeneous	  nuclear	  ribonucleoprotein	  H3 18 23.99 14 19.94 10 13.87
P31943 Heterogeneous	  nuclear	  ribonucleoprotein	  H 32 36.08 33 34.52 24 32.07
P31946 14-­‐3-­‐3	  protein	  beta/alpha 46 63.41 31 38.21 32 41.87
P31948 Stress-­‐induced-­‐phosphoprotein	  1 31 34.62 18 20.99 16 17.50
P31949 Protein	  S100-­‐A11 11 40.95 11 49.52 9 49.52
P32119 Peroxiredoxin-­‐2 32 32.32 30 40.40 26 31.82
P32189 Glycerol	  kinase 2 4.47 0 0.00 0 0.00
P32322 Pyrroline-­‐5-­‐carboxylate	  reductase	  1,	  mitochondrial 2 9.72 1 4.08 0 0.00
P32455 Interferon-­‐induced	  guanylate-­‐binding	  protein	  1 4 6.08 2 2.70 0 0.00
P32456 Interferon-­‐induced	  guanylate-­‐binding	  protein	  2 2 2.71 2 2.71 0 0.00
P32969 60S	  ribosomal	  protein	  L9 11 47.92 9 42.71 4 29.17
P33121 Long-­‐chain-­‐fatty-­‐acid-­‐-­‐CoA	  ligase	  1 17 22.78 6 11.60 11 19.91
P33176 Kinesin-­‐1	  heavy	  chain 25 28.35 10 10.28 10 9.35
P33240 Cleavage	  stimulation	  factor	  subunit	  2 2 5.20 4 8.67 2 4.68
P33316 Deoxyuridine	  5'-­‐triphosphate	  nucleotidohydrolase,	  mitochondrial 16 46.03 6 24.60 6 20.63
P33778 Histone	  H2B	  type	  1-­‐B 59 67.46 60 62.70 41 57.14
P33993 DNA	  replication	  licensing	  factor	  MCM7 2 3.62 0 0.00 0 0.00
P34059 N-­‐acetylgalactosamine-­‐6-­‐sulfatase 1 1.72 2 3.26 0 0.00
P34896 Serine	  hydroxymethyltransferase,	  cytosolic 15 28.36 7 20.91 10 24.22
P34897 Serine	  hydroxymethyltransferase,	  mitochondrial 12 18.45 0 0.00 4 11.51
P34913 Epoxide	  hydrolase	  2 3 12.07 6 12.79 5 10.99
P34932 Heat	  shock	  70	  kDa	  protein	  4 36 33.57 26 25.83 24 24.40
P35052 Glypican-­‐1 1 3.23 0 0.00 0 0.00
P35221 Catenin	  alpha-­‐1 51 40.84 19 15.34 27 27.59
P35222 Catenin	  beta-­‐1 30 33.80 20 24.58 21 26.25
P35232 Prohibitin 64 75.74 48 76.10 30 64.71
P35241 Radixin 19 16.98 11 13.21 15 17.84
P35244 Replication	  protein	  A	  14	  kDa	  subunit 3 14.05 2 14.05 2 14.05
P35251 Replication	  factor	  C	  subunit	  1 1 0.87 1 0.96 0 0.00
P35268 60S	  ribosomal	  protein	  L22 7 18.75 6 18.75 6 18.75
P35270 Sepiapterin	  reductase 16 55.17 7 24.90 6 20.69
P35527 Keratin,	  type	  I	  cytoskeletal	  9 5 12.68 4 8.83 0 0.00
P35555 Fibrillin-­‐1 6 1.99 1 0.31 3 1.50
P35573 Glycogen	  debranching	  enzyme 18 16.45 9 6.72 7 6.20
P35579 Myosin-­‐9 255 48.21 197 43.27 191 40.26
P35580 Myosin-­‐10 136 38.56 84 25.15 90 29.45
P35606 Coatomer	  subunit	  beta' 12 15.78 7 9.82 10 13.58
P35610 Sterol	  O-­‐acyltransferase	  1 1 2.91 2 3.82 1 2.91
P35611 Alpha-­‐adducin 4 7.06 0 0.00 0 0.00
P35613 Basigin 10 12.47 8 14.55 9 15.84
P35658 Nuclear	  pore	  complex	  protein	  Nup214 6 3.40 3 2.11 0 0.00
P35659 Protein	  DEK 4 6.40 3 6.13 3 6.13
P35749 Myosin-­‐11 52 11.41 44 14.15 40 10.95
P35813 Protein	  phosphatase	  1A 5 10.21 2 7.07 3 4.71
P35914 Hydroxymethylglutaryl-­‐CoA	  lyase,	  mitochondrial 7 18.77 7 18.77 4 12.00
P35998 26S	  protease	  regulatory	  subunit	  7 14 27.02 7 17.09 7 21.48
P36269 Gamma-­‐glutamyltransferase	  5 6 13.82 5 8.36 4 8.36
P36405 ADP-­‐ribosylation	  factor-­‐like	  protein	  3 4 24.73 3 21.43 2 18.13
P36507 Dual	  specificity	  mitogen-­‐activated	  protein	  kinase	  kinase	  2 11 32.00 0 0.00 2 10.75
P36542 ATP	  synthase	  subunit	  gamma,	  mitochondrial 15 27.85 12 18.79 7 15.44
P36543 V-­‐type	  proton	  ATPase	  subunit	  E	  1 12 25.22 10 15.93 6 14.60
P36551 Coproporphyrinogen-­‐III	  oxidase,	  mitochondrial 5 11.23 0 0.00 0 0.00
P36578 60S	  ribosomal	  protein	  L4 40 33.72 31 28.57 23 31.62
P36776 Lon	  protease	  homolog,	  mitochondrial 30 24.40 16 12.10 14 12.20
P36871 Phosphoglucomutase-­‐1 12 29.18 7 18.51 9 20.82
P36915 Guanine	  nucleotide-­‐binding	  protein-­‐like	  1 10 15.49 3 4.45 4 9.06
P36954 DNA-­‐directed	  RNA	  polymerase	  II	  subunit	  RPB9 3 18.40 3 18.40 0 0.00
P36955 Pigment	  epithelium-­‐derived	  factor 21 34.93 16 26.79 18 32.54
P36957 Dihydrolipoyllysine-­‐residue	  succinyltransferase	  component	  of	  2-­‐oxoglutarate	  dehydrogenase	  complex,	  mitochondrial23 35.10 16 22.74 13 22.74
P36959 GMP	  reductase	  1 12 33.62 5 4.35 5 9.27
P36969 Phospholipid	  hydroperoxide	  glutathione	  peroxidase,	  mitochondrial 1 7.11 0 0.00 0 0.00
P37108 Signal	  recognition	  particle	  14	  kDa	  protein 3 17.65 0 0.00 0 0.00
P37198 Nuclear	  pore	  glycoprotein	  p62 10 20.69 7 8.24 3 5.56
P37235 Hippocalcin-­‐like	  protein	  1 6 19.69 2 4.15 1 4.15
P37802 Transgelin-­‐2 37 62.31 10 32.66 20 46.73
P37837 Transaldolase 28 33.23 14 18.69 11 21.36
P37840 Alpha-­‐synuclein 11 47.86 4 30.00 7 41.43
P38117 Electron	  transfer	  flavoprotein	  subunit	  beta 16 41.18 9 33.33 8 34.12
P38159 Heterogeneous	  nuclear	  ribonucleoprotein	  G 7 16.88 2 6.65 2 3.58
P38571 Lysosomal	  acid	  lipase/cholesteryl	  ester	  hydrolase 2 5.76 0 0.00 0 0.00
P38606 V-­‐type	  proton	  ATPase	  catalytic	  subunit	  A 35 43.11 27 32.74 29 39.22
P38646 Stress-­‐70	  protein,	  mitochondrial 81 50.07 55 38.29 51 38.29
P38919 Eukaryotic	  initiation	  factor	  4A-­‐III 16 27.25 14 31.63 12 20.92
P39019 40S	  ribosomal	  protein	  S19 12 49.66 9 37.24 7 28.97
P39023 60S	  ribosomal	  protein	  L3 20 32.01 19 28.29 11 20.35
P39060 Collagen	  alpha-­‐1(XVIII)	  chain 11 7.13 6 6.78 5 3.71
P39210 Protein	  Mpv17 2 13.07 1 13.07 2 13.07
P39656 Dolichyl-­‐diphosphooligosaccharide-­‐-­‐protein	  glycosyltransferase	  48	  kDa	  subunit 12 21.49 9 16.67 10 19.08
P39687 Acidic	  leucine-­‐rich	  nuclear	  phosphoprotein	  32	  family	  member	  A 14 23.69 12 19.28 15 19.28
P39748 Flap	  endonuclease	  1 3 10.00 0 0.00 0 0.00
P40121 Macrophage-­‐capping	  protein 8 18.10 4 3.74 8 18.10
P40222 Alpha-­‐taxilin 3 5.49 0 0.00 0 0.00
P40227 T-­‐complex	  protein	  1	  subunit	  zeta 37 44.44 30 32.96 31 36.35
P40306 Proteasome	  subunit	  beta	  type-­‐10 3 7.33 1 7.33 1 7.33
P40429 60S	  ribosomal	  protein	  L13a 5 17.24 4 10.84 2 10.84
P40616 ADP-­‐ribosylation	  factor-­‐like	  protein	  1 6 34.25 5 25.97 6 39.78
P40763 Signal	  transducer	  and	  activator	  of	  transcription	  3 12 12.86 8 8.96 7 11.43
P40925 Malate	  dehydrogenase,	  cytoplasmic 29 33.23 21 33.23 23 29.04
P40926 Malate	  dehydrogenase,	  mitochondrial 84 71.60 54 67.16 44 58.28
P40939 Trifunctional	  enzyme	  subunit	  alpha,	  mitochondrial 70 54.13 42 41.15 43 38.14
P40967 Melanocyte	  protein	  PMEL 21 18.91 18 16.04 16 14.37
P41091 Eukaryotic	  translation	  initiation	  factor	  2	  subunit	  3 10 13.98 6 11.02 4 8.69
P41219 Peripherin 24 12.34 0 0.00 0 0.00
P41222 Prostaglandin-­‐H2	  D-­‐isomerase 1 8.95 2 8.95 2 17.37
P41229 Lysine-­‐specific	  demethylase	  5C 1 0.90 0 0.00 0 0.00
P41240 Tyrosine-­‐protein	  kinase	  CSK 3 9.33 4 10.89 2 6.00
P41250 Glycyl-­‐tRNA	  synthetase 9 12.58 8 12.58 6 12.58
P41252 Isoleucyl-­‐tRNA	  synthetase,	  cytoplasmic 24 16.96 11 9.27 15 13.07
P41567 Eukaryotic	  translation	  initiation	  factor	  1 10 63.72 6 50.44 7 50.44
P42126 Enoyl-­‐CoA	  delta	  isomerase	  1,	  mitochondrial 12 25.83 5 12.58 4 9.27
P42167 Lamina-­‐associated	  polypeptide	  2,	  isoforms	  beta/gamma 13 22.25 10 17.84 14 26.87
P42224 Signal	  transducer	  and	  activator	  of	  transcription	  1-­‐alpha/beta 13 20.67 15 17.07 13 16.40
P42226 Signal	  transducer	  and	  activator	  of	  transcription	  6 5 6.61 2 2.71 1 1.18
P42229 Signal	  transducer	  and	  activator	  of	  transcription	  5A 6 11.21 4 7.43 5 6.55
P42285 Superkiller	  viralicidic	  activity	  2-­‐like	  2 8 6.62 7 3.45 4 5.57
P42345 Serine/threonine-­‐protein	  kinase	  mTOR 6 3.22 9 4.20 5 2.16
P42356 Phosphatidylinositol	  4-­‐kinase	  alpha 10 7.14 4 2.89 5 3.13
P42566 Epidermal	  growth	  factor	  receptor	  substrate	  15 6 8.48 2 2.79 0 0.00
P42677 40S	  ribosomal	  protein	  S27 3 22.62 0 0.00 0 0.00
P42704 Leucine-­‐rich	  PPR	  motif-­‐containing	  protein,	  mitochondrial 73 38.09 50 27.04 49 29.20
P42765 3-­‐ketoacyl-­‐CoA	  thiolase,	  mitochondrial 9 29.22 5 17.38 6 16.12
P42785 Lysosomal	  Pro-­‐X	  carboxypeptidase 6 9.88 2 4.23 1 4.23
P42858 Huntingtin 11 4.49 6 2.23 3 1.53
P43007 Neutral	  amino	  acid	  transporter	  A 4 4.51 0 0.00 3 4.51
P43034 Platelet-­‐activating	  factor	  acetylhydrolase	  IB	  subunit	  alpha 7 20.24 1 2.93 5 13.66
P43121 Cell	  surface	  glycoprotein	  MUC18 14 23.68 2 5.73 9 19.97
P43155 Carnitine	  O-­‐acetyltransferase 3 5.91 0 0.00 0 0.00
P43243 Matrin-­‐3 38 29.16 23 25.27 21 21.02
P43246 DNA	  mismatch	  repair	  protein	  Msh2 7 7.17 2 3.21 3 4.39
P43304 Glycerol-­‐3-­‐phosphate	  dehydrogenase,	  mitochondrial 21 27.65 13 21.87 14 17.74
P43307 Translocon-­‐associated	  protein	  subunit	  alpha 3 9.09 3 5.25 4 9.09
P43320 Beta-­‐crystallin	  B2 2 11.71 1 7.32 2 11.22
P43487 Ran-­‐specific	  GTPase-­‐activating	  protein 3 16.92 3 5.47 2 5.47
P43490 Nicotinamide	  phosphoribosyltransferase 12 25.05 4 5.91 9 15.07
P43652 Afamin 3 5.68 6 8.35 2 2.17
P43686 26S	  protease	  regulatory	  subunit	  6B 15 22.97 15 17.94 9 15.07
P43897 Elongation	  factor	  Ts,	  mitochondrial 4 16.31 0 0.00 1 5.23
P45880 Voltage-­‐dependent	  anion-­‐selective	  channel	  protein	  2 22 50.34 11 29.25 19 35.71
P45954 Short/branched	  chain	  specific	  acyl-­‐CoA	  dehydrogenase,	  mitochondrial 7 10.65 2 5.09 0 0.00
P45974 Ubiquitin	  carboxyl-­‐terminal	  hydrolase	  5 34 34.62 15 22.14 9 13.17
P46013 Antigen	  KI-­‐67 1 0.40 0 0.00 0 0.00
P46019 Phosphorylase	  b	  kinase	  regulatory	  subunit	  alpha,	  liver	  isoform 1 1.46 1 1.46 1 1.46
P46060 Ran	  GTPase-­‐activating	  protein	  1 9 20.10 4 5.79 4 8.35
P46108 Adapter	  molecule	  crk 4 24.67 4 20.39 1 9.87
P46109 Crk-­‐like	  protein 5 17.49 4 10.56 0 0.00
P46199 Translation	  initiation	  factor	  IF-­‐2,	  mitochondrial 2 3.03 4 6.19 0 0.00
P46379 Large	  proline-­‐rich	  protein	  BAG6 5 7.60 4 6.09 7 11.04
P46439 Glutathione	  S-­‐transferase	  Mu	  5 3 7.80 0 0.00 0 0.00
P46459 Vesicle-­‐fusing	  ATPase 12 16.13 6 10.89 6 7.39
P46776 60S	  ribosomal	  protein	  L27a 2 14.19 2 12.16 3 6.76
P46777 60S	  ribosomal	  protein	  L5 19 39.06 15 29.97 14 29.97
P46778 60S	  ribosomal	  protein	  L21 4 31.87 1 6.88 2 9.38
P46779 60S	  ribosomal	  protein	  L28 4 16.06 4 20.44 6 25.55
P46781 40S	  ribosomal	  protein	  S9 18 32.47 10 26.80 8 18.56
P46782 40S	  ribosomal	  protein	  S5 23 33.33 14 28.43 16 28.43
P46783 40S	  ribosomal	  protein	  S10 19 47.88 21 32.73 12 23.64
P46926 Glucosamine-­‐6-­‐phosphate	  isomerase	  1 9 34.95 4 21.45 8 37.02
P46939 Utrophin 13 5.21 7 2.39 5 2.50
P46940 Ras	  GTPase-­‐activating-­‐like	  protein	  IQGAP1 65 33.80 60 29.33 56 26.80
P46976 Glycogenin-­‐1 2 5.71 2 5.71 2 2.86
P46977 Dolichyl-­‐diphosphooligosaccharide-­‐-­‐protein	  glycosyltransferase	  subunit	  STT3A 7 9.22 0 0.00 2 2.84
P47755 F-­‐actin-­‐capping	  protein	  subunit	  alpha-­‐2 11 21.68 10 29.37 10 25.87
P47756 F-­‐actin-­‐capping	  protein	  subunit	  beta 17 27.08 12 22.02 7 13.36
P47804 RPE-­‐retinal	  G	  protein-­‐coupled	  receptor 4 7.90 4 7.90 1 4.47
P47813 Eukaryotic	  translation	  initiation	  factor	  1A,	  X-­‐chromosomal 4 14.58 0 0.00 2 14.58
P47897 Glutaminyl-­‐tRNA	  synthetase 14 18.71 9 12.26 7 8.65
P47914 60S	  ribosomal	  protein	  L29 7 14.47 3 9.43 1 9.43
P47985 Cytochrome	  b-­‐c1	  complex	  subunit	  Rieske,	  mitochondrial 12 37.96 9 27.01 5 21.90
P48047 ATP	  synthase	  subunit	  O,	  mitochondrial 24 46.48 11 35.21 10 35.21
P48059 LIM	  and	  senescent	  cell	  antigen-­‐like-­‐containing	  domain	  protein	  1 1 3.38 0 0.00 0 0.00
P48147 Prolyl	  endopeptidase 14 23.94 11 17.18 13 18.45
P48163 NADP-­‐dependent	  malic	  enzyme 6 8.39 4 9.97 2 4.72
P48426 Phosphatidylinositol-­‐5-­‐phosphate	  4-­‐kinase	  type-­‐2	  alpha 15 22.41 11 16.01 15 18.72
P48444 Coatomer	  subunit	  delta 14 19.37 5 8.61 10 13.31
P48556 26S	  proteasome	  non-­‐ATPase	  regulatory	  subunit	  8 4 15.43 4 13.71 3 10.86
P48637 Glutathione	  synthetase 12 23.00 8 20.25 5 15.19
P48643 T-­‐complex	  protein	  1	  subunit	  epsilon 28 30.13 13 24.95 17 26.25
P48651 Phosphatidylserine	  synthase	  1 1 2.96 0 0.00 1 2.96
P48668 Keratin,	  type	  II	  cytoskeletal	  6C 2 1.24 0 0.00 0 0.00
P48681 Nestin 7 4.94 2 1.73 7 5.12
P48723 Heat	  shock	  70	  kDa	  protein	  13 1 2.76 0 0.00 0 0.00
P48729 Casein	  kinase	  I	  isoform	  alpha 2 6.23 0 0.00 1 2.97
P48735 Isocitrate	  dehydrogenase	  [NADP],	  mitochondrial 29 36.06 9 21.68 11 21.90
P48960 CD97	  antigen 4 8.98 3 5.87 2 3.95
P49006 MARCKS-­‐related	  protein 1 7.69 2 7.69 3 25.13
P49023 Paxillin 3 8.63 0 0.00 2 5.58
P49189 4-­‐trimethylaminobutyraldehyde	  dehydrogenase 22 35.63 13 25.10 11 20.85
P49207 60S	  ribosomal	  protein	  L34 1 6.84 0 0.00 0 0.00
P49257 Protein	  ERGIC-­‐53 9 20.59 8 24.90 5 18.43
P49321 Nuclear	  autoantigenic	  sperm	  protein 3 2.92 0 0.00 0 0.00
P49327 Fatty	  acid	  synthase 74 26.64 51 21.66 55 24.41
P49354 Protein	  farnesyltransferase/geranylgeranyltransferase	  type-­‐1	  subunit	  alpha 6 15.83 5 10.82 7 15.04
P49368 T-­‐complex	  protein	  1	  subunit	  gamma 42 48.62 21 36.15 23 35.78
P49406 39S	  ribosomal	  protein	  L19,	  mitochondrial 3 8.22 3 8.22 2 4.79
P49407 Beta-­‐arrestin-­‐1 5 17.70 0 0.00 0 0.00
P49411 Elongation	  factor	  Tu,	  mitochondrial 66 51.77 45 47.35 29 38.50
P49419 Alpha-­‐aminoadipic	  semialdehyde	  dehydrogenase 22 35.99 13 32.84 8 15.77
P49458 Signal	  recognition	  particle	  9	  kDa	  protein 4 25.58 2 25.58 3 25.58
P49585 Choline-­‐phosphate	  cytidylyltransferase	  A 3 11.99 2 8.72 2 8.72
P49588 Alanyl-­‐tRNA	  synthetase,	  cytoplasmic 28 21.90 15 17.36 16 15.50
P49589 Cysteinyl-­‐tRNA	  synthetase,	  cytoplasmic 4 4.95 3 3.61 3 5.48
P49591 Seryl-­‐tRNA	  synthetase,	  cytoplasmic 13 17.32 9 13.81 8 10.89
P49593 Protein	  phosphatase	  1F 19 32.82 15 29.52 12 25.99
P49720 Proteasome	  subunit	  beta	  type-­‐3 7 34.63 7 28.29 4 16.59
P49721 Proteasome	  subunit	  beta	  type-­‐2 10 26.87 4 19.90 6 16.92
P49748 Very	  long-­‐chain	  specific	  acyl-­‐CoA	  dehydrogenase,	  mitochondrial 38 38.02 17 20.15 16 20.00
P49750 YLP	  motif-­‐containing	  protein	  1 3 1.49 0 0.00 0 0.00
P49753 Acyl-­‐coenzyme	  A	  thioesterase	  2,	  mitochondrial 23 39.54 13 29.40 12 20.91
P49754 Vacuolar	  protein	  sorting-­‐associated	  protein	  41	  homolog 3 5.74 0 0.00 1 2.58
P49755 Transmembrane	  emp24	  domain-­‐containing	  protein	  10 21 36.53 10 31.05 7 30.59
P49756 RNA-­‐binding	  protein	  25 10 11.63 5 6.29 3 4.86
P49773 Histidine	  triad	  nucleotide-­‐binding	  protein	  1 6 40.48 6 34.92 0 0.00
P49789 Bis(5'-­‐adenosyl)-­‐triphosphatase 2 8.84 0 0.00 0 0.00
P49792 E3	  SUMO-­‐protein	  ligase	  RanBP2 10 3.44 5 2.11 5 2.26
P49821 NADH	  dehydrogenase	  [ubiquinone]	  flavoprotein	  1,	  mitochondrial 22 40.95 8 23.71 11 22.41
P49902 Cytosolic	  purine	  5'-­‐nucleotidase 3 8.20 2 4.99 1 2.32
P49915 GMP	  synthase	  [glutamine-­‐hydrolyzing] 5 11.11 2 4.47 3 7.94
P49916 DNA	  ligase	  3 3 4.06 2 2.38 2 2.58
P49959 Double-­‐strand	  break	  repair	  protein	  MRE11A 5 8.19 6 8.47 3 4.80
P50148 Guanine	  nucleotide-­‐binding	  protein	  G(q)	  subunit	  alpha 9 26.74 6 18.94 7 22.56
P50213 Isocitrate	  dehydrogenase	  [NAD]	  subunit	  alpha,	  mitochondrial 19 36.34 8 16.94 9 19.67
P50225 Sulfotransferase	  1A1 8 26.78 0 0.00 5 16.27
P50226 Sulfotransferase	  1A2 8 26.78 0 0.00 5 16.27
P50395 Rab	  GDP	  dissociation	  inhibitor	  beta 44 50.11 35 37.53 33 31.69
P50402 Emerin 7 20.08 6 20.08 6 14.96
P50453 Serpin	  B9 25 32.98 17 30.59 13 24.20
P50454 Serpin	  H1 34 36.60 29 37.80 22 33.49
P50502 Hsc70-­‐interacting	  protein 15 18.97 8 16.53 8 11.65
P50552 Vasodilator-­‐stimulated	  phosphoprotein 7 9.74 5 6.58 4 6.58
P50570 Dynamin-­‐2 8 9.77 8 10.46 6 4.60
P50579 Methionine	  aminopeptidase	  2 5 12.76 2 7.74 4 15.06
P50851 Lipopolysaccharide-­‐responsive	  and	  beige-­‐like	  anchor	  protein 4 1.82 3 1.47 4 1.40
P50897 Palmitoyl-­‐protein	  thioesterase	  1 3 15.03 1 4.90 3 10.78
P50914 60S	  ribosomal	  protein	  L14 9 22.33 7 19.07 5 11.16
P50990 T-­‐complex	  protein	  1	  subunit	  theta 48 52.74 27 34.67 34 36.13
P50991 T-­‐complex	  protein	  1	  subunit	  delta 41 46.57 22 38.78 28 44.90
P50995 Annexin	  A11 31 29.90 19 28.12 16 22.97
P51114 Fragile	  X	  mental	  retardation	  syndrome-­‐related	  protein	  1 7 8.53 5 8.53 5 12.56
P51116 Fragile	  X	  mental	  retardation	  syndrome-­‐related	  protein	  2 8 12.04 0 0.00 5 8.02
P51148 Ras-­‐related	  protein	  Rab-­‐5C 22 54.17 13 46.76 13 41.20
P51149 Ras-­‐related	  protein	  Rab-­‐7a 35 55.56 27 55.56 26 50.24
P51159 Ras-­‐related	  protein	  Rab-­‐27A 10 27.60 0 0.00 5 14.93
P51178 1-­‐phosphatidylinositol-­‐4,5-­‐bisphosphate	  phosphodiesterase	  delta-­‐1 4 9.26 0 0.00 3 5.03
P51398 28S	  ribosomal	  protein	  S29,	  mitochondrial 6 15.83 1 5.03 3 12.56
P51452 Dual	  specificity	  protein	  phosphatase	  3 7 23.24 9 23.24 7 23.24
P51532 Transcription	  activator	  BRG1 6 3.04 3 2.43 3 1.52
P51553 Isocitrate	  dehydrogenase	  [NAD]	  subunit	  gamma,	  mitochondrial 12 29.52 5 20.87 4 21.63
P51570 Galactokinase 12 23.47 8 15.31 7 15.31
P51571 Translocon-­‐associated	  protein	  subunit	  delta 7 17.34 7 17.34 7 17.34
P51572 B-­‐cell	  receptor-­‐associated	  protein	  31 9 21.95 5 14.63 6 12.20
P51606 N-­‐acylglucosamine	  2-­‐epimerase 14 22.25 6 14.99 7 18.03
P51608 Methyl-­‐CpG-­‐binding	  protein	  2 5 13.58 0 0.00 3 8.85
P51648 Fatty	  aldehyde	  dehydrogenase 6 14.23 0 0.00 7 10.10
P51659 Peroxisomal	  multifunctional	  enzyme	  type	  2 13 14.95 1 0.82 8 11.82
P51665 26S	  proteasome	  non-­‐ATPase	  regulatory	  subunit	  7 14 27.78 9 17.28 5 12.65
P51668 Ubiquitin-­‐conjugating	  enzyme	  E2	  D1 4 12.24 3 12.24 2 12.24
P51687 Sulfite	  oxidase,	  mitochondrial 2 4.40 1 4.40 0 0.00
P51689 Arylsulfatase	  D 1 2.53 0 0.00 0 0.00
P51790 H(+)/Cl(-­‐)	  exchange	  transporter	  3 2 1.35 0 0.00 0 0.00
P51798 H(+)/Cl(-­‐)	  exchange	  transporter	  7 8 11.55 5 5.34 4 7.33
P51810 G-­‐protein	  coupled	  receptor	  143 13 25.50 7 10.40 7 12.87
P51812 Ribosomal	  protein	  S6	  kinase	  alpha-­‐3 6 5.54 3 2.57 1 2.70
P51858 Hepatoma-­‐derived	  growth	  factor 17 47.08 8 33.75 5 25.00
P51884 Lumican 19 32.84 15 14.79 15 22.49
P51888 Prolargin 8 19.11 5 9.42 4 9.95
P51948 CDK-­‐activating	  kinase	  assembly	  factor	  MAT1 1 4.21 0 0.00 1 4.21
P51991 Heterogeneous	  nuclear	  ribonucleoprotein	  A3 31 27.78 21 21.16 18 21.16
P52209 6-­‐phosphogluconate	  dehydrogenase,	  decarboxylating 13 20.70 13 20.70 9 15.32
P52272 Heterogeneous	  nuclear	  ribonucleoprotein	  M 56 49.32 48 40.68 31 33.29
P52292 Importin	  subunit	  alpha-­‐2 1 4.16 0 0.00 0 0.00
P52294 Importin	  subunit	  alpha-­‐1 1 2.60 0 0.00 1 2.60
P52434 DNA-­‐directed	  RNA	  polymerases	  I,	  II,	  and	  III	  subunit	  RPABC3 2 8.67 0 0.00 0 0.00
P52565 Rho	  GDP-­‐dissociation	  inhibitor	  1 23 28.43 17 38.73 19 25.00
P52566 Rho	  GDP-­‐dissociation	  inhibitor	  2 3 12.44 0 0.00 0 0.00
P52597 Heterogeneous	  nuclear	  ribonucleoprotein	  F 27 31.81 25 29.88 15 16.63
P52630 Signal	  transducer	  and	  activator	  of	  transcription	  2 8 14.81 3 4.58 6 8.70
P52655 Transcription	  initiation	  factor	  IIA	  subunit	  1 2 2.93 3 7.45 3 7.45
P52735 Guanine	  nucleotide	  exchange	  factor	  VAV2 3 3.42 0 0.00 0 0.00
P52758 Ribonuclease	  UK114 2 11.68 0 0.00 2 11.68
P52788 Spermine	  synthase 6 20.49 6 27.05 4 13.39
P52815 39S	  ribosomal	  protein	  L12,	  mitochondrial 3 28.79 3 27.78 0 0.00
P52907 F-­‐actin-­‐capping	  protein	  subunit	  alpha-­‐1 19 42.31 19 40.21 16 39.51
P52948 Nuclear	  pore	  complex	  protein	  Nup98-­‐Nup96 6 4.35 1 0.83 0 0.00
P53004 Biliverdin	  reductase	  A 9 26.01 9 30.41 7 17.57
P53007 Tricarboxylate	  transport	  protein,	  mitochondrial 3 9.97 0 0.00 0 0.00
P53041 Serine/threonine-­‐protein	  phosphatase	  5 5 12.63 4 11.42 6 13.43
P53384 Cytosolic	  Fe-­‐S	  cluster	  assembly	  factor	  NUBP1 2 5.62 0 0.00 2 14.06
P53396 ATP-­‐citrate	  synthase 24 23.52 14 12.90 11 9.90
P53597 Succinyl-­‐CoA	  ligase	  [ADP/GDP-­‐forming]	  subunit	  alpha,	  mitochondrial 12 30.64 10 21.68 7 15.61
P53618 Coatomer	  subunit	  beta 20 22.56 12 15.74 11 16.05
P53621 Coatomer	  subunit	  alpha 22 18.30 16 14.95 18 16.50
P53634 Dipeptidyl	  peptidase	  1 6 9.29 4 9.93 1 2.59
P53675 Clathrin	  heavy	  chain	  2 52 13.41 0 0.00 0 0.00
P53677 AP-­‐3	  complex	  subunit	  mu-­‐2 1 2.87 0 0.00 0 0.00
P53801 Pituitary	  tumor-­‐transforming	  gene	  1	  protein-­‐interacting	  protein 3 10.00 0 0.00 0 0.00
P53814 Smoothelin 1 0.87 0 0.00 0 0.00
P53985 Monocarboxylate	  transporter	  1 3 2.40 3 2.40 1 2.40
P53990 IST1	  homolog 1 5.22 4 7.69 2 5.22
P53992 Protein	  transport	  protein	  Sec24C 7 7.31 2 2.74 9 7.68
P53999 Activated	  RNA	  polymerase	  II	  transcriptional	  coactivator	  p15 5 18.90 4 18.90 3 18.90
P54136 Arginyl-­‐tRNA	  synthetase,	  cytoplasmic 20 23.64 16 25.30 10 16.67
P54577 Tyrosyl-­‐tRNA	  synthetase,	  cytoplasmic 10 17.42 5 12.31 4 10.98
P54578 Ubiquitin	  carboxyl-­‐terminal	  hydrolase	  14 12 21.86 8 18.22 9 25.30
P54619 5'-­‐AMP-­‐activated	  protein	  kinase	  subunit	  gamma-­‐1 5 10.57 4 9.37 4 9.37
P54652 Heat	  shock-­‐related	  70	  kDa	  protein	  2 73 33.33 60 31.46 51 28.33
P54709 Sodium/potassium-­‐transporting	  ATPase	  subunit	  beta-­‐3 8 17.56 7 17.92 6 15.77
P54727 UV	  excision	  repair	  protein	  RAD23	  homolog	  B 9 18.58 7 21.03 7 16.87
P54802 Alpha-­‐N-­‐acetylglucosaminidase 7 14.54 5 11.44 6 11.44
P54819 Adenylate	  kinase	  2,	  mitochondrial 29 59.83 24 48.12 17 38.08
P54886 Delta-­‐1-­‐pyrroline-­‐5-­‐carboxylate	  synthase 4 5.79 0 0.00 0 0.00
P54920 Alpha-­‐soluble	  NSF	  attachment	  protein 10 30.85 9 23.39 6 17.97
P55001 Microfibrillar-­‐associated	  protein	  2 2 5.46 0 0.00 0 0.00
P55010 Eukaryotic	  translation	  initiation	  factor	  5 10 14.62 5 10.44 4 5.80
P55039 Developmentally-­‐regulated	  GTP-­‐binding	  protein	  2 4 12.09 0 0.00 0 0.00
P55058 Phospholipid	  transfer	  protein 1 3.04 0 0.00 0 0.00
P55060 Exportin-­‐2 18 18.23 15 11.33 9 8.34
P55072 Transitional	  endoplasmic	  reticulum	  ATPase 104 61.41 83 59.31 69 52.23
P55081 Microfibrillar-­‐associated	  protein	  1 1 4.10 0 0.00 0 0.00
P55084 Trifunctional	  enzyme	  subunit	  beta,	  mitochondrial 35 37.97 25 31.65 20 35.23
P55145 Mesencephalic	  astrocyte-­‐derived	  neurotrophic	  factor 1 5.49 0 0.00 0 0.00
P55209 Nucleosome	  assembly	  protein	  1-­‐like	  1 11 17.65 10 17.39 8 16.88
P55265 Double-­‐stranded	  RNA-­‐specific	  adenosine	  deaminase 8 8.48 0 0.00 4 4.32
P55268 Laminin	  subunit	  beta-­‐2 26 12.24 12 6.56 13 7.45
P55327 Tumor	  protein	  D52 3 20.54 0 0.00 0 0.00
P55735 Protein	  SEC13	  homolog 3 11.49 3 18.63 2 15.22
P55769 NHP2-­‐like	  protein	  1 9 49.22 3 18.75 3 18.75
P55786 Puromycin-­‐sensitive	  aminopeptidase 35 29.82 25 24.05 27 23.29
P55795 Heterogeneous	  nuclear	  ribonucleoprotein	  H2 24 33.18 21 30.07 15 24.72
P55809 Succinyl-­‐CoA:3-­‐ketoacid-­‐coenzyme	  A	  transferase	  1,	  mitochondrial 25 40.38 12 25.00 15 28.85
P55854 Small	  ubiquitin-­‐related	  modifier	  3 4 20.39 3 11.65 1 11.65
P55884 Eukaryotic	  translation	  initiation	  factor	  3	  subunit	  B 29 29.12 14 18.06 16 23.46
P55957 BH3-­‐interacting	  domain	  death	  agonist 3 15.38 5 22.05 2 14.36
P56134 ATP	  synthase	  subunit	  f,	  mitochondrial 8 25.53 4 25.53 4 25.53
P56182 Ribosomal	  RNA	  processing	  protein	  1	  homolog	  A 1 3.04 0 0.00 0 0.00
P56192 Methionyl-­‐tRNA	  synthetase,	  cytoplasmic 25 24.78 11 14.11 16 20.33
P56377 AP-­‐1	  complex	  subunit	  sigma-­‐2 4 20.38 1 10.19 2 10.19
P56385 ATP	  synthase	  subunit	  e,	  mitochondrial 3 34.78 2 34.78 0 0.00
P56537 Eukaryotic	  translation	  initiation	  factor	  6 3 19.59 3 23.67 1 9.80
P56545 C-­‐terminal-­‐binding	  protein	  2 5 8.99 0 0.00 4 6.52
P56693 Transcription	  factor	  SOX-­‐10 1 1.93 0 0.00 1 5.58
P57053 Histone	  H2B	  type	  F-­‐S 59 62.70 61 62.70 43 57.94
P57088 Transmembrane	  protein	  33 7 15.79 4 6.88 4 4.86
P57105 Synaptojanin-­‐2-­‐binding	  protein 4 22.76 0 0.00 3 14.48
P57678 Gem-­‐associated	  protein	  4 1 1.61 0 0.00 0 0.00
P57729 Ras-­‐related	  protein	  Rab-­‐38 22 49.76 16 45.50 16 49.76
P57740 Nuclear	  pore	  complex	  protein	  Nup107 4 6.59 2 3.89 0 0.00
P58107 Epiplakin 21 17.07 16 13.75 14 7.33
P58546 Myotrophin 4 14.41 3 14.41 2 14.41
P58876 Histone	  H2B	  type	  1-­‐D 61 67.46 61 62.70 43 57.94
P59768 Guanine	  nucleotide-­‐binding	  protein	  G(I)/G(S)/G(O)	  subunit	  gamma-­‐2 1 22.54 0 0.00 1 22.54
P59998 Actin-­‐related	  protein	  2/3	  complex	  subunit	  4 11 41.07 8 41.07 9 36.31
P60033 CD81	  antigen 5 15.25 5 15.25 5 15.25
P60174 Triosephosphate	  isomerase 93 73.08 80 70.63 73 73.08
P60228 Eukaryotic	  translation	  initiation	  factor	  3	  subunit	  E 12 17.53 10 15.51 7 16.40
P60660 Myosin	  light	  polypeptide	  6 42 76.16 30 66.23 23 68.87
P60709 Actin,	  cytoplasmic	  1 187 66.67 138 56.27 119 62.13
P60763 Ras-­‐related	  C3	  botulinum	  toxin	  substrate	  3 5 19.79 4 19.79 5 23.96
P60842 Eukaryotic	  initiation	  factor	  4A-­‐I 38 39.66 29 39.66 31 39.66
P60866 40S	  ribosomal	  protein	  S20 6 19.33 6 25.21 3 19.33
P60891 Ribose-­‐phosphate	  pyrophosphokinase	  1 6 22.96 7 19.81 7 21.70
P60900 Proteasome	  subunit	  alpha	  type-­‐6 18 36.99 8 17.48 7 21.14
P60903 Protein	  S100-­‐A10 2 17.53 0 0.00 3 17.53
P60953 Cell	  division	  control	  protein	  42	  homolog 19 47.64 16 32.46 18 40.31
P60981 Destrin 5 26.06 3 24.24 2 17.58
P60983 Glia	  maturation	  factor	  beta 9 30.28 5 16.20 5 16.20
P61006 Ras-­‐related	  protein	  Rab-­‐8A 7 23.19 5 17.39 7 23.19
P61011 Signal	  recognition	  particle	  54	  kDa	  protein 2 4.17 0 0.00 0 0.00
P61018 Ras-­‐related	  protein	  Rab-­‐4B 4 15.96 0 0.00 0 0.00
P61019 Ras-­‐related	  protein	  Rab-­‐2A 27 67.45 11 45.28 19 58.49
P61020 Ras-­‐related	  protein	  Rab-­‐5B 12 43.26 9 36.74 8 42.33
P61026 Ras-­‐related	  protein	  Rab-­‐10 14 30.00 8 22.50 10 22.50
P61077 Ubiquitin-­‐conjugating	  enzyme	  E2	  D3 4 12.24 3 12.24 2 12.24
P61081 NEDD8-­‐conjugating	  enzyme	  Ubc12 4 17.49 1 6.01 0 0.00
P61086 Ubiquitin-­‐conjugating	  enzyme	  E2	  K 6 26.00 4 13.50 2 9.50
P61088 Ubiquitin-­‐conjugating	  enzyme	  E2	  N 19 52.63 11 36.84 7 34.87
P61106 Ras-­‐related	  protein	  Rab-­‐14 20 76.28 11 60.00 14 52.56
P61158 Actin-­‐related	  protein	  3 23 35.17 14 27.51 12 25.12
P61160 Actin-­‐related	  protein	  2 18 35.28 13 35.79 13 32.49
P61163 Alpha-­‐centractin 15 26.86 12 22.87 12 29.79
P61201 COP9	  signalosome	  complex	  subunit	  2 7 15.35 0 0.00 1 1.13
P61204 ADP-­‐ribosylation	  factor	  3 38 54.70 31 56.35 28 53.59
P61221 ATP-­‐binding	  cassette	  sub-­‐family	  E	  member	  1 2 2.84 2 4.84 4 7.01
P61224 Ras-­‐related	  protein	  Rap-­‐1b 22 61.96 14 40.22 16 53.26
P61225 Ras-­‐related	  protein	  Rap-­‐2b 10 32.24 6 26.23 7 32.24
P61247 40S	  ribosomal	  protein	  S3a 14 35.98 14 26.52 15 24.62
P61254 60S	  ribosomal	  protein	  L26 8 26.90 5 20.69 3 20.00
P61289 Proteasome	  activator	  complex	  subunit	  3 10 38.98 3 15.35 7 18.90
P61313 60S	  ribosomal	  protein	  L15 9 20.59 8 17.16 6 20.59
P61326 Protein	  mago	  nashi	  homolog 1 13.70 0 0.00 0 0.00
P61353 60S	  ribosomal	  protein	  L27 6 29.41 6 27.94 5 27.94
P61421 V-­‐type	  proton	  ATPase	  subunit	  d	  1 9 19.37 8 17.09 7 19.94
P61457 Pterin-­‐4-­‐alpha-­‐carbinolamine	  dehydratase 2 9.62 0 0.00 0 0.00
P61586 Transforming	  protein	  RhoA 28 69.95 18 44.56 15 52.33
P61604 10	  kDa	  heat	  shock	  protein,	  mitochondrial 24 60.78 14 51.96 14 51.96
P61619 Protein	  transport	  protein	  Sec61	  subunit	  alpha	  isoform	  1 4 7.35 3 12.18 2 10.08
P61758 Prefoldin	  subunit	  3 6 21.32 4 16.24 5 16.24
P61764 Syntaxin-­‐binding	  protein	  1 14 22.05 2 6.40 7 16.50
P61769 Beta-­‐2-­‐microglobulin 5 22.69 0 0.00 1 8.40
P61803 Dolichyl-­‐diphosphooligosaccharide-­‐-­‐protein	  glycosyltransferase	  subunit	  DAD1 4 28.32 3 28.32 2 19.47
P61916 Epididymal	  secretory	  protein	  E1 5 15.23 5 15.23 0 0.00
P61923 Coatomer	  subunit	  zeta-­‐1 4 16.95 2 16.95 1 10.73
P61956 Small	  ubiquitin-­‐related	  modifier	  2 3 12.63 3 12.63 1 12.63
P61960 Ubiquitin-­‐fold	  modifier	  1 3 50.59 1 32.94 3 50.59
P61970 Nuclear	  transport	  factor	  2 9 43.31 3 21.26 2 23.62
P61978 Heterogeneous	  nuclear	  ribonucleoprotein	  K 62 60.91 53 46.65 46 44.92
P61981 14-­‐3-­‐3	  protein	  gamma 36 44.53 24 36.84 22 30.77
P62070 Ras-­‐related	  protein	  R-­‐Ras2 3 17.16 0 0.00 0 0.00
P62072 Mitochondrial	  import	  inner	  membrane	  translocase	  subunit	  Tim10 1 21.11 1 7.78 0 0.00
P62081 40S	  ribosomal	  protein	  S7 13 30.41 19 30.41 13 26.29
P62136 Serine/threonine-­‐protein	  phosphatase	  PP1-­‐alpha	  catalytic	  subunit 27 49.70 18 25.76 13 24.24
P62140 Serine/threonine-­‐protein	  phosphatase	  PP1-­‐beta	  catalytic	  subunit 25 46.79 19 29.97 15 29.05
P62158 Calmodulin 30 44.30 23 44.30 13 42.95
P62166 Neuronal	  calcium	  sensor	  1 1 5.79 0 0.00 0 0.00
P62191 26S	  protease	  regulatory	  subunit	  4 18 40.45 11 25.91 13 22.05
P62195 26S	  protease	  regulatory	  subunit	  8 14 33.99 11 23.15 13 27.09
P62241 40S	  ribosomal	  protein	  S8 19 38.46 15 34.13 19 45.67
P62244 40S	  ribosomal	  protein	  S15a 6 39.23 7 32.31 6 32.31
P62249 40S	  ribosomal	  protein	  S16 16 38.36 14 43.84 7 22.60
P62258 14-­‐3-­‐3	  protein	  epsilon 63 63.53 44 50.59 47 54.90
P62263 40S	  ribosomal	  protein	  S14 7 36.42 8 36.42 9 36.42
P62266 40S	  ribosomal	  protein	  S23 7 23.08 5 28.67 3 11.89
P62269 40S	  ribosomal	  protein	  S18 16 48.03 10 36.18 8 30.26
P62277 40S	  ribosomal	  protein	  S13 15 40.40 18 35.76 10 35.76
P62280 40S	  ribosomal	  protein	  S11 10 39.24 8 29.11 6 22.15
P62304 Small	  nuclear	  ribonucleoprotein	  E 3 11.96 2 11.96 2 11.96
P62306 Small	  nuclear	  ribonucleoprotein	  F 1 15.12 1 15.12 1 15.12
P62308 Small	  nuclear	  ribonucleoprotein	  G 3 15.79 0 0.00 3 15.79
P62310 U6	  snRNA-­‐associated	  Sm-­‐like	  protein	  LSm3 2 21.57 1 11.76 0 0.00
P62314 Small	  nuclear	  ribonucleoprotein	  Sm	  D1 6 54.62 7 36.97 0 0.00
P62316 Small	  nuclear	  ribonucleoprotein	  Sm	  D2 6 40.68 5 32.20 5 32.20
P62318 Small	  nuclear	  ribonucleoprotein	  Sm	  D3 11 31.75 7 31.75 4 24.60
P62330 ADP-­‐ribosylation	  factor	  6 3 17.71 4 24.00 1 5.71
P62333 26S	  protease	  regulatory	  subunit	  10B 21 44.73 16 33.16 11 30.08
P62424 60S	  ribosomal	  protein	  L7a 17 27.44 9 14.29 9 17.67
P62495 Eukaryotic	  peptide	  chain	  release	  factor	  subunit	  1 3 6.41 3 9.84 0 0.00
P62633 Cellular	  nucleic	  acid-­‐binding	  protein 3 8.47 2 8.47 2 8.47
P62701 40S	  ribosomal	  protein	  S4,	  X	  isoform 19 42.21 18 35.36 13 34.22
P62714 Serine/threonine-­‐protein	  phosphatase	  2A	  catalytic	  subunit	  beta	  isoform 16 36.57 9 39.16 8 23.30
P62736 Actin,	  aortic	  smooth	  muscle 220 50.13 79 54.64 126 55.17
P62750 60S	  ribosomal	  protein	  L23a 6 20.51 3 8.33 3 13.46
P62753 40S	  ribosomal	  protein	  S6 7 18.07 0 0.00 6 22.09
P62805 Histone	  H4 59 56.31 42 56.31 26 51.46
P62807 Histone	  H2B	  type	  1-­‐C/E/F/G/I 61 67.46 61 62.70 43 57.94
P62820 Ras-­‐related	  protein	  Rab-­‐1A 23 58.05 14 38.05 15 38.05
P62826 GTP-­‐binding	  nuclear	  protein	  Ran 21 39.35 13 34.26 10 25.93
P62829 60S	  ribosomal	  protein	  L23 6 32.14 8 30.71 8 32.14
P62837 Ubiquitin-­‐conjugating	  enzyme	  E2	  D2 4 12.24 3 12.24 2 12.24
P62841 40S	  ribosomal	  protein	  S15 5 23.45 0 0.00 0 0.00
P62847 40S	  ribosomal	  protein	  S24 4 28.57 6 28.57 5 28.57
P62851 40S	  ribosomal	  protein	  S25 12 29.60 10 24.00 3 22.40
P62854 40S	  ribosomal	  protein	  S26 5 20.87 0 0.00 4 20.87
P62857 40S	  ribosomal	  protein	  S28 5 46.38 3 17.39 6 46.38
P62873 Guanine	  nucleotide-­‐binding	  protein	  G(I)/G(S)/G(T)	  subunit	  beta-­‐1 13 22.35 5 15.29 11 25.29
P62879 Guanine	  nucleotide-­‐binding	  protein	  G(I)/G(S)/G(T)	  subunit	  beta-­‐2 11 37.06 4 22.35 7 21.47
P62888 60S	  ribosomal	  protein	  L30 5 24.35 4 24.35 4 24.35
P62899 60S	  ribosomal	  protein	  L31 7 31.20 5 25.60 3 11.20
P62906 60S	  ribosomal	  protein	  L10a 9 29.49 6 19.35 5 23.50
P62910 60S	  ribosomal	  protein	  L32 4 20.74 3 22.22 2 14.81
P62913 60S	  ribosomal	  protein	  L11 7 21.91 3 12.36 5 17.42
P62917 60S	  ribosomal	  protein	  L8 9 18.68 4 10.51 3 10.51
P62937 Peptidyl-­‐prolyl	  cis-­‐trans	  isomerase	  A 79 76.97 55 72.12 51 53.33
P62942 Peptidyl-­‐prolyl	  cis-­‐trans	  isomerase	  FKBP1A 10 39.81 0 0.00 0 0.00
P62979 Ubiquitin-­‐40S	  ribosomal	  protein	  S27a 35 50.00 26 50.00 22 46.15
P62993 Growth	  factor	  receptor-­‐bound	  protein	  2 2 10.14 0 0.00 0 0.00
P62995 Transformer-­‐2	  protein	  homolog	  beta 3 11.81 4 9.72 2 4.86
P63000 Ras-­‐related	  C3	  botulinum	  toxin	  substrate	  1 6 27.08 4 19.79 6 27.08
P63010 AP-­‐2	  complex	  subunit	  beta 20 19.32 20 17.61 18 19.64
P63027 Vesicle-­‐associated	  membrane	  protein	  2 6 35.34 1 14.66 6 29.31
P63092 Guanine	  nucleotide-­‐binding	  protein	  G(s)	  subunit	  alpha	  isoforms	  short 18 42.89 10 27.66 8 23.35
P63096 Guanine	  nucleotide-­‐binding	  protein	  G(i)	  subunit	  alpha-­‐1 7 15.82 6 12.43 5 15.82
P63104 14-­‐3-­‐3	  protein	  zeta/delta 96 68.16 63 54.29 66 47.76
P63151 Serine/threonine-­‐protein	  phosphatase	  2A	  55	  kDa	  regulatory	  subunit	  B	  alpha	  isoform 9 21.48 7 12.53 3 5.59
P63167 Dynein	  light	  chain	  1,	  cytoplasmic 4 44.94 3 32.58 0 0.00
P63173 60S	  ribosomal	  protein	  L38 4 48.57 0 0.00 0 0.00
P63208 S-­‐phase	  kinase-­‐associated	  protein	  1 10 46.63 5 19.63 6 15.95
P63220 40S	  ribosomal	  protein	  S21 8 54.22 6 42.17 0 0.00
P63241 Eukaryotic	  translation	  initiation	  factor	  5A-­‐1 25 36.36 26 33.77 15 28.57
P63244 Guanine	  nucleotide-­‐binding	  protein	  subunit	  beta-­‐2-­‐like	  1 30 57.73 25 46.06 20 40.06
P63261 Actin,	  cytoplasmic	  2 187 66.67 138 56.27 119 62.13
P63267 Actin,	  gamma-­‐enteric	  smooth	  muscle 104 46.81 74 51.33 60 51.86
P63279 SUMO-­‐conjugating	  enzyme	  UBC9 2 13.92 0 0.00 0 0.00
P63313 Thymosin	  beta-­‐10 3 47.73 3 47.73 0 0.00
P67775 Serine/threonine-­‐protein	  phosphatase	  2A	  catalytic	  subunit	  alpha	  isoform 15 32.36 9 39.16 8 23.30
P67809 Nuclease-­‐sensitive	  element-­‐binding	  protein	  1 25 37.96 15 27.47 20 30.86
P67812 Signal	  peptidase	  complex	  catalytic	  subunit	  SEC11A 3 15.64 2 10.61 3 15.64
P67870 Casein	  kinase	  II	  subunit	  beta 3 15.81 2 10.70 0 0.00
P67936 Tropomyosin	  alpha-­‐4	  chain 37 50.40 27 37.50 25 33.06
P68032 Actin,	  alpha	  cardiac	  muscle	  1 110 50.13 79 54.64 63 55.17
P68036 Ubiquitin-­‐conjugating	  enzyme	  E2	  L3 16 38.96 10 36.36 13 46.10
P68104 Elongation	  factor	  1-­‐alpha	  1 107 62.77 75 47.84 58 48.27
P68133 Actin,	  alpha	  skeletal	  muscle 120 50.13 86 54.91 70 55.44
P68363 Tubulin	  alpha-­‐1B	  chain 157 74.06 127 65.19 0 0.00
P68366 Tubulin	  alpha-­‐4A	  chain 125 62.28 107 54.69 95 60.27
P68371 Tubulin	  beta-­‐4B	  chain 169 75.73 118 74.16 0 0.00
P68400 Casein	  kinase	  II	  subunit	  alpha 5 19.69 3 13.30 1 3.33
P68402 Platelet-­‐activating	  factor	  acetylhydrolase	  IB	  subunit	  beta 9 19.21 8 14.41 9 14.41
P68431 Histone	  H3.1 18 44.85 13 38.24 7 21.32
P68871 Hemoglobin	  subunit	  beta 207 93.88 216 93.88 180 91.84
P69849 Nodal	  modulator	  3 10 10.15 5 4.75 6 7.20
P69891 Hemoglobin	  subunit	  gamma-­‐1 31 30.61 0 0.00 0 0.00
P69892 Hemoglobin	  subunit	  gamma-­‐2 31 30.61 0 0.00 0 0.00
P69905 Hemoglobin	  subunit	  alpha 118 85.21 167 87.32 103 64.08
P78324 Tyrosine-­‐protein	  phosphatase	  non-­‐receptor	  type	  substrate	  1 9 16.07 3 7.14 0 0.00
P78344 Eukaryotic	  translation	  initiation	  factor	  4	  gamma	  2 5 2.87 2 1.10 2 1.10
P78347 General	  transcription	  factor	  II-­‐I 11 10.02 4 2.00 2 2.00
P78371 T-­‐complex	  protein	  1	  subunit	  beta 55 55.51 34 45.61 32 47.29
P78385 Keratin,	  type	  II	  cuticular	  Hb3 3 3.04 0 0.00 0 0.00
P78386 Keratin,	  type	  II	  cuticular	  Hb5 2 1.38 0 0.00 0 0.00
P78406 mRNA	  export	  factor 1 4.08 1 4.08 1 4.08
P78417 Glutathione	  S-­‐transferase	  omega-­‐1 17 29.46 13 26.97 16 36.51
P78527 DNA-­‐dependent	  protein	  kinase	  catalytic	  subunit 127 23.62 79 17.90 70 15.55
P79483 HLA	  class	  II	  histocompatibility	  antigen,	  DR	  beta	  3	  chain 6 13.16 3 4.89 3 9.77
P80303 Nucleobindin-­‐2 6 12.86 1 2.14 1 2.14
P80362 Ig	  kappa	  chain	  V-­‐I	  region	  WAT 5 16.67 6 16.67 9 22.22
P80723 Brain	  acid	  soluble	  protein	  1 6 29.96 3 14.54 5 24.23
P80748 Ig	  lambda	  chain	  V-­‐III	  region	  LOI 3 21.62 6 22.52 0 0.00
P82663 28S	  ribosomal	  protein	  S25,	  mitochondrial 2 16.18 1 6.36 0 0.00
P82675 28S	  ribosomal	  protein	  S5,	  mitochondrial 2 5.12 2 4.65 3 7.67
P82909 28S	  ribosomal	  protein	  S36,	  mitochondrial 3 35.92 0 0.00 0 0.00
P82932 28S	  ribosomal	  protein	  S6,	  mitochondrial 1 19.20 0 0.00 0 0.00
P82933 28S	  ribosomal	  protein	  S9,	  mitochondrial 3 7.83 3 9.09 0 0.00
P83731 60S	  ribosomal	  protein	  L24 6 20.38 3 20.38 3 19.11
P84022 Mothers	  against	  decapentaplegic	  homolog	  3 2 5.65 0 0.00 0 0.00
P84077 ADP-­‐ribosylation	  factor	  1 38 54.70 30 53.59 28 53.59
P84090 Enhancer	  of	  rudimentary	  homolog 4 16.35 1 5.77 2 16.35
P84095 Rho-­‐related	  GTP-­‐binding	  protein	  RhoG 3 18.85 3 24.61 4 24.61
P84098 60S	  ribosomal	  protein	  L19 3 7.65 0 0.00 0 0.00
P84103 Serine/arginine-­‐rich	  splicing	  factor	  3 8 30.49 6 30.49 0 0.00
P84157 Matrix-­‐remodeling-­‐associated	  protein	  7 14 34.31 6 32.35 6 32.35
P84243 Histone	  H3.3 16 38.24 12 31.62 7 21.32
P85037 Forkhead	  box	  protein	  K1 1 1.77 0 0.00 0 0.00
P86790 Vacuolar	  fusion	  protein	  CCZ1	  homolog-­‐like 1 2.49 0 0.00 0 0.00
P86791 Vacuolar	  fusion	  protein	  CCZ1	  homolog 1 2.49 0 0.00 0 0.00
P98160 Basement	  membrane-­‐specific	  heparan	  sulfate	  proteoglycan	  core	  protein 29 7.49 34 9.06 26 7.20
P98175 RNA-­‐binding	  protein	  10 1 1.61 0 0.00 0 0.00
P98179 Putative	  RNA-­‐binding	  protein	  3 4 24.20 4 24.20 4 24.20
P99999 Cytochrome	  c 25 55.24 18 55.24 11 47.62
Q00059 Transcription	  factor	  A,	  mitochondrial 7 14.63 3 8.54 2 4.06
Q00169 Phosphatidylinositol	  transfer	  protein	  alpha	  isoform 4 11.48 5 20.00 3 20.00
Q00325 Phosphate	  carrier	  protein,	  mitochondrial 22 21.55 12 19.34 8 13.26
Q00341 Vigilin 16 15.30 10 9.15 10 9.39
Q00577 Transcriptional	  activator	  protein	  Pur-­‐alpha 14 36.96 14 34.16 11 26.71
Q00610 Clathrin	  heavy	  chain	  1 168 50.75 123 42.99 107 41.01
Q00613 Heat	  shock	  factor	  protein	  1 1 5.10 0 0.00 0 0.00
Q00653 Nuclear	  factor	  NF-­‐kappa-­‐B	  p100	  subunit 4 4.33 0 0.00 1 1.44
Q00688 Peptidyl-­‐prolyl	  cis-­‐trans	  isomerase	  FKBP3 6 18.30 2 9.82 1 4.91
Q00765 Receptor	  expression-­‐enhancing	  protein	  5 3 14.81 0 0.00 1 5.29
Q00796 Sorbitol	  dehydrogenase 20 32.21 13 25.49 15 36.97
Q00839 Heterogeneous	  nuclear	  ribonucleoprotein	  U 56 36.12 46 30.55 30 17.82
Q01081 Splicing	  factor	  U2AF	  35	  kDa	  subunit 6 12.92 0 0.00 0 0.00
Q01082 Spectrin	  beta	  chain,	  brain	  1 154 46.28 88 31.43 80 27.62
Q01085 Nucleolysin	  TIAR 2 9.33 0 0.00 0 0.00
Q01105 Protein	  SET 46 32.76 33 26.21 24 26.21
Q01130 Serine/arginine-­‐rich	  splicing	  factor	  2 5 21.72 6 18.55 0 0.00
Q01433 AMP	  deaminase	  2 3 4.55 1 2.05 3 5.92
Q01469 Fatty	  acid-­‐binding	  protein,	  epidermal 6 39.26 2 6.67 2 6.67
Q01484 Ankyrin-­‐2 3 0.54 0 0.00 4 1.02
Q01518 Adenylyl	  cyclase-­‐associated	  protein	  1 32 33.68 30 31.16 25 27.79
Q01546 Keratin,	  type	  II	  cytoskeletal	  2	  oral 2 1.10 0 0.00 0 0.00
Q01628 Interferon-­‐induced	  transmembrane	  protein	  3 6 24.81 0 0.00 0 0.00
Q01629 Interferon-­‐induced	  transmembrane	  protein	  2 4 24.24 0 0.00 0 0.00
Q01650 Large	  neutral	  amino	  acids	  transporter	  small	  subunit	  1 9 9.47 5 6.31 5 6.31
Q01658 Protein	  Dr1 1 7.39 0 0.00 1 7.39
Q01813 6-­‐phosphofructokinase	  type	  C 12 19.01 6 9.95 7 9.06
Q01844 RNA-­‐binding	  protein	  EWS 5 8.54 6 11.89 7 5.79
Q01970 1-­‐phosphatidylinositol-­‐4,5-­‐bisphosphate	  phosphodiesterase	  beta-­‐3 3 3.49 1 1.62 2 2.67
Q01995 Transgelin 5 25.37 5 25.37 3 12.44
Q02218 2-­‐oxoglutarate	  dehydrogenase,	  mitochondrial 43 29.52 32 25.12 27 17.99
Q02252 Methylmalonate-­‐semialdehyde	  dehydrogenase	  [acylating],	  mitochondrial 24 36.07 15 21.87 13 22.80
Q02318 Sterol	  26-­‐hydroxylase,	  mitochondrial 14 28.81 0 0.00 0 0.00
Q02338 D-­‐beta-­‐hydroxybutyrate	  dehydrogenase,	  mitochondrial 3 6.41 5 14.29 2 3.21
Q02447 Transcription	  factor	  Sp3 1 2.05 1 2.05 1 2.05
Q02539 Histone	  H1.1 19 24.19 0 0.00 0 0.00
Q02543 60S	  ribosomal	  protein	  L18a 7 30.68 9 34.66 4 15.34
Q02750 Dual	  specificity	  mitogen-­‐activated	  protein	  kinase	  kinase	  1 4 9.41 0 0.00 0 0.00
Q02790 Peptidyl-­‐prolyl	  cis-­‐trans	  isomerase	  FKBP4 7 17.86 6 14.38 7 11.76
Q02818 Nucleobindin-­‐1 19 33.84 14 22.34 12 19.31
Q02878 60S	  ribosomal	  protein	  L6 24 31.94 16 28.47 11 22.22
Q02952 A-­‐kinase	  anchor	  protein	  12 28 16.55 15 11.05 21 14.42
Q02978 Mitochondrial	  2-­‐oxoglutarate/malate	  carrier	  protein 21 50.64 13 35.99 12 32.48
Q03013 Glutathione	  S-­‐transferase	  Mu	  4 7 25.23 0 0.00 0 0.00
Q03135 Caveolin-­‐1 6 25.28 3 19.66 2 11.80
Q03154 Aminoacylase-­‐1 12 33.33 15 33.33 3 12.75
Q03252 Lamin-­‐B2 50 48.00 38 40.50 26 29.83
Q03518 Antigen	  peptide	  transporter	  1 7 14.11 0 0.00 0 0.00
Q04323 UBX	  domain-­‐containing	  protein	  1 3 24.92 3 24.92 4 16.16
Q04446 1,4-­‐alpha-­‐glucan-­‐branching	  enzyme 9 14.96 8 12.54 7 8.55
Q04637 Eukaryotic	  translation	  initiation	  factor	  4	  gamma	  1 14 6.50 5 3.44 4 2.25
Q04671 P	  protein 1 1.19 0 0.00 0 0.00
Q04760 Lactoylglutathione	  lyase 25 44.57 16 24.46 11 24.46
Q04826 HLA	  class	  I	  histocompatibility	  antigen,	  B-­‐40	  alpha	  chain 16 26.52 5 14.09 9 17.40
Q04837 Single-­‐stranded	  DNA-­‐binding	  protein,	  mitochondrial 9 41.89 6 20.27 6 20.27
Q04917 14-­‐3-­‐3	  protein	  eta 29 51.63 22 47.56 23 44.31
Q05397 Focal	  adhesion	  kinase	  1 6 4.47 0 0.00 3 3.71
Q05519 Serine/arginine-­‐rich	  splicing	  factor	  11 3 4.34 2 4.34 0 0.00
Q05682 Caldesmon 23 18.41 10 13.62 10 14.00
Q05707 Collagen	  alpha-­‐1(XIV)	  chain 5 3.84 0 0.00 0 0.00
Q06124 Tyrosine-­‐protein	  phosphatase	  non-­‐receptor	  type	  11 5 11.22 3 7.20 0 0.00
Q06136 3-­‐ketodihydrosphingosine	  reductase 3 7.53 2 3.31 4 10.54
Q06265 Exosome	  complex	  component	  RRP45 1 2.28 0 0.00 0 0.00
Q06323 Proteasome	  activator	  complex	  subunit	  1 22 39.36 21 42.57 19 34.94
Q06546 GA-­‐binding	  protein	  alpha	  chain 2 5.95 2 5.95 2 5.95
Q06787 Fragile	  X	  mental	  retardation	  1	  protein 8 9.81 4 5.54 4 8.54
Q06830 Peroxiredoxin-­‐1 45 55.28 26 49.25 23 49.25
Q07020 60S	  ribosomal	  protein	  L18 9 25.00 6 25.00 5 19.68
Q07021 Complement	  component	  1	  Q	  subcomponent-­‐binding	  protein,	  mitochondrial 36 31.56 22 26.24 20 26.95
Q07065 Cytoskeleton-­‐associated	  protein	  4 15 24.58 11 18.77 12 17.77
Q07157 Tight	  junction	  protein	  ZO-­‐1 5 4.81 0 0.00 7 3.78
Q07666 KH	  domain-­‐containing,	  RNA-­‐binding,	  signal	  transduction-­‐associated	  protein	  1 11 14.00 9 9.26 2 6.09
Q07812 Apoptosis	  regulator	  BAX 4 19.27 2 12.50 0 0.00
Q07817 Bcl-­‐2-­‐like	  protein	  1 1 4.29 0 0.00 0 0.00
Q07866 Kinesin	  light	  chain	  1 9 17.98 0 0.00 5 10.47
Q07954 Prolow-­‐density	  lipoprotein	  receptor-­‐related	  protein	  1 9 2.84 9 2.51 7 2.58
Q07955 Serine/arginine-­‐rich	  splicing	  factor	  1 20 40.73 14 30.65 10 22.58
Q07960 Rho	  GTPase-­‐activating	  protein	  1 21 31.44 9 28.70 11 24.60
Q08170 Serine/arginine-­‐rich	  splicing	  factor	  4 8 11.13 3 6.68 0 0.00
Q08211 ATP-­‐dependent	  RNA	  helicase	  A 55 22.83 42 21.50 32 19.69
Q08257 Quinone	  oxidoreductase 9 42.25 7 31.00 4 12.46
Q08378 Golgin	  subfamily	  A	  member	  3 7 6.34 0 0.00 3 1.94
Q08380 Galectin-­‐3-­‐binding	  protein 36 31.62 15 14.53 19 18.97
Q08623 Pseudouridine-­‐5'-­‐monophosphatase 3 13.16 5 13.16 3 13.16
Q08722 Leukocyte	  surface	  antigen	  CD47 2 6.19 0 0.00 1 2.48
Q08752 Peptidyl-­‐prolyl	  cis-­‐trans	  isomerase	  D 2 4.05 0 0.00 0 0.00
Q08945 FACT	  complex	  subunit	  SSRP1 6 12.13 6 9.87 2 4.94
Q08AD1 Calmodulin-­‐regulated	  spectrin-­‐associated	  protein	  2 1 0.60 0 0.00 0 0.00
Q08AM6 Protein	  VAC14	  homolog 11 16.24 6 9.08 7 12.53
Q08J23 tRNA	  (cytosine(34)-­‐C(5))-­‐methyltransferase 11 16.30 5 8.21 4 6.00
Q09028 Histone-­‐binding	  protein	  RBBP4 5 14.59 7 16.71 4 9.18
Q09161 Nuclear	  cap-­‐binding	  protein	  subunit	  1 5 5.82 4 5.82 0 0.00
Q09666 Neuroblast	  differentiation-­‐associated	  protein	  AHNAK 170 37.56 134 30.29 146 31.39
Q0VDG4 Secernin-­‐3 1 2.59 1 2.59 1 2.59
Q10567 AP-­‐1	  complex	  subunit	  beta-­‐1 28 20.02 14 15.28 22 21.81
Q10588 ADP-­‐ribosyl	  cyclase	  2 3 9.75 0 0.00 0 0.00
Q10713 Mitochondrial-­‐processing	  peptidase	  subunit	  alpha 12 24.76 9 17.71 4 10.67
Q12765 Secernin-­‐1 2 3.86 2 3.86 3 7.01
Q12767 Uncharacterized	  protein	  KIAA0195 1 0.88 3 2.06 0 0.00
Q12768 WASH	  complex	  subunit	  strumpellin 13 6.47 8 3.71 8 6.13
Q12788 Transducin	  beta-­‐like	  protein	  3 6 7.92 0 0.00 1 1.61
Q12797 Aspartyl/asparaginyl	  beta-­‐hydroxylase 21 26.39 5 9.10 11 16.36
Q12802 A-­‐kinase	  anchor	  protein	  13 2 0.75 0 0.00 0 0.00
Q12824 SWI/SNF-­‐related	  matrix-­‐associated	  actin-­‐dependent	  regulator	  of	  chromatin	  subfamily	  B	  member	  12 7.01 0 0.00 1 3.38
Q12849 G-­‐rich	  sequence	  factor	  1 3 8.75 1 2.50 0 0.00
Q12874 Splicing	  factor	  3A	  subunit	  3 9 20.16 3 10.38 3 10.38
Q12904 Aminoacyl	  tRNA	  synthase	  complex-­‐interacting	  multifunctional	  protein	  1 8 19.55 8 20.51 6 13.78
Q12905 Interleukin	  enhancer-­‐binding	  factor	  2 22 43.59 20 46.41 22 42.05
Q12906 Interleukin	  enhancer-­‐binding	  factor	  3 45 33.67 36 24.05 28 26.62
Q12907 Vesicular	  integral-­‐membrane	  protein	  VIP36 7 18.26 5 12.64 3 9.55
Q12929 Epidermal	  growth	  factor	  receptor	  kinase	  substrate	  8 10 13.99 3 7.06 4 5.11
Q12931 Heat	  shock	  protein	  75	  kDa,	  mitochondrial 22 20.74 10 16.48 11 12.07
Q12959 Disks	  large	  homolog	  1 2 2.32 1 1.00 0 0.00
Q13011 Delta(3,5)-­‐Delta(2,4)-­‐dienoyl-­‐CoA	  isomerase,	  mitochondrial 12 41.16 7 25.00 7 27.74
Q13033 Striatin-­‐3 2 2.13 0 0.00 0 0.00
Q13043 Serine/threonine-­‐protein	  kinase	  4 2 4.93 0 0.00 1 3.29
Q13045 Protein	  flightless-­‐1	  homolog 15 9.85 9 4.57 8 6.93
Q13057 Bifunctional	  coenzyme	  A	  synthase 6 13.83 3 6.74 4 8.87
Q13084 39S	  ribosomal	  protein	  L28,	  mitochondrial 3 19.92 0 0.00 0 0.00
Q13098 COP9	  signalosome	  complex	  subunit	  1 3 4.68 2 5.70 1 3.26
Q13126 S-­‐methyl-­‐5'-­‐thioadenosine	  phosphorylase 16 55.12 13 50.18 11 46.64
Q13136 Liprin-­‐alpha-­‐1 2 2.58 0 0.00 0 0.00
Q13144 Translation	  initiation	  factor	  eIF-­‐2B	  subunit	  epsilon 4 8.46 2 4.58 2 4.30
Q13148 TAR	  DNA-­‐binding	  protein	  43 7 19.81 6 13.04 4 13.04
Q13151 Heterogeneous	  nuclear	  ribonucleoprotein	  A0 14 30.49 11 25.90 6 15.74
Q13155 Aminoacyl	  tRNA	  synthase	  complex-­‐interacting	  multifunctional	  protein	  2 11 21.88 8 19.37 4 14.06
Q13162 Peroxiredoxin-­‐4 17 30.26 10 19.19 9 14.39
Q13177 Serine/threonine-­‐protein	  kinase	  PAK	  2 2 4.96 0 0.00 2 8.97
Q13185 Chromobox	  protein	  homolog	  3 13 39.34 6 28.42 7 22.40
Q13200 26S	  proteasome	  non-­‐ATPase	  regulatory	  subunit	  2 19 28.74 16 21.70 14 15.31
Q13228 Selenium-­‐binding	  protein	  1 41 45.55 28 39.41 16 33.26
Q13242 Serine/arginine-­‐rich	  splicing	  factor	  9 4 19.00 0 0.00 0 0.00
Q13247 Serine/arginine-­‐rich	  splicing	  factor	  6 9 17.73 4 12.21 0 0.00
Q13263 Transcription	  intermediary	  factor	  1-­‐beta 23 25.75 13 8.62 14 19.04
Q13283 Ras	  GTPase-­‐activating	  protein-­‐binding	  protein	  1 13 25.97 7 14.81 6 15.02
Q13303 Voltage-­‐gated	  potassium	  channel	  subunit	  beta-­‐2 7 23.16 6 23.71 4 18.53
Q13308 Inactive	  tyrosine-­‐protein	  kinase	  7 4 5.89 4 5.14 3 5.05
Q13315 Serine-­‐protein	  kinase	  ATM 3 1.18 2 0.95 2 0.79
Q13347 Eukaryotic	  translation	  initiation	  factor	  3	  subunit	  I 7 23.08 0 0.00 5 21.23
Q13362 Serine/threonine-­‐protein	  phosphatase	  2A	  56	  kDa	  regulatory	  subunit	  gamma	  isoform 2 4.77 0 0.00 1 2.67
Q13363 C-­‐terminal-­‐binding	  protein	  1 6 14.77 0 0.00 3 6.59
Q13405 39S	  ribosomal	  protein	  L49,	  mitochondrial 5 30.12 5 23.49 2 15.06
Q13409 Cytoplasmic	  dynein	  1	  intermediate	  chain	  2 11 16.61 9 17.40 6 13.79
Q13418 Integrin-­‐linked	  protein	  kinase 4 5.53 2 5.31 1 3.10
Q13423 NAD(P)	  transhydrogenase,	  mitochondrial 46 33.24 19 16.76 21 19.15
Q13425 Beta-­‐2-­‐syntrophin 5 8.33 0 0.00 3 5.37
Q13428 Treacle	  protein 6 5.04 4 2.08 3 1.95
Q13435 Splicing	  factor	  3B	  subunit	  2 13 14.86 4 6.37 6 7.04
Q13442 28	  kDa	  heat-­‐	  and	  acid-­‐stable	  phosphoprotein 4 16.57 3 7.73 4 7.73
Q13459 Myosin-­‐IXb 15 9.50 8 5.10 10 5.93
Q13485 Mothers	  against	  decapentaplegic	  homolog	  4 2 3.80 0 0.00 2 3.80
Q13488 V-­‐type	  proton	  ATPase	  116	  kDa	  subunit	  a	  isoform	  3 3 5.06 0 0.00 0 0.00
Q13491 Neuronal	  membrane	  glycoprotein	  M6-­‐b 2 7.55 0 0.00 0 0.00
Q13492 Phosphatidylinositol-­‐binding	  clathrin	  assembly	  protein 5 9.82 0 0.00 0 0.00
Q13505 Metaxin-­‐1 4 9.01 1 3.00 0 0.00
Q13509 Tubulin	  beta-­‐3	  chain 105 59.56 0 0.00 0 0.00
Q13510 Acid	  ceramidase 34 44.05 23 31.65 29 37.22
Q13523 Serine/threonine-­‐protein	  kinase	  PRP4	  homolog 2 2.78 0 0.00 0 0.00
Q13541 Eukaryotic	  translation	  initiation	  factor	  4E-­‐binding	  protein	  1 1 22.03 1 22.03 0 0.00
Q13557 Calcium/calmodulin-­‐dependent	  protein	  kinase	  type	  II	  subunit	  delta 5 6.21 3 7.62 1 2.60
Q13561 Dynactin	  subunit	  2 24 48.88 18 33.42 14 24.19
Q13586 Stromal	  interaction	  molecule	  1 5 9.63 0 0.00 6 11.24
Q13595 Transformer-­‐2	  protein	  homolog	  alpha 3 12.06 4 11.35 0 0.00
Q13596 Sorting	  nexin-­‐1 9 21.07 0 0.00 0 0.00
Q13601 KRR1	  small	  subunit	  processome	  component	  homolog 2 6.82 0 0.00 2 6.82
Q13617 Cullin-­‐2 3 5.23 2 2.95 0 0.00
Q13618 Cullin-­‐3 7 9.12 2 3.78 3 4.69
Q13619 Cullin-­‐4A 10 9.88 6 5.80 8 6.46
Q13620 Cullin-­‐4B 11 12.27 4 4.49 8 6.35
Q13630 GDP-­‐L-­‐fucose	  synthase 13 29.91 7 26.48 5 14.02
Q13637 Ras-­‐related	  protein	  Rab-­‐32 13 45.33 11 32.00 13 26.22
Q13642 Four	  and	  a	  half	  LIM	  domains	  protein	  1 4 5.26 1 3.71 0 0.00
Q13685 Angio-­‐associated	  migratory	  cell	  protein 1 2.54 0 0.00 0 0.00
Q13724 Mannosyl-­‐oligosaccharide	  glucosidase 11 15.89 8 11.35 8 9.20
Q13748 Tubulin	  alpha-­‐3C/D	  chain 140 66.44 109 53.78 0 0.00
Q13765 Nascent	  polypeptide-­‐associated	  complex	  subunit	  alpha 10 25.58 6 25.58 6 19.53
Q13813 Spectrin	  alpha	  chain,	  brain 211 50.61 145 39.36 117 33.29
Q13838 Spliceosome	  RNA	  helicase	  DDX39B 36 43.69 26 30.61 21 22.43
Q13867 Bleomycin	  hydrolase 3 5.49 3 5.93 3 5.93
Q13885 Tubulin	  beta-­‐2A	  chain 172 70.11 106 68.99 92 68.54
Q13895 Bystin 7 15.33 4 11.67 3 8.70
Q13907 Isopentenyl-­‐diphosphate	  Delta-­‐isomerase	  1 1 8.81 1 8.81 2 17.18
Q13938 Calcyphosin 2 14.29 0 0.00 0 0.00
Q14008 Cytoskeleton-­‐associated	  protein	  5 5 2.66 0 0.00 0 0.00
Q14011 Cold-­‐inducible	  RNA-­‐binding	  protein 7 33.14 8 26.74 7 26.74
Q14019 Coactosin-­‐like	  protein 5 46.48 2 30.28 2 30.28
Q14103 Heterogeneous	  nuclear	  ribonucleoprotein	  D0 23 30.14 22 19.72 15 20.00
Q14108 Lysosome	  membrane	  protein	  2 10 16.74 4 8.58 5 8.58
Q14112 Nidogen-­‐2 2 2.11 2 2.11 1 2.11
Q14137 Ribosome	  biogenesis	  protein	  BOP1 5 10.46 6 14.21 3 5.90
Q14139 Ubiquitin	  conjugation	  factor	  E4	  A 6 7.04 3 3.94 2 3.94
Q14151 Scaffold	  attachment	  factor	  B2 6 5.04 0 0.00 4 3.78
Q14152 Eukaryotic	  translation	  initiation	  factor	  3	  subunit	  A 24 14.98 14 9.41 18 12.01
Q14155 Rho	  guanine	  nucleotide	  exchange	  factor	  7 2 2.37 0 0.00 1 1.49
Q14156 Protein	  EFR3	  homolog	  A 4 6.94 2 3.65 3 5.36
Q14157 Ubiquitin-­‐associated	  protein	  2-­‐like 6 6.72 4 5.34 2 1.84
Q14160 Protein	  scribble	  homolog 14 11.66 5 3.56 2 0.80
Q14165 Malectin 10 29.45 0 0.00 0 0.00
Q14166 Tubulin-­‐-­‐tyrosine	  ligase-­‐like	  protein	  12 10 17.24 5 10.71 9 15.53
Q14185 Dedicator	  of	  cytokinesis	  protein	  1 3 2.47 0 0.00 1 1.18
Q14195 Dihydropyrimidinase-­‐related	  protein	  3 11 24.56 9 21.75 5 12.81
Q14203 Dynactin	  subunit	  1 28 25.82 16 14.40 15 15.26
Q14204 Cytoplasmic	  dynein	  1	  heavy	  chain	  1 191 31.19 111 19.89 122 24.24
Q14232 Translation	  initiation	  factor	  eIF-­‐2B	  subunit	  alpha 3 11.48 2 7.21 0 0.00
Q14240 Eukaryotic	  initiation	  factor	  4A-­‐II 29 42.01 21 26.54 27 26.54
Q14247 Src	  substrate	  cortactin 15 27.82 8 10.55 9 15.09
Q14254 Flotillin-­‐2 23 41.36 15 29.67 13 26.40
Q14257 Reticulocalbin-­‐2 5 26.50 7 24.29 2 13.25
Q14258 E3	  ubiquitin/ISG15	  ligase	  TRIM25 9 11.75 4 5.71 4 8.09
Q14315 Filamin-­‐C 17 7.19 0 0.00 7 2.94
Q14318 Peptidyl-­‐prolyl	  cis-­‐trans	  isomerase	  FKBP8 1 3.88 0 0.00 0 0.00
Q14344 Guanine	  nucleotide-­‐binding	  protein	  subunit	  alpha-­‐13 8 26.79 4 7.43 4 15.65
Q14376 UDP-­‐glucose	  4-­‐epimerase 7 28.45 6 20.11 5 21.26
Q14409 Putative	  glycerol	  kinase	  3 2 4.52 0 0.00 0 0.00
Q14410 Glycerol	  kinase	  2 1 2.17 0 0.00 0 0.00
Q14498 RNA-­‐binding	  protein	  39 11 25.85 5 15.66 5 14.72
Q14533 Keratin,	  type	  II	  cuticular	  Hb1 3 2.97 0 0.00 0 0.00
Q14558 Phosphoribosyl	  pyrophosphate	  synthase-­‐associated	  protein	  1 4 12.64 4 12.08 4 12.64
Q14624 Inter-­‐alpha-­‐trypsin	  inhibitor	  heavy	  chain	  H4 15 19.78 13 16.77 7 12.90
Q14657 L	  antigen	  family	  member	  3 4 37.06 3 37.06 2 37.06
Q14667 UPF0378	  protein	  KIAA0100 1 0.76 1 0.76 1 0.76
Q14683 Structural	  maintenance	  of	  chromosomes	  protein	  1A 5 5.51 3 3.00 0 0.00
Q14690 Protein	  RRP5	  homolog 3 1.98 0 0.00 0 0.00
Q14693 Phosphatidate	  phosphatase	  LPIN1 1 2.47 1 2.47 1 2.47
Q14696 LDLR	  chaperone	  MESD 5 17.95 1 9.40 2 11.54
Q14697 Neutral	  alpha-­‐glucosidase	  AB 71 45.23 48 33.05 45 36.86
Q14728 Major	  facilitator	  superfamily	  domain-­‐containing	  protein	  10 1 2.86 1 2.86 1 2.86
Q14738 Serine/threonine-­‐protein	  phosphatase	  2A	  56	  kDa	  regulatory	  subunit	  delta	  isoform 6 13.12 0 0.00 3 6.48
Q14764 Major	  vault	  protein 24 25.98 16 21.16 13 15.12
Q14789 Golgin	  subfamily	  B	  member	  1 4 1.26 4 1.29 3 1.35
Q14839 Chromodomain-­‐helicase-­‐DNA-­‐binding	  protein	  4 8 5.07 2 1.57 2 1.57
Q14847 LIM	  and	  SH3	  domain	  protein	  1 15 36.02 5 8.81 4 10.34
Q14894 Thiomorpholine-­‐carboxylate	  dehydrogenase 1 4.78 0 0.00 0 0.00
Q14914 Prostaglandin	  reductase	  1 5 15.50 4 18.54 5 23.10
Q14956 Transmembrane	  glycoprotein	  NMB 30 11.01 18 10.49 22 10.49
Q14974 Importin	  subunit	  beta-­‐1 53 30.71 37 28.08 31 26.60
Q14978 Nucleolar	  and	  coiled-­‐body	  phosphoprotein	  1 6 5.72 4 3.72 2 2.15
Q14980 Nuclear	  mitotic	  apparatus	  protein	  1 54 21.61 30 14.89 33 15.93
Q14999 Cullin-­‐7 3 2.47 2 1.65 0 0.00
Q14C86 GTPase-­‐activating	  protein	  and	  VPS9	  domain-­‐containing	  protein	  1 1 1.29 0 0.00 0 0.00
Q15005 Signal	  peptidase	  complex	  subunit	  2 3 12.39 3 12.39 2 8.41
Q15008 26S	  proteasome	  non-­‐ATPase	  regulatory	  subunit	  6 10 16.97 9 17.22 9 18.25
Q15019 Septin-­‐2 21 44.04 14 33.24 17 39.61
Q15020 Squamous	  cell	  carcinoma	  antigen	  recognized	  by	  T-­‐cells	  3 6 5.19 2 2.18 4 5.50
Q15029 116	  kDa	  U5	  small	  nuclear	  ribonucleoprotein	  component 21 17.39 16 17.59 19 16.05
Q15042 Rab3	  GTPase-­‐activating	  protein	  catalytic	  subunit 2 2.35 2 1.63 0 0.00
Q15043 Zinc	  transporter	  ZIP14 2 2.44 0 0.00 0 0.00
Q15046 Lysyl-­‐tRNA	  synthetase 9 14.24 9 14.24 9 12.06
Q15056 Eukaryotic	  translation	  initiation	  factor	  4H 7 23.79 4 16.53 3 10.89
Q15063 Periostin 13 20.93 25 24.88 17 24.28
Q15075 Early	  endosome	  antigen	  1 8 7.16 3 2.83 0 0.00
Q15084 Protein	  disulfide-­‐isomerase	  A6 38 51.82 19 38.18 23 37.05
Q15102 Platelet-­‐activating	  factor	  acetylhydrolase	  IB	  subunit	  gamma 6 26.84 5 23.38 3 12.99
Q15121 Astrocytic	  phosphoprotein	  PEA-­‐15 9 36.92 5 22.31 5 34.62
Q15124 Phosphoglucomutase-­‐like	  protein	  5 1 2.65 0 0.00 0 0.00
Q15126 Phosphomevalonate	  kinase 4 24.48 0 0.00 0 0.00
Q15149 Plectin 257 38.36 132 24.53 147 25.98
Q15155 Nodal	  modulator	  1 10 10.15 5 4.75 6 7.20
Q15165 Serum	  paraoxonase/arylesterase	  2 1 2.54 0 0.00 0 0.00
Q15172 Serine/threonine-­‐protein	  phosphatase	  2A	  56	  kDa	  regulatory	  subunit	  alpha	  isoform 1 2.88 0 0.00 1 2.68
Q15181 Inorganic	  pyrophosphatase 15 42.91 8 20.76 8 24.22
Q15185 Prostaglandin	  E	  synthase	  3 4 28.13 0 0.00 0 0.00
Q15233 Non-­‐POU	  domain-­‐containing	  octamer-­‐binding	  protein 13 30.57 9 21.87 10 20.59
Q15257 Serine/threonine-­‐protein	  phosphatase	  2A	  activator 2 2.79 2 2.79 4 6.42
Q15274 Nicotinate-­‐nucleotide	  pyrophosphorylase	  [carboxylating] 4 10.44 4 11.78 4 10.44
Q15287 RNA-­‐binding	  protein	  with	  serine-­‐rich	  domain	  1 4 17.70 3 13.77 2 4.92
Q15293 Reticulocalbin-­‐1 11 29.61 9 24.17 6 12.08
Q15345 Leucine-­‐rich	  repeat-­‐containing	  protein	  41 1 2.22 2 2.83 1 2.22
Q15363 Transmembrane	  emp24	  domain-­‐containing	  protein	  2 6 22.89 0 0.00 0 0.00
Q15365 Poly(rC)-­‐binding	  protein	  1 30 50.84 20 40.17 25 57.02
Q15366 Poly(rC)-­‐binding	  protein	  2 22 37.81 16 22.19 18 27.12
Q15369 Transcription	  elongation	  factor	  B	  polypeptide	  1 6 49.11 2 28.57 0 0.00
Q15370 Transcription	  elongation	  factor	  B	  polypeptide	  2 5 27.12 0 0.00 0 0.00
Q15393 Splicing	  factor	  3B	  subunit	  3 13 9.94 8 7.81 9 9.78
Q15397 Pumilio	  domain-­‐containing	  protein	  KIAA0020 1 1.24 2 2.62 0 0.00
Q15404 Ras	  suppressor	  protein	  1 2 12.64 0 0.00 1 6.50
Q15417 Calponin-­‐3 7 13.68 5 13.68 2 7.29
Q15424 Scaffold	  attachment	  factor	  B1 8 6.99 5 6.12 4 3.93
Q15435 Protein	  phosphatase	  1	  regulatory	  subunit	  7 17 38.61 9 26.94 7 22.22
Q15436 Protein	  transport	  protein	  Sec23A 12 14.64 0 0.00 0 0.00
Q15459 Splicing	  factor	  3A	  subunit	  1 9 15.01 3 4.29 3 5.93
Q15477 Helicase	  SKI2W 7 8.03 5 7.14 7 5.38
Q15582 Transforming	  growth	  factor-­‐beta-­‐induced	  protein	  ig-­‐h3 2 4.10 8 13.03 4 8.64
Q15599 Na(+)/H(+)	  exchange	  regulatory	  cofactor	  NHE-­‐RF2 4 13.95 2 9.79 0 0.00
Q15628 Tumor	  necrosis	  factor	  receptor	  type	  1-­‐associated	  DEATH	  domain	  protein 1 4.49 1 5.13 0 0.00
Q15629 Translocating	  chain-­‐associated	  membrane	  protein	  1 2 2.94 0 0.00 0 0.00
Q15631 Translin 16 45.61 14 40.79 12 37.72
Q15637 Splicing	  factor	  1 10 15.65 4 5.32 6 9.86
Q15651 High	  mobility	  group	  nucleosome-­‐binding	  domain-­‐containing	  protein	  3 1 12.12 0 0.00 0 0.00
Q15654 Thyroid	  receptor-­‐interacting	  protein	  6 9 24.58 5 18.28 0 0.00
Q15661 Tryptase	  alpha/beta-­‐1 6 13.09 3 9.82 2 7.64
Q15691 Microtubule-­‐associated	  protein	  RP/EB	  family	  member	  1 3 9.70 1 7.09 1 2.99
Q15717 ELAV-­‐like	  protein	  1 10 31.60 7 15.03 9 27.91
Q15738 Sterol-­‐4-­‐alpha-­‐carboxylate	  3-­‐dehydrogenase,	  decarboxylating 3 12.33 1 5.09 2 9.92
Q15746 Myosin	  light	  chain	  kinase,	  smooth	  muscle 2 1.36 1 0.94 2 1.52
Q15758 Neutral	  amino	  acid	  transporter	  B(0) 2 4.44 4 7.76 2 4.44
Q15785 Mitochondrial	  import	  receptor	  subunit	  TOM34 2 10.03 0 0.00 1 2.91
Q15796 Mothers	  against	  decapentaplegic	  homolog	  2 2 5.14 0 0.00 0 0.00
Q15819 Ubiquitin-­‐conjugating	  enzyme	  E2	  variant	  2 5 39.31 4 26.21 3 21.38
Q15833 Syntaxin-­‐binding	  protein	  2 4 8.94 2 6.07 4 11.47
Q15836 Vesicle-­‐associated	  membrane	  protein	  3 4 24.00 1 17.00 0 0.00
Q15843 NEDD8 5 30.86 6 30.86 5 30.86
Q15907 Ras-­‐related	  protein	  Rab-­‐11B 22 57.80 20 48.62 22 49.08
Q15942 Zyxin 5 13.11 0 0.00 0 0.00
Q16082 Heat	  shock	  protein	  beta-­‐2 3 14.29 0 0.00 0 0.00
Q16181 Septin-­‐7 26 24.26 15 20.37 14 18.54
Q16363 Laminin	  subunit	  alpha-­‐4 2 1.43 0 0.00 0 0.00
Q16401 26S	  proteasome	  non-­‐ATPase	  regulatory	  subunit	  5 8 11.71 5 8.13 8 9.52
Q16518 Retinoid	  isomerohydrolase 29 31.52 16 19.89 16 18.57
Q16531 DNA	  damage-­‐binding	  protein	  1 17 12.28 6 7.37 10 10.70
Q16537 Serine/threonine-­‐protein	  phosphatase	  2A	  56	  kDa	  regulatory	  subunit	  epsilon	  isoform 4 9.64 1 3.00 1 3.00
Q16539 Mitogen-­‐activated	  protein	  kinase	  14 5 10.56 3 8.33 3 8.33
Q16543 Hsp90	  co-­‐chaperone	  Cdc37 10 17.72 6 14.81 4 5.56
Q16555 Dihydropyrimidinase-­‐related	  protein	  2 22 40.03 27 36.19 22 36.54
Q16563 Synaptophysin-­‐like	  protein	  1 3 10.04 0 0.00 2 4.25
Q16576 Histone-­‐binding	  protein	  RBBP7 4 11.29 0 0.00 0 0.00
Q16595 Frataxin,	  mitochondrial 3 13.33 0 0.00 0 0.00
Q16629 Serine/arginine-­‐rich	  splicing	  factor	  7 10 32.35 0 0.00 5 13.87
Q16630 Cleavage	  and	  polyadenylation	  specificity	  factor	  subunit	  6 8 11.62 4 7.44 3 7.08
Q16643 Drebrin 4 6.93 3 4.47 3 6.32
Q16655 Melanoma	  antigen	  recognized	  by	  T-­‐cells	  1 6 32.20 4 27.12 2 19.49
Q16658 Fascin 22 40.16 20 30.22 11 25.56
Q16666 Gamma-­‐interferon-­‐inducible	  protein	  16 4 7.52 3 4.46 8 8.66
Q16695 Histone	  H3.1t 17 33.09 11 26.47 7 21.32
Q16698 2,4-­‐dienoyl-­‐CoA	  reductase,	  mitochondrial 31 35.22 12 33.13 19 34.63
Q16718 NADH	  dehydrogenase	  [ubiquinone]	  1	  alpha	  subcomplex	  subunit	  5 9 57.76 7 44.83 5 43.97
Q16740 Putative	  ATP-­‐dependent	  Clp	  protease	  proteolytic	  subunit,	  mitochondrial 3 13.72 0 0.00 0 0.00
Q16762 Thiosulfate	  sulfurtransferase 12 43.10 7 21.21 5 17.17
Q16774 Guanylate	  kinase 5 28.93 3 20.30 0 0.00
Q16777 Histone	  H2A	  type	  2-­‐C 55 52.71 55 37.98 36 42.64
Q16778 Histone	  H2B	  type	  2-­‐E 59 67.46 60 62.70 41 57.14
Q16795 NADH	  dehydrogenase	  [ubiquinone]	  1	  alpha	  subcomplex	  subunit	  9,	  mitochondrial 27 39.26 14 25.46 10 27.85
Q16822 Phosphoenolpyruvate	  carboxykinase	  [GTP],	  mitochondrial 5 7.34 2 2.50 3 3.59
Q16836 Hydroxyacyl-­‐coenzyme	  A	  dehydrogenase,	  mitochondrial 23 52.55 14 33.12 8 24.84
Q16851 UTP-­‐-­‐glucose-­‐1-­‐phosphate	  uridylyltransferase 9 20.28 4 12.20 4 11.61
Q16864 V-­‐type	  proton	  ATPase	  subunit	  F 7 47.90 4 40.34 5 24.37
Q16881 Thioredoxin	  reductase	  1,	  cytoplasmic 10 17.57 4 8.32 9 16.18
Q16890 Tumor	  protein	  D53 1 6.86 1 6.86 1 6.86
Q16891 Mitochondrial	  inner	  membrane	  protein 37 33.11 22 23.48 26 22.82
Q17R60 Interphotoreceptor	  matrix	  proteoglycan	  1 2 3.26 0 0.00 1 1.88
Q17RN3 Protein	  FAM98C 1 7.74 0 0.00 0 0.00
Q1KMD3 Heterogeneous	  nuclear	  ribonucleoprotein	  U-­‐like	  protein	  2 18 20.48 16 17.00 10 12.32
Q27J81 Inverted	  formin-­‐2 17 16.57 9 8.41 17 16.17
Q29718 HLA	  class	  I	  histocompatibility	  antigen,	  B-­‐82	  alpha	  chain 13 23.20 5 14.09 8 20.44
Q29836 HLA	  class	  I	  histocompatibility	  antigen,	  B-­‐67	  alpha	  chain 15 26.24 5 14.09 9 22.65
Q29974 HLA	  class	  II	  histocompatibility	  antigen,	  DRB1-­‐16	  beta	  chain 8 21.80 4 13.53 5 22.18
Q29RF7 Sister	  chromatid	  cohesion	  protein	  PDS5	  homolog	  A 1 0.97 2 1.65 1 1.50
Q2M389 WASH	  complex	  subunit	  7 2 1.62 2 2.64 4 4.60
Q2TAA2 Isoamyl	  acetate-­‐hydrolyzing	  esterase	  1	  homolog 10 26.21 3 12.90 2 12.90
Q2TAA5 GDP-­‐Man:Man(3)GlcNAc(2)-­‐PP-­‐Dol	  alpha-­‐1,2-­‐mannosyltransferase 1 2.24 0 0.00 1 2.24
Q2TAY7 WD40	  repeat-­‐containing	  protein	  SMU1 3 6.04 0 0.00 2 5.46
Q2VIR3 Putative	  eukaryotic	  translation	  initiation	  factor	  2	  subunit	  3-­‐like	  protein 10 13.98 6 11.02 4 8.69
Q2VPB7 Uncharacterized	  protein	  DKFZp761E198 1 2.56 2 3.65 1 1.46
Q30154 HLA	  class	  II	  histocompatibility	  antigen,	  DR	  beta	  5	  chain 7 16.92 4 13.53 3 13.53
Q31610 HLA	  class	  I	  histocompatibility	  antigen,	  B-­‐81	  alpha	  chain 13 25.41 4 6.63 12 22.38
Q32MZ4 Leucine-­‐rich	  repeat	  flightless-­‐interacting	  protein	  1 11 10.64 4 6.19 3 3.71
Q330K2 UPF0551	  protein	  C8orf38,	  mitochondrial 2 4.81 0 0.00 0 0.00
Q3KQV9 UDP-­‐N-­‐acetylhexosamine	  pyrophosphorylase-­‐like	  protein	  1 6 12.43 3 7.50 2 5.72
Q3LXA3 Bifunctional	  ATP-­‐dependent	  dihydroxyacetone	  kinase/FAD-­‐AMP	  lyase	  (cyclizing) 5 14.09 7 14.96 4 9.57
Q3SXM5 Inactive	  hydroxysteroid	  dehydrogenase-­‐like	  protein	  1 2 5.15 1 4.24 0 0.00
Q3SY69 Mitochondrial	  10-­‐formyltetrahydrofolate	  dehydrogenase 22 21.13 2 3.25 4 4.87
Q3YEC7 Putative	  GTP-­‐binding	  protein	  Parf 5 7.55 2 3.70 3 3.98
Q3ZAQ7 Vacuolar	  ATPase	  assembly	  integral	  membrane	  protein	  VMA21 2 11.88 0 0.00 0 0.00
Q3ZCQ8 Mitochondrial	  import	  inner	  membrane	  translocase	  subunit	  TIM50 12 21.81 8 20.11 9 15.30
Q3ZCW2 Galectin-­‐related	  protein 1 11.05 0 0.00 1 11.05
Q49A26 Putative	  oxidoreductase	  GLYR1 3 2.35 2 2.35 2 2.35
Q4G0N4 NAD	  kinase	  domain-­‐containing	  protein	  1 4 11.31 0 0.00 0 0.00
Q4V328 GRIP1-­‐associated	  protein	  1 5 8.56 0 0.00 0 0.00
Q53EL6 Programmed	  cell	  death	  protein	  4 26 40.30 17 31.98 24 36.89
Q53EP0 Fibronectin	  type	  III	  domain-­‐containing	  protein	  3B 1 1.16 1 1.16 1 1.16
Q53GL7 Poly	  [ADP-­‐ribose]	  polymerase	  10 4 6.73 1 1.76 0 0.00
Q53GQ0 Estradiol	  17-­‐beta-­‐dehydrogenase	  12 12 22.12 6 17.63 7 20.19
Q53GS9 U4/U6.U5	  tri-­‐snRNP-­‐associated	  protein	  2 3 6.19 3 2.83 3 6.19
Q53H12 Acylglycerol	  kinase,	  mitochondrial 4 13.03 0 0.00 0 0.00
Q53H82 Beta-­‐lactamase-­‐like	  protein	  2 5 14.58 1 3.13 2 10.07
Q53H96 Pyrroline-­‐5-­‐carboxylate	  reductase	  3 4 17.52 0 0.00 0 0.00
Q53T59 HCLS1-­‐binding	  protein	  3 8 34.69 4 14.54 8 21.17
Q562E7 WD	  repeat-­‐containing	  protein	  81 7 8.76 4 6.85 2 2.70
Q562R1 Beta-­‐actin-­‐like	  protein	  2 63 44.41 0 0.00 0 0.00
Q567U6 Coiled-­‐coil	  domain-­‐containing	  protein	  93 3 4.75 2 2.69 1 2.06
Q5BJH7 Protein	  YIF1B 4 16.88 0 0.00 0 0.00
Q5EBL4 RILP-­‐like	  protein	  1 1 2.73 0 0.00 1 2.73
Q5EBM0 UMP-­‐CMP	  kinase	  2,	  mitochondrial 4 14.70 0 0.00 0 0.00
Q5H9L2 Transcription	  elongation	  factor	  A	  protein-­‐like	  5 1 4.37 1 4.37 0 0.00
Q5HYK3 2-­‐methoxy-­‐6-­‐polyprenyl-­‐1,4-­‐benzoquinol	  methylase,	  mitochondrial 3 15.60 0 0.00 0 0.00
Q5JNZ5 Putative	  40S	  ribosomal	  protein	  S26-­‐like	  1 2 7.83 0 0.00 0 0.00
Q5JPE7 Nodal	  modulator	  2 10 9.79 5 4.58 6 6.95
Q5JPH6 Probable	  glutamyl-­‐tRNA	  synthetase,	  mitochondrial 3 4.78 0 0.00 2 6.12
Q5JRX3 Presequence	  protease,	  mitochondrial 27 22.66 6 4.72 5 6.94
Q5JSH3 WD	  repeat-­‐containing	  protein	  44 2 2.30 0 0.00 0 0.00
Q5JTD0 Tight	  junction-­‐associated	  protein	  1 1 3.05 0 0.00 0 0.00
Q5JTH9 RRP12-­‐like	  protein 4 3.78 0 0.00 0 0.00
Q5JTV8 Torsin-­‐1A-­‐interacting	  protein	  1 11 17.32 2 4.63 3 8.75
Q5JTZ9 Alanyl-­‐tRNA	  synthetase,	  mitochondrial 8 11.47 0 0.00 0 0.00
Q5JVF3 PCI	  domain-­‐containing	  protein	  2 2 6.52 0 0.00 0 0.00
Q5JVS0 Intracellular	  hyaluronan-­‐binding	  protein	  4 2 3.87 0 0.00 0 0.00
Q5JWF2 Guanine	  nucleotide-­‐binding	  protein	  G(s)	  subunit	  alpha	  isoforms	  XLas 18 16.30 10 10.51 8 8.87
Q5JY77 G-­‐protein	  coupled	  receptor-­‐associated	  sorting	  protein	  1 1 1.29 0 0.00 0 0.00
Q5K4L6 Long-­‐chain	  fatty	  acid	  transport	  protein	  3 1 2.74 2 3.42 1 2.74
Q5QNW6 Histone	  H2B	  type	  2-­‐F 61 67.46 61 62.70 43 57.94
Q5R3I4 Tetratricopeptide	  repeat	  protein	  38 4 6.18 2 6.18 3 4.26
Q5RI15 Protein	  FAM36A 2 22.03 0 0.00 1 11.86
Q5SNT2 Transmembrane	  protein	  201 4 2.85 0 0.00 3 3.60
Q5SRE5 Nucleoporin	  NUP188	  homolog 7 4.52 3 2.52 3 2.29
Q5SRE7 Phytanoyl-­‐CoA	  dioxygenase	  domain-­‐containing	  protein	  1 2 12.37 3 12.37 0 0.00
Q5SSJ5 Heterochromatin	  protein	  1-­‐binding	  protein	  3 19 21.70 9 16.27 6 10.13
Q5ST30 Valyl-­‐tRNA	  synthetase,	  mitochondrial 3 2.54 0 0.00 0 0.00
Q5SWX8 Protein	  odr-­‐4	  homolog 2 5.73 0 0.00 0 0.00
Q5T0F9 Coiled-­‐coil	  and	  C2	  domain-­‐containing	  protein	  1B 4 7.46 1 2.45 0 0.00
Q5T160 Probable	  arginyl-­‐tRNA	  synthetase,	  mitochondrial 1 2.77 0 0.00 0 0.00
Q5T2R2 Decaprenyl-­‐diphosphate	  synthase	  subunit	  1 1 4.34 0 0.00 0 0.00
Q5T440 Putative	  transferase	  CAF17,	  mitochondrial 1 3.37 0 0.00 2 5.90
Q5T4S7 E3	  ubiquitin-­‐protein	  ligase	  UBR4 11 3.80 3 1.41 8 2.60
Q5T653 39S	  ribosomal	  protein	  L2,	  mitochondrial 3 18.69 0 0.00 0 0.00
Q5T6V5 UPF0553	  protein	  C9orf64 4 9.97 2 8.21 1 4.40
Q5TFE4 5'-­‐nucleotidase	  domain-­‐containing	  protein	  1 5 12.53 0 0.00 0 0.00
Q5TFQ8 Signal-­‐regulatory	  protein	  beta-­‐1	  isoform	  3 8 17.09 3 9.04 0 0.00
Q5TI25 Neuroblastoma	  breakpoint	  family	  member	  14 1 0.98 0 0.00 0 0.00
Q5TZA2 Rootletin 5 2.43 4 1.59 6 3.42
Q5VT66 MOSC	  domain-­‐containing	  protein	  1,	  mitochondrial 1 4.45 0 0.00 0 0.00
Q5VTL8 Pre-­‐mRNA-­‐splicing	  factor	  38B 1 1.83 0 0.00 0 0.00
Q5VWZ2 Lysophospholipase-­‐like	  protein	  1 1 4.22 0 0.00 0 0.00
Q5VYK3 Proteasome-­‐associated	  protein	  ECM29	  homolog 15 9.38 8 4.99 3 1.95
Q5XKE5 Keratin,	  type	  II	  cytoskeletal	  79 2 1.31 0 0.00 0 0.00
Q63HN8 RING	  finger	  protein	  213 20 8.05 6 2.62 8 3.57
Q63ZY3 KN	  motif	  and	  ankyrin	  repeat	  domain-­‐containing	  protein	  2 7 8.58 1 1.06 4 5.87
Q658Y4 Protein	  FAM91A1 2 3.10 0 0.00 0 0.00
Q66K14 TBC1	  domain	  family	  member	  9B 5 5.52 2 2.08 4 4.72
Q66K74 Microtubule-­‐associated	  protein	  1S 7 7.46 0 0.00 4 5.95
Q68E01 Integrator	  complex	  subunit	  3 7 10.45 0 0.00 3 6.52
Q68EM7 Rho	  GTPase-­‐activating	  protein	  17 5 8.97 4 3.63 1 1.02
Q6BCY4 NADH-­‐cytochrome	  b5	  reductase	  2 3 13.77 0 0.00 0 0.00
Q6DD88 Atlastin-­‐3 5 16.64 5 13.86 7 13.86
Q6DKK2 Tetratricopeptide	  repeat	  protein	  19,	  mitochondrial 5 16.84 0 0.00 2 3.16
Q6DN03 Putative	  histone	  H2B	  type	  2-­‐C 10 15.03 0 0.00 5 16.06
Q6DRA6 Putative	  histone	  H2B	  type	  2-­‐D 10 17.68 0 0.00 5 18.90
Q6EEV4 Protein	  GRINL1A,	  isoforms	  4/5 1 16.22 0 0.00 1 16.22
Q6EEV6 Small	  ubiquitin-­‐related	  modifier	  4 3 12.63 3 12.63 1 12.63
Q6FI13 Histone	  H2A	  type	  2-­‐A 54 47.69 55 37.69 35 37.69
Q6FI81 Anamorsin 2 3.85 1 3.85 0 0.00
Q6IAA8 Ragulator	  complex	  protein	  LAMTOR1 5 45.34 7 45.34 6 60.25
Q6IAN0 Dehydrogenase/reductase	  SDR	  family	  member	  7B 6 16.62 3 9.54 5 13.23
Q6IBS0 Twinfilin-­‐2 7 24.07 5 15.76 5 15.76
Q6ICL3 Uncharacterized	  protein	  C22orf25 3 16.30 5 19.20 2 10.14
Q6IN85 Serine/threonine-­‐protein	  phosphatase	  4	  regulatory	  subunit	  3A 1 2.04 1 2.04 2 4.32
Q6IQ26 DENN	  domain-­‐containing	  protein	  5A 1 1.32 0 0.00 0 0.00
Q6JQN1 Acyl-­‐CoA	  dehydrogenase	  family	  member	  10 5 4.53 0 0.00 1 1.98
Q6KC79 Nipped-­‐B-­‐like	  protein 1 0.78 0 0.00 2 0.78
Q6L8Q7 2',5'-­‐phosphodiesterase	  12 4 6.24 0 0.00 1 2.30
Q6NUK1 Calcium-­‐binding	  mitochondrial	  carrier	  protein	  SCaMC-­‐1 11 20.55 9 17.40 4 8.60
Q6NUM9 All-­‐trans-­‐retinol	  13,14-­‐reductase 2 3.93 1 1.97 3 4.92
Q6NVV1 Putative	  60S	  ribosomal	  protein	  L13a-­‐like	  MGC87657 3 21.57 4 21.57 2 21.57
Q6NVY1 3-­‐hydroxyisobutyryl-­‐CoA	  hydrolase,	  mitochondrial 9 15.03 7 9.07 4 8.81
Q6NZI2 Polymerase	  I	  and	  transcript	  release	  factor 14 25.13 14 25.38 10 22.31
Q6P158 Putative	  ATP-­‐dependent	  RNA	  helicase	  DHX57 1 0.94 0 0.00 0 0.00
Q6P179 Endoplasmic	  reticulum	  aminopeptidase	  2 1 1.56 0 0.00 0 0.00
Q6P1N0 Coiled-­‐coil	  and	  C2	  domain-­‐containing	  protein	  1A 2 3.58 0 0.00 0 0.00
Q6P1N9 Putative	  deoxyribonuclease	  TATDN1 1 3.70 0 0.00 1 3.70
Q6P1Q0 LETM1	  domain-­‐containing	  protein	  1 2 3.61 1 3.61 0 0.00
Q6P1X6 UPF0598	  protein	  C8orf82 6 25.46 3 15.28 1 6.94
Q6P2E9 Enhancer	  of	  mRNA-­‐decapping	  protein	  4 6 6.57 5 4.71 4 7.14
Q6P2Q9 Pre-­‐mRNA-­‐processing-­‐splicing	  factor	  8 41 16.19 20 8.22 26 11.26
Q6P4F2 Adrenodoxin-­‐like	  protein,	  mitochondrial 2 18.58 0 0.00 0 0.00
Q6P587 Acylpyruvase	  FAHD1,	  mitochondrial 3 22.77 0 0.00 0 0.00
Q6P597 Kinesin	  light	  chain	  3 4 8.13 0 0.00 0 0.00
Q6P6C2 Probable	  alpha-­‐ketoglutarate-­‐dependent	  dioxygenase	  ABH5 2 8.52 0 0.00 0 0.00
Q6P996 Pyridoxal-­‐dependent	  decarboxylase	  domain-­‐containing	  protein	  1 5 6.85 2 4.32 3 6.73
Q6PCB7 Long-­‐chain	  fatty	  acid	  transport	  protein	  1 9 13.47 7 16.87 10 14.71
Q6PEY2 Tubulin	  alpha-­‐3E	  chain 132 64.44 103 50.22 0 0.00
Q6PGP7 Tetratricopeptide	  repeat	  protein	  37 3 2.49 2 2.17 3 2.94
Q6PI48 Aspartyl-­‐tRNA	  synthetase,	  mitochondrial 8 13.80 9 16.12 7 12.09
Q6PKG0 La-­‐related	  protein	  1 4 4.74 0 0.00 5 7.03
Q6RW13 Type-­‐1	  angiotensin	  II	  receptor-­‐associated	  protein 1 10.69 4 24.53 1 10.69
Q6STE5 SWI/SNF-­‐related	  matrix-­‐associated	  actin-­‐dependent	  regulator	  of	  chromatin	  subfamily	  D	  member	  32 6.21 0 0.00 0 0.00
Q6U841 Sodium-­‐driven	  chloride	  bicarbonate	  exchanger 1 0.98 0 0.00 0 0.00
Q6UB35 Monofunctional	  C1-­‐tetrahydrofolate	  synthase,	  mitochondrial 2 2.45 2 1.33 6 7.26
Q6UN15 Pre-­‐mRNA	  3'-­‐end-­‐processing	  factor	  FIP1 3 2.86 1 2.86 1 2.86
Q6UVK1 Chondroitin	  sulfate	  proteoglycan	  4 29 15.93 14 8.14 10 7.67
Q6UW68 Transmembrane	  protein	  205 5 9.00 2 9.00 1 9.00
Q6UWE0 E3	  ubiquitin-­‐protein	  ligase	  LRSAM1 1 1.94 0 0.00 0 0.00
Q6UWR7 Ectonucleotide	  pyrophosphatase/phosphodiesterase	  family	  member	  6 3 7.05 0 0.00 0 0.00
Q6V1P9 Protocadherin-­‐23 2 0.48 0 0.00 0 0.00
Q6VEQ5 WAS	  protein	  family	  homolog	  2 2 7.31 1 3.01 1 3.01
Q6VUC0 Transcription	  factor	  AP-­‐2-­‐epsilon 3 6.56 3 6.56 3 6.56
Q6VY07 Phosphofurin	  acidic	  cluster	  sorting	  protein	  1 2 1.45 3 1.45 1 1.45
Q6WCQ1 Myosin	  phosphatase	  Rho-­‐interacting	  protein 5 7.02 0 0.00 4 5.46
Q6WKZ4 Rab11	  family-­‐interacting	  protein	  1 5 4.37 0 0.00 3 2.10
Q6XQN6 Nicotinate	  phosphoribosyltransferase 20 36.62 13 19.14 14 19.14
Q6Y288 Beta-­‐1,3-­‐glucosyltransferase 3 7.83 1 4.02 3 4.02
Q6Y7W6 PERQ	  amino	  acid-­‐rich	  with	  GYF	  domain-­‐containing	  protein	  2 3 3.39 0 0.00 1 1.00
Q6YN16 Hydroxysteroid	  dehydrogenase-­‐like	  protein	  2 10 21.05 5 18.90 4 13.88
Q6ZMZ3 Nesprin-­‐3 2 2.77 0 0.00 1 1.13
Q6ZNW5 GDP-­‐D-­‐glucose	  phosphorylase	  C15orf58 2 8.57 0 0.00 0 0.00
Q6ZS17 Protein	  FAM65A 1 1.39 2 2.21 2 3.02
Q6ZUT9 DENN	  domain-­‐containing	  protein	  5B 1 1.33 0 0.00 0 0.00
Q6ZUX7 Lipoma	  HMGIC	  fusion	  partner-­‐like	  2	  protein 1 10.96 0 0.00 1 10.96
Q6ZVM7 TOM1-­‐like	  protein	  2 3 11.05 2 7.10 2 6.51
Q6ZXV5 Transmembrane	  and	  TPR	  repeat-­‐containing	  protein	  3 1 1.09 1 1.09 1 1.09
Q709C8 Vacuolar	  protein	  sorting-­‐associated	  protein	  13C 14 4.10 9 3.52 10 3.01
Q71DI3 Histone	  H3.2 18 44.85 13 38.24 7 21.32
Q71U36 Tubulin	  alpha-­‐1A	  chain 152 74.06 119 65.19 113 68.51
Q71UI9 Histone	  H2A.V 17 45.31 17 49.22 7 28.91
Q75N90 Fibrillin-­‐3 1 0.39 0 0.00 0 0.00
Q765P7 MTSS1-­‐like	  protein 2 2.94 0 0.00 0 0.00
Q7KZ85 Transcription	  elongation	  factor	  SPT6 2 1.74 0 0.00 0 0.00
Q7KZF4 Staphylococcal	  nuclease	  domain-­‐containing	  protein	  1 34 31.98 20 21.98 23 19.89
Q7L014 Probable	  ATP-­‐dependent	  RNA	  helicase	  DDX46 8 7.76 6 6.40 5 5.24
Q7L2E3 Putative	  ATP-­‐dependent	  RNA	  helicase	  DHX30 10 7.87 7 5.11 5 4.19
Q7L2H7 Eukaryotic	  translation	  initiation	  factor	  3	  subunit	  M 5 16.31 2 7.49 2 7.49
Q7L576 Cytoplasmic	  FMR1-­‐interacting	  protein	  1 16 13.09 11 9.82 9 7.26
Q7L5D6 Golgi	  to	  ER	  traffic	  protein	  4	  homolog 2 4.59 0 0.00 3 4.59
Q7L5N1 COP9	  signalosome	  complex	  subunit	  6 4 8.56 3 8.56 3 8.56
Q7L5Y9 Macrophage	  erythroblast	  attacher 1 2.27 0 0.00 0 0.00
Q7L7X3 Serine/threonine-­‐protein	  kinase	  TAO1 2 4.00 0 0.00 0 0.00
Q7LG56 Ribonucleoside-­‐diphosphate	  reductase	  subunit	  M2	  B 2 5.41 0 0.00 0 0.00
Q7Z2K6 Endoplasmic	  reticulum	  metallopeptidase	  1 9 7.96 5 3.98 3 3.98
Q7Z2W4 Zinc	  finger	  CCCH-­‐type	  antiviral	  protein	  1 3 5.21 0 0.00 0 0.00
Q7Z2Z2 Elongation	  factor	  Tu	  GTP-­‐binding	  domain-­‐containing	  protein	  1 2 2.95 0 0.00 1 1.79
Q7Z3C6 Autophagy-­‐related	  protein	  9A 1 1.07 0 0.00 1 1.07
Q7Z3E5 LisH	  domain-­‐containing	  protein	  ARMC9 5 7.22 4 6.85 4 5.02
Q7Z3T8 Zinc	  finger	  FYVE	  domain-­‐containing	  protein	  16 3 2.47 0 0.00 0 0.00
Q7Z406 Myosin-­‐14 51 17.09 33 13.28 35 11.78
Q7Z434 Mitochondrial	  antiviral-­‐signaling	  protein 10 13.52 6 8.52 3 8.52
Q7Z460 CLIP-­‐associating	  protein	  1 5 4.23 1 0.91 2 2.15
Q7Z478 ATP-­‐dependent	  RNA	  helicase	  DHX29 3 2.41 0 0.00 0 0.00
Q7Z4H3 HD	  domain-­‐containing	  protein	  2 4 20.59 0 0.00 3 15.20
Q7Z4I7 LIM	  and	  senescent	  cell	  antigen-­‐like-­‐containing	  domain	  protein	  2 1 3.23 0 0.00 0 0.00
Q7Z4Q2 HEAT	  repeat-­‐containing	  protein	  3 1 1.91 0 0.00 1 1.91
Q7Z4V5 Hepatoma-­‐derived	  growth	  factor-­‐related	  protein	  2 4 6.41 0 0.00 1 2.38
Q7Z4W1 L-­‐xylulose	  reductase 6 28.28 5 24.18 3 11.07
Q7Z6B7 SLIT-­‐ROBO	  Rho	  GTPase-­‐activating	  protein	  1 2 1.11 3 1.11 0 0.00
Q7Z6Z7 E3	  ubiquitin-­‐protein	  ligase	  HUWE1 36 9.05 13 4.98 13 4.71
Q7Z739 YTH	  domain	  family	  protein	  3 1 1.54 0 0.00 0 0.00
Q7Z7H8 39S	  ribosomal	  protein	  L10,	  mitochondrial 2 11.11 1 7.28 2 11.11
Q86SX6 Glutaredoxin-­‐related	  protein	  5,	  mitochondrial 5 28.03 1 8.92 0 0.00
Q86TV6 Tetratricopeptide	  repeat	  protein	  7B 1 1.66 4 2.49 1 1.66
Q86TW2 Uncharacterized	  aarF	  domain-­‐containing	  protein	  kinase	  1 1 3.58 0 0.00 0 0.00
Q86TX2 Acyl-­‐coenzyme	  A	  thioesterase	  1 22 39.67 13 33.73 12 23.99
Q86U28 Iron-­‐sulfur	  cluster	  assembly	  2	  homolog,	  mitochondrial 3 15.58 0 0.00 2 15.58
Q86U38 Pumilio	  domain-­‐containing	  protein	  C14orf21 4 9.75 1 2.20 3 7.39
Q86U42 Polyadenylate-­‐binding	  protein	  2 2 3.60 5 25.82 4 8.50
Q86U86 Protein	  polybromo-­‐1 1 1.13 1 1.13 1 1.13
Q86UE4 Protein	  LYRIC 11 11.51 8 9.62 10 11.68
Q86UP2 Kinectin 17 12.09 9 6.85 10 5.97
Q86UT6 NLR	  family	  member	  X1 8 7.59 4 5.44 5 6.36
Q86UU1 Pleckstrin	  homology-­‐like	  domain	  family	  B	  member	  1 2 2.03 0 0.00 0 0.00
Q86UX7 Fermitin	  family	  homolog	  3 22 34.03 10 21.89 18 33.28
Q86UY8 5'-­‐nucleotidase	  domain-­‐containing	  protein	  3 7 20.62 4 8.03 0 0.00
Q86V81 THO	  complex	  subunit	  4 3 9.34 0 0.00 3 16.34
Q86VB7 Scavenger	  receptor	  cysteine-­‐rich	  type	  1	  protein	  M130 1 0.95 0 0.00 0 0.00
Q86VP6 Cullin-­‐associated	  NEDD8-­‐dissociated	  protein	  1 58 32.44 41 24.23 38 24.07
Q86VR2 Protein	  FAM134C 4 8.37 0 0.00 2 5.15
Q86VS8 Protein	  Hook	  homolog	  3 4 8.36 0 0.00 4 6.41
Q86VU5 Catechol	  O-­‐methyltransferase	  domain-­‐containing	  protein	  1 1 9.16 1 9.16 1 9.16
Q86VV8 Rotatin 2 0.63 4 1.98 1 0.63
Q86W42 THO	  complex	  subunit	  6	  homolog 2 8.80 1 5.57 1 5.57
Q86W92 Liprin-­‐beta-­‐1 2 2.18 1 0.89 0 0.00
Q86WA6 Valacyclovir	  hydrolase 4 11.00 5 14.78 3 8.25
Q86WJ1 Chromodomain-­‐helicase-­‐DNA-­‐binding	  protein	  1-­‐like 1 1.45 1 1.45 1 1.45
Q86WV6 Transmembrane	  protein	  173 3 11.87 0 0.00 3 9.50
Q86X10 Ral	  GTPase-­‐activating	  protein	  subunit	  beta 2 2.34 0 0.00 3 1.41
Q86X55 Histone-­‐arginine	  methyltransferase	  CARM1 3 4.44 0 0.00 3 5.43
Q86X76 Nitrilase	  homolog	  1 6 19.27 0 0.00 0 0.00
Q86X83 COMM	  domain-­‐containing	  protein	  2 3 22.61 0 0.00 0 0.00
Q86XA9 HEAT	  repeat-­‐containing	  protein	  5A 2 1.77 0 0.00 1 0.93
Q86XP3 ATP-­‐dependent	  RNA	  helicase	  DDX42 5 7.78 4 7.78 4 7.25
Q86Y56 HEAT	  repeat-­‐containing	  protein	  2 2 2.81 0 0.00 2 2.81
Q86Y79 Probable	  peptidyl-­‐tRNA	  hydrolase 1 4.67 1 4.67 2 7.01
Q86Y82 Syntaxin-­‐12 3 15.58 4 15.58 4 21.01
Q86YN1 Dolichyldiphosphatase	  1 1 7.14 0 0.00 0 0.00
Q86YV9 Hermansky-­‐Pudlak	  syndrome	  6	  protein 4 6.71 0 0.00 0 0.00
Q8IUD2 ELKS/Rab6-­‐interacting/CAST	  family	  member	  1 4 3.05 0 0.00 1 1.08
Q8IUX7 Adipocyte	  enhancer-­‐binding	  protein	  1 9 10.28 5 5.87 0 0.00
Q8IV08 Phospholipase	  D3 10 13.67 11 17.55 7 13.27
Q8IVD9 NudC	  domain-­‐containing	  protein	  3 2 6.37 0 0.00 2 10.53
Q8IVF2 Protein	  AHNAK2 16 12.72 0 0.00 11 7.82
Q8IVH4 Methylmalonic	  aciduria	  type	  A	  protein,	  mitochondrial 1 3.83 1 3.83 1 3.83
Q8IVM0 Coiled-­‐coil	  domain-­‐containing	  protein	  50 3 3.92 0 0.00 0 0.00
Q8IVP5 FUN14	  domain-­‐containing	  protein	  1 2 10.97 1 10.97 1 10.97
Q8IW45 Carbohydrate	  kinase	  domain-­‐containing	  protein 5 21.61 0 0.00 0 0.00
Q8IWA5 Choline	  transporter-­‐like	  protein	  2 3 3.97 3 5.67 0 0.00
Q8IWB7 WD	  repeat	  and	  FYVE	  domain-­‐containing	  protein	  1 10 18.05 6 14.39 4 8.29
Q8IWE2 Protein	  NOXP20 2 2.66 0 0.00 1 2.66
Q8IWF6 Protein	  FAM116A 1 2.14 0 0.00 0 0.00
Q8IWX8 Calcium	  homeostasis	  endoplasmic	  reticulum	  protein 3 4.37 2 2.73 1 1.53
Q8IXB1 DnaJ	  homolog	  subfamily	  C	  member	  10 1 1.26 0 0.00 1 1.26
Q8IXH7 Negative	  elongation	  factor	  C/D 4 9.15 3 9.15 0 0.00
Q8IXI1 Mitochondrial	  Rho	  GTPase	  2 3 6.47 0 0.00 0 0.00
Q8IXI2 Mitochondrial	  Rho	  GTPase	  1 2 3.24 0 0.00 0 0.00
Q8IXT5 RNA-­‐binding	  protein	  12B 2 1.40 2 1.40 2 2.80
Q8IY17 Neuropathy	  target	  esterase 3 3.95 4 4.32 3 3.51
Q8IY81 Putative	  rRNA	  methyltransferase	  3 7 12.28 8 9.68 5 7.20
Q8IYB8 ATP-­‐dependent	  RNA	  helicase	  SUPV3L1,	  mitochondrial 6 10.81 1 2.16 0 0.00
Q8IYM9 E3	  ubiquitin-­‐protein	  ligase	  TRIM22 2 6.02 0 0.00 1 4.62
Q8IZ52 Chondroitin	  sulfate	  synthase	  2 1 2.06 0 0.00 0 0.00
Q8IZ83 Aldehyde	  dehydrogenase	  family	  16	  member	  A1 11 13.59 7 10.22 7 7.86
Q8IZL8 Proline-­‐,	  glutamic	  acid-­‐	  and	  leucine-­‐rich	  protein	  1 2 3.63 4 5.66 3 5.22
Q8IZP0 Abl	  interactor	  1 1 2.16 0 0.00 0 0.00
Q8IZQ5 Selenoprotein	  H 2 18.03 1 9.84 0 0.00
Q8IZR5 CKLF-­‐like	  MARVEL	  transmembrane	  domain-­‐containing	  protein	  4 1 4.27 0 0.00 0 0.00
Q8IZU2 WD	  repeat-­‐containing	  protein	  17 1 0.53 0 0.00 0 0.00
Q8N0U8 Vitamin	  K	  epoxide	  reductase	  complex	  subunit	  1-­‐like	  protein	  1 1 5.68 0 0.00 0 0.00
Q8N0V3 Putative	  ribosome-­‐binding	  factor	  A,	  mitochondrial 2 5.83 0 0.00 1 5.83
Q8N0W3 L-­‐fucose	  kinase 5 8.12 1 2.40 1 2.40
Q8N0X4 Citrate	  lyase	  subunit	  beta-­‐like	  protein,	  mitochondrial 3 11.76 0 0.00 2 5.88
Q8N122 Regulatory-­‐associated	  protein	  of	  mTOR 4 4.42 0 0.00 6 3.15
Q8N163 Protein	  KIAA1967 14 15.93 11 15.93 10 14.95
Q8N183 Mimitin,	  mitochondrial 3 21.30 1 10.65 1 10.65
Q8N1B4 Vacuolar	  protein	  sorting-­‐associated	  protein	  52	  homolog 4 5.81 0 0.00 3 6.50
Q8N1F7 Nuclear	  pore	  complex	  protein	  Nup93 10 16.00 4 7.81 8 12.33
Q8N1F8 Serine/threonine-­‐protein	  kinase	  11-­‐interacting	  protein 2 2.09 0 0.00 2 2.09
Q8N1G4 Leucine-­‐rich	  repeat-­‐containing	  protein	  47 19 28.82 12 18.52 11 21.10
Q8N1N4 Keratin,	  type	  II	  cytoskeletal	  78 2 1.35 0 0.00 0 0.00
Q8N257 Histone	  H2B	  type	  3-­‐B 55 61.90 0 0.00 35 41.27
Q8N2F6 Armadillo	  repeat-­‐containing	  protein	  10 2 9.62 2 9.62 2 4.66
Q8N2G8 GH3	  domain-­‐containing	  protein 3 6.04 1 2.83 0 0.00
Q8N2H3 Pyridine	  nucleotide-­‐disulfide	  oxidoreductase	  domain-­‐containing	  protein	  2 5 9.47 0 0.00 0 0.00
Q8N2K0 Monoacylglycerol	  lipase	  ABHD12 7 22.11 1 5.78 3 6.28
Q8N357 Transmembrane	  protein	  C2orf18 2 3.23 1 3.23 0 0.00
Q8N3E9 1-­‐phosphatidylinositol-­‐4,5-­‐bisphosphate	  phosphodiesterase	  delta-­‐3 2 3.68 1 2.91 0 0.00
Q8N3U4 Cohesin	  subunit	  SA-­‐2 2 3.33 0 0.00 0 0.00
Q8N490 Probable	  hydrolase	  PNKD 2 5.45 0 0.00 0 0.00
Q8N4H5 Mitochondrial	  import	  receptor	  subunit	  TOM5	  homolog 1 15.69 0 0.00 0 0.00
Q8N4Q1 Mitochondrial	  intermembrane	  space	  import	  and	  assembly	  protein	  40 1 12.68 0 0.00 0 0.00
Q8N5K1 CDGSH	  iron-­‐sulfur	  domain-­‐containing	  protein	  2 8 31.11 3 31.11 7 31.11
Q8N5M1 ATP	  synthase	  mitochondrial	  F1	  complex	  assembly	  factor	  2 3 7.96 0 0.00 1 4.15
Q8N5M9 Protein	  jagunal	  homolog	  1 1 6.56 1 6.56 0 0.00
Q8N5N7 39S	  ribosomal	  protein	  L50,	  mitochondrial 1 8.23 2 20.25 2 20.89
Q8N6H7 ADP-­‐ribosylation	  factor	  GTPase-­‐activating	  protein	  2 1 1.73 0 0.00 0 0.00
Q8N6T3 ADP-­‐ribosylation	  factor	  GTPase-­‐activating	  protein	  1 2 8.37 0 0.00 0 0.00
Q8N752 Casein	  kinase	  I	  isoform	  alpha-­‐like 1 2.97 0 0.00 1 2.97
Q8N766 Uncharacterized	  protein	  KIAA0090 8 9.67 9 12.89 6 6.45
Q8N7H5 RNA	  polymerase	  II-­‐associated	  factor	  1	  homolog 1 2.07 0 0.00 0 0.00
Q8N7J2 Protein	  FAM123A 1 1.64 0 0.00 0 0.00
Q8N8N7 Prostaglandin	  reductase	  2 4 19.66 1 5.13 1 5.13
Q8N983 39S	  ribosomal	  protein	  L43,	  mitochondrial 4 16.28 0 0.00 0 0.00
Q8N9N2 Activating	  signal	  cointegrator	  1	  complex	  subunit	  1 1 2.25 0 0.00 0 0.00
Q8NB37 Parkinson	  disease	  7	  domain-­‐containing	  protein	  1 3 22.27 0 0.00 1 10.91
Q8NBJ5 Procollagen	  galactosyltransferase	  1 6 9.16 5 7.40 5 7.40
Q8NBJ7 Sulfatase-­‐modifying	  factor	  2 9 22.92 0 0.00 4 10.96
Q8NBM8 Prenylcysteine	  oxidase-­‐like 3 7.08 3 7.08 0 0.00
Q8NBN3 Transmembrane	  protein	  87A 3 5.40 3 5.05 3 7.75
Q8NBN7 Retinol	  dehydrogenase	  13 6 22.66 4 16.92 6 16.92
Q8NBQ5 Estradiol	  17-­‐beta-­‐dehydrogenase	  11 5 21.00 4 15.00 4 15.00
Q8NBS9 Thioredoxin	  domain-­‐containing	  protein	  5 33 44.21 29 36.81 24 28.01
Q8NBU5 ATPase	  family	  AAA	  domain-­‐containing	  protein	  1 1 3.88 0 0.00 1 3.88
Q8NBX0 Saccharopine	  dehydrogenase-­‐like	  oxidoreductase 2 8.39 1 5.36 0 0.00
Q8NC44 Protein	  FAM134A 1 4.60 0 0.00 0 0.00
Q8NC51 Plasminogen	  activator	  inhibitor	  1	  RNA-­‐binding	  protein 11 18.14 15 22.06 6 15.44
Q8NC56 LEM	  domain-­‐containing	  protein	  2 12 17.50 4 11.73 5 13.72
Q8NCW5 Apolipoprotein	  A-­‐I-­‐binding	  protein 13 31.60 9 20.83 8 24.65
Q8ND90 Paraneoplastic	  antigen	  Ma1 1 4.82 0 0.00 1 4.82
Q8NDH3 Probable	  aminopeptidase	  NPEPL1 6 12.62 0 0.00 4 4.78
Q8NE01 Metal	  transporter	  CNNM3 2 5.80 1 2.55 1 2.55
Q8NE71 ATP-­‐binding	  cassette	  sub-­‐family	  F	  member	  1 8 9.59 5 5.80 4 4.38
Q8NEU8 DCC-­‐interacting	  protein	  13-­‐beta 2 2.11 0 0.00 0 0.00
Q8NF37 Lysophosphatidylcholine	  acyltransferase	  1 7 15.73 1 2.43 1 2.81
Q8NF91 Nesprin-­‐1 3 0.41 0 0.00 0 0.00
Q8NFF5 FAD	  synthase 5 14.65 3 9.71 3 9.71
Q8NFP9 Neurobeachin 2 0.98 0 0.00 0 0.00
Q8NFV4 Abhydrolase	  domain-­‐containing	  protein	  11 6 18.73 4 13.97 1 4.13
Q8NFW8 N-­‐acylneuraminate	  cytidylyltransferase 3 4.84 0 0.00 0 0.00
Q8NG11 Tetraspanin-­‐14 3 10.37 0 0.00 0 0.00
Q8NHP6 Motile	  sperm	  domain-­‐containing	  protein	  2 1 4.25 0 0.00 0 0.00
Q8NI22 Multiple	  coagulation	  factor	  deficiency	  protein	  2 2 16.44 2 16.44 3 16.44
Q8NI27 THO	  complex	  subunit	  2 2 1.44 0 0.00 1 0.57
Q8TAE8 Growth	  arrest	  and	  DNA	  damage-­‐inducible	  proteins-­‐interacting	  protein	  1 1 7.21 2 9.46 1 7.21
Q8TAQ2 SWI/SNF	  complex	  subunit	  SMARCC2 7 6.76 4 2.88 4 4.61
Q8TAT6 Nuclear	  protein	  localization	  protein	  4	  homolog 6 9.87 6 10.20 7 12.83
Q8TB22 Spermatogenesis-­‐associated	  protein	  20 7 11.96 0 0.00 1 1.53
Q8TB36 Ganglioside-­‐induced	  differentiation-­‐associated	  protein	  1 3 8.10 0 0.00 0 0.00
Q8TB37 Iron-­‐sulfur	  protein	  NUBPL 2 11.29 0 0.00 1 5.02
Q8TBA6 Golgin	  subfamily	  A	  member	  5 1 1.78 0 0.00 0 0.00
Q8TBC4 NEDD8-­‐activating	  enzyme	  E1	  catalytic	  subunit 1 2.16 0 0.00 3 9.72
Q8TBX8 Phosphatidylinositol-­‐5-­‐phosphate	  4-­‐kinase	  type-­‐2	  gamma 7 13.78 3 10.45 4 10.45
Q8TC12 Retinol	  dehydrogenase	  11 6 18.55 4 10.06 5 18.55
Q8TCD5 5'(3')-­‐deoxyribonucleotidase,	  cytosolic	  type 3 23.38 1 8.96 2 8.96
Q8TCF1 AN1-­‐type	  zinc	  finger	  protein	  1 1 3.73 1 2.61 0 0.00
Q8TCJ2 Dolichyl-­‐diphosphooligosaccharide-­‐-­‐protein	  glycosyltransferase	  subunit	  STT3B 3 4.12 0 0.00 0 0.00
Q8TCS8 Polyribonucleotide	  nucleotidyltransferase	  1,	  mitochondrial 4 6.13 0 0.00 0 0.00
Q8TCT9 Minor	  histocompatibility	  antigen	  H13 5 10.34 0 0.00 1 2.65
Q8TD55 Pleckstrin	  homology	  domain-­‐containing	  family	  O	  member	  2 3 9.80 1 4.69 2 9.80
Q8TDD1 ATP-­‐dependent	  RNA	  helicase	  DDX54 1 2.04 3 3.86 1 1.82
Q8TDN6 Ribosome	  biogenesis	  protein	  BRX1	  homolog 5 16.71 4 13.60 2 10.20
Q8TDQ7 Glucosamine-­‐6-­‐phosphate	  isomerase	  2 6 28.62 3 22.46 4 28.62
Q8TDX7 Serine/threonine-­‐protein	  kinase	  Nek7 1 4.30 0 0.00 1 3.97
Q8TDZ2 NEDD9-­‐interacting	  protein	  with	  calponin	  homology	  and	  LIM	  domains 3 3.28 2 1.78 0 0.00
Q8TEM1 Nuclear	  pore	  membrane	  glycoprotein	  210 2 1.17 0 0.00 0 0.00
Q8TEQ8 GPI	  ethanolamine	  phosphate	  transferase	  3 2 2.57 2 2.57 3 2.57
Q8TES7 Fas-­‐binding	  factor	  1 1 2.91 2 2.91 0 0.00
Q8TET4 Neutral	  alpha-­‐glucosidase	  C 1 1.75 1 1.75 0 0.00
Q8TEX9 Importin-­‐4 8 9.16 4 5.18 5 6.66
Q8TF09 Dynein	  light	  chain	  roadblock-­‐type	  2 2 12.50 0 0.00 2 12.50
Q8TF74 WAS/WASL-­‐interacting	  protein	  family	  member	  2 1 5.23 0 0.00 0 0.00
Q8WU76 Sec1	  family	  domain-­‐containing	  protein	  2 3 3.95 2 1.61 0 0.00
Q8WU79 Stromal	  membrane-­‐associated	  protein	  2 1 3.03 0 0.00 0 0.00
Q8WU90 Zinc	  finger	  CCCH	  domain-­‐containing	  protein	  15 2 4.93 0 0.00 1 3.29
Q8WUA2 Peptidyl-­‐prolyl	  cis-­‐trans	  isomerase-­‐like	  4 1 3.25 0 0.00 0 0.00
Q8WUK0 Protein-­‐tyrosine	  phosphatase	  mitochondrial	  1 3 12.44 1 6.47 0 0.00
Q8WUM0 Nuclear	  pore	  complex	  protein	  Nup133 5 5.62 3 3.81 4 4.41
Q8WUM4 Programmed	  cell	  death	  6-­‐interacting	  protein 18 15.44 8 13.02 8 12.10
Q8WUW1 Protein	  BRICK1 3 28.00 1 14.67 0 0.00
Q8WUX9 Charged	  multivesicular	  body	  protein	  7 2 3.75 1 3.53 2 3.53
Q8WUY1 UPF0670	  protein	  C8orf55 7 29.33 3 16.35 1 7.69
Q8WUY3 Protein	  prune	  homolog	  2 4 1.46 2 1.26 3 0.97
Q8WVC6 Dephospho-­‐CoA	  kinase	  domain-­‐containing	  protein 4 16.02 1 4.76 1 5.20
Q8WVM0 Dimethyladenosine	  transferase	  1,	  mitochondrial 1 4.05 0 0.00 0 0.00
Q8WVM8 Sec1	  family	  domain-­‐containing	  protein	  1 8 19.63 6 13.86 11 14.64
Q8WVV9 Heterogeneous	  nuclear	  ribonucleoprotein	  L-­‐like 5 8.86 0 0.00 3 6.09
Q8WVY7 Ubiquitin-­‐like	  domain-­‐containing	  CTD	  phosphatase	  1 3 11.95 1 4.40 0 0.00
Q8WWC4 Uncharacterized	  protein	  C2orf47,	  mitochondrial 1 3.44 0 0.00 0 0.00
Q8WWM7 Ataxin-­‐2-­‐like	  protein 1 0.93 0 0.00 1 2.70
Q8WWP7 GTPase	  IMAP	  family	  member	  1 1 5.23 0 0.00 0 0.00
Q8WWX9 Selenoprotein	  M 2 19.31 0 0.00 0 0.00
Q8WWY3 U4/U6	  small	  nuclear	  ribonucleoprotein	  Prp31 5 12.63 2 7.62 0 0.00
Q8WXF1 Paraspeckle	  component	  1 13 21.99 8 14.15 7 13.96
Q8WXH0 Nesprin-­‐2 15 2.66 12 2.14 7 1.13
Q8WYA6 Beta-­‐catenin-­‐like	  protein	  1 3 4.26 0 0.00 1 1.42
Q8WZ82 Ovarian	  cancer-­‐associated	  gene	  2	  protein 2 11.45 1 15.42 2 22.03
Q92481 Transcription	  factor	  AP-­‐2-­‐beta 3 6.30 3 6.30 3 6.30
Q92499 ATP-­‐dependent	  RNA	  helicase	  DDX1 22 19.19 20 18.78 15 17.70
Q92506 Estradiol	  17-­‐beta-­‐dehydrogenase	  8 5 21.46 6 16.86 5 15.71
Q92522 Histone	  H1x 2 11.74 3 11.74 2 4.70
Q92523 Carnitine	  O-­‐palmitoyltransferase	  1,	  muscle	  isoform 1 1.68 4 5.96 0 0.00
Q92542 Nicastrin 8 9.17 4 4.79 4 7.62
Q92552 28S	  ribosomal	  protein	  S27,	  mitochondrial 2 2.66 1 2.66 1 2.66
Q92556 Engulfment	  and	  cell	  motility	  protein	  1 2 2.34 0 0.00 0 0.00
Q92575 UBX	  domain-­‐containing	  protein	  4 2 7.87 0 0.00 2 7.87
Q92581 Sodium/hydrogen	  exchanger	  6 1 1.79 0 0.00 0 0.00
Q92597 Protein	  NDRG1 23 30.71 11 25.63 6 20.05
Q92598 Heat	  shock	  protein	  105	  kDa 24 22.73 10 15.62 11 12.59
Q92599 Septin-­‐8 7 16.36 2 4.14 4 9.32
Q92614 Myosin-­‐XVIIIa 16 10.08 0 0.00 0 0.00
Q92616 Translational	  activator	  GCN1 37 18.35 27 12.95 25 13.18
Q92621 Nuclear	  pore	  complex	  protein	  Nup205 12 8.90 5 4.08 4 2.44
Q92625 Ankyrin	  repeat	  and	  SAM	  domain-­‐containing	  protein	  1A 2 2.56 0 0.00 0 0.00
Q92665 28S	  ribosomal	  protein	  S31,	  mitochondrial 4 9.62 5 9.62 2 9.62
Q92688 Acidic	  leucine-­‐rich	  nuclear	  phosphoprotein	  32	  family	  member	  B 15 28.69 11 24.30 12 21.12
Q92696 Geranylgeranyl	  transferase	  type-­‐2	  subunit	  alpha 3 3.70 2 1.94 2 1.94
Q92734 Protein	  TFG 6 18.25 2 6.75 0 0.00
Q92759 General	  transcription	  factor	  IIH	  subunit	  4 1 4.54 1 4.54 2 6.28
Q92781 11-­‐cis	  retinol	  dehydrogenase 13 29.87 7 26.42 7 26.42
Q92783 Signal	  transducing	  adapter	  molecule	  1 9 19.81 5 16.30 3 9.63
Q92785 Zinc	  finger	  protein	  ubi-­‐d4 2 5.88 0 0.00 0 0.00
Q92804 TATA-­‐binding	  protein-­‐associated	  factor	  2N 4 5.24 4 3.88 4 3.88
Q92820 Gamma-­‐glutamyl	  hydrolase 13 27.36 3 9.12 4 13.21
Q92831 Histone	  acetyltransferase	  KAT2B 1 1.80 0 0.00 0 0.00
Q92841 Probable	  ATP-­‐dependent	  RNA	  helicase	  DDX17 31 27.69 15 19.54 13 14.62
Q92859 Neogenin 3 2.46 0 0.00 0 0.00
Q92878 DNA	  repair	  protein	  RAD50 6 5.11 5 4.35 1 1.37
Q92882 Osteoclast-­‐stimulating	  factor	  1 5 17.29 3 17.29 2 5.61
Q92888 Rho	  guanine	  nucleotide	  exchange	  factor	  1 3 4.28 0 0.00 3 3.18
Q92890 Ubiquitin	  fusion	  degradation	  protein	  1	  homolog 5 13.68 3 7.82 2 7.82
Q92896 Golgi	  apparatus	  protein	  1 12 10.52 3 2.37 3 2.88
Q92900 Regulator	  of	  nonsense	  transcripts	  1 12 11.96 6 7.71 4 6.29
Q92905 COP9	  signalosome	  complex	  subunit	  5 3 6.59 0 0.00 4 9.28
Q92925 SWI/SNF-­‐related	  matrix-­‐associated	  actin-­‐dependent	  regulator	  of	  chromatin	  subfamily	  D	  member	  21 3.20 1 2.07 0 0.00
Q92930 Ras-­‐related	  protein	  Rab-­‐8B 8 23.19 7 23.19 8 23.19
Q92945 Far	  upstream	  element-­‐binding	  protein	  2 35 32.49 31 33.76 20 21.10
Q92947 Glutaryl-­‐CoA	  dehydrogenase,	  mitochondrial 4 16.67 1 3.88 0 0.00
Q92973 Transportin-­‐1 9 10.02 7 8.13 6 8.35
Q92974 Rho	  guanine	  nucleotide	  exchange	  factor	  2 1 1.72 0 0.00 0 0.00
Q93008 Probable	  ubiquitin	  carboxyl-­‐terminal	  hydrolase	  FAF-­‐X 10 4.40 0 0.00 6 2.69
Q93009 Ubiquitin	  carboxyl-­‐terminal	  hydrolase	  7 7 8.53 4 3.63 4 6.99
Q93034 Cullin-­‐5 3 2.82 0 0.00 0 0.00
Q93050 V-­‐type	  proton	  ATPase	  116	  kDa	  subunit	  a	  isoform	  1 28 20.55 11 10.87 11 7.77
Q93052 Lipoma-­‐preferred	  partner 4 6.70 4 6.70 1 2.45
Q93077 Histone	  H2A	  type	  1-­‐C 54 47.69 55 37.69 35 37.69
Q93079 Histone	  H2B	  type	  1-­‐H 61 67.46 61 62.70 43 57.94
Q95365 HLA	  class	  I	  histocompatibility	  antigen,	  B-­‐38	  alpha	  chain 15 26.24 5 14.09 9 22.65
Q969E4 Transcription	  elongation	  factor	  A	  protein-­‐like	  3 1 4.50 1 4.50 1 10.50
Q969G3 SWI/SNF-­‐related	  matrix-­‐associated	  actin-­‐dependent	  regulator	  of	  chromatin	  subfamily	  E	  member	  12 5.60 0 0.00 0 0.00
Q969H8 UPF0556	  protein	  C19orf10 2 13.87 0 0.00 0 0.00
Q969N2 GPI	  transamidase	  component	  PIG-­‐T 1 2.59 1 2.59 1 2.59
Q969P0 Immunoglobulin	  superfamily	  member	  8 4 9.30 0 0.00 0 0.00
Q969S9 Ribosome-­‐releasing	  factor	  2,	  mitochondrial 3 6.16 0 0.00 1 2.44
Q969T4 Ubiquitin-­‐conjugating	  enzyme	  E2	  E3 2 9.66 0 0.00 0 0.00
Q969V3 Nicalin 9 14.03 4 4.97 7 12.08
Q969X5 Endoplasmic	  reticulum-­‐Golgi	  intermediate	  compartment	  protein	  1 3 11.03 1 8.28 0 0.00
Q969Y2 tRNA	  modification	  GTPase	  GTPBP3,	  mitochondrial 2 8.94 1 4.27 1 4.27
Q969Z3 MOSC	  domain-­‐containing	  protein	  2,	  mitochondrial 1 4.48 0 0.00 0 0.00
Q96A33 Coiled-­‐coil	  domain-­‐containing	  protein	  47 2 4.55 0 0.00 0 0.00
Q96A65 Exocyst	  complex	  component	  4 8 10.68 0 0.00 2 3.39
Q96A72 Protein	  mago	  nashi	  homolog	  2 1 13.51 0 0.00 0 0.00
Q96AB3 Isochorismatase	  domain-­‐containing	  protein	  2,	  mitochondrial 9 38.54 3 17.07 3 17.07
Q96AB6 Protein	  N-­‐terminal	  asparagine	  amidohydrolase 1 7.10 2 7.10 2 7.10
Q96AC1 Fermitin	  family	  homolog	  2 5 13.24 0 0.00 5 14.41
Q96AE4 Far	  upstream	  element-­‐binding	  protein	  1 12 13.98 6 9.32 0 0.00
Q96AG3 Solute	  carrier	  family	  25	  member	  46 2 5.50 0 0.00 0 0.00
Q96AG4 Leucine-­‐rich	  repeat-­‐containing	  protein	  59 13 29.97 8 22.15 2 7.17
Q96AQ6 Pre-­‐B-­‐cell	  leukemia	  transcription	  factor-­‐interacting	  protein	  1 5 7.11 2 3.69 1 2.19
Q96AX1 Vacuolar	  protein	  sorting-­‐associated	  protein	  33A 5 5.71 4 8.05 3 5.37
Q96AY2 Crossover	  junction	  endonuclease	  EME1 1 2.11 0 0.00 0 0.00
Q96AY3 Peptidyl-­‐prolyl	  cis-­‐trans	  isomerase	  FKBP10 6 9.62 3 4.81 3 7.22
Q96B97 SH3	  domain-­‐containing	  kinase-­‐binding	  protein	  1 1 2.11 0 0.00 0 0.00
Q96BM9 ADP-­‐ribosylation	  factor-­‐like	  protein	  8A 4 17.20 0 0.00 0 0.00
Q96BW5 Phosphotriesterase-­‐related	  protein 3 16.62 0 0.00 0 0.00
Q96BY6 Dedicator	  of	  cytokinesis	  protein	  10 1 0.73 0 0.00 0 0.00
Q96C01 Protein	  FAM136A 1 5.80 0 0.00 0 0.00
Q96C19 EF-­‐hand	  domain-­‐containing	  protein	  D2 4 16.25 4 13.33 0 0.00
Q96C23 Aldose	  1-­‐epimerase 10 31.87 6 17.84 3 8.48
Q96C36 Pyrroline-­‐5-­‐carboxylate	  reductase	  2 4 15.00 2 7.81 0 0.00
Q96C86 Scavenger	  mRNA-­‐decapping	  enzyme	  DcpS 16 34.72 11 32.64 11 29.67
Q96C90 Protein	  phosphatase	  1	  regulatory	  subunit	  14B 2 8.84 0 0.00 0 0.00
Q96CD0 F-­‐box/LRR-­‐repeat	  protein	  8 2 7.75 2 9.09 2 7.75
Q96CM8 Acyl-­‐CoA	  synthetase	  family	  member	  2,	  mitochondrial 4 9.27 3 6.02 2 2.76
Q96CN7 Isochorismatase	  domain-­‐containing	  protein	  1 2 8.39 2 11.07 3 14.77
Q96CS3 FAS-­‐associated	  factor	  2 5 16.85 3 8.54 3 9.89
Q96CT7 Coiled-­‐coil	  domain-­‐containing	  protein	  124 6 24.22 8 24.22 7 18.39
Q96CU9 FAD-­‐dependent	  oxidoreductase	  domain-­‐containing	  protein	  1 1 2.68 0 0.00 0 0.00
Q96CV9 Optineurin 2 4.51 0 0.00 0 0.00
Q96CW1 AP-­‐2	  complex	  subunit	  mu 2 6.44 0 0.00 0 0.00
Q96CW5 Gamma-­‐tubulin	  complex	  component	  3 4 5.40 2 4.08 3 3.31
Q96CX2 BTB/POZ	  domain-­‐containing	  protein	  KCTD12 8 15.38 4 14.46 3 10.46
Q96D09 G-­‐protein	  coupled	  receptor-­‐associated	  sorting	  protein	  2 1 2.15 0 0.00 0 0.00
Q96D31 Calcium	  release-­‐activated	  calcium	  channel	  protein	  1 1 4.32 1 4.32 1 4.32
Q96D96 Voltage-­‐gated	  hydrogen	  channel	  1 3 10.26 0 0.00 0 0.00
Q96DB5 Regulator	  of	  microtubule	  dynamics	  protein	  1 11 25.16 3 9.55 7 11.78
Q96DC8 Enoyl-­‐CoA	  hydratase	  domain-­‐containing	  protein	  3,	  mitochondrial 1 5.94 0 0.00 1 5.94
Q96DC9 Ubiquitin	  thioesterase	  OTUB2 1 2.99 0 0.00 0 0.00
Q96DG6 Carboxymethylenebutenolidase	  homolog 2 10.20 2 6.94 2 11.02
Q96DT6 Cysteine	  protease	  ATG4C 2 5.68 0 0.00 0 0.00
Q96DV4 39S	  ribosomal	  protein	  L38,	  mitochondrial 2 7.11 0 0.00 0 0.00
Q96DX5 Ankyrin	  repeat	  and	  SOCS	  box	  protein	  9 6 12.24 2 6.46 3 6.46
Q96EB1 Elongator	  complex	  protein	  4 1 4.48 1 4.48 1 4.48
Q96EC8 Protein	  YIPF6 1 5.09 0 0.00 0 0.00
Q96EL3 39S	  ribosomal	  protein	  L53,	  mitochondrial 1 13.39 2 16.07 0 0.00
Q96EP5 DAZ-­‐associated	  protein	  1 5 11.30 0 0.00 1 3.69
Q96EY1 DnaJ	  homolog	  subfamily	  A	  member	  3,	  mitochondrial 7 10.63 2 4.79 4 4.79
Q96EY8 Cob(I)yrinic	  acid	  a,c-­‐diamide	  adenosyltransferase,	  mitochondrial 6 22.00 0 0.00 2 4.00
Q96FV2 Secernin-­‐2 4 17.88 2 8.47 3 10.82
Q96FW1 Ubiquitin	  thioesterase	  OTUB1 16 36.90 9 21.03 9 30.63
Q96G03 Phosphoglucomutase-­‐2 14 21.73 10 15.69 8 17.48
Q96G23 Ceramide	  synthase	  2 2 2.37 0 0.00 1 2.37
Q96GC9 Vacuole	  membrane	  protein	  1 3 7.39 0 0.00 2 7.39
Q96GD0 Pyridoxal	  phosphate	  phosphatase 3 12.84 0 0.00 1 6.76
Q96GK7 Fumarylacetoacetate	  hydrolase	  domain-­‐containing	  protein	  2A 14 28.98 6 25.48 4 11.15
Q96GM5 SWI/SNF-­‐related	  matrix-­‐associated	  actin-­‐dependent	  regulator	  of	  chromatin	  subfamily	  D	  member	  11 3.30 0 0.00 0 0.00
Q96HE7 ERO1-­‐like	  protein	  alpha 9 24.36 0 0.00 6 16.03
Q96HN2 Putative	  adenosylhomocysteinase	  3 4 5.40 0 0.00 2 3.27
Q96HP0 Dedicator	  of	  cytokinesis	  protein	  6 1 0.83 1 0.83 1 0.83
Q96HR9 Receptor	  expression-­‐enhancing	  protein	  6 2 7.06 2 7.06 3 12.50
Q96HS1 Serine/threonine-­‐protein	  phosphatase	  PGAM5,	  mitochondrial 3 13.84 0 0.00 0 0.00
Q96HW7 Integrator	  complex	  subunit	  4 2 3.22 0 0.00 0 0.00
Q96HY6 DDRGK	  domain-­‐containing	  protein	  1 14 37.90 7 19.43 5 15.61
Q96I15 Selenocysteine	  lyase 6 11.01 5 12.81 5 12.81
Q96I24 Far	  upstream	  element-­‐binding	  protein	  3 7 5.42 3 4.02 4 4.02
Q96I25 Splicing	  factor	  45 5 14.71 0 0.00 0 0.00
Q96I59 Probable	  asparaginyl-­‐tRNA	  synthetase,	  mitochondrial 8 19.08 7 19.50 3 9.01
Q96I99 Succinyl-­‐CoA	  ligase	  [GDP-­‐forming]	  subunit	  beta,	  mitochondrial 17 31.02 12 30.32 13 26.16
Q96IU4 Abhydrolase	  domain-­‐containing	  protein	  14B 9 34.76 9 28.10 8 28.10
Q96JB5 CDK5	  regulatory	  subunit-­‐associated	  protein	  3 5 12.85 4 7.11 6 10.28
Q96JC1 Vam6/Vps39-­‐like	  protein 1 1.58 0 0.00 1 1.24
Q96JF0 Beta-­‐galactoside	  alpha-­‐2,6-­‐sialyltransferase	  2 1 2.08 0 0.00 0 0.00
Q96JG6 Coiled-­‐coil	  domain-­‐containing	  protein	  132 1 1.45 0 0.00 0 0.00
Q96JJ3 Engulfment	  and	  cell	  motility	  protein	  2 2 2.36 0 0.00 0 0.00
Q96JM3 Zinc	  finger	  protein	  828 1 1.11 0 0.00 0 0.00
Q96K19 RING	  finger	  protein	  170 2 5.43 0 0.00 0 0.00
Q96K76 Ubiquitin	  carboxyl-­‐terminal	  hydrolase	  47 3 2.04 0 0.00 1 1.31
Q96KK5 Histone	  H2A	  type	  1-­‐H 54 48.44 55 38.28 35 38.28
Q96KP1 Exocyst	  complex	  component	  2 7 6.06 4 6.06 4 4.00
Q96KP4 Cytosolic	  non-­‐specific	  dipeptidase 57 53.89 34 37.68 30 43.58
Q96KR6 Transmembrane	  protein	  C20orf108 3 18.23 2 18.23 2 18.23
Q96LJ7 Dehydrogenase/reductase	  SDR	  family	  member	  1 4 15.97 0 0.00 0 0.00
Q96M27 Protein	  PRRC1 6 13.71 2 7.64 4 10.34
Q96M96 FYVE,	  RhoGEF	  and	  PH	  domain-­‐containing	  protein	  4 2 3.66 0 0.00 0 0.00
Q96MW5 Conserved	  oligomeric	  Golgi	  complex	  subunit	  8 5 8.66 0 0.00 0 0.00
Q96N66 Lysophospholipid	  acyltransferase	  7 4 8.47 2 2.54 2 2.54
Q96N67 Dedicator	  of	  cytokinesis	  protein	  7 10 4.67 8 5.47 8 4.67
Q96NY7 Chloride	  intracellular	  channel	  protein	  6 14 21.88 5 11.79 7 16.05
Q96P48 Arf-­‐GAP	  with	  Rho-­‐GAP	  domain,	  ANK	  repeat	  and	  PH	  domain-­‐containing	  protein	  1 2 2.07 1 0.90 2 2.62
Q96P70 Importin-­‐9 6 8.36 4 5.48 3 1.73
Q96PK2 Microtubule-­‐actin	  cross-­‐linking	  factor	  1,	  isoform	  4 6 1.06 5 0.79 6 1.33
Q96PK6 RNA-­‐binding	  protein	  14 7 10.16 5 8.97 6 7.18
Q96PU5 E3	  ubiquitin-­‐protein	  ligase	  NEDD4-­‐like 7 5.85 2 1.03 4 3.38
Q96PU8 Protein	  quaking 4 13.20 0 0.00 3 12.90
Q96PY5 Formin-­‐like	  protein	  2 1 1.29 0 0.00 1 1.29
Q96QK1 Vacuolar	  protein	  sorting-­‐associated	  protein	  35 32 32.04 21 25.25 18 23.62
Q96QR8 Transcriptional	  activator	  protein	  Pur-­‐beta 4 23.08 5 24.04 5 24.36
Q96QV6 Histone	  H2A	  type	  1-­‐A 57 39.69 60 29.77 40 29.77
Q96RF0 Sorting	  nexin-­‐18 2 4.62 1 2.71 2 4.62
Q96RQ3 Methylcrotonoyl-­‐CoA	  carboxylase	  subunit	  alpha,	  mitochondrial 1 2.48 1 1.79 1 2.48
Q96RT1 Protein	  LAP2 2 2.55 0 0.00 2 3.12
Q96RT7 Gamma-­‐tubulin	  complex	  component	  6 2 1.32 0 0.00 2 1.04
Q96S44 TP53-­‐regulating	  kinase 4 22.53 0 0.00 1 8.30
Q96S52 GPI	  transamidase	  component	  PIG-­‐S 6 12.61 5 14.23 4 10.81
Q96SB3 Neurabin-­‐2 5 6.26 0 0.00 0 0.00
Q96ST3 Paired	  amphipathic	  helix	  protein	  Sin3a 2 1.02 2 2.20 2 1.02
Q96SZ5 2-­‐aminoethanethiol	  dioxygenase 2 14.07 0 0.00 0 0.00
Q96T51 RUN	  and	  FYVE	  domain-­‐containing	  protein	  1 4 6.50 0 0.00 0 0.00
Q96T76 MMS19	  nucleotide	  excision	  repair	  protein	  homolog 10 10.68 5 6.31 5 7.77
Q96TA1 Niban-­‐like	  protein	  1 8 13.40 6 6.03 8 13.94
Q96TC7 Regulator	  of	  microtubule	  dynamics	  protein	  3 5 10.85 3 9.57 3 7.23
Q99426 Tubulin-­‐folding	  cofactor	  B 2 11.89 2 8.61 2 11.89
Q99436 Proteasome	  subunit	  beta	  type-­‐7 5 14.44 1 3.61 3 7.22
Q99447 Ethanolamine-­‐phosphate	  cytidylyltransferase 3 5.91 0 0.00 1 3.60
Q99459 Cell	  division	  cycle	  5-­‐like	  protein 4 8.35 1 1.50 1 2.37
Q99460 26S	  proteasome	  non-­‐ATPase	  regulatory	  subunit	  1 25 25.39 14 20.15 15 18.89
Q99471 Prefoldin	  subunit	  5 3 21.43 3 11.69 2 11.69
Q99497 Protein	  DJ-­‐1 38 78.84 37 78.84 25 70.90
Q99523 Sortilin 11 17.57 8 10.71 8 8.91
Q99536 Synaptic	  vesicle	  membrane	  protein	  VAT-­‐1	  homolog 64 65.39 46 62.09 49 64.38
Q99538 Legumain 1 3.93 1 3.93 1 3.93
Q99567 Nuclear	  pore	  complex	  protein	  Nup88 4 8.77 3 6.75 0 0.00
Q99569 Plakophilin-­‐4 1 0.84 0 0.00 1 0.84
Q99572 P2X	  purinoceptor	  7 8 10.25 6 8.57 4 6.72
Q99575 Ribonucleases	  P/MRP	  protein	  subunit	  POP1 1 1.17 0 0.00 0 0.00
Q99584 Protein	  S100-­‐A13 5 31.63 3 20.41 3 12.24
Q99598 Translin-­‐associated	  protein	  X 2 6.55 2 13.45 3 14.14
Q99613 Eukaryotic	  translation	  initiation	  factor	  3	  subunit	  C 23 20.48 15 10.30 15 17.85
Q99615 DnaJ	  homolog	  subfamily	  C	  member	  7 2 4.25 0 0.00 0 0.00
Q99623 Prohibitin-­‐2 56 66.89 38 52.51 26 55.52
Q99674 Cell	  growth	  regulator	  with	  EF	  hand	  domain	  protein	  1 2 8.97 0 0.00 0 0.00
Q99700 Ataxin-­‐2 1 0.76 0 0.00 0 0.00
Q99714 3-­‐hydroxyacyl-­‐CoA	  dehydrogenase	  type-­‐2 22 70.11 12 49.04 16 67.82
Q99729 Heterogeneous	  nuclear	  ribonucleoprotein	  A/B 11 19.58 10 18.98 8 17.47
Q99733 Nucleosome	  assembly	  protein	  1-­‐like	  4 16 37.60 9 15.20 8 23.20
Q99747 Gamma-­‐soluble	  NSF	  attachment	  protein 1 3.20 0 0.00 2 8.65
Q99757 Thioredoxin,	  mitochondrial 5 32.53 3 32.53 0 0.00
Q99797 Mitochondrial	  intermediate	  peptidase 3 6.17 0 0.00 0 0.00
Q99798 Aconitate	  hydratase,	  mitochondrial 109 47.82 69 41.79 46 30.51
Q99805 Transmembrane	  9	  superfamily	  member	  2 11 9.80 6 5.28 8 5.28
Q99829 Copine-­‐1 14 13.97 4 8.38 8 15.08
Q99832 T-­‐complex	  protein	  1	  subunit	  eta 35 43.46 21 31.31 20 30.76
Q99848 Probable	  rRNA-­‐processing	  protein	  EBP2 2 3.92 0 0.00 0 0.00
Q99873 Protein	  arginine	  N-­‐methyltransferase	  1 7 8.59 3 6.37 3 6.37
Q99877 Histone	  H2B	  type	  1-­‐N 61 67.46 61 62.70 43 57.94
Q99878 Histone	  H2A	  type	  1-­‐J 54 48.44 55 38.28 35 38.28
Q99961 Endophilin-­‐A2 1 3.53 0 0.00 0 0.00
Q9BPW8 Protein	  NipSnap	  homolog	  1 2 4.93 0 0.00 2 4.93
Q9BPX5 Actin-­‐related	  protein	  2/3	  complex	  subunit	  5-­‐like	  protein 4 16.34 1 17.65 5 33.99
Q9BQ67 Glutamate-­‐rich	  WD	  repeat-­‐containing	  protein	  1 3 10.54 2 7.40 2 7.40
Q9BQ69 MACRO	  domain-­‐containing	  protein	  1 10 22.77 8 19.38 9 19.38
Q9BQ70 Transcription	  factor	  25 1 2.22 0 0.00 0 0.00
Q9BQ95 Evolutionarily	  conserved	  signaling	  intermediate	  in	  Toll	  pathway,	  mitochondrial 1 3.94 0 0.00 1 3.94
Q9BQA9 Uncharacterized	  protein	  C17orf62 1 9.63 0 0.00 0 0.00
Q9BQE5 Apolipoprotein	  L2 3 6.53 1 3.26 0 0.00
Q9BQG0 Myb-­‐binding	  protein	  1A 16 10.77 12 6.70 8 5.35
Q9BR76 Coronin-­‐1B 10 22.29 8 17.38 4 11.45
Q9BRA2 Thioredoxin	  domain-­‐containing	  protein	  17 4 26.83 2 11.38 4 19.51
Q9BRF8 Calcineurin-­‐like	  phosphoesterase	  domain-­‐containing	  protein	  1 8 24.52 7 21.02 7 20.38
Q9BRG1 Vacuolar	  protein-­‐sorting-­‐associated	  protein	  25 5 14.20 5 22.16 3 14.20
Q9BRJ2 39S	  ribosomal	  protein	  L45,	  mitochondrial 2 8.50 1 3.27 1 3.27
Q9BRP4 Proteasomal	  ATPase-­‐associated	  factor	  1 2 5.10 0 0.00 0 0.00
Q9BRR6 ADP-­‐dependent	  glucokinase 3 10.26 2 7.45 0 0.00
Q9BRT3 Migration	  and	  invasion	  enhancer	  1 2 15.65 0 0.00 0 0.00
Q9BRX8 Redox-­‐regulatory	  protein	  PAMM 15 31.88 13 24.45 10 20.96
Q9BRZ2 E3	  ubiquitin-­‐protein	  ligase	  TRIM56 5 9.40 0 0.00 0 0.00
Q9BS26 Endoplasmic	  reticulum	  resident	  protein	  44 15 27.09 8 27.59 7 21.18
Q9BSD7 Cancer-­‐related	  nucleoside-­‐triphosphatase 7 38.42 4 22.63 2 14.21
Q9BSH5 Haloacid	  dehalogenase-­‐like	  hydrolase	  domain-­‐containing	  protein	  3 7 27.49 4 23.90 2 14.34
Q9BSJ2 Gamma-­‐tubulin	  complex	  component	  2 4 7.65 0 0.00 0 0.00
Q9BSJ8 Extended	  synaptotagmin-­‐1 10 11.87 9 9.96 8 9.78
Q9BT09 Protein	  canopy	  homolog	  3 1 3.60 1 2.52 0 0.00
Q9BT22 Chitobiosyldiphosphodolichol	  beta-­‐mannosyltransferase 4 8.19 3 6.25 2 6.25
Q9BT40 Inositol	  polyphosphate	  5-­‐phosphatase	  K 2 5.58 1 2.23 2 2.23
Q9BT78 COP9	  signalosome	  complex	  subunit	  4 11 22.66 5 15.52 6 21.43
Q9BTE6 Alanyl-­‐tRNA	  editing	  protein	  Aarsd1 3 10.68 0 0.00 1 3.64
Q9BTM1 Histone	  H2A.J 55 55.04 55 37.98 36 44.96
Q9BTT0 Acidic	  leucine-­‐rich	  nuclear	  phosphoprotein	  32	  family	  member	  E 6 24.63 5 23.88 4 21.27
Q9BTU6 Phosphatidylinositol	  4-­‐kinase	  type	  2-­‐alpha 2 1.88 2 1.88 2 1.88
Q9BTV4 Transmembrane	  protein	  43 4 19.25 3 16.00 3 16.00
Q9BTW9 Tubulin-­‐specific	  chaperone	  D 13 13.67 10 12.42 9 8.73
Q9BTY7 Protein	  FAM203A 7 32.82 4 21.79 5 25.13
Q9BTZ2 Dehydrogenase/reductase	  SDR	  family	  member	  4 3 7.91 0 0.00 0 0.00
Q9BU23 Lipase	  maturation	  factor	  2 2 2.26 2 4.81 0 0.00
Q9BUF5 Tubulin	  beta-­‐6	  chain 87 62.56 57 47.98 0 0.00
Q9BUJ2 Heterogeneous	  nuclear	  ribonucleoprotein	  U-­‐like	  protein	  1 13 14.60 8 12.73 6 9.81
Q9BUP0 EF-­‐hand	  domain-­‐containing	  protein	  D1 12 44.35 22 48.54 13 44.35
Q9BUQ8 Probable	  ATP-­‐dependent	  RNA	  helicase	  DDX23 4 5.00 2 2.68 0 0.00
Q9BUR5 Apolipoprotein	  O 3 18.18 0 0.00 0 0.00
Q9BUT1 3-­‐hydroxybutyrate	  dehydrogenase	  type	  2 6 22.04 2 13.06 3 13.47
Q9BV10 Dol-­‐P-­‐Man:Man(7)GlcNAc(2)-­‐PP-­‐Dol	  alpha-­‐1,6-­‐mannosyltransferase 1 3.28 0 0.00 1 3.28
Q9BV36 Melanophilin 19 25.67 7 20.50 14 21.17
Q9BV38 WD	  repeat-­‐containing	  protein	  18 2 5.56 0 0.00 0 0.00
Q9BV57 1,2-­‐dihydroxy-­‐3-­‐keto-­‐5-­‐methylthiopentene	  dioxygenase 1 7.26 1 7.26 1 7.26
Q9BV79 Trans-­‐2-­‐enoyl-­‐CoA	  reductase,	  mitochondrial 3 6.70 3 6.70 3 6.70
Q9BV86 Alpha	  N-­‐terminal	  protein	  methyltransferase	  1A 2 3.14 0 0.00 0 0.00
Q9BVA1 Tubulin	  beta-­‐2B	  chain 169 67.42 105 66.29 91 65.84
Q9BVC6 Transmembrane	  protein	  109 5 9.05 2 4.94 3 4.94
Q9BVG4 UPF0368	  protein	  Cxorf26 2 4.29 0 0.00 0 0.00
Q9BVI4 Nucleolar	  complex	  protein	  4	  homolog 3 5.62 0 0.00 0 0.00
Q9BVJ7 Dual	  specificity	  protein	  phosphatase	  23 3 22.00 0 0.00 0 0.00
Q9BVK6 Transmembrane	  emp24	  domain-­‐containing	  protein	  9 6 20.00 2 9.36 5 16.17
Q9BVK8 Transmembrane	  protein	  147 1 7.59 0 0.00 1 7.59
Q9BVL4 Selenoprotein	  O 4 8.22 0 0.00 1 2.99
Q9BVP2 Guanine	  nucleotide-­‐binding	  protein-­‐like	  3 2 2.73 4 9.11 3 4.92
Q9BW72 HIG1	  domain	  family	  member	  2A 2 23.58 1 23.58 0 0.00
Q9BW92 Threonyl-­‐tRNA	  synthetase,	  mitochondrial 4 6.68 0 0.00 0 0.00
Q9BWD1 Acetyl-­‐CoA	  acetyltransferase,	  cytosolic 6 16.62 2 9.57 3 14.61
Q9BWF3 RNA-­‐binding	  protein	  4 4 23.35 4 22.25 5 19.78
Q9BWM7 Sideroflexin-­‐3 18 40.62 8 27.38 7 27.38
Q9BWS9 Chitinase	  domain-­‐containing	  protein	  1 6 19.34 1 3.56 6 15.78
Q9BX66 Sorbin	  and	  SH3	  domain-­‐containing	  protein	  1 18 11.53 7 5.42 12 10.60
Q9BX68 Histidine	  triad	  nucleotide-­‐binding	  protein	  2,	  mitochondrial 8 31.90 6 31.90 4 31.90
Q9BX70 BTB/POZ	  domain-­‐containing	  protein	  2 1 2.67 0 0.00 0 0.00
Q9BXJ9 N-­‐alpha-­‐acetyltransferase	  15,	  NatA	  auxiliary	  subunit 7 9.81 3 5.08 3 5.08
Q9BXK5 Bcl-­‐2-­‐like	  protein	  13 26 39.59 12 24.54 14 25.36
Q9BXP2 Solute	  carrier	  family	  12	  member	  9 6 10.83 1 1.09 0 0.00
Q9BXP5 Serrate	  RNA	  effector	  molecule	  homolog 4 5.48 0 0.00 0 0.00
Q9BXS5 AP-­‐1	  complex	  subunit	  mu-­‐1 7 14.89 2 5.91 2 7.80
Q9BXV9 Uncharacterized	  protein	  C14orf142 2 18.00 0 0.00 2 18.00
Q9BXW6 Oxysterol-­‐binding	  protein-­‐related	  protein	  1 3 3.89 0 0.00 1 1.68
Q9BXW7 Cat	  eye	  syndrome	  critical	  region	  protein	  5 5 8.51 3 11.58 0 0.00
Q9BXY0 Protein	  MAK16	  homolog 1 4.67 0 0.00 1 4.67
Q9BY32 Inosine	  triphosphate	  pyrophosphatase 3 14.95 0 0.00 1 8.76
Q9BY50 Signal	  peptidase	  complex	  catalytic	  subunit	  SEC11C 2 5.21 1 5.21 3 15.63
Q9BYD1 39S	  ribosomal	  protein	  L13,	  mitochondrial 5 22.47 5 28.65 2 8.43
Q9BYD2 39S	  ribosomal	  protein	  L9,	  mitochondrial 2 10.11 1 6.37 1 6.37
Q9BYD3 39S	  ribosomal	  protein	  L4,	  mitochondrial 7 28.30 1 5.14 2 11.25
Q9BYI3 Hyccin 2 6.33 2 3.07 1 2.11
Q9BYJ9 YTH	  domain	  family	  protein	  1 1 1.61 0 0.00 0 0.00
Q9BYT8 Neurolysin,	  mitochondrial 6 9.66 2 4.54 5 5.82
Q9BZ67 FERM	  domain-­‐containing	  protein	  8 1 2.37 1 2.37 0 0.00
Q9BZE1 39S	  ribosomal	  protein	  L37,	  mitochondrial 3 7.56 2 5.44 0 0.00
Q9BZE9 Tether	  containing	  UBX	  domain	  for	  GLUT4 3 6.15 3 6.51 3 4.70
Q9BZF1 Oxysterol-­‐binding	  protein-­‐related	  protein	  8 4 4.72 4 5.96 7 8.55
Q9BZF9 Uveal	  autoantigen	  with	  coiled-­‐coil	  domains	  and	  ankyrin	  repeats 3 2.82 1 0.71 2 1.06
Q9BZH6 WD	  repeat-­‐containing	  protein	  11 4 4.57 3 3.43 2 2.78
Q9BZJ0 Crooked	  neck-­‐like	  protein	  1 2 2.83 0 0.00 0 0.00
Q9BZJ3 Tryptase	  delta 4 9.92 2 6.20 2 8.68
Q9BZL4 Protein	  phosphatase	  1	  regulatory	  subunit	  12C 3 5.12 0 0.00 0 0.00
Q9BZQ8 Protein	  Niban 9 11.85 11 12.82 10 10.78
Q9BZZ5 Apoptosis	  inhibitor	  5 11 18.13 4 9.35 3 3.44
Q9C005 Protein	  dpy-­‐30	  homolog 9 45.45 7 45.45 4 36.36
Q9C0C2 182	  kDa	  tankyrase-­‐1-­‐binding	  protein 2 0.87 1 0.87 0 0.00
Q9C0E2 Exportin-­‐4 5 4.52 2 2.35 2 1.48
Q9C0E8 Protein	  lunapark 6 19.39 0 0.00 0 0.00
Q9C0H2 Protein	  tweety	  homolog	  3 2 4.97 0 0.00 0 0.00
Q9GIY3 HLA	  class	  II	  histocompatibility	  antigen,	  DRB1-­‐14	  beta	  chain 4 16.92 0 0.00 0 0.00
Q9GZM8 Nuclear	  distribution	  protein	  nudE-­‐like	  1 2 3.48 0 0.00 0 0.00
Q9GZR7 ATP-­‐dependent	  RNA	  helicase	  DDX24 4 6.87 4 6.05 2 3.03
Q9GZS3 WD	  repeat-­‐containing	  protein	  61 1 5.57 0 0.00 0 0.00
Q9GZT3 SRA	  stem-­‐loop-­‐interacting	  RNA-­‐binding	  protein,	  mitochondrial 4 22.02 2 12.84 1 12.84
Q9GZT8 NIF3-­‐like	  protein	  1 3 10.08 4 14.06 2 6.37
Q9GZY8 Mitochondrial	  fission	  factor 10 23.10 9 19.88 7 19.01
Q9H008 Phospholysine	  phosphohistidine	  inorganic	  pyrophosphate	  phosphatase 10 18.52 8 21.48 4 18.52
Q9H061 Transmembrane	  protein	  126A 2 9.74 3 17.95 3 20.00
Q9H0A0 N-­‐acetyltransferase	  10 5 8.59 6 5.85 7 9.37
Q9H0A8 COMM	  domain-­‐containing	  protein	  4 2 17.09 0 0.00 2 20.10
Q9H0B6 Kinesin	  light	  chain	  2 6 11.41 0 0.00 0 0.00
Q9H0C8 Integrin-­‐linked	  kinase-­‐associated	  serine/threonine	  phosphatase	  2C 4 8.42 0 0.00 0 0.00
Q9H0D6 5'-­‐3'	  exoribonuclease	  2 7 12.32 5 8.63 6 10.00
Q9H0E2 Toll-­‐interacting	  protein 7 15.33 3 10.58 3 9.85
Q9H0E9 Bromodomain-­‐containing	  protein	  8 1 1.05 1 1.05 0 0.00
Q9H0F6 Sharpin 1 3.88 0 0.00 0 0.00
Q9H0R4 Haloacid	  dehalogenase-­‐like	  hydrolase	  domain-­‐containing	  protein	  2 10 27.41 9 27.80 1 11.20
Q9H0U3 Magnesium	  transporter	  protein	  1 1 2.99 0 0.00 0 0.00
Q9H0W9 Ester	  hydrolase	  C11orf54 3 9.21 1 3.81 3 9.21
Q9H1A3 Methyltransferase-­‐like	  protein	  9 5 16.98 2 9.12 3 14.15
Q9H1A4 Anaphase-­‐promoting	  complex	  subunit	  1 2 1.80 0 0.00 0 0.00
Q9H1E3 Nuclear	  ubiquitous	  casein	  and	  cyclin-­‐dependent	  kinases	  substrate 10 11.93 4 8.23 6 8.23
Q9H1E5 Thioredoxin-­‐related	  transmembrane	  protein	  4 2 7.74 2 4.30 1 4.30
Q9H1H9 Kinesin-­‐like	  protein	  KIF13A 4 2.82 0 0.00 0 0.00
Q9H1I8 Activating	  signal	  cointegrator	  1	  complex	  subunit	  2 1 1.72 0 0.00 0 0.00
Q9H1K0 Rabenosyn-­‐5 1 1.53 0 0.00 0 0.00
Q9H1K1 Iron-­‐sulfur	  cluster	  assembly	  enzyme	  ISCU,	  mitochondrial 1 5.39 1 5.39 0 0.00
Q9H1Z4 WD	  repeat-­‐containing	  protein	  13 4 8.25 3 5.36 0 0.00
Q9H1Z9 Tetraspanin-­‐10 5 10.14 1 3.10 0 0.00
Q9H201 Epsin-­‐3 2 1.58 1 1.58 1 1.58
Q9H223 EH	  domain-­‐containing	  protein	  4 18 24.21 9 14.42 11 16.45
Q9H246 Uncharacterized	  protein	  C1orf21 1 8.26 0 0.00 0 0.00
Q9H267 Vacuolar	  protein	  sorting-­‐associated	  protein	  33B 4 9.40 1 2.11 2 5.19
Q9H269 Vacuolar	  protein	  sorting-­‐associated	  protein	  16	  homolog 7 5.01 6 5.01 3 2.26
Q9H270 Vacuolar	  protein	  sorting-­‐associated	  protein	  11	  homolog 2 3.83 6 5.63 2 3.83
Q9H299 SH3	  domain-­‐binding	  glutamic	  acid-­‐rich-­‐like	  protein	  3 3 26.88 2 26.88 3 16.13
Q9H2D6 TRIO	  and	  F-­‐actin-­‐binding	  protein 5 1.78 0 0.00 0 0.00
Q9H2G2 STE20-­‐like	  serine/threonine-­‐protein	  kinase 5 4.45 1 1.86 5 4.45
Q9H2I8 Leucine-­‐rich	  repeat-­‐containing	  protein	  C10orf11 1 11.62 0 0.00 1 11.62
Q9H2M9 Rab3	  GTPase-­‐activating	  protein	  non-­‐catalytic	  subunit 8 5.03 3 2.15 1 1.15
Q9H2U1 Probable	  ATP-­‐dependent	  RNA	  helicase	  DHX36 1 1.59 0 0.00 0 0.00
Q9H2U2 Inorganic	  pyrophosphatase	  2,	  mitochondrial 19 44.91 8 22.46 5 14.07
Q9H2V7 Protein	  spinster	  homolog	  1 3 5.87 0 0.00 0 0.00
Q9H307 Pinin 6 7.67 0 0.00 0 0.00
Q9H330 Transmembrane	  protein	  C9orf5 2 2.53 0 0.00 0 0.00
Q9H3G5 Probable	  serine	  carboxypeptidase	  CPVL 16 18.91 11 18.91 6 13.87
Q9H3K6 BolA-­‐like	  protein	  2 4 40.70 4 40.70 3 18.60
Q9H3N1 Thioredoxin-­‐related	  transmembrane	  protein	  1 5 12.14 2 6.79 0 0.00
Q9H3P7 Golgi	  resident	  protein	  GCP60 5 11.17 3 7.01 4 7.01
Q9H3Q1 Cdc42	  effector	  protein	  4 2 5.34 1 5.34 1 4.49
Q9H3S7 Tyrosine-­‐protein	  phosphatase	  non-­‐receptor	  type	  23 8 5.75 5 3.67 4 3.91
Q9H446 RWD	  domain-­‐containing	  protein	  1 1 7.00 0 0.00 0 0.00
Q9H479 Fructosamine-­‐3-­‐kinase 4 16.83 0 0.00 0 0.00
Q9H490 Phosphatidylinositol	  glycan	  anchor	  biosynthesis	  class	  U	  protein 1 3.91 2 3.91 2 3.91
Q9H4A3 Serine/threonine-­‐protein	  kinase	  WNK1 3 1.13 0 0.00 0 0.00
Q9H4A4 Aminopeptidase	  B 24 34.31 15 16.31 14 14.62
Q9H4A5 Golgi	  phosphoprotein	  3-­‐like 1 4.56 1 4.56 0 0.00
Q9H4A6 Golgi	  phosphoprotein	  3 1 4.36 1 4.36 0 0.00
Q9H4B0 Probable	  tRNA	  threonylcarbamoyladenosine	  biosynthesis	  protein	  OSGEPL1 2 6.52 2 4.35 0 0.00
Q9H4G4 Golgi-­‐associated	  plant	  pathogenesis-­‐related	  protein	  1 2 16.88 0 0.00 3 16.88
Q9H4M9 EH	  domain-­‐containing	  protein	  1 12 23.60 9 13.67 8 13.30
Q9H583 HEAT	  repeat-­‐containing	  protein	  1 3 2.01 1 0.75 2 1.40
Q9H5N1 Rab	  GTPase-­‐binding	  effector	  protein	  2 2 3.16 0 0.00 0 0.00
Q9H5X1 MIP18	  family	  protein	  FAM96A 1 5.62 1 5.62 2 8.75
Q9H6F5 Coiled-­‐coil	  domain-­‐containing	  protein	  86 1 3.06 0 0.00 0 0.00
Q9H6K4 Optic	  atrophy	  3	  protein 6 20.67 3 16.76 2 16.76
Q9H6R4 Nucleolar	  protein	  6 6 5.41 5 5.41 4 5.06
Q9H6S3 Epidermal	  growth	  factor	  receptor	  kinase	  substrate	  8-­‐like	  protein	  2 3 5.03 0 0.00 1 2.80
Q9H6V9 UPF0554	  protein	  C2orf43 1 2.77 0 0.00 2 3.08
Q9H6Z4 Ran-­‐binding	  protein	  3 1 2.12 0 0.00 0 0.00
Q9H773 dCTP	  pyrophosphatase	  1 5 26.47 0 0.00 0 0.00
Q9H7B2 Ribosome	  production	  factor	  2	  homolog 4 13.07 0 0.00 1 2.61
Q9H7C9 UPF0366	  protein	  C11orf67 2 22.13 0 0.00 0 0.00
Q9H7D7 WD	  repeat-­‐containing	  protein	  26 5 5.60 4 7.87 3 7.87
Q9H7Z7 Prostaglandin	  E	  synthase	  2 18 32.63 11 25.99 8 19.63
Q9H845 Acyl-­‐CoA	  dehydrogenase	  family	  member	  9,	  mitochondrial 2 3.54 3 4.51 3 5.96
Q9H871 Protein	  RMD5	  homolog	  A 1 3.33 1 3.33 0 0.00
Q9H8H2 Probable	  ATP-­‐dependent	  RNA	  helicase	  DDX31 2 2.00 1 2.00 1 2.00
Q9H8Y8 Golgi	  reassembly-­‐stacking	  protein	  2 3 10.84 0 0.00 4 14.82
Q9H910 Hematological	  and	  neurological	  expressed	  1-­‐like	  protein 4 22.11 1 7.37 0 0.00
Q9H936 Mitochondrial	  glutamate	  carrier	  1 3 12.69 0 0.00 0 0.00
Q9H9B4 Sideroflexin-­‐1 6 19.57 0 0.00 0 0.00
Q9H9C1 VPS33B-­‐interacting	  protein 4 7.91 1 1.42 0 0.00
Q9H9J2 39S	  ribosomal	  protein	  L44,	  mitochondrial 1 5.12 1 5.12 0 0.00
Q9H9P8 L-­‐2-­‐hydroxyglutarate	  dehydrogenase,	  mitochondrial 4 7.13 0 0.00 1 2.59
Q9H9S3 Protein	  transport	  protein	  Sec61	  subunit	  alpha	  isoform	  2 3 5.25 0 0.00 0 0.00
Q9HA82 Ceramide	  synthase	  4 3 5.58 0 0.00 0 0.00
Q9HAV7 GrpE	  protein	  homolog	  1,	  mitochondrial 6 17.05 3 12.90 2 5.07
Q9HB07 UPF0160	  protein	  MYG1,	  mitochondrial 8 15.43 3 9.04 0 0.00
Q9HB90 Ras-­‐related	  GTP-­‐binding	  protein	  C 2 5.76 1 2.26 0 0.00
Q9HBH5 Retinol	  dehydrogenase	  14 3 9.82 0 0.00 0 0.00
Q9HBJ8 Collectrin 1 6.31 0 0.00 0 0.00
Q9HBL7 Transmembrane	  protein	  C9orf46 2 14.29 0 0.00 0 0.00
Q9HC35 Echinoderm	  microtubule-­‐associated	  protein-­‐like	  4 2 2.85 0 0.00 0 0.00
Q9HC38 Glyoxalase	  domain-­‐containing	  protein	  4 13 33.23 6 23.64 5 23.00
Q9HCC0 Methylcrotonoyl-­‐CoA	  carboxylase	  beta	  chain,	  mitochondrial 9 19.72 6 11.90 3 7.81
Q9HCD5 Nuclear	  receptor	  coactivator	  5 2 3.11 3 3.11 2 3.11
Q9HCE1 Putative	  helicase	  MOV-­‐10 7 9.67 0 0.00 0 0.00
Q9HCF4 Protein	  ALO17 4 3.03 1 0.77 1 0.77
Q9HCJ6 Synaptic	  vesicle	  membrane	  protein	  VAT-­‐1	  homolog-­‐like 2 5.25 1 2.86 0 0.00
Q9HCN8 Stromal	  cell-­‐derived	  factor	  2-­‐like	  protein	  1 1 9.05 0 0.00 0 0.00
Q9HD20 Probable	  cation-­‐transporting	  ATPase	  13A1 13 9.80 5 4.48 8 6.81
Q9HD26 Golgi-­‐associated	  PDZ	  and	  coiled-­‐coil	  motif-­‐containing	  protein 2 4.11 1 4.11 0 0.00
Q9HD33 39S	  ribosomal	  protein	  L47,	  mitochondrial 4 8.40 2 4.80 1 4.80
Q9HD45 Transmembrane	  9	  superfamily	  member	  3 2 3.06 0 0.00 0 0.00
Q9HD67 Myosin-­‐X 8 5.15 3 2.19 4 2.28
Q9HDC9 Adipocyte	  plasma	  membrane-­‐associated	  protein 6 18.27 6 20.43 9 18.27
Q9NNW7 Thioredoxin	  reductase	  2,	  mitochondrial 7 20.23 0 0.00 3 9.73
Q9NP66 High	  mobility	  group	  protein	  20A 3 13.26 0 0.00 0 0.00
Q9NP72 Ras-­‐related	  protein	  Rab-­‐18 3 13.11 2 13.11 2 13.11
Q9NP81 Seryl-­‐tRNA	  synthetase,	  mitochondrial 13 29.34 5 15.06 6 18.53
Q9NP97 Dynein	  light	  chain	  roadblock-­‐type	  1 3 29.17 4 29.17 4 29.17
Q9NPF4 Probable	  tRNA	  threonylcarbamoyladenosine	  biosynthesis	  protein	  OSGEP 4 13.73 4 14.03 2 7.46
Q9NPJ6 Mediator	  of	  RNA	  polymerase	  II	  transcription	  subunit	  4 2 11.11 1 4.81 1 4.81
Q9NPL8 Translocase	  of	  inner	  mitochondrial	  membrane	  domain-­‐containing	  protein	  1 5 21.40 0 0.00 2 10.18
Q9NPQ8 Synembryn-­‐A 4 11.49 3 8.66 5 12.43
Q9NQ50 39S	  ribosomal	  protein	  L40,	  mitochondrial 3 23.30 3 14.56 0 0.00
Q9NQ79 Cartilage	  acidic	  protein	  1 5 10.59 5 8.02 4 6.50
Q9NQ88 Probable	  fructose-­‐2,6-­‐bisphosphatase	  TIGAR 3 12.96 1 4.07 2 12.96
Q9NQC3 Reticulon-­‐4 8 5.96 7 5.96 11 8.98
Q9NQG5 Regulation	  of	  nuclear	  pre-­‐mRNA	  domain-­‐containing	  protein	  1B 7 13.80 4 11.35 4 14.42
Q9NQL2 Ras-­‐related	  GTP-­‐binding	  protein	  D 2 5.75 1 2.25 0 0.00
Q9NQP4 Prefoldin	  subunit	  4 6 36.57 3 20.15 6 20.15
Q9NQR4 Omega-­‐amidase	  NIT2 13 32.61 11 26.45 11 38.04
Q9NQT8 Kinesin-­‐like	  protein	  KIF13B 4 2.90 0 0.00 4 2.41
Q9NQU5 Serine/threonine-­‐protein	  kinase	  PAK	  6 1 1.61 0 0.00 0 0.00
Q9NQW7 Xaa-­‐Pro	  aminopeptidase	  1 12 17.82 6 13.64 9 17.01
Q9NQX3 Gephyrin 1 2.72 2 2.72 3 5.84
Q9NR28 Diablo	  homolog,	  mitochondrial 12 28.03 8 20.50 5 16.32
Q9NR30 Nucleolar	  RNA	  helicase	  2 5 5.24 2 4.09 2 4.21
Q9NR31 GTP-­‐binding	  protein	  SAR1a 18 54.55 10 34.85 8 23.23
Q9NR45 Sialic	  acid	  synthase 14 28.41 8 21.45 9 21.45
Q9NRF8 CTP	  synthase	  2 8 12.80 0 0.00 4 6.83
Q9NRG7 Epimerase	  family	  protein	  SDR39U1 2 10.66 1 5.02 2 5.02
Q9NRH3 Tubulin	  gamma-­‐2	  chain 12 23.73 8 28.38 8 26.39
Q9NRP0 Oligosaccharyltransferase	  complex	  subunit	  OSTC 5 8.05 2 8.05 0 0.00
Q9NRV9 Heme-­‐binding	  protein	  1 17 64.02 5 19.58 7 44.97
Q9NRW7 Vacuolar	  protein	  sorting-­‐associated	  protein	  45 8 10.70 3 4.39 3 4.39
Q9NRX4 14	  kDa	  phosphohistidine	  phosphatase 3 25.60 3 24.00 0 0.00
Q9NRZ7 1-­‐acyl-­‐sn-­‐glycerol-­‐3-­‐phosphate	  acyltransferase	  gamma 3 5.58 0 0.00 0 0.00
Q9NS69 Mitochondrial	  import	  receptor	  subunit	  TOM22	  homolog 7 33.80 3 25.35 2 17.61
Q9NS86 LanC-­‐like	  protein	  2 2 7.11 0 0.00 0 0.00
Q9NSB2 Keratin,	  type	  II	  cuticular	  Hb4 5 2.50 0 0.00 0 0.00
Q9NSD9 Phenylalanyl-­‐tRNA	  synthetase	  beta	  chain 23 28.01 14 14.77 15 18.34
Q9NSE4 Isoleucyl-­‐tRNA	  synthetase,	  mitochondrial 21 22.63 12 10.87 9 7.61
Q9NSK0 Kinesin	  light	  chain	  4 8 12.92 0 0.00 0 0.00
Q9NT62 Ubiquitin-­‐like-­‐conjugating	  enzyme	  ATG3 2 7.33 2 7.33 2 7.33
Q9NTG7 NAD-­‐dependent	  deacetylase	  sirtuin-­‐3,	  mitochondrial 3 5.51 2 2.76 2 2.76
Q9NTI5 Sister	  chromatid	  cohesion	  protein	  PDS5	  homolog	  B 3 1.59 0 0.00 2 1.93
Q9NTJ4 Alpha-­‐mannosidase	  2C1 2 2.50 2 2.50 3 3.46
Q9NTJ5 Phosphatidylinositide	  phosphatase	  SAC1 8 14.82 0 0.00 1 1.70
Q9NTK5 Obg-­‐like	  ATPase	  1 10 15.66 7 11.62 7 13.89
Q9NTX5 Enoyl-­‐CoA	  hydratase	  domain-­‐containing	  protein	  1 4 10.10 1 3.91 2 9.77
Q9NTZ6 RNA-­‐binding	  protein	  12 4 3.65 3 2.58 2 2.58
Q9NUJ1 Abhydrolase	  domain-­‐containing	  protein	  10,	  mitochondrial 5 17.32 7 17.32 3 8.17
Q9NUL5 UPF0515	  protein	  C19orf66 1 6.19 0 0.00 1 6.19
Q9NUN5 Probable	  lysosomal	  cobalamin	  transporter 1 3.33 0 0.00 0 0.00
Q9NUP1 Protein	  cappuccino	  homolog 2 14.29 0 0.00 0 0.00
Q9NUQ7 Ufm1-­‐specific	  protease	  2 2 6.82 0 0.00 2 3.62
Q9NUQ9 Protein	  FAM49B 12 30.25 6 17.90 6 17.90
Q9NV06 DDB1-­‐	  and	  CUL4-­‐associated	  factor	  13 1 3.60 0 0.00 0 0.00
Q9NVA2 Septin-­‐11 7 22.84 0 0.00 0 0.00
Q9NVD7 Alpha-­‐parvin 3 7.53 3 8.60 3 11.29
Q9NVE7 Pantothenate	  kinase	  4 2 3.88 1 1.81 1 1.81
Q9NVG8 TBC1	  domain	  family	  member	  13 4 13.00 3 11.00 0 0.00
Q9NVH1 DnaJ	  homolog	  subfamily	  C	  member	  11 4 8.05 8 14.31 0 0.00
Q9NVI7 ATPase	  family	  AAA	  domain-­‐containing	  protein	  3A 13 20.50 10 14.83 8 12.62
Q9NVJ2 ADP-­‐ribosylation	  factor-­‐like	  protein	  8B 3 12.37 0 0.00 0 0.00
Q9NVS9 Pyridoxine-­‐5'-­‐phosphate	  oxidase 3 16.09 2 12.64 0 0.00
Q9NVZ3 Adaptin	  ear-­‐binding	  coat-­‐associated	  protein	  2 2 9.51 2 3.80 1 3.80
Q9NW81 ATP	  synthase	  subunit	  s-­‐like	  protein 1 7.00 0 0.00 0 0.00
Q9NWQ8 Phosphoprotein	  associated	  with	  glycosphingolipid-­‐enriched	  microdomains	  1 1 2.55 0 0.00 0 0.00
Q9NWU2 Protein	  C20orf11 4 9.65 3 16.23 2 16.23
Q9NWV4 UPF0587	  protein	  C1orf123 5 25.62 4 40.63 1 10.00
Q9NWV8 BRISC	  and	  BRCA1-­‐A	  complex	  member	  1 3 16.11 0 0.00 0 0.00
Q9NWW5 Ceroid-­‐lipofuscinosis	  neuronal	  protein	  6 1 6.75 2 10.29 2 6.75
Q9NX08 COMM	  domain-­‐containing	  protein	  8 1 6.56 0 0.00 1 6.56
Q9NX14 NADH	  dehydrogenase	  [ubiquinone]	  1	  beta	  subcomplex	  subunit	  11,	  mitochondrial 2 22.22 0 0.00 0 0.00
Q9NX18 Succinate	  dehydrogenase	  assembly	  factor	  2,	  mitochondrial 1 7.23 0 0.00 1 7.23
Q9NX24 H/ACA	  ribonucleoprotein	  complex	  subunit	  2 2 23.53 0 0.00 1 12.42
Q9NX40 OCIA	  domain-­‐containing	  protein	  1 9 31.43 2 8.98 0 0.00
Q9NX46 Poly(ADP-­‐ribose)	  glycohydrolase	  ARH3 6 20.11 3 11.85 3 11.85
Q9NX55 Huntingtin-­‐interacting	  protein	  K 2 11.63 1 11.63 2 11.63
Q9NX58 Cell	  growth-­‐regulating	  nucleolar	  protein 2 3.69 2 10.29 1 3.69
Q9NX62 Inositol	  monophosphatase	  3 1 3.34 0 0.00 0 0.00
Q9NX63 Coiled-­‐coil-­‐helix-­‐coiled-­‐coil-­‐helix	  domain-­‐containing	  protein	  3,	  mitochondrial 9 18.94 7 25.99 4 14.98
Q9NXA8 NAD-­‐dependent	  deacetylase	  sirtuin-­‐5 2 4.19 1 5.48 0 0.00
Q9NXD2 Myotubularin-­‐related	  protein	  10 1 2.57 0 0.00 1 1.67
Q9NXE4 Sphingomyelin	  phosphodiesterase	  4 1 1.81 1 1.81 2 3.75
Q9NXF1 Testis-­‐expressed	  sequence	  10	  protein 5 5.27 2 3.66 2 3.44
Q9NXR1 Nuclear	  distribution	  protein	  nudE	  homolog	  1 2 3.47 0 0.00 0 0.00
Q9NXR7 BRCA1-­‐A	  complex	  subunit	  BRE 2 6.27 1 3.66 0 0.00
Q9NY12 H/ACA	  ribonucleoprotein	  complex	  subunit	  1 2 4.15 0 0.00 0 0.00
Q9NY15 Stabilin-­‐1 2 1.28 5 2.76 0 0.00
Q9NY27 Serine/threonine-­‐protein	  phosphatase	  4	  regulatory	  subunit	  2 1 3.60 0 0.00 0 0.00
Q9NY33 Dipeptidyl	  peptidase	  3 13 24.97 8 17.37 9 21.17
Q9NY65 Tubulin	  alpha-­‐8	  chain 88 48.55 70 41.43 64 44.10
Q9NYF8 Bcl-­‐2-­‐associated	  transcription	  factor	  1 2 1.74 0 0.00 0 0.00
Q9NYK5 39S	  ribosomal	  protein	  L39,	  mitochondrial 2 7.69 2 7.69 1 4.44
Q9NYL4 Peptidyl-­‐prolyl	  cis-­‐trans	  isomerase	  FKBP11 6 24.88 0 0.00 0 0.00
Q9NYL9 Tropomodulin-­‐3 2 9.09 0 0.00 0 0.00
Q9NYU2 UDP-­‐glucose:glycoprotein	  glucosyltransferase	  1 20 15.05 8 9.71 14 11.25
Q9NYY8 FAST	  kinase	  domain-­‐containing	  protein	  2 1 1.13 0 0.00 0 0.00
Q9NZ01 Trans-­‐2,3-­‐enoyl-­‐CoA	  reductase 7 13.96 3 6.82 4 10.06
Q9NZ32 Actin-­‐related	  protein	  10 5 12.71 1 3.36 1 3.36
Q9NZ45 CDGSH	  iron-­‐sulfur	  domain-­‐containing	  protein	  1 4 34.26 0 0.00 2 13.89
Q9NZ53 Podocalyxin-­‐like	  protein	  2 2 2.31 1 2.31 1 2.31
Q9NZB2 Constitutive	  coactivator	  of	  PPAR-­‐gamma-­‐like	  protein	  1 12 11.54 1 1.70 2 3.76
Q9NZH0 G-­‐protein	  coupled	  receptor	  family	  C	  group	  5	  member	  B 1 2.98 2 5.95 3 2.98
Q9NZJ7 Mitochondrial	  carrier	  homolog	  1 3 11.31 0 0.00 0 0.00
Q9NZL9 Methionine	  adenosyltransferase	  2	  subunit	  beta 5 18.26 1 7.49 2 11.08
Q9NZM1 Myoferlin 6 4.27 0 0.00 0 0.00
Q9NZM5 Glioma	  tumor	  suppressor	  candidate	  region	  gene	  2	  protein 1 3.77 0 0.00 1 3.77
Q9NZN4 EH	  domain-­‐containing	  protein	  2 7 12.34 5 8.29 7 8.29
Q9NZT2 Opioid	  growth	  factor	  receptor 4 5.76 3 3.69 2 2.36
Q9NZZ3 Charged	  multivesicular	  body	  protein	  5 1 7.31 1 7.31 2 7.31
Q9P000 COMM	  domain-­‐containing	  protein	  9 7 48.48 3 23.74 0 0.00
Q9P015 39S	  ribosomal	  protein	  L15,	  mitochondrial 2 8.45 2 8.45 2 8.45
Q9P032 NADH	  dehydrogenase	  [ubiquinone]	  1	  alpha	  subcomplex	  assembly	  factor	  4 1 8.00 1 8.00 0 0.00
Q9P035 3-­‐hydroxyacyl-­‐CoA	  dehydratase	  3 14 24.86 12 18.78 11 15.47
Q9P0J0 NADH	  dehydrogenase	  [ubiquinone]	  1	  alpha	  subcomplex	  subunit	  13 11 44.44 5 26.39 5 18.06
Q9P0J7 E3	  ubiquitin-­‐protein	  ligase	  KCMF1 4 8.14 4 8.14 3 8.14
Q9P0K7 Ankycorbin 2 2.86 0 0.00 2 3.47
Q9P0L0 Vesicle-­‐associated	  membrane	  protein-­‐associated	  protein	  A 7 15.26 6 15.26 0 0.00
Q9P0M6 Core	  histone	  macro-­‐H2A.2 13 16.40 0 0.00 11 16.40
Q9P0V9 Septin-­‐10 5 8.15 0 0.00 2 6.83
Q9P1F3 Costars	  family	  protein	  C6orf115 5 35.80 4 35.80 0 0.00
Q9P253 Vacuolar	  protein	  sorting-­‐associated	  protein	  18	  homolog 1 1.13 3 4.63 0 0.00
Q9P258 Protein	  RCC2 6 12.26 7 14.75 3 4.98
Q9P260 LisH	  domain	  and	  HEAT	  repeat-­‐containing	  protein	  KIAA1468 6 5.43 2 0.99 0 0.00
Q9P265 Disco-­‐interacting	  protein	  2	  homolog	  B 6 5.08 3 2.73 4 4.00
Q9P273 Teneurin-­‐3 1 0.37 0 0.00 0 0.00
Q9P286 Serine/threonine-­‐protein	  kinase	  PAK	  7 1 1.53 0 0.00 0 0.00
Q9P2B2 Prostaglandin	  F2	  receptor	  negative	  regulator 1 1.59 0 0.00 0 0.00
Q9P2E9 Ribosome-­‐binding	  protein	  1 44 37.66 17 13.33 21 15.32
Q9P2J5 Leucyl-­‐tRNA	  synthetase,	  cytoplasmic 19 19.90 11 13.44 12 12.41
Q9P2R3 Ankyrin	  repeat	  and	  FYVE	  domain-­‐containing	  protein	  1 10 12.23 4 5.90 6 8.04
Q9P2R7 Succinyl-­‐CoA	  ligase	  [ADP-­‐forming]	  subunit	  beta,	  mitochondrial 14 28.94 6 12.10 4 9.50
Q9P2T1 GMP	  reductase	  2 3 12.36 2 10.34 0 0.00
Q9P2X0 Dolichol-­‐phosphate	  mannosyltransferase	  subunit	  3 1 10.87 0 0.00 0 0.00
Q9P2X3 Protein	  IMPACT 3 13.12 1 6.25 4 13.12
Q9TQE0 HLA	  class	  II	  histocompatibility	  antigen,	  DRB1-­‐9	  beta	  chain 6 13.16 3 4.89 3 9.77
Q9UBB4 Ataxin-­‐10 2 6.95 1 3.58 1 3.58
Q9UBB6 Neurochondrin 1 1.65 0 0.00 0 0.00
Q9UBB9 Tuftelin-­‐interacting	  protein	  11 1 2.75 0 0.00 0 0.00
Q9UBC2 Epidermal	  growth	  factor	  receptor	  substrate	  15-­‐like	  1 6 8.68 1 1.62 2 1.62
Q9UBE0 SUMO-­‐activating	  enzyme	  subunit	  1 14 23.12 8 17.92 9 17.92
Q9UBF2 Coatomer	  subunit	  gamma-­‐2 8 10.56 0 0.00 7 9.18
Q9UBI6 Guanine	  nucleotide-­‐binding	  protein	  G(I)/G(S)/G(O)	  subunit	  gamma-­‐12 10 66.67 8 56.94 9 66.67
Q9UBP0 Spastin 1 1.79 0 0.00 0 0.00
Q9UBQ0 Vacuolar	  protein	  sorting-­‐associated	  protein	  29 10 25.82 7 25.82 2 20.33
Q9UBQ5 Eukaryotic	  translation	  initiation	  factor	  3	  subunit	  K 4 17.89 3 11.47 0 0.00
Q9UBQ7 Glyoxylate	  reductase/hydroxypyruvate	  reductase 18 42.99 9 26.52 13 31.40
Q9UBR2 Cathepsin	  Z 8 12.54 4 7.26 3 7.26
Q9UBS4 DnaJ	  homolog	  subfamily	  B	  member	  11 6 13.97 6 13.97 3 13.97
Q9UBS8 E3	  ubiquitin-­‐protein	  ligase	  RNF14 1 4.22 0 0.00 1 4.22
Q9UBT2 SUMO-­‐activating	  enzyme	  subunit	  2 10 20.31 8 8.75 11 17.50
Q9UBV2 Protein	  sel-­‐1	  homolog	  1 2 4.91 1 2.39 0 0.00
Q9UBV8 Peflin 3 8.45 0 0.00 1 4.58
Q9UBW8 COP9	  signalosome	  complex	  subunit	  7a 5 20.73 5 17.09 6 21.45
Q9UDW1 Cytochrome	  b-­‐c1	  complex	  subunit	  9 4 38.10 0 0.00 2 26.98
Q9UDY2 Tight	  junction	  protein	  ZO-­‐2 3 3.02 6 4.03 2 1.77
Q9UEU0 Vesicle	  transport	  through	  interaction	  with	  t-­‐SNAREs	  homolog	  1B 6 24.57 2 10.34 0 0.00
Q9UEW8 STE20/SPS1-­‐related	  proline-­‐alanine-­‐rich	  protein	  kinase 2 4.59 3 9.17 2 4.59
Q9UFG5 UPF0449	  protein	  C19orf25 3 39.83 3 39.83 2 35.59
Q9UFN0 Protein	  NipSnap	  homolog	  3A 9 36.84 5 24.29 4 16.19
Q9UG56 Phosphatidylserine	  decarboxylase	  proenzyme 2 6.85 2 6.85 0 0.00
Q9UG63 ATP-­‐binding	  cassette	  sub-­‐family	  F	  member	  2 4 4.49 3 3.53 0 0.00
Q9UGT4 Sushi	  domain-­‐containing	  protein	  2 1 1.70 1 1.70 0 0.00
Q9UH65 Switch-­‐associated	  protein	  70 13 17.09 10 13.33 8 10.09
Q9UH99 SUN	  domain-­‐containing	  protein	  2 5 9.76 7 10.46 1 2.09
Q9UHA4 Ragulator	  complex	  protein	  LAMTOR3 5 43.55 4 43.55 5 20.97
Q9UHB6 LIM	  domain	  and	  actin-­‐binding	  protein	  1 4 5.53 0 0.00 0 0.00
Q9UHB9 Signal	  recognition	  particle	  68	  kDa	  protein 4 7.02 2 3.51 3 7.02
Q9UHD8 Septin-­‐9 24 30.72 9 10.24 11 17.24
Q9UHG3 Prenylcysteine	  oxidase	  1 6 12.08 4 11.09 3 8.32
Q9UHK6 Alpha-­‐methylacyl-­‐CoA	  racemase 3 10.73 0 0.00 0 0.00
Q9UHL4 Dipeptidyl	  peptidase	  2 21 30.89 12 24.80 13 33.54
Q9UHQ9 NADH-­‐cytochrome	  b5	  reductase	  1 15 28.52 9 34.75 10 26.23
Q9UHV9 Prefoldin	  subunit	  2 3 29.22 2 9.09 3 21.43
Q9UHX1 Poly(U)-­‐binding-­‐splicing	  factor	  PUF60 13 17.17 5 14.13 6 14.31
Q9UHY1 Nuclear	  receptor-­‐binding	  protein 4 10.47 1 2.80 1 2.80
Q9UHY7 Enolase-­‐phosphatase	  E1 6 25.29 4 25.29 2 9.19
Q9UI09 NADH	  dehydrogenase	  [ubiquinone]	  1	  alpha	  subcomplex	  subunit	  12 2 8.28 2 8.28 2 20.00
Q9UI12 V-­‐type	  proton	  ATPase	  subunit	  H 12 14.08 14 14.49 7 15.11
Q9UI30 tRNA	  methyltransferase	  112	  homolog 3 32.80 2 21.60 2 11.20
Q9UIG0 Tyrosine-­‐protein	  kinase	  BAZ1B 5 3.51 0 0.00 0 0.00
Q9UII2 ATPase	  inhibitor,	  mitochondrial 5 31.13 2 14.15 0 0.00
Q9UIJ7 GTP:AMP	  phosphotransferase,	  mitochondrial 15 48.90 4 26.43 6 24.67
Q9UIQ6 Leucyl-­‐cystinyl	  aminopeptidase 7 6.83 3 4.29 6 6.93
Q9UIW2 Plexin-­‐A1 3 1.63 1 0.79 0 0.00
Q9UJ70 N-­‐acetyl-­‐D-­‐glucosamine	  kinase 9 22.97 4 15.41 7 20.06
Q9UJA5 tRNA	  (adenine(58)-­‐N(1))-­‐methyltransferase	  non-­‐catalytic	  subunit	  TRM6 1 3.22 0 0.00 2 3.22
Q9UJS0 Calcium-­‐binding	  mitochondrial	  carrier	  protein	  Aralar2 20 26.81 14 22.22 12 22.22
Q9UJU6 Drebrin-­‐like	  protein 12 33.95 9 20.70 8 25.58
Q9UJV9 Probable	  ATP-­‐dependent	  RNA	  helicase	  DDX41 1 3.22 0 0.00 0 0.00
Q9UJX5 Anaphase-­‐promoting	  complex	  subunit	  4 2 1.98 0 0.00 0 0.00
Q9UJY4 ADP-­‐ribosylation	  factor-­‐binding	  protein	  GGA2 2 6.20 0 0.00 0 0.00
Q9UJZ1 Stomatin-­‐like	  protein	  2 15 43.26 12 35.39 8 26.69
Q9UK45 U6	  snRNA-­‐associated	  Sm-­‐like	  protein	  LSm7 2 17.48 2 25.24 2 17.48
Q9UKD2 mRNA	  turnover	  protein	  4	  homolog 2 9.62 0 0.00 0 0.00
Q9UKK3 Poly	  [ADP-­‐ribose]	  polymerase	  4 2 1.45 0 0.00 0 0.00
Q9UKK9 ADP-­‐sugar	  pyrophosphatase 5 23.29 3 12.79 2 12.79
Q9UKS6 Protein	  kinase	  C	  and	  casein	  kinase	  substrate	  in	  neurons	  protein	  3 6 12.97 3 7.55 3 7.55
Q9UKU0 Long-­‐chain-­‐fatty-­‐acid-­‐-­‐CoA	  ligase	  6 1 1.43 0 0.00 0 0.00
Q9UKU7 Isobutyryl-­‐CoA	  dehydrogenase,	  mitochondrial 5 11.57 1 3.37 0 0.00
Q9UKV3 Apoptotic	  chromatin	  condensation	  inducer	  in	  the	  nucleus 11 7.53 7 5.67 6 3.80
Q9UKY7 Protein	  CDV3	  homolog 3 31.40 2 22.09 2 24.03
Q9UL12 Sarcosine	  dehydrogenase,	  mitochondrial 3 3.60 1 1.85 0 0.00
Q9UL15 BAG	  family	  molecular	  chaperone	  regulator	  5 1 3.36 0 0.00 0 0.00
Q9UL25 Ras-­‐related	  protein	  Rab-­‐21 10 22.67 6 16.89 6 22.67
Q9UL41 Paraneoplastic	  antigen	  Ma3 4 10.37 0 0.00 0 0.00
Q9UL45 Pallidin 4 11.05 2 11.05 0 0.00
Q9UL46 Proteasome	  activator	  complex	  subunit	  2 14 30.54 16 34.73 14 30.54
Q9ULA0 Aspartyl	  aminopeptidase 8 20.42 5 8.42 4 17.05
Q9ULE4 Protein	  FAM184B 1 0.94 0 0.00 1 0.94
Q9ULV4 Coronin-­‐1C 10 18.35 2 3.38 4 6.12
Q9ULZ3 Apoptosis-­‐associated	  speck-­‐like	  protein	  containing	  a	  CARD 6 23.59 0 0.00 0 0.00
Q9UM00 Transmembrane	  and	  coiled-­‐coil	  domain-­‐containing	  protein	  1 3 12.23 2 7.98 3 7.98
Q9UM54 Myosin-­‐VI 4 4.10 0 0.00 3 3.40
Q9UMS0 NFU1	  iron-­‐sulfur	  cluster	  scaffold	  homolog,	  mitochondrial 3 14.57 0 0.00 0 0.00
Q9UMS4 Pre-­‐mRNA-­‐processing	  factor	  19 10 21.83 11 21.83 6 21.63
Q9UMX0 Ubiquilin-­‐1 9 13.07 12 13.92 9 11.04
Q9UMY4 Sorting	  nexin-­‐12 2 13.37 3 14.53 1 8.14
Q9UN37 Vacuolar	  protein	  sorting-­‐associated	  protein	  4A 5 11.44 0 0.00 1 2.52
Q9UN86 Ras	  GTPase-­‐activating	  protein-­‐binding	  protein	  2 5 8.71 2 5.19 2 3.53
Q9UNF0 Protein	  kinase	  C	  and	  casein	  kinase	  substrate	  in	  neurons	  protein	  2 13 20.16 5 9.67 3 2.26
Q9UNF1 Melanoma-­‐associated	  antigen	  D2 5 8.91 2 5.28 0 0.00
Q9UNH7 Sorting	  nexin-­‐6 5 5.17 4 9.36 5 10.84
Q9UNK0 Syntaxin-­‐8 2 12.29 0 0.00 0 0.00
Q9UNL2 Translocon-­‐associated	  protein	  subunit	  gamma 3 7.57 3 7.57 3 7.57
Q9UNM6 26S	  proteasome	  non-­‐ATPase	  regulatory	  subunit	  13 15 23.94 10 25.00 7 13.56
Q9UNN5 FAS-­‐associated	  factor	  1 2 3.38 0 0.00 0 0.00
Q9UNX3 60S	  ribosomal	  protein	  L26-­‐like	  1 8 26.90 5 20.69 3 20.00
Q9UNX4 WD	  repeat-­‐containing	  protein	  3 1 1.80 2 2.76 2 2.76
Q9UNZ2 NSFL1	  cofactor	  p47 11 31.08 11 23.78 12 21.89
Q9UP83 Conserved	  oligomeric	  Golgi	  complex	  subunit	  5 4 6.44 0 0.00 0 0.00
Q9UPN3 Microtubule-­‐actin	  cross-­‐linking	  factor	  1,	  isoforms	  1/2/3/5 7 1.04 0 0.00 8 1.42
Q9UPQ0 LIM	  and	  calponin	  homology	  domains-­‐containing	  protein	  1 3 2.58 1 1.48 0 0.00
Q9UPT5 Exocyst	  complex	  component	  7 5 7.35 0 0.00 0 0.00
Q9UPT8 Zinc	  finger	  CCCH	  domain-­‐containing	  protein	  4 2 2.53 0 0.00 0 0.00
Q9UQ80 Proliferation-­‐associated	  protein	  2G4 22 43.15 15 34.77 13 23.35
Q9UQ90 Paraplegin 7 10.94 0 0.00 0 0.00
Q9UQB3 Catenin	  delta-­‐2 2 1.96 0 0.00 1 0.82
Q9UQE7 Structural	  maintenance	  of	  chromosomes	  protein	  3 6 5.83 6 5.67 2 1.81
Q9Y224 UPF0568	  protein	  C14orf166 14 33.20 11 27.05 11 29.92
Q9Y230 RuvB-­‐like	  2 8 18.79 7 18.14 3 5.83
Q9Y259 Choline/ethanolamine	  kinase 4 12.91 0 0.00 2 7.09
Q9Y262 Eukaryotic	  translation	  initiation	  factor	  3	  subunit	  L 15 18.62 8 15.43 12 21.28
Q9Y263 Phospholipase	  A-­‐2-­‐activating	  protein 3 6.16 2 3.65 2 3.65
Q9Y265 RuvB-­‐like	  1 20 35.09 18 28.29 10 24.56
Q9Y266 Nuclear	  migration	  protein	  nudC 4 7.25 1 4.53 0 0.00
Q9Y276 Mitochondrial	  chaperone	  BCS1 12 33.17 9 22.91 3 12.65
Q9Y277 Voltage-­‐dependent	  anion-­‐selective	  channel	  protein	  3 10 23.32 8 16.25 5 8.13
Q9Y285 Phenylalanyl-­‐tRNA	  synthetase	  alpha	  chain 14 24.21 6 16.34 8 16.34
Q9Y2A7 Nck-­‐associated	  protein	  1 9 8.78 4 3.72 0 0.00
Q9Y2B0 Protein	  canopy	  homolog	  2 16 47.25 9 41.76 14 41.76
Q9Y2D0 Carbonic	  anhydrase	  5B,	  mitochondrial 1 5.36 1 5.36 2 5.36
Q9Y2D4 Exocyst	  complex	  component	  6B 6 9.86 0 0.00 1 1.60
Q9Y2E5 Epididymis-­‐specific	  alpha-­‐mannosidase 1 1.59 0 0.00 0 0.00
Q9Y2J2 Band	  4.1-­‐like	  protein	  3 9 9.66 3 2.21 4 4.14
Q9Y2J4 Angiomotin-­‐like	  protein	  2 2 1.93 0 0.00 0 0.00
Q9Y2P8 RNA	  3'-­‐terminal	  phosphate	  cyclase-­‐like	  protein 1 2.14 0 0.00 1 2.14
Q9Y2Q3 Glutathione	  S-­‐transferase	  kappa	  1 13 45.13 7 34.51 3 24.34
Q9Y2R0 Coiled-­‐coil	  domain-­‐containing	  protein	  56 3 17.92 0 0.00 0 0.00
Q9Y2R9 28S	  ribosomal	  protein	  S7,	  mitochondrial 3 10.33 0 0.00 0 0.00
Q9Y2S2 Lambda-­‐crystallin	  homolog 36 55.49 24 41.07 26 37.93
Q9Y2U8 Inner	  nuclear	  membrane	  protein	  Man1 3 3.84 1 1.43 1 1.43
Q9Y2V2 Calcium-­‐regulated	  heat	  stable	  protein	  1 1 10.88 4 10.88 3 10.88
Q9Y2W1 Thyroid	  hormone	  receptor-­‐associated	  protein	  3 11 10.16 4 4.08 3 3.66
Q9Y2W2 WW	  domain-­‐binding	  protein	  11 2 3.59 0 0.00 0 0.00
Q9Y2X3 Nucleolar	  protein	  58 20 35.92 21 34.03 14 22.68
Q9Y2X7 ARF	  GTPase-­‐activating	  protein	  GIT1 5 6.18 0 0.00 0 0.00
Q9Y2X8 Ubiquitin-­‐conjugating	  enzyme	  E2	  D4 4 12.24 3 12.24 2 12.24
Q9Y2Z0 Suppressor	  of	  G2	  allele	  of	  SKP1	  homolog 3 11.78 0 0.00 0 0.00
Q9Y2Z4 Tyrosyl-­‐tRNA	  synthetase,	  mitochondrial 5 13.00 4 8.60 3 4.40
Q9Y303 Putative	  N-­‐acetylglucosamine-­‐6-­‐phosphate	  deacetylase 12 30.56 13 30.56 10 24.94
Q9Y305 Acyl-­‐coenzyme	  A	  thioesterase	  9,	  mitochondrial 7 24.15 5 14.35 4 11.39
Q9Y315 Putative	  deoxyribose-­‐phosphate	  aldolase 5 21.38 0 0.00 4 20.13
Q9Y320 Thioredoxin-­‐related	  transmembrane	  protein	  2 2 9.12 0 0.00 0 0.00
Q9Y333 U6	  snRNA-­‐associated	  Sm-­‐like	  protein	  LSm2 3 40.00 2 27.37 1 20.00
Q9Y376 Calcium-­‐binding	  protein	  39 5 12.90 3 9.68 0 0.00
Q9Y383 Putative	  RNA-­‐binding	  protein	  Luc7-­‐like	  2 6 11.73 6 12.50 7 11.99
Q9Y394 Dehydrogenase/reductase	  SDR	  family	  member	  7 8 22.42 2 5.90 4 12.39
Q9Y3A5 Ribosome	  maturation	  protein	  SBDS 4 15.20 2 10.80 1 4.00
Q9Y3A6 Transmembrane	  emp24	  domain-­‐containing	  protein	  5 2 5.24 1 5.24 1 5.24
Q9Y3B3 Transmembrane	  emp24	  domain-­‐containing	  protein	  7 4 9.82 1 4.46 3 9.82
Q9Y3B7 39S	  ribosomal	  protein	  L11,	  mitochondrial 1 9.38 0 0.00 0 0.00
Q9Y3B8 Oligoribonuclease,	  mitochondrial 1 7.59 3 15.61 0 0.00
Q9Y3C4 TP53RK-­‐binding	  protein 2 18.29 2 26.29 1 16.00
Q9Y3C8 Ubiquitin-­‐fold	  modifier-­‐conjugating	  enzyme	  1 1 5.39 0 0.00 0 0.00
Q9Y3D6 Mitochondrial	  fission	  1	  protein 9 31.58 7 23.03 7 23.03
Q9Y3D9 28S	  ribosomal	  protein	  S23,	  mitochondrial 5 20.00 1 5.26 2 13.68
Q9Y3E0 Vesicle	  transport	  protein	  GOT1B 3 10.87 2 10.87 0 0.00
Q9Y3E1 Hepatoma-­‐derived	  growth	  factor-­‐related	  protein	  3 3 16.26 0 0.00 0 0.00
Q9Y3E5 Peptidyl-­‐tRNA	  hydrolase	  2,	  mitochondrial 3 21.23 2 8.38 5 31.84
Q9Y3E7 Charged	  multivesicular	  body	  protein	  3 1 5.40 0 0.00 0 0.00
Q9Y3I0 tRNA-­‐splicing	  ligase	  RtcB	  homolog 10 19.80 5 13.47 4 12.48
Q9Y3Q8 TSC22	  domain	  family	  protein	  4 3 10.89 0 0.00 1 4.56
Q9Y3T9 Nucleolar	  complex	  protein	  2	  homolog 1 1.33 2 1.33 2 1.33
Q9Y3U8 60S	  ribosomal	  protein	  L36 6 29.52 2 20.00 2 20.00
Q9Y3X0 Coiled-­‐coil	  domain-­‐containing	  protein	  9 1 2.26 0 0.00 0 0.00
Q9Y3Y2 Chromatin	  target	  of	  PRMT1	  protein 4 17.34 0 0.00 1 8.07
Q9Y3Z3 SAM	  domain	  and	  HD	  domain-­‐containing	  protein	  1 21 33.07 19 27.16 11 22.04
Q9Y450 HBS1-­‐like	  protein 1 2.34 0 0.00 0 0.00
Q9Y490 Talin-­‐1 146 42.58 109 36.13 104 34.32
Q9Y4C8 Probable	  RNA-­‐binding	  protein	  19 1 1.67 0 0.00 0 0.00
Q9Y4F1 FERM,	  RhoGEF	  and	  pleckstrin	  domain-­‐containing	  protein	  1 7 7.08 4 4.79 4 6.12
Q9Y4G6 Talin-­‐2 22 9.68 9 4.37 0 0.00
Q9Y4I1 Myosin-­‐Va 40 18.22 28 16.17 20 13.96
Q9Y4L1 Hypoxia	  up-­‐regulated	  protein	  1 20 18.92 15 18.12 11 16.72
Q9Y4P3 Transducin	  beta-­‐like	  protein	  2 2 5.37 0 0.00 1 2.91
Q9Y4W2 Protein	  LAS1	  homolog 1 1.91 1 1.23 1 1.91
Q9Y4W6 AFG3-­‐like	  protein	  2 26 24.59 11 12.80 10 8.78
Q9Y570 Protein	  phosphatase	  methylesterase	  1 3 5.18 0 0.00 4 8.55
Q9Y580 RNA-­‐binding	  protein	  7 1 6.77 0 0.00 0 0.00
Q9Y5A9 YTH	  domain	  family	  protein	  2 1 1.55 0 0.00 0 0.00
Q9Y5B0 RNA	  polymerase	  II	  subunit	  A	  C-­‐terminal	  domain	  phosphatase 1 0.94 0 0.00 0 0.00
Q9Y5B9 FACT	  complex	  subunit	  SPT16 10 8.60 4 5.73 6 5.64
Q9Y5K5 Ubiquitin	  carboxyl-­‐terminal	  hydrolase	  isozyme	  L5 4 14.59 2 8.21 2 8.51
Q9Y5K6 CD2-­‐associated	  protein 6 11.11 1 3.91 2 6.42
Q9Y5K8 V-­‐type	  proton	  ATPase	  subunit	  D 10 40.49 7 29.96 5 29.96
Q9Y5L0 Transportin-­‐3 4 5.96 2 4.12 3 4.01
Q9Y5L4 Mitochondrial	  import	  inner	  membrane	  translocase	  subunit	  Tim13 5 36.84 1 14.74 2 14.74
Q9Y5M8 Signal	  recognition	  particle	  receptor	  subunit	  beta 7 21.77 2 9.59 2 9.59
Q9Y5P4 Collagen	  type	  IV	  alpha-­‐3-­‐binding	  protein 2 3.36 0 0.00 2 3.36
Q9Y5Q9 General	  transcription	  factor	  3C	  polypeptide	  3 1 1.69 1 1.69 3 3.16
Q9Y5S1 Transient	  receptor	  potential	  cation	  channel	  subfamily	  V	  member	  2 5 7.46 0 0.00 5 7.46
Q9Y5S2 Serine/threonine-­‐protein	  kinase	  MRCK	  beta 6 5.03 3 2.51 4 2.69
Q9Y5S9 RNA-­‐binding	  protein	  8A 9 32.18 7 47.70 1 6.32
Q9Y5X1 Sorting	  nexin-­‐9 5 9.08 3 3.87 3 7.56
Q9Y5X2 Sorting	  nexin-­‐8 8 12.04 6 11.40 6 13.12
Q9Y5X3 Sorting	  nexin-­‐5 3 7.67 0 0.00 0 0.00
Q9Y5Y2 Cytosolic	  Fe-­‐S	  cluster	  assembly	  factor	  NUBP2 4 25.09 3 25.09 2 19.56
Q9Y5Z4 Heme-­‐binding	  protein	  2 4 13.66 0 0.00 2 6.34
Q9Y606 tRNA	  pseudouridine	  synthase	  A,	  mitochondrial 5 12.88 0 0.00 1 2.81
Q9Y608 Leucine-­‐rich	  repeat	  flightless-­‐interacting	  protein	  2 3 3.47 0 0.00 1 1.94
Q9Y617 Phosphoserine	  aminotransferase 4 11.89 3 9.19 0 0.00
Q9Y618 Nuclear	  receptor	  corepressor	  2 2 1.27 0 0.00 0 0.00
Q9Y639 Neuroplastin 7 12.31 4 7.03 0 0.00
Q9Y646 Plasma	  glutamate	  carboxypeptidase 2 4.66 0 0.00 0 0.00
Q9Y653 G-­‐protein	  coupled	  receptor	  56 1 3.46 1 3.46 2 3.46
Q9Y672 Dolichyl	  pyrophosphate	  Man9GlcNAc2	  alpha-­‐1,3-­‐glucosyltransferase 2 4.14 0 0.00 0 0.00
Q9Y678 Coatomer	  subunit	  gamma 21 25.97 9 11.33 12 18.19
Q9Y679 Ancient	  ubiquitous	  protein	  1 7 10.29 2 6.30 2 6.30
Q9Y696 Chloride	  intracellular	  channel	  protein	  4 12 43.08 9 20.95 3 9.49
Q9Y697 Cysteine	  desulfurase,	  mitochondrial 3 9.19 1 3.06 0 0.00
Q9Y6B6 GTP-­‐binding	  protein	  SAR1b 9 36.87 4 34.34 2 17.17
Q9Y6C2 EMILIN-­‐1 4 7.28 0 0.00 1 2.26
Q9Y6C9 Mitochondrial	  carrier	  homolog	  2 9 12.21 6 17.49 4 12.21
Q9Y6D5 Brefeldin	  A-­‐inhibited	  guanine	  nucleotide-­‐exchange	  protein	  2 7 6.55 2 1.23 4 3.14
Q9Y6D6 Brefeldin	  A-­‐inhibited	  guanine	  nucleotide-­‐exchange	  protein	  1 4 2.76 0 0.00 5 3.62
Q9Y6E0 Serine/threonine-­‐protein	  kinase	  24 7 17.83 1 3.39 3 11.06
Q9Y6G9 Cytoplasmic	  dynein	  1	  light	  intermediate	  chain	  1 3 8.99 1 3.63 3 8.60
Q9Y6K5 2'-­‐5'-­‐oligoadenylate	  synthase	  3 7 7.54 0 0.00 0 0.00
Q9Y6K9 NF-­‐kappa-­‐B	  essential	  modulator 1 3.82 0 0.00 0 0.00
Q9Y6M1 Insulin-­‐like	  growth	  factor	  2	  mRNA-­‐binding	  protein	  2 4 9.18 4 7.01 5 12.02
Q9Y6M9 NADH	  dehydrogenase	  [ubiquinone]	  1	  beta	  subcomplex	  subunit	  9 6 21.79 2 13.97 2 12.85
Q9Y6N5 Sulfide:quinone	  oxidoreductase,	  mitochondrial 6 16.44 0 0.00 0 0.00
Q9Y6U3 Adseverin 16 21.12 0 0.00 0 0.00
Q9Y6Y8 SEC23-­‐interacting	  protein 2 3.60 0 0.00 1 1.50
RRRRRA6NF79 REVERSED	  Zinc	  finger	  protein	  734 1 2.86 0 0.00 0 0.00
RRRRRA6NHR9 REVERSED	  Structural	  maintenance	  of	  chromosomes	  flexible	  hinge	  domain-­‐containing	  protein	  12 0.65 0 0.00 0 0.00
RRRRRA6NK21 REVERSED	  Putative	  zinc	  finger	  protein	  LOC730110 1 2.92 0 0.00 0 0.00
RRRRRA6NK75 REVERSED	  Zinc	  finger	  protein	  98 1 2.80 0 0.00 0 0.00
RRRRRA6NKZ1 REVERSED	  Zinc	  finger	  protein	  733 1 3.06 0 0.00 0 0.00
RRRRRA6NN14 REVERSED	  Zinc	  finger	  protein	  729 1 4.09 0 0.00 0 0.00
RRRRRA6NNF4 REVERSED	  Zinc	  finger	  protein	  726 1 5.42 0 0.00 0 0.00
RRRRRA6NP11 REVERSED	  Zinc	  finger	  protein	  716 1 1.66 0 0.00 0 0.00
RRRRRA8MTY0 REVERSED	  Putative	  zinc	  finger	  protein	  724 1 3.88 0 0.00 0 0.00
RRRRRA8MUZ8 REVERSED	  Putative	  zinc	  finger	  protein	  705G 1 2.67 0 0.00 0 0.00
RRRRRA8MWA4 REVERSED	  Putative	  zinc	  finger	  protein	  705E 1 2.65 0 0.00 0 0.00
RRRRRA8MXY4 REVERSED	  Zinc	  finger	  protein	  99 1 3.09 0 0.00 0 0.00
RRRRRB4DXR9 REVERSED	  Zinc	  finger	  protein	  732 1 1.37 0 0.00 0 0.00
RRRRRO43309 REVERSED	  Zinc	  finger	  and	  SCAN	  domain-­‐containing	  protein	  12 2 2.15 0 0.00 0 0.00
RRRRRO43345 REVERSED	  Zinc	  finger	  protein	  208 1 0.69 0 0.00 0 0.00
RRRRRO75373 REVERSED	  Zinc	  finger	  protein	  737 1 1.49 0 0.00 0 0.00
RRRRRO75437 REVERSED	  Zinc	  finger	  protein	  254 1 4.86 0 0.00 0 0.00
RRRRRP0C7V5 REVERSED	  Putative	  zinc	  finger	  protein	  812 1 1.76 0 0.00 0 0.00
RRRRRP0CB33 REVERSED	  Putative	  zinc	  finger	  protein	  735 1 3.88 0 0.00 0 0.00
RRRRRP17019 REVERSED	  Zinc	  finger	  protein	  708 1 5.68 0 0.00 0 0.00
RRRRRP17029 REVERSED	  Zinc	  finger	  protein	  with	  KRAB	  and	  SCAN	  domains	  1 1 1.42 0 0.00 0 0.00
RRRRRP17038 REVERSED	  Zinc	  finger	  protein	  43 1 1.98 0 0.00 0 0.00
RRRRRP49959 REVERSED	  Double-­‐strand	  break	  repair	  protein	  MRE11A 1 0.99 0 0.00 0 0.00
RRRRRP56381 REVERSED	  ATP	  synthase	  subunit	  epsilon,	  mitochondrial 1 15.69 0 0.00 0 0.00
RRRRRQ03923 REVERSED	  Zinc	  finger	  protein	  85 1 8.07 0 0.00 0 0.00
RRRRRQ03924 REVERSED	  Zinc	  finger	  protein	  117 1 1.66 0 0.00 0 0.00
RRRRRQ03936 REVERSED	  Zinc	  finger	  protein	  92 1 6.83 0 0.00 0 0.00
RRRRRQ05481 REVERSED	  Zinc	  finger	  protein	  91 1 4.03 0 0.00 0 0.00
RRRRRQ14593 REVERSED	  Zinc	  finger	  protein	  273 1 1.41 0 0.00 0 0.00
RRRRRQ15928 REVERSED	  Zinc	  finger	  protein	  141 1 1.69 0 0.00 0 0.00
RRRRRQ5JVG8 REVERSED	  Zinc	  finger	  protein	  506 1 3.60 0 0.00 0 0.00
RRRRRQ5T0T0 REVERSED	  E3	  ubiquitin-­‐protein	  ligase	  MARCH8 1 2.06 0 0.00 0 0.00
RRRRRQ5VTU8 REVERSED	  ATP	  synthase	  subunit	  epsilon-­‐like	  protein,	  mitochondrial 1 15.69 0 0.00 0 0.00
RRRRRQ68DY1 REVERSED	  Zinc	  finger	  protein	  626 1 3.03 0 0.00 0 0.00
RRRRRQ6IPT2 REVERSED	  Protein	  FAM71E1 2 2.83 0 0.00 0 0.00
RRRRRQ6ZN08 REVERSED	  Putative	  zinc	  finger	  protein	  66 1 5.39 0 0.00 0 0.00
RRRRRQ6ZN79 REVERSED	  Zinc	  finger	  protein	  705A 1 2.67 0 0.00 0 0.00
RRRRRQ6ZNG1 REVERSED	  Zinc	  finger	  protein	  600 1 1.11 0 0.00 0 0.00
RRRRRQ6ZR52 REVERSED	  Zinc	  finger	  protein	  493 1 2.48 0 0.00 0 0.00
RRRRRQ70YC5 REVERSED	  Protein	  ZNF365 1 1.97 0 0.00 0 0.00
RRRRRQ8IYB9 REVERSED	  Zinc	  finger	  protein	  595 1 1.24 0 0.00 0 0.00
RRRRRQ8IYN0 REVERSED	  Zinc	  finger	  protein	  100 1 1.48 0 0.00 0 0.00
RRRRRQ8IYX0 REVERSED	  Zinc	  finger	  protein	  679 1 1.95 0 0.00 0 0.00
RRRRRQ8N7Q3 REVERSED	  Zinc	  finger	  protein	  676 1 5.44 0 0.00 0 0.00
RRRRRQ8TCQ1 REVERSED	  E3	  ubiquitin-­‐protein	  ligase	  MARCH1 1 2.08 0 0.00 0 0.00
RRRRRQ8TD23 REVERSED	  Zinc	  finger	  protein	  675 1 2.82 0 0.00 0 0.00
RRRRRQ8TF32 REVERSED	  Zinc	  finger	  protein	  431 1 6.94 0 0.00 0 0.00
RRRRRQ96GX1 REVERSED	  Tectonic-­‐2 1 1.29 0 0.00 1 1.29
RRRRRQ96H40 REVERSED	  Zinc	  finger	  protein	  486 1 1.73 0 0.00 0 0.00
RRRRRQ96JC4 REVERSED	  Zinc	  finger	  protein	  479 1 3.05 0 0.00 0 0.00
RRRRRQ96N22 REVERSED	  Zinc	  finger	  protein	  681 1 3.72 0 0.00 0 0.00
RRRRRQ96N38 REVERSED	  Zinc	  finger	  protein	  714 1 2.88 0 0.00 0 0.00
RRRRRQ96N58 REVERSED	  Zinc	  finger	  protein	  578 1 2.19 0 0.00 0 0.00
RRRRRQ9BV36 REVERSED	  Melanophilin 1 1.17 0 0.00 0 0.00
RRRRRQ9BX10 REVERSED	  GTP-­‐binding	  protein	  2 1 1.00 0 0.00 0 0.00
RRRRRQ9H8G1 REVERSED	  Zinc	  finger	  protein	  430 1 5.61 0 0.00 0 0.00
RRRRRQ9NSC5 REVERSED	  Homer	  protein	  homolog	  3 1 2.22 0 0.00 0 0.00
RRRRRQ9NZU7 REVERSED	  Calcium-­‐binding	  protein	  1 1 2.16 0 0.00 0 0.00
RRRRRQ9P241 REVERSED	  Probable	  phospholipid-­‐transporting	  ATPase	  VD 1 0.49 0 0.00 0 0.00
RRRRRQ9P255 REVERSED	  Zinc	  finger	  protein	  492 1 3.01 0 0.00 0 0.00
RRRRRQ9UII5 REVERSED	  Zinc	  finger	  protein	  107 1 5.11 0 0.00 0 0.00
RRRRRQ9Y2Q1 REVERSED	  Zinc	  finger	  protein	  257 1 5.68 0 0.00 0 0.00
Sample iTRAQ	  ratio cyto	  int cyto	  % IHC	  tot iTRAQ	  ratio cyto	  int cyto	  % IHC	  tot iTRAQ	  ratio cyto	  int cyto	  % cyto	  tot nucl	  % IHC	  tot
S065-­‐12	  HR 4.365 2 3 6 1.138 2 2 4 2.399 2 3 6 0 6
S166-­‐11	  HR 5.546 3 1 3 2.355 3 3 9 1.888 1 3 3 3 6
S067-­‐11	  HR 1.572 2 2 4 1.282 3 2 6 1.393 1 3 3 2 5
S061-­‐11	  HR 0.643 2 1 2 0.063 0 0 0 2.63 2 2 4 2 6
S165-­‐11	  HR 1.803 N/A N/A 0.445 N/A N/A 1.528 N/A N/A N/A
S228-­‐11	  HR 1.888 1 3 3 1.086 2 3 6 0.787 1 2 2 1 3
S116-­‐12	  HR 0.698 1 1 1 #N/A 0 0 0 4.831 2 3 6 2 8
S197-­‐12	  HR 0.832 2 1 2 #N/A 1 2 2 8.091 0 0 0 0 0
S216-­‐12	  HR 0.847 2 1 2 #N/A 2 1 2 0.832 0 0 0 0 0
S195-­‐12	  HR 0.661 1 1 1 #N/A 1 4 4 3.945 1 1 1 2 3
Mean 1.886 2.7 1.062 3.7 2.832 2.8 1.3 4.1
S159-­‐11	  LR 1.871 0 0 0 0.153 0 0 0 8.71 2 4 8 3 11
S196-­‐11	  LR 0.233 1 1 1 2.606 1 1 1 1.271 1 4 4 1 5
S042-­‐11	  LR 1.213 1 1 1 0.205 0 0 0 5.495 0 0 0 2 2
S124-­‐12	  LR 1.33 1 1 1 0.221 0 0 0 4.365 0 0 0 3 3
S070-­‐12	  LR 1.086 1 2 2 0.231 0 0 0 5.058 1 4 4 3 7
S147-­‐12	  LR 0.236 1 1 1 0.377 1 1 1 4.018 3 1 3 3 6
S194-­‐12	  LR 0.474 2 1 1 0.067 0 0 0 3.436 1 3 3 2 5
S113-­‐12	  LR 0.592 1 3 3 #N/A 0 0 0 6.792 1 4 4 2 6
S163-­‐12	  LR 0.394 1 1 1 #N/A 1 1 1 8.63 2 4 8 3 11
S204-­‐12	  LR 0.759 1 2 2 #N/A 1 1 1 7.87 3 3 9 1 10
Mean 0.819 1.3 0.551 0.4 5.565 4.3 2.3 6.6
Nesprin	  2 S100	  A6 PDCD4
Appendix	  2.	  Semi-­‐quantitative	  immunohistochemical	  validation	  of	  iTRAQ	  relative	  quantification
HR:	  high	  risk,	  LR:	  low	  risk;	  cyto:	  cytoplasmic;	  nucl:	  nuclear;	  int:	  intensity;	  IHC	  tot:	  overall	  immunohistochemical	  scoring	  (details	  explained	  in	  Table	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Despite successful treatment of the primary uveal melanoma (UM), almost 
50% of patients develop metastatic disease, which usually involves the 
liver, with a fatal outcome. Current screening for metastatic disease relies 
on 6-monthly imaging and liver function tests, with low sensitivity and 
specificity. A secreted biomarker that can be measured in blood samples 
would allow earlier detection of metastatic disease and aid monitoring of 
systemic adjuvant therapy in high risk UM patients.1   
Analysis and characterisation of the cancer secretome (the complex set of 
molecules secreted or shed from the surface of living cells) using 
proteomics profiling is a relevant approach to biomarker discovery. In UM, 
analysis of biological fluids proximal to the tumor, e.g. subretinal fluid, is 
limited by  their availability. It has been shown in other malignancies that 
proteins secreted by tumor cells in vitro are similar to those released by the 
same tumors in vivo. However, optimised procedures have to be followed 
for culture, collection and preparation of the samples.2 
Purpose 
!  Adherent vs non-adherent culture conditions 
Mel270 and Omm2.5 cell lines were grown in duplicate as adherent, 
clonogenic adherent and clonogenic suspension in a 75cm2 flask for 5 days, 
then progressively adapted to serum depletion and incubated for 48 hours 
in serum free medium (SFM). 
!    Adherent cultures with different media 
Mel270 and Omm2.5 cell lines, as well as cells from one high risk 
monosomy 3 (M3) and one low risk disomy 3 (D3) primary UM were grown 
as adherent cultures in three different media: RPMI-based, DMEM-based, 
αMEM-based. Cell proliferation was assessed at day 0, 2, 4, 5, 7 using the 
sulforhodamine B (SRB) method. 
!    Different incubation times in SFM 
Primary UM cells where grown under adherent conditions in αMEM-based 
medium in eight identical 75cm2 flask (1.5x106 cells/flask) until 70% 
confluence. Cells were then either washed 4x with PBS and incubated with 
serum free and phenol red free medium for 24 or 48 hours or they were 
progressively depleted of serum in phenol red free medium over 4 days 
prior to incubation for 24 or 48 hours as above. Viability of the cells under 
each condition was assessed by trypan blue.  
!     Genetic and phenotypic characterization of cultured cells  
For each primary culture, cells were also grown in 2x8-well chamber slides, 
which were then fixed and examined by immunofluorescence. In all cases, 
DNA was extracted from cells at the end of the incubation in SFM and 
analised by multiplex ligation-dependent probe amplification. 
Methods: cell culture 
Aim 
To identify the best culture conditions for the production and analysis of 














































Figure 2. Assessment of cell number in different media using SRB. The growth of Mel270 and Omm2.5 cell lines (top) was 
not influenced by culture medium. Disomy 3 (D3, bottom left) primary UM cells did not grow in the short term culture, 
irrespective of the medium used. Monosomy 3 (M3, bottom right) primary UM cells showed the greatest increase in cell number 
in the αMEM-based medium. 
Results 
Figure 1B. Cultured cells (CC) from a M3 UM, showing high 
proliferative capacity in culture (Ki67), low expression of 
melanoma specific antigens (HMB45, MelanA, Vimentin, 
MITF), large number of cells positive for the myofibroblast 
marker αSMA and positive staining for Oil Red O and NFP. 
 
Figure 1A. Cultured cells (CC) from a D3 UM, showing low 
proliferative capacity in culture (Ki67), high expression of 
melanoma specific antigens (HMB45, MelanA, Vimentin, 
MITF), small number of cells positive for the myofibroblast 
marker αSMA, but no positive staining for Oil Red O. 
 
!  Sample preparation 
Conditioned SFM was collected, centrifuged and filtered to remove cellular debris, 
concentrated on ultracentrifugation (Amicon Ultra 3KDa), desalted using a HPLC column, 
reduced/alkylated, trypsin digested and ZipTipped (C18). 
!  Protein identification 
Proteins were analysed by nanoLC-MS/MS (ABSciex 5600) and identified using Protein Pilot 
(4.0) with a False Discovery Rate set to 5%. Secreted proteins were identified searching the 
SwissProt database and using the PANTHER Classification System. 
 
Methods: mass spectrometry 
Culture of primary UM cells in an αMEM-based medium under 
adherent conditions up to 80% confluence, followed by rinsing 
and incubation in serum-free and phenol red-free medium for 48 
hour is optimal for in vitro UM secretome analysis.  
Future work will validate the presence of candidate proteins in 
ocular fluids, such as subretinal fluid, extracted from the same 
patient as the cultured UM cells. In this way, we hypothesize that 
prognostic biomarkers of clinical relevance in UM will be 




Figure 3. Multiplex Ligation-dependent Probe Amplification (MLPA) of UM cells 
before and after culture. Molecular genetic analysis of DNA extracted from the primary 
tumour and from the cultured cells at the time of secretome collection did not differ.  
Left: normal chromosome 3 and chromosome 8 copy numbers in the less aggressive, slow 
growing D3 tumour and CC. Right: Loss of one copy of chromosome 3 and gains of 
chromosome arm 8q in the more aggressive, faster growing M3 tumour and CC. 
1) Triozzi PL, Singh AD Future Oncol 2012;8:205-15. 2) Makridakis M, Vlahou A  
J Proteomics 2010;73:2291-305. 3) Pardo M et al. J Proteome Res 2007;6:2082-11.  
4) Chen St et al. J Proteome Res 2008;7:1379-87. 
!    Adherent vs non-adherent culture conditions 
An average of 320 proteins has been identified in conditioned 
SFM from adherent cells grown to 80% confluence, six folds more 
than in conditioned SFM from the other culture conditions.  
!    Different incubation times in SFM 
At the end of the incubation time in SFM, trypan blue showed a 
greater number of non-viable cells in the progressively serum-
depleted flasks (40% at 48 hours). The number of non-viable cells 
did not significantly differ after 24 (15%) and 48 (17%) incubation 
straight into 100%SFM.  
!    Proteins of interest 
Putative secreted proteins, already identified as potential 
biomarkers in UM (cathepsin D, protein DJ-1)3 or in other cancer 
types (galectin 3, galectin-3-binding protein, osteopontin, 
SPARC)4 were  identified with greater confidence in conditioned 
SFM after 48 hours of incubation. Proteins associated with cell 
leakage were present in all conditions. 
 
 
Appendix	  3.	  Optimisation	  of	  culture	  conditions	  and	  serum	  depletion	  for	  secretome	  production	  from	  primary	  UM	  cells	  in	  culture	  
	  
Appendix	  4.	  Details	  of	  the	  18	  proteins	  that	  discriminate	  between	  HR	  and	  LR	  secretome	  samples	  	  
Expression	   Accession	  
no.	  
Name	   Gene	   Function	   GO	  biological	  process	   GO	  cellular	  component	  
LR>HR	   P04083	   Annexin	  A1	  
(Lipocortin	  I)	  
ANXA1	   Calcium/phospholipid-­‐binding	  
protein	   which	   promotes	   membrane	  
fusion	   and	   is	   involved	   in	   exocytosis.	  
This	  protein	  regulates	  phospholipase	  
A2	   activity.	   It	   seems	   to	   bind	   from	  
two	   to	   four	   calcium	   ions	   with	   high	  
affinity.	  
Cell	  surface	  receptor	  
signaling	  pathway;	  
hepatocyte	  differentiation	  
negative	  regulation	  of	  
apoptotic	  process;	  positive	  







HR>LR	   P13674	   Prolyl	  4-­‐
hydroxylase	  
subunit	  alpha-­‐1	  
P4HA1	   Catalyzes	   the	   post-­‐translational	  
formation	   of	   4-­‐hydroxyproline	   in	   -­‐
Xaa-­‐Pro-­‐Gly-­‐	   sequences	   in	   collagens	  
and	  other	  proteins	  
Collagen	  fibril	  organization	   Endoplasmic	  reticulum,	  
mitochondrion	  
LR>HR	   P02545	   Prelamin-­‐A/C	   LMNA	   Laminins	   are	   components	   of	   the	  
nuclear	  lamina,	  a	  fibrous	  layer	  on	  the	  
nucleoplasmic	   side	   of	   the	   inner	  
nuclear	  membrane,	  which	  is	  thought	  
to	   provide	   a	   framework	   for	   the	  
nuclear	   envelope	   and	   may	   also	  
interact	   with	   chromatin.	   	   Required	  
for	   normal	   development	   of	  
peripheral	   nervous	   system	   and	  
skeletal	   muscle	   and	   for	   muscle	  
satellite	   cell	   proliferation.	   Required	  
for	   osteoblastogenesis	   and	   bone	  
formation.	  
Apoptotic	  process;	  
activation	  of	  signaling	  
protein	  activity	  involved	  in	  
unfolded	  protein	  
response;	  cellular	  
response	  to	  hypoxia	  
Nucleus.	  Nucleus	  envelope.	  
Nucleus	  lamina.	  Perinuclear	  
region	  of	  cytoplasm	  
LR>HR	   B4DNM8	   B4DNM8	  (cDNA	  
FLJ53395,	  highly	  
similar	  to	  Prolyl	  3-­‐
hydroxylase	  1)	  
B4DNM8	   L-­‐ascorbic	  acid	  and	  iron	  binding	   N/A	   N/A	  
LR>HR	   P17096	   High	  mobility	  
group	  protein	  
HMG-­‐I/HMG-­‐Y	  
HMGA1	   HMG-­‐I/Y	  bind	  preferentially	  to	  the	  
minor	  groove	  of	  A+T	  rich	  regions	  in	  
double-­‐stranded	  DNA.	  It	  is	  suggested	  
that	  these	  proteins	  could	  function	  in	  
nucleosome	  phasing	  and	  in	  the	  3'-­‐
end	  processing	  of	  mRNA	  transcripts.	  
They	  are	  also	  involved	  in	  the	  
transcription	  regulation	  of	  genes	  









HR>LR	   G3V394	   Unconventional	  
myosin-­‐Va	  
MYO5A	   ATP	  biniding,	  motor	  activity	   Nucleotide-­‐binding	   Myosin	  complex	  




HNRNPA1	   Involved	  in	  the	  packaging	  of	  pre-­‐
mRNA	  into	  hnRNP	  particles,	  
transport	  of	  poly(A)	  mRNA	  from	  the	  
nucleus	  to	  the	  cytoplasm	  and	  may	  
modulate	  splice	  site	  selection.	  
Nucleic	  acid	  binding	   Cytoplasm	  
Nucleus	  
Spliceosome	  
LR>HR	   B4DN87	   Serpin	  H1	   SERPINH1	   Binds	  specifically	  to	  collagen.	  Could	  
be	  involved	  as	  a	  chaperone	  in	  the	  
biosynthetic	  pathway	  of	  
collagen.Stress	  response	  protein,	  
induction	  by	  heat	  shock	  
Collagen	  biosynthetic	  





LR>HR	   P21291	   Cysteine	  and	  
glycine-­‐rich	  
protein	  1	  
CSRP1	   May	  play	  a	  role	  in	  neuronal	  
development.	  
RNA	  binding	   Extracellular	  vesicular	  
exosome,	  nucleous	  
HR>LR	   O60486	   Plexin-­‐C1	   PLXNC1	   Receptor	  for	  SEMA7A,	  for	  smallpox	  
semaphorin	  A39R,	  vaccinia	  virus	  
semaphorin	  A39R	  and	  for	  
herpesvirus	  Sema	  protein.	  Binding	  of	  
semaphorins	  triggers	  cellular	  
responses	  leading	  to	  the	  
rearrangement	  of	  the	  cytoskeleton	  




Membrane;	  Single-­‐pass	  type	  
I	  membrane	  protein	  	  
HR>LR	   F5H6I0	   Beta-­‐2-­‐
microglobulin	  
B2M	   Component	  of	  the	  class	  I	  major	  
histocompatibility	  complex	  (MHC).	  
Involved	  in	  the	  presentation	  of	  
peptide	  antigens	  to	  the	  immune	  
system	  
Immunity	   Secreted	  




TXNDC5	   Endoplasmic	  reticulum	  resident	  
protein,	  possesses	  thioredoxin	  
activity.	  Has	  been	  shown	  to	  reduce	  
insulin	  disulfide	  bonds.	  
Membrane	  organization;	  






exosome,	  lysosomal	  lumen	  




HNRNPA3	   Plays	  a	  role	  in	  cytoplasmic	  trafficking	  
of	  RNA.	  





HR>LR	   B4DDF9	   Annexin	   ANXA4	   Calcium/phospholipid-­‐binding	  
protein	  which	  promotes	  membrane	  
fusion	  and	  is	  involved	  in	  exocytosis	  




HR>LR	   P14174	   Macrophage	  
migration	  
inhibitory	  factor	  
MIF	   Pro-­‐inflammatory	  cytokine.	  Mediator	  
in	  regulating	  the	  function	  of	  
macrophages	  in	  host	  defense.	  	  
Innate	  immunity,	  negative	  
regulation	  of	  apoptotic	  
process,	  positive	  
chemotaxis,	  positive	  
regulation	  of	  MAP	  kinase	  
activity,	  positive	  





HR>LR	   H9KVA0	   Thymidine	  
phosphorylase	  
TYMP	   Platelet-­‐derived	  endothelial	  cell	  
growth	  factor.	  Has	  growth	  promoting	  
activity	  on	  endothelial	  cells,	  
angiogenic	  activity	  in	  vivo	  and	  
chemotactic	  activity	  on	  endothelial	  





LR>HR	   Q15393	   Splicing	  factor	  3B	  
subunit	  3	  
SF3B3	   Subunit	  of	  the	  splicing	  factor	  SF3B	  





HR>LR	   B5MCV4	   Complement	  C1s	  
sub-­‐component	  
C1S	   Component	  of	  complement	  (classical	  
pathway),	  protease	  
Complement	  activation,	  
classical	  pathway	  
Blood	  microparticle,	  
extracellular	  region	  
	  
